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1. ABSTRACT 
“An Investigation into the MicroRNA-gene interactions involved in the 
pathogenesis of Systemic Lupus Erythematosus” 
S.J. Pitts 
MSc Thesis,  
South African National Bioinformatics Institute, 
University of the Western Cape 
Systemic lupus erythematosus is a chronic, inflammatory disease characterised 
by the production of autoantibodies which target particularly the nuclear 
components of multiple cell types throughout the body. MicroRNA’s have been 
well-established to regulate gene function by partial-, or complete binding to the 
3’-UTR of the target genes, causing repression or complete degradation of the 
target gene. As a result, proteins normally produced by the targeted mRNA 
would exhibit a decrease in production. 
The aim of this study was to investigate the interactions between genes and 
microRNAs implicated in the pathogenesis of SLE. Objectives included curating 
lists of miRNAs and genes associated with lupus pathogenesis, to identify 
regulatory targets of miRNAs and genes targeted by miRNAs, and to find the 
intersections of these outputs. By examining the intersections of the resultant 
targets, we aimed to identify novel interactions using Pathway Analysis, which 
have not been previously reported in scientific literature, to be associated with 
the pathogenesis of SLE. 
Understanding the miRNA-gene target interactions in the progression of SLE may 
provide us with essential biomarkers and targets for disease diagnosis and 
therapy.  
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8. INTRODUCTION 
8.1. Maintenance of Immune System Homeostasis 
8.1.1. Normal functioning of the immune system  
8.1.1.1. Innate immunity 
The innate immune system serves as the first line of defence against pathogens 
which have breached the protective barriers of the human body. The innate 
immune system is made up of mast cells, natural killer cells, complement 
proteins, and granulocytes which comprise the largest percentage of peripheral 
blood mononuclear cells (PBMC’s) in the circulatory blood. Granulocytes, arising 
from immune stem cells, further subdivide into neutrophils, eosinophils, 
basophils, mast cells, and monocytes which subdivide into  dendritic cell and 
macrophage populations, as can be seen in Figure 1 (Dranoff, 2004).  
 
Figure 1: The immune system consists of two core components: the Innate immune system, and the 
Adaptive immune system. The Innate immune system provides a rapid, first-line response to invading 
pathogens, and the adaptive immune system responds progressively, with increasing memory for antigens 
(Dranoff, 2004) 
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The innate immune system plays the important role of producing responses 
against specialized classes of pathogens, via the activation of pattern recognition 
receptors, such as Toll-like receptors (TLRs) (Fairweather, 2007). Found on the 
membrane of monocytes, TLRs recognize and bind to specific microbial products 
called pathogen-associated molecular patterns (PAMPS), and subsequently 
trigger downstream signalling pathways to initiate inflammatory responses. To 
prevent excessive inflammation, various classes of negative regulators control 
TLR signalling, and recent studies have revealed that miRNAs both regulate and 
fine-tune innate immune responses to pathogenic insult (Dai and Ahmed, 2011). 
TLRs 7, 8, and 9 have been shown to be associated with Systemic Lupus 
Erythematosus (SLE) (De Azevedo Silva et al., 2014) 
8.1.1.2. Adaptive immunity 
Cells of the adaptive immune system are activated for proliferation in response 
to a secondary response of stimulus, hence the synonymous name of acquired 
immunity. Arising from immune stem cells, lymphocytes are subdivided into B 
cell progenitors, and T cell progenitors. B cell progenitors produce antibodies 
upon stimulation by helper T cells (Th) and thus fight extracellular pathogens. T 
cell progenitors mature into Th and cytotoxic T cells (Tc), and B cell progenitors 
mature into plasma cells and memory cells. Tc cells release toxic compounds 
directed at the infected cell and thus fight intracellular pathogens (Murphy et al., 
2011). Regulatory T cells (Tregs) suppress the activation of effector T cells to 
maintain immune system homeostasis and tolerance to self-antigens. Various 
miRNAs have been shown to play critical roles in the regulation of T cell 
development and/or function (Dai and Ahmed, 2011). 
8.1.1.3. Apoptosis   
An intricate balance between the proliferation of new cells and the death of aged 
cells is required for tissue homeostasis. Dead or dying cells – due to age, 
exposure to toxicants, or due to other factors – require clearance from the 
functional component of the human body, by means of controlled degradation 
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and elimination by cells of the immune system. During normal functioning of the 
immune system, a dying cell may undergo one of several pathways of cell death: 
apoptosis, necrosis or autophagy. 
The physiological process of apoptosis is considered to be a fundamental 
component of mammalian development of the embryo, the immune system and 
cell death induced by harmful agents (Elmore, 2007). There are three main 
processes of apoptosis: the extrinsic or death receptor pathway, the intrinsic or 
mitochondrial pathway, and the perforin/granzyme pathway. Two key pathways 
of apoptosis have been identified to date: a p53-dependent pathway and a p53-
independent pathway. In the p53-dependent pathway, irradiation or drug-
induced DNA damage (e.g. corticosteroids) may result in activation of this 
apoptotic pathway. Apoptosis can also be induced by ligand-binding of Fas or 
TNF receptors expressed on the surfaces of various cells. In some cells, a default 
death pathway governs cell survival and a hormone or growth factor is required 
to block the death pathway (Elmore, 2007). 
During the early stages of apoptosis the cell shrinks considerably, resulting in 
dense packaging of the cytoplasm and organelles. Chromatin condensation, 
termed ‘Pyknosis’, is the most common identifiable feature of apoptosis. The 
apoptotic cell appears as a round or oval mass with dense nuclear chromatin 
fragments. In the subsequent stages of apoptosis, phosphatidylserine (PS) 
molecules usually embedded in the inner membrane of the cell, translocate to 
the outer membrane. The negative charges which these PS molecules carry, 
results in repulsion between adjacent PS molecules. These repulsive forces result 
in the observation of plasma membrane blebbing. During the process of plasma 
membrane blebbing (or budding), apoptotic bodies consisting of cytoplasm with 
tightly packed organelles with or without a nuclear fragment are formed, 
enclosed in an intact plasma membrane. Now present on the outer membrane, 
PS acts as “eat me” signals for circulating macrophages  (Hochreiter-Hufford and 
Ravichandran, 2013).  
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Macrophages, parenchymal cells, or neoplastic cells engulf and digest these 
apoptotic bodies by means of phagolysosomal organelles. These macrophages 
are termed “tingible body macrophages” because these bodies are the 
fragments of nuclear debris within the apoptotic cell. These macrophages are 
commonly found within the lymphoid follicles or the thymic cortex (Elmore, 
2007).  
The process of apoptosis does not result in any inflammatory response being 
evoked for a number of reasons. Firstly, apoptotic cells contain their debris 
within the cell membrane, and thus do not release any debris into the 
surrounding tissues. Apoptotic cells are also rapidly phagocytosed by circulating 
macrophages, thereby preventing the onset of secondary necrosis. Lastly, 
macrophages engulf these apoptotic bodies without producing any cytokines 
which may promote inflammation (Elmore, 2007).  
8.1.1.4. Secondary necrosis: Chronic inflammation 
During the observation of cell death, there is often an overlap between the 
process of apoptosis and secondary necrosis. Injury-causing stimuli such as 
radiation, heat, hypoxia and cytotoxic anticancer drugs could induce apoptosis at 
low dosages, whereas higher doses could result in activation of a necrotic form 
of cell death (Elmore, 2007). Necrosis is an alternative cell removal process to 
apoptosis and is considered to be a toxic process as it involves swelling, and 
subsequent bursting of the cell (Hochreiter-Hufford and Ravichandran, 2013).  
The process of necrosis is poorly controlled and progresses passively, usually 
affecting a large group of cells. In contrast, apoptosis is a tightly-controlled and 
energy-dependent process clearing specific cells (Elmore, 2007). The interplay 
between these two pathways has led to the description of an “apoptosis-necrosis 
continuum” for the shared biochemical network. An example of the relationship 
between these two pathways exists such that an ongoing apoptotic process will 
be converted into a necrotic process when there is a decrease in the availability 
intracellular adenosine triphosphate (ATP) and caspases (Elmore, 2007). Thus, 
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necrosis can be seen as an inflammatory activity that adversely affects the host, 
whereas apoptosis is a cell-clearing process aimed at protecting the host by 
removing damaged or infected cells.  
8.1.2. Dysregulation of the immune system in SLE 
Using both mouse and human models for lupus, numerous immunological 
abnormalities have been identified, including  dysregulations observed in B - and 
T-lymphocyte functions, TLR functioning, NF-κβ signalling pathways, abnormal 
interactions among immune cells, and aberrations in the Type I IFN network (Dai 
and Ahmed, 2011). In addition to genetic loci which have been identified to be 
associated with the onset of SLE, dysregulation in epigenetic mechanisms such as 
histone modifications and DNA methylation have also been linked to the 
pathogenesis of lupus (Dai and Ahmed, 2011).  
8.1.2.1. Impaired removal of apoptotic bodies 
One hypothesis of the cellular processes driving the onset of SLE, is that the 
inadequate removal of apoptotic bodies results in the formation of self-antigens 
which are recognized by the immune system as “danger signalling” molecules 
(Tiffin et al., 2013). Apoptotic cells which are ready for engulfment by phagocytes 
present numerous molecules on their surface, such as altered sugar molecules, 
ICAM3, and C1q. In response, phagocytic cells present lectins on their cell 
surface, which bind to sugar molecules on the apoptotic cell surface. CD14, and a 
LRP1/CD91 complex, are also present on the surface of phagocytic cells, binding 
to ICAM3, and C1q, respectively (Hochreiter-Hufford and Ravichandran, 2013).  
In contrast, healthy, living cells express CD47 – an integrin-associated protein. 
CD47 inhibits the engulfment of the living cell by phagocytes. However, during 
apoptosis, the expression of CD47 is suppressed thereby allowing for the 
effective removal of the dying cells (Hochreiter-Hufford and Ravichandran, 
2013). A study by Junker et al. described the critical findings of three miRNAs 
which targeted the CD47 protein in the lesions of patients with active multiple 
sclerosis (MS) (Junker et al., 2009). Thus, it may be hypothesised that the miRNA-
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mediated regulation of CD47 protein expression may have increased the 
engulfment of undamaged cells by phagocytes in these MS patients.  
8.1.2.2. Autoantibody production 
Autoantibodies can circulate within a patient for many years prior to the onset of 
an active autoimmune disease (Arbuckle et al., 2003). These autoantibodies are 
produced in response to misrecognizing self-antigens as foreign bodies, thereby 
eliciting an immune response, and SLE is biochemically characterized by the 
presence of vast amounts of circulating autoantibodies (De Azevedo Silva et al., 
2014).   
The production of anti-nuclear antibodies (ANAs) often results in a systemic end-
organ damage phenotype caused by the immune complex (Apostolidis et al., 
2011). Numerous miRNAs have been described to influence the production of 
various autoantibodies, including anti-ds DNA antibody, anti-histone antibody, 
and anti-ribonucleoprotein antibody (Zan et al., 2014). Lupus patients commonly 
test positive for ANAs, whereas anti-Smith and anti-ds DNA autoantibodies have 
demonstrated a high degree of specificity amongst lupus patients (Apostolidis et 
al., 2011). 
A phenomenon known as ‘inflammaging’ first described in 2000, was coined to 
describe the observations of a loss of protective immunity and an increase in 
low-grade chronic inflammation, accompanying the process of ageing. An 
increase in ANAs has also been observed with a progression in age (Jeffries and 
Sawalha, 2011). Late-onset SLE, in which patients are 50 years old and above at 
first diagnosis, has been noted to be particularly severe in terms of the 
morbidities associated with the disease (Pons-Estel et al., 2010). Thus, the 
increased production of ANAs with progressing age may result in a more severe 
manifestation of lupus.  
8.1.2.3. Interferon signalling 
The pathogenesis of SLE is largely characterised by the production of ANAs 
against various cell types, as well as a sustained immune activation of the Type 1 
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interferon (IFN-I) pathway. The sustained response of the IFN-I pathway results 
in the upregulation of numerous genes which respond to IFN-I and Interferon-α-
inducible cytokines, and central to this response are plasmacytoid dendritic cells 
(PDCs) which are activated during lupus flare to rapidly secrete IFNα (De Azevedo 
Silva et al., 2014). A key event in the onset of SLE is nucleic acids binding to TLRs. 
This binding results in the activation of plasmacytoid dendritic cells – an event 
which links the adaptive and innate arms of the immune system. Specific 
miRNA’s have been identified to contribute to the IFNα regulation of expression 
by plasmacytoid dendritic cells, IFNα sensitivity, and receptor expression for 
cytokines in target cells (Carlsen et al., 2013). 
8.2. Systemic Lupus Erythematosus 
Systemic Lupus Erythematosus (SLE or lupus) is a chronic autoimmune disease, 
characterised by the production of autoantibodies against degraded nucleic acids 
(DNA and RNA), and associated proteins. During periods of lupus-flare (or disease 
state) inflammation of the skin, central nervous system, kidneys, lungs and joints 
may be experienced by the patient. The onset of active lupus is largely 
multifactorial and varies between patients. However, it is generally accepted that 
environmental- and genetic factors, and sex hormones may be responsible for 
the onset of the disease (Tiffin et al., 2013). 
8.2.1. Prevalence 
Lupus predominantly affects women of child-bearing age, with the ratio of 
females to males affected with SLE estimated to be as high as 12:1 (Aggarwal et 
al., 2010). However, the prevalence of SLE has been approximated at eight 
females affected for every male affected, per 100 000 individuals in the United 
Kingdom (UK) (Tiffin et al., 2014).  
Women of African-American origin have shown to be three to four times more 
affected with SLE than Caucasian women (Kyttaris, 2010). However, the highest 
recognized incidence of SLE is amongst women of Afro-Caribbean origin 
(Danchenko et al., 2006). Women of African-American ethnicity are more 
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commonly affected by lupus, followed by Hispanic, Asian, and lastly Caucasian 
women, as observed in the United States (Fessel, 1974; Weckerle and Niewold, 
2011). Racial admixture has also been suggested to increase the risk of 
developing SLE (Molokhia et al., 2001; Tikly and Navarra, 2008).  
In the UK, the incidence of SLE has been estimated at 25 people affected for 
every 100 000 individuals in the country.  An investigation into the epidemiology 
of lupus revealed that the highest incidence of lupus was found in the United 
States of America (USA) and France, whilst the lowest incidence was found in 
Iceland and Japan (Jeffries and Sawalha, 2011). These observations suggest 
possible genetic and environmental factors influencing the geographical 
incidence of lupus; although socio-economic factors and access to health care 
may also affect incidence rates in different geographical groups (Danchenko et 
al., 2006).  
8.2.2. Diagnosis 
Lupus is a multi-systemic disorder affecting populations of varying ethnicities and 
socio-economic statuses. The disease is characterised by, and often diagnosed by 
(but not restricted to) inflammation of various tissues throughout the body. The 
aberrant activation of autoreactive T- and B cells leads to the production of 
pathogenic autoantibodies against the nuclei and phospholipid antigens of 
various cells, and their binding proteins, leading subsequently to tissue injury 
(Choi et al., 2012).   
The procedure for diagnosing a patient with SLE is a complex process involving 
the close observation of both physical changes, and biochemical changes within 
patients.  Numerous scoring systems have been developed, and used over the 
years. The SLEDAI (SLE Disease Activity Index) score is one of the most commonly 
used scoring systems, rating the state of disease activity on a scale of 0-10. A 
weighted index across nine organ systems determines the outcome of the 
SLEDAI score (Bombardier et al., 1992). In 1971, the American Rheumatism 
Association developed the first set of 11 criteria used in identifying, and 
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diagnosing active SLE, in which a minimum of four out of the 11 criteria had to be 
met (Pons-Estel et al., 2010). With the advancements made in medical 
technology, and the unveiling of new mechanisms involved in diseases processes, 
revision of the criteria was conducted in 1982, and again in 1997. Lastly, the 
Systemic Lupus International Collaborating Clinics (SLICC) criteria was derived 
and validated in a recent study by (Petri et al., 2013). The SLICC criterion for SLE 
assessment makes use of 11 clinical criteria, and six immunologic criteria, of 
which at least four criteria must be met for the diagnosis of active SLE.  
There is also a likelihood for the under diagnosis, and over diagnosis of the 
disease using these scoring methods. Due to the gold standard (SLEDAI) being set 
at four out of the 11 criteria observed in order to make a positive diagnosis, 
under diagnosis may occur when any mild cases present, in which less than four 
of the criteria are clinically and/or biochemically observed. Over diagnosis of the 
disease is also possible if clinicians only use the presence of ANAs in the blood 
sample as an indicator for active disease (Liu et al., 2013). The degree to which 
SLE affects African populations is largely unknown due to a variety of reasons. 
These include varying qualities of available health care, under-diagnosis, and 
poor recognition of the disease, making lupus a supposed “rarity” in southern 
Africa and other tropical regions. The disparity of disease prevalence amongst 
different races is possibly due to poor diagnostic tools available in different 
geographical regions, and poor disease recognition due to the contrast in 
phenotype of any two patients diagnosed with SLE (Tiffin et al., 2014).  
8.2.3. Onset of SLE 
A self-antigen is an antigen, as a constituent of the normal bodily tissues, which 
provokes the response of the innate immune system to produce antibodies 
against it, and are therefore termed autoantibodies. The general loss of 
recognition and tolerance for auto-antigens, as the key cause for the 
inflammation observed during lupus-flare, may occur as result of various factors 
including environmental, hormonal, and epigenetic factors. 
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Many checkpoints exist to maintain immunological tolerance at both central and 
peripheral lymphoid organ systems and mechanisms of these checkpoints are 
aimed at ensuring that randomly autoreactive B and T lymphocytes are either 
silenced or deleted. However, in exceptional cases, where autoimmunity is 
imminent, these auto-reactive lymphocytes manage to escape the checkpoints 
and survive in peripheral lymphoid tissues. Once activated, these autoreactive 
immune cells launch a detrimental attack on normal tissues, resulting in the 
onset of an autoimmune disease such as lupus (Dai and Ahmed, 2011).  
Various hormones including estrogens, androgens and dihydrotestosterone have 
been shown to influence the risk for developing SLE (Jeffries and Sawalha, 2011). 
A prominent observation in many autoimmune diseases in both animal models 
and humans is that females are more susceptible to autoimmune diseases than 
their male counterparts, and more than 80% of patients suffering from 
scleroderma, thyroiditis, SLE, and Sjögrens syndrome are women. Thus, in 
addition to the genetic factors associated with autoimmune disease 
susceptibility, sex hormones such as androgens and estrogens are believed to 
play an important role in the development of this subset of diseases (Dai and 
Ahmed, 2011). 
B cell tolerance has been shown to be broken with estrogen treatment, even in 
normal, non-autoimmune prone mice, resulting in the production of several 
lupus-related autoantibodies including those against cardiolipin, phospholipids 
and double-stranded DNA. Two investigations into the influence of estrogens on 
lupus onset revealed contradictory results. The Nurses’ cohort studies reported 
that the use of hormone replacement therapy (HRT) and oral contraceptive pills 
(OCP) increased the risk for developing SLE (Bernier et al., 2009). In contrast, 
studies by the Safety of Estrogen in Lupus: National Assessment (SELENA) trials 
on using HRT’s and OCP’s reported that the use of OCP has no significant effect 
on global lupus disease activity and incidence of flares, and the use of HRT is only 
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associated with a small risk for mild and moderate lupus flare, but not severe 
flare (Bernier et al., 2009; Petri et al., 2005; Sanchez-Guerrero et al., 1995). 
Endogenous retroviruses and retroviral elements are found in abundance 
throughout the genetic codes of vertebrates, and may constitute up to 40% of 
the human genome. Numerous studies have implicated the retroviral group in 
the pathogenesis of SLE, as viral components have been found in the sera and 
organs of lupus patients. Retroviruses are particularly implicated in SLE by means 
of the detection of the p30 gag protein in renal glomeruli of SLE patients. Along 
with this, SLE patients have been reported to demonstrate reactivity to the p30 
gag antigen (Francis and Perl, 2010). It has been illustrated that retroviruses may 
contribute to the onset of autoimmune diseases by either directly encoding 
reactive auto-antigens, or by altering the expression of immune-regulatory genes 
(Jeffries and Sawalha, 2011) 
The Human T cell lymphotrophic virus 1 (HRES-1) and Endogenous Retrovirus 
Group 3 (ERV-3) genes are endogenous retroviral auto-antigens which have been 
identified in lupus patients. HRES-1 has been found in 21-52% of lupus patients, 
while ERV-3 has been found in up to 32% of lupus patients. The expression of 
endogenous retroviral sequences has in part been shown to be regulated by DNA 
methylation processes previously discussed (Jeffries and Sawalha, 2011).  
Infection with the Epstein-Barr virus (EBV) affects more that 90% of the world’s 
adult human population and as with other members of its gamma herpes virus 
family, EBV typically results in a lifelong, mostly asymptomatic infection in its 
host (Cameron et al., 2008; Dolcetti and Masucci, 2003). The latent membrane 
protein 1 (LMP1) gene is the latency viral gene most frequently implicated in 
tumour formation due to EBV-associated malignancies. LMP1 is a six-
transmembrane, active signalling molecule that functionally mimics members of 
the cellular tumour necrosis factor receptor (TNFR) family (Cameron et al., 2008).  
Among others, LMP1 regulates the interferon type I (IFN alpha/beta) pathway, 
which is partially induced by IFN regulatory factor 7 (IRF7). The BIC transcript, 
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which encodes miR-155, was shown to be upregulated in B cell lymphomas, 
including lymphoproliferative diseases associated with EBV infection (Cameron et 
al., 2008). EBV infection was also shown to induce the expression of miR-155 and 
miR-146a in a NF-kB dependent manner (Dai and Ahmed, 2011). Dysregulation of 
miR-155, and miR-146a expression as result of EBV infection was shown to be 
associated with SLE (Dai and Ahmed, 2011; Tang et al., 2009).  It has also been 
reported that the anti-Smith antigen, a biomarker highly specific for SLE disease 
flare, is mimicked by the EBV-nuclear antigen-1 (Jeffries and Sawalha, 2011). 
8.2.4. Clinical presentation and treatments 
The clinical manifestations often observed for SLE are a butterfly rash (across the 
cheekbones and forehead), as well as the appearance of oral ulcers, and an 
unusual sensitivity to light (De Azevedo Silva et al., 2014). Diseases which may 
occur secondarily to the onset of SLE include pericarditis, arthritis, pleuritis, 
neural abnormalities including seizures and psychosis, and kidney disease, 
including nephritis (Maidhof and Hilas, 2012; Weckerle and Niewold, 2011).  
Infection with malaria-carrying parasites has also been suggested to contribute 
the onset of SLE. The low reported incidence of SLE occurrence in tropical 
regions of Africa has resulted in numerous scientific literature reviews suggesting 
that malaria infection confers some form of protection against the onset of SLE 
(Borchers et al., 2010; Gilkeson et al., 2011; Tikly and Navarra, 2008) . It is 
hypothesised that malaria, and other infections caused by parasites may alter 
the natural immune response, thereby conferring a form of tolerance to the 
onset of SLE (Borchers et al., 2010). An infection predominantly occurring in 
tropical regions, malaria has been shown to protect individuals in these regions 
against developing SLE and there are two main mechanisms proposed to explain 
these observations (Clatworthy et al 2007). 
First, there is a hypothesis that infection with malaria confers some form of 
resistance due to the activation of the production for the tumour necrosis factor 
(TNF) cytokine. The activation of macrophages and neutrophils by TNF results in 
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a rapid response to the control of the replicating Plasmodium parasite during the 
early stages of the disease (Francis and Perl, 2010). It is proposed that when 
infected with the malaria parasite, patients who are asymptomatic for the 
disease produce high concentrations of reactive nitrogen intermediates by 
means of activated macrophages. These reactive nitrogen species are thereby 
proposed to minimise autoreactive T cell proliferation , and subsequently reduce 
the chance of onset of autoimmune diseases (Clark et al., 1996).  
A second hypothesis is that resistance to SLE results from the activation of the 
FcγRIIb receptor. It is hypothesised that the activation of this receptor by 
circulating auto-antigens may result in the hyper-activation of T- and B immune 
cells, a typical observation made in lupus patients (Choi et al., 2012). 
Anti-malarial drugs have been used for decades to treat rheumatic diseases, 
including SLE and rheumatoid arthritis (RA) (Rynes, 1997). The mechanism of 
effectivity has not yet been well-described. Treatments include the 
administration of hydroxychloroquine, steroids, and cytotoxic drugs such as 
cyclophosphamide and methotrexate (Mishra, 2008; Wakeland et al., 2001).  
Table 1:  An extensive review of genes associated with numerous SLE phenotypes  (De Azevedo 
Silva et al., 2014) 
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The prevalence of SLE has been demonstrated with up to 10% of SLE patients 
having a first degree relative with the disorder, as well as up to 20% of 
monozygotic twins showing disease concordance (Aggarwal et al., 2010). SLE has 
been well-described as an autoimmune disease of polygenic aetiology. 
Biomedical research has focused on numerous aspects of SLE in an attempt to 
find therapeutic targets to alleviate the morbidity, and mortality caused by this 
autoimmune disease. Through multiple research studies, many genes in the 
mammalian genome have been identified to play a role in numerous biological 
processes dysregulated during the active disease state. A recent review by De 
Azevedo Silva et al. tabulated the genes (see Table 1) found in various biomedical 
research studies, to be associated with defining phenotypes experienced by 
lupus patients in the active disease state. 
8.2.5. Epigenetic mechanisms contributing to the onset of SLE 
Epigenetics can be described as the biological study of heritable alterations in 
gene-expression patterns that do not alter the underlying DNA sequence. Three 
mechanisms most frequently involved in epigenetic control of gene expression 
are DNA methylation, histone modifications and the involvement of RNA 
interference (RNAi). These mechanisms, along with other epigenetic factors such 
as pharmaceutical drugs, infection with viruses, and endogenous hormones are 
also believed to influence the onset of SLE. 
8.2.5.1. DNA methylation 
A well-known example of epigenetic modification of the mammalian genome is 
the DNA modifications at the 5th position carbon in the pyramidine ring, which 
leads to the formation of 5-methylcytosine (5mC) (Balada et al., 2007). DNA 
methylation processes are catalysed by DNA methyltransferases (DNMTs), 
facilitating the regulation of chromatin modelling and transcriptional silencing 
(Tu et al., 2015). DNA methylation is a specific mechanism of epigenetic 
modifications in which a methyl group is added to the 5’ group of cytokines 
within the Cytosine-phosphate-Guanine (CpG) dinucleotide sequence. In 
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mammals, DNA methylation is performed by de novo methyltransferases, namely 
DNMT3a and DNMT3b and is maintained by DNA Cytosine-5-Methyltransferase 1 
(DNMT1)  which has an affinity for hemi-methylated daughter strands produced 
during DNA replication (Jeffries and Sawalha, 2011). DNMT2 functions to 
methylate RNA (Jeffries and Sawalha, 2011). CpG dinucleotides are clustered into 
islands, often at the promoter regions of genes where transcription factors bind 
to initiate replication. These islands tend to be protected from methylation but 
when methylation does occur at the CpG island, there is a silencing of gene 
expression. DNA methylation is a mitotically heritable modification and is 
thought to be irreversible, except by failure of DNMT1 to maintain methylation. 
Active DNA methylation appears to play essential roles in a variety of cellular 
responses to environmental stimuli, including hypoxia, hormonal signalling, viral 
latency and reactivation, and X-chromosome inactivation (Jeffries and Sawalha, 
2011). It has also been found that T cells isolated from SLE patients exhibited 
lower levels of methylated DNA (Balada et al., 2007)  
Early studies into the epigenetic mechanisms associated with lupus showed that 
CD4+ T cells treated with 5-azacytidine (5-azaC), a DNA methylation inhibitor, lost 
antigen selectivity properties and responded to the presentation of self-antigens. 
Thus, it was suggested that drugs causing DNA demethylation resulted in the 
onset of autoimmune-like diseases (Jeffries and Sawalha, 2011). Between 15 000 
and 30 000 cases of Drug-induced Lupus (DIL) are reported in the United States 
each year. DIL has shown decreased bias in women, and in African-Americans, 
when compared to idiopathic SLE (Borchers et al., 2007). 
Procainamide and hydralazine both resulted in the production of positive 
antinuclear antibodies in patients taking them, thereby resulting in the onset of a 
lupus-like syndrome in a genetically-susceptible subset of patients. Both drugs 
were found to inhibit deoxyribonucleic acid (DNA) methylation and induce 
murine lupus, however, the mechanism used was distinct for both drugs. 
Procainamide demonstrated to act as a competitive antagonist in the 
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maintenance of DNA methylation by DNMT1, whereas Hydralazine was found to 
inhibit the ERK pathway by blocking signalling through protein kinase C δ (PKC δ) 
(Jeffries and Sawalha, 2011).  
DNA demethylation (hypomethylation) is a process in which a methyl group is 
removed from the DNA sequence, and is shown to occur in early developmental 
stages such as during primordial germ cell development. DNA demethylation 
processes can also be catalysed by a family of enzymes known as the ten-eleven 
translocation (TET) enzymes. TET enzymes have shown involvement in DNA 
demethylation processes via the oxidation of 5-mC (Kohli and Zhang, 2013).                    
T cells isolated from SLE patients have demonstrated elevated concentrations of 
TET1 and TET2 protein expression, which subsequently is likely to affect DNA 
demethylation, thereby altering gene expression (Tsokos, 2016).  
For a parent cell to faithfully copy DNA methylation patterns to the daughter cell, 
DNMT1 requires a source of methyl group donors, specifically S-
adenosylmethionine (SAM), to perform the reaction needed to methylate a CpG 
island. A study by Liu et al. demonstrated that a restriction of methionine via 
supplementation with homocysteine resulted in functional hypomethylation 
TNFSF (Liu et al., 2013). By examining T cells of healthy adults over the age of 50, 
it was noted that there was a reduced level of methylation of the KIR gene family 
and TNFSF (Liu et al., 2013). The concentration of DNMT1 in T cells declines 
notably with age and studies have shown that T cells become hypersensitive to 
their environmental micronutrient levels, and when methyl donors become 
restricted, may result in an up-regulation of methylation-sensitive genes. It is 
also observed that DNA methylation is globally reduced in T cells of lupus 
patients, as in that of ageing T cells (Jeffries and Sawalha, 2011). 
A secondary mechanism by which DNA methylation could lead to gene silencing 
is when methylated CpG molecules prohibit transcription factor binding and thus 
directly alter gene expression (Liu et al., 2013; Ramos et al., 2010). Over-
expression of specific hypomethylated genes are often observed in lupus 
 
 
 
 
17 
 
patients. In T cells, these genes include ITGAL (CD11a), CD40LG (CD40L), TNFSF7 
(CD70), KIR2D44, PRF1 (perforin), and in B cells, CD5 (Jeffries and Sawalha, 2011).  
Ultraviolet (UV) radiation – more specifically UVB, can induce the expression and 
secretion of various interleukins. These include IL-1 and TNF-α in keratinocytes, 
mast cells, and Langerhans cells, and these cells may function in recruiting 
dendritic and T cells in the mounting of an immune response. When compared to 
baseline controls, lupus patients exhibited significantly reduced global DNA 
methylation levels when exposed to both moderate and high doses of UVB 
radiation. This observation is independent of DNMT1 levels, which remained 
stable after exposure to UV radiation. Healthy controls only demonstrated 
significant reduction in DNA methylation when exposed to high doses of UVB 
radiation (Jeffries and Sawalha, 2011). It was also found that following exposure 
to UV light, an increase in the expression of Gadd45A resulted in a reduction in 
genomic DNA methylation – a process counteracted in part by the knockdown of 
Gadd45A. Early knock-out studies of Gadd45a revealed a protective role as 
exerted by the gene product Gadd45A. Knockout of Gadd45a in mice resulted in 
the development of an SLE-like autoimmune disorder (Hughes and Sawalha, 
2011).  
Early epigenetic studies of SLE onset revealed that the treatment of CD4+ T cells 
with the DNA methylation inhibitor 5-azaC resulted in a loss of antigen selectivity 
and an increased response to self-antigens (Patel and Richardson, 2010). It has 
been well-established that a core mechanism in lupus pathogenesis, in 
comparison to healthy individuals, is the impaired clearance of apoptotic DNA, 
resulting in the presence of self-antigens. Isolation of DNA-anti-DNA antigen-
antibody complexes from lupus patients were exactly the correct size to have 
resulted from the extracellular breakdown of apoptotic chromatin. 
Hypomethylation of either normal or necrotic DNA due to treatment with 5-azaC 
greatly increased its potential to stimulate an autoimmune response. This 
selective response of 5-azaC to hypomethylated DNA is likely initiated by TLR 9 
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signalling (Jeffries and Sawalha, 2011). DNA demethylation is a factor known to 
influence lupus progression, and thus a greater level of demethylation may be 
correlated with increased levels of disease activity.   
8.2.5.2. Histone modifications 
Histone modifications by means of acetylation and methylation have been 
described in the aetiology of some lupus cases, and are another example of an 
epigenetic factor which may influence the onset of SLE (Patel and Richardson, 
2013). Histone modifications such as an increased global H4 acetylation in 
monocytes of SLE patients are often observed (Jeffries and Sawalha, 2011; Patel 
and Richardson, 2010; Wu et al., 2015). It has been hypothesised that over-
expression of the miRNA miR-101 may contribute to the decrease in repression 
observed in the CD4+ T cells of lupus patients (Hughes and Sawalha, 2011). 
Furthermore, study by Sun et al. 2008 also revealed a close association between 
the production of anti-histone antibodies and the disease activity index of SLE 
patients tested (Sun et al., 2008).  
8.2.6. MicroRNAs in SLE 
MicroRNA’s (miRNAs) are small, non-protein-coding RNA molecules ranging 
between 20 and 25 nucleotides in length (Alevizos and Illei, 2010a). Previously 
termed to be part of the “junk DNA” of the human genome, miRNAs have proven 
to be considerable contributors to the transcriptional and post-transcriptional 
regulation of gene expression. MiRNAs perform these functions by inducing 
translational repression on the target messenger RNA (mRNA) or by directly 
facilitating the degradation of the mRNA strand.  The first miRNA identified  was 
lin-4 in the nematode Caenorhabditis elegans, and was implicated in mechanisms 
controlling the progression and timing of this organism’s life cycle (Lee et al., 
1993.  
More than 1000 human miRNAs have since been identified to be able to 
influence the translation of mRNA’s, thereby depicting a strong role of miRNAs in 
gene regulation (Dai and Ahmed, 2011). The duality of miRNA-based translation 
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regulation is demonstrated by a single miRNA being able to bind to and regulate 
multiple mRNA’s in one instance; while in another, many miRNAs may 
collectively perform regulatory activities on a single mRNA (Alevizos and Illei, 
2010a; Lee et al., 2004). An analysis of 72 lupus susceptibility genes using 
computational prediction analyses revealed that 71 out of those 72 genes 
examined contained at least one miRNA target site for more than 140 miRNAs 
(Vinuesa et al., 2009).  
8.2.6.1. Biogenesis 
The biogenesis of miRNAs involves intricate processing in both the nucleus and 
the cytoplasm. Genomic miRNA is transcribed into primary-miRNA (pri-miRNA) 
by RNA polymerase II. Pri-miRNA transcripts vary from 100’s to 1000’s of 
nucleotides in length and may contain a single or several hairpin-loop structures 
(Lee et al., 2004). Pri-miRNA may then follow either a canonical or non-canonical 
pathway of nuclear-cytoplasmic processing. In the canonical pathway, pri-
miRNAs undergo nuclear cleavage by the RNAse III enzyme, Drosha, and the 
double-stranded RNA-binding protein, DGCRB. This cleavage produces nuclear, 
hairpin-shaped precursor-miRNAs (pre-miRNAs) (Dai and Ahmed, 2011; Lee et 
al., 2004). In some instances, the primary transcript may contain several hairpin 
structures, and will subsequently result in different miRNAs being produced via 
transcription of the different hairpins. These pri-miRNA transcripts are termed 
“polycistronic” and each resultant miRNA is given a unique name (Ambros et al., 
2003). 
In the non-canonical pathway of processing, genomic miRNA is directly 
translated by RNA polymerase II into mirtrons which lack a lower stem-loop 
structure, as well as the single-stranded flanking segments which are essential 
for processing by the Drosha RNAse III enzyme. Mirtrons therefore do not 
undergo processing by Drosha and Dicer, but undergo splicing by a spliceosome 
to produce branched precursor-mirtrons (pre-mirtrons). Pre-mirtrons then 
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undergo lariate-mediated debranching to produce pre-miRNAs as a result of the 
non-canonical pathway of processing (Dai and Ahmed, 2011).  
Following both pathways of processing, pre-miRNAs are exported from the 
nucleus via the nucleoplasmic shuttle protein, Exportin-5. Pre-miRNAs are 
processed by the RNAse III enzyme, Dicer, to produce miRNA/miRNA* duplexes 
of approximately 22 nucleotides long, with imperfectly matched sequences. The 
miRNA/miRNA duplex is loaded into the Argonaute protein, forming an RNA-
induced silencing complex (RISC). Within the RISC complex, the passenger miRNA 
(miRNA*) is degraded by the RISC complex, whilst the guided miRNA strand 
remains localized within the RISC complex in the form of mature miRNA (Dai and 
Ahmed, 2011).  
The strand which is to become a mature miRNA (guided strand) is determined by 
the relative internal stability of the two ends of the duplex, and the strand with a 
less stable 5’ end (e.g. the strand with a G:U pair versus a G:C pair at the 5’end) 
will survive preferably over the passenger strand which undergoes degradation 
by an unknown nuclease (Lee et al., 2004). This mature miRNA is capable of 
interacting with the 3’ untranslated region (3’ UTR) of its target mRNA, thereby 
inducing either its translational repression or degradation activities, possibly by 
transporting the complex to a perinuclear compartment referred to as GW or P 
bodies, and thereby sequestering the mRNA away from the Golgi apparatus 
(Cameron et al., 2008; Dai and Ahmed, 2011).  
Many human miRNA molecules have been shown to exert their regulatory 
effects by having perfect or imperfect complementarity to the 3’UTR of the 
mRNA strand. For imperfect complementarity to be successful, target matching 
between the miRNA and the target mRNA needs to occur perfect. Starting from 
the 5’ end of the miRNA, this matching occurs from the 2nd through to the 7th 
nucleotides (Alevizos and Illei, 2010b). In contrast, most plant miRNAs exert their 
regulatory functions through binding sites located in the exons of target genes 
(Ehrenreich and Purugganan, 2008). 
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8.2.6.2. miRNA action as a mechanism of RNA interference (RNAi) 
Transcriptional gene silencing of newly transcribed mRNAs can be performed by 
a number of biological processes, including RNA interference (RNAi). Central to 
this mechanism of RNAi, is the binding of a dsRNA to a target mRNA, resulting in 
translational inhibition of the target protein (de França et al., 2010). RNA 
interference is a mechanism of gene regulation performed by non-coding small 
RNA’s, including miRNAs. In SLE, miR-21, miR-148a and miR-126 have been 
shown to perform these regulatory activities on the expression of certain 
proteins by targeted mRNA translational repression or degradation (Jeffries and 
Sawalha, 2011; Wu et al., 2015).   
8.2.6.3. miRNA nomenclature 
MiRNA naming should follow a standard procedure as aptly described in Ambros 
et al. 2003 and Griffiths-Jones et al. 2006. Standard naming procedures of 
experimentally-validated miRNAs are meant to be employed prior to the 
publication of the author’s discovery. The naming procedure should follow 
several steps which will be described here.  
The use of ‘miR-‘ indicates a mature miRNA sequence, whereas ‘mir-‘ indicates a 
precursor hairpin miRNA which has not yet given rise to a mature miRNA (Wright 
and Bruford, 2011). The three letters preceding ‘miR’ or ‘mir’ and joined by a 
dash ‘-‘ to indicate the species from which the miRNA is derived, e.g. ‘hsa-‘ is 
used for human miRNAs, ‘mmu-’ for mouse, and ‘oar-‘ for sheep. Other prefixes 
include the addition of a ‘v’ for viral miRNAs and a ‘d’ for miRNAs of the 
Drosophila fruit fly species (Griffiths-Jones et al., 2006).  
The prefix ‘miR-‘or ‘mir’ is followed by a numerically assigned value, indicating 
the order in which the miRNA was discovered. For example, ‘miR-101’ was 
discovered and named prior to ‘miR-456’. Pre-miRNAs and pri-miRNAs which 
have different loci in the genome but lead to the production of an identical 
mature miRNA are given an additional dash-numbered suffix. An example of such 
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a case is with miRNAs ‘hsa-mir-194-1’ and ‘hsa-mir-194-2’ (Griffiths-Jones et al., 
2006).  
Numerous studies have shown that many miRNA sequences are evolutionarily 
conserved (Ambros et al., 2003; Park et al., 2002). Orthologous miRNA 
sequences are given the same numeric suffix, but are differentiated by the 
species prefix, e.g. ‘hsa-miR-101’ and ‘mmu-miR-101’. In contrast, paralogue 
miRNA sequences which are very near to being completely identical (i.e. the 
sequences only differ by one or two nucleotides), are annotated with an 
additional lettered suffix, e.g. ‘mmu-miR-101a’ and ‘mmu-miR-101b’ which are 
paralogues (Griffiths-Jones et al., 2006).  
Lastly, when two mature miRNAs originate from opposite arms of the same 
precursor hairpin miRNA, and both mature miRNAs are produced in a relatively 
equal abundance, these mature miRNAs are denoted by a ‘-3p’ or a ‘-5p’ 
(Griffiths-Jones et al., 2006). However, in nature one of the mature miRNAs 
produced is often in a greater abundance. In this case, the less abundant miRNA 
is indicated by an asterisk (*) (Ambros et al., 2003). 
8.2.6.4. Other causes of miRNA dysfunction in SLE 
Genetic and environmental factors may contribute to lupus pathogenesis 
through altering the expression and/or function of miRNAs. The genetic 
polymorphisms in a miRNA gene and the 3’UTR sequences of its target genes, 
gene translocation, gene amplification or deletion in a host genome can all 
contribute to dysregulated miRNA expression and/or function in diseases. For 
example, a single nucleotide polymorphism (SNP) in pre-miR-146a decreased the 
expression of mature miR-146a, which has been shown to be related to the 
genetic predisposition to papillary thyroid carcinoma (Alevizos and Illei, 2010a). 
Pre-miR-146a is known to specifically target the IRAK1 gene (which encodes the 
interleukin-1 receptor-associated kinase 1 protein ) and TRAF6 gene (which 
encodes the TNF-receptor-associated factor 6 protein) (Alevizos and Illei, 2010a). 
Both IRAK1 and TRAF6 are known lupus-associated genes  (Tiffin et al., 2013). 
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Estrogen has been shown to exert both anti-inflammatory and pro-inflammatory 
immune responses in different studies and it was found that estrogen not only 
modulated key transcription factors involved in inflammation, but also regulated 
miRNA expression to promote inflammatory responses in activated spleen cells 
from estrogen-treated mice. Using a combination of high throughput microarrays 
and Realtime RT-PCR as a confirmatory test, a number of miRNAs were identified 
to be dysregulated in splenocytes from estrogen-treated orchi-ectomised male 
C57BL/6 mice when compared to placebo controls (Dai and Ahmed, 2011). 
In a study by Dai and others, it was found that miR-451, miR-486, miR-223, miR-
148a, miR-18a, and miR-708 were up-regulated in response to estrogen 
treatment. They also found that miR-146a, miR-125a, miR-125b, miR-143, miR-
145, let-7e, miR-126, miR-181a were down-regulated in response to treatment 
with this sex-hormone which plays a critical role during the onset of puberty in 
females (Dai et al., 2008). Down-regulation of miR-146a and up-regulation of 
miR-223 was found to contribute to enhanced interferon gamma (IFNγ) 
production in LPS activated splenocytes from estrogen-treated mice (Dai et al., 
2008). The decreased levels of miR-146a and miR-125a, and increased level of 
miR-148a have been identified in human lupus patients and reported to 
contribute to lupus pathogenesis by regulating the type I IFN pathway, the 
inflammatory chemokine RANTES and DNA methylation, respectively (Pan et al., 
2010; Tang et al., 2009; Zhao et al., 2010). 
8.2.6.5. miRNAs dysregulated in SLE 
Numerous miRNAs have been identified to be associated with the onset and 
progression of SLE. The critical regulatory functions of miRNAs - by means of 
direct binding to the target gene - results in decreased production of the 
intended protein. This potent regulatory mechanism has implicated numerous 
miRNAs in biological pathways which are dysregulated during lupus flare. A 
recent review by Zan et al. summarised the functions of miRNAs implicated 
through various studies with lupus pathogenesis.  
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The DNMT1 gene was reported to be a target for miR-21, miR-126, and miR-
148a. MiR-155 was reported to target CD62L and SHIP1, regulating Treg 
phenotype and B cell activation, respectively. MiR-23b was reported to target               
IL-17 and Blimp1, suppressing inflammation in autoimmunity, and regulating the 
production of antibodies, respectively. MiR-146a was reported to target both 
TRAF6 and IRAK1, and as a consequence, negatively regulated the activities of 
NFKβ (Zan et al., 2014). Numerous other miRNAs have been described in their 
functioning as regulators of target genes which have been shown to be critical in 
the onset and progression of SLE (Carlsen et al., 2013; Lu et al., 2012; Pan et al., 
2010; Stagakis et al., 2011; Tiffin et al., 2013). 
8.2.6.6. Methods used to identify dysregulated miRNAs 
Using microarray assays, numerous miRNAs have been found to be dysregulated 
in lupus. It has however been proposed that these results require further 
verification using Real-Time RT-PCR and Northern blotting laboratory techniques. 
It has been demonstrated that results from one study showing dysregulated 
miRNAs in lupus, is not often reproduced in follow-up studies. One example of 
this is that Dai et al. reported a contradiction in the expression levels of hsa-miR-
146a  in PBMCs of lupus patients, between their study and the study performed 
by Tang et al. (Dai et al., 2007; Tang et al., 2009). The discrepancies in the results 
retrieved from these human lupus studies may be due to a number of variable 
factors. It may be due to the type of samples collected, and the subsequent 
storage methods, or it may be due to the sensitivity of the methods used to 
detect the miRNAs. The differences in the results may also be due to the 
variability of patient health histories, the length of the disease state, the severity 
of the disease at the time of collecting the sample, as well as the ethnic race of 
the patient (Dai and Ahmed, 2011; Yan et al., 2014).  
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8.3. Introduction to Methods  
8.3.1. Databases used to verify the IDs of miRNAs of interest  
8.3.1.1. miRBase 
The miRBase database is a searchable, freely-accessible online database 
containing curated miRNA sequences, their annotation, standardised 
nomenclature, and target prediction. Numerous versions of the miRBase 
database have been released since its conception in 2002. Formally known as the 
microRNA Registry, the creators of the database aimed to create a repository of 
miRNA data which could undergo updating as new information became available 
for these important regulators of gene expression (Kozomara and Griffiths-Jones, 
2011). The home page can be accessed at http://www.mirbase.org/index.shtml, 
and Release 21 (June 2014) of the miRBase database is reported to contain 
28 645 entries.  
8.3.1.2. Ensembl BioMart 
The Ensembl BioMart database is a collaborative project between EMBL-EBI and 
the Wellcome Trust Sanger Institute. The main goal of the Ensembl project, 
started in 1999, was to create a system of automated annotation of the human 
genome. The current version of the database, Release 82, became publically 
available in September 2015, and can be accessed at (http://www.ensembl.org). 
The database provides recent updated annotations, which include comparative 
genomics, gene models, variations in the genome, and regulatory regions 
(Cunningham et al., 2014). The BioMart tool allows users to search for a user-
defined dataset, across numerous species, and to filter across multiple 
parameters. The BioMart tool hosted on the Ensembl website also allows users 
to convert between dataset formats.  
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8.3.2. MiRNA target prediction 
8.3.2.1. Algorithm-based miRNA target prediction 
8.3.2.1.1. Principles and examples of Algorithms 
Predicting miRNA targets in animals using computational tools is often observed 
to be much more challenging than predicting miRNA targets in plants. This is 
mainly because in animals, miRNAs often perform imperfect base-pairing with 
the target sites of the target mRNA, whereas in plants, regulatory miRNAs mostly 
perform perfect base pairing to their targets (Wang et al., 2007). Over the past 
few years, the scientific community has seen a growth spurt in the field of miRNA 
target prediction algorithm development. Some of the earlier algorithms include 
DIANA-microT, MicroInspector, PicTar, TargetScan, and TargetScanS (Xiao et al., 
2009).  
These algorithms are based on the use of one or more core principles derived 
from observations of known miRNA-target interactions. Not listed in any 
particular order of importance, these principles include: 
 Near-perfect complementarity between the 6-8 nucleotide region (‘seed’ 
region) of the miRNA - near the miRNA’s 5’ end -  with the 3’ UTR of the 
sequence targeted.  
 Evolutionary conservation of the binding sites between species 
 Strong thermodynamic stability for the miRNA-mRNA duplex structure 
 Cooperation between multiple target sites in close proximity to each other 
 Existence of a centralised, non-matched area within the sequence, forming a 
loop structure, or bulge.  
 Dinucleotide composition of the flanking sequence (Rehmsmeier et al., 2004) 
 Secondary structure accessibility (Leclercq et al., 2013) 
 Target-site accessibility (Long et al., 2007).  
Two examples of miRNA target prediction algorithms are RNAHybrid and RNA22. 
The RNAHybrid algorithm searches for the most favourable hybridizations 
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according to the free energy available between the miRNA and its target mRNA/s 
(Rehmsmeier et al., 2004). The Rna22 algorithm attempts to identify significant 
sequence motifs amongst all of the known miRNA sequences. Rna22 then 
proceeds to define specific regions within the target mRNA, where reverse 
complementarity of the miRNA sequences accumulate. The algorithm then 
centres its search for miRNA target sites on these selected regions (Miranda et 
al., 2006).  
8.3.2.2. Experimental validation of miRNA targets 
Experimental validation of gene regulation by miRNAs can be a time-consuming 
and expensive process. Thus, an essential part of the research process is to first 
perform miRNA target prediction utilising algorithm-based methods. Numerous 
algorithms, following various principles have been developed over the past few 
years to provide insight into the putative binding sites of these regulatory 
elements. Once the miRNA binding sites have been identified within the mRNA 
target by one or more computational algorithms, the predicted interactions can 
be validated using a variety of molecular experiments. These molecular 
experiments include Reporter assays, Northern blots, and quantitative 
Polymerase Chain Reaction (qPCR). 
8.3.2.2.1. Principles and types of Experimental validation 
methods 
The rationale of the reporter assay technique used for validating a miRNA-Target 
Interaction (MTI), is that the interaction of a specific miRNA to its targeted 
binding site on the mRNA will repress the production of the protein produced, 
thereby resulting in a reduced expression of the protein which can then be 
quantitatively compared to the expression of the control (Hsu et al., 2014). 
Northern blot analysis makes use of the isolation of total RNA from a chosen cell 
type and examines the co-expression of both the miRNA, and its targeted mRNA.  
Molecular experiments for identifying interactions between miRNAs and their 
associated targets can become an expensive and time-consuming process, which 
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until recently was unable to produce meaningful results for large-scale 
experiments. Recent studies have shown that miRNA-target interactions can be 
discovered using next-generation sequencing (NGS) as a high-throughput 
screening method of choice (Hsu et al., 2014).  
8.3.2.2.2. Examples of databases integrating data generated 
from these methods  
miRTarBase 
miRTarBase is a database housing a vast number of experimentally validated 
MTI’s. The database is accessible at the following website: 
http://miRTarBase.mbc.nctu.edu.tw/. Version 1 of the miRTarBase database was 
launched in 2010, comprising of data curated from more than 100 published 
studies. miRTarBase is built using several algorithms and database updates are 
performed every two months (Hsu et al., 2014). Algorithms include miRBase 
version 20, HMDD version 2.0, miR2Disease, Gene Ontology and KEGG pathway 
analysis. MiRNA-target interactions can be downloaded in Excel format, 
catalogued by species, experimental evidence, or as a complete dataset for all 
species, at the following web link:  http://miRTarBase.mbc.nctu.edu.tw/php 
/download.php?opt=list.  
The current curation of the database, version 4.5, was released on November 01, 
2013, and cites 2 636 articles for the curation of miRNA-target interactions 
(MTIs). The database contains interaction data for 17 520 target genes and 1 232 
miRNAs, across 18 species with a total number of 51 460 miRNA-target 
interactions presented, curated from 2 636 research articles.  
Each publication of interest was perused by at least two of the database 
developers to confirm an experimentally-validated miRNA-target interaction. 
Molecular validation experiments include reporter assay, microarray, Western 
blots, pSILAC (pulsed stable isotope labelling with amino acids in culture), or 
qPCR. In the publication of the updated version of miRTarBase, Hsu et al. 
describes the database as having a 14-fold increase in the miRNA-target 
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interactions present in the updated version versus the 2010 version, as well as 
the inclusion of NGS data generated using Degradome-seq or CLIP-seq methods 
as support types. In the latest version of the database, 38 113 human miRNA-
target interactions (MTIs) with experimental support were collected from 2 143 
research articles. These MTIs were reported as the cumulative interactions 
between 587 miRNAs and 12 194 targeted genes (Hsu et al., 2014).  
Experimental validations are split into two categories. The first is “Strong 
evidence”, which is comprised of experiments validated with Western blot 
analyses and/or Reporter assays. Less strong evidence consists of experimental 
validations performed by pSILAC, microarray, or NGS assays. This updated 
version of miRTarBase contains 1 778 and 3 026 MTIs, experimentally validated 
by Western blot, and reporter assay techniques, respectively (Hsu et al., 2014).  
The current version of miRTarBase database (Version 4.5) integrates human MTI 
expression profiled using 21 GEO datasets, all of which used microarray 
platforms for molecular experimentation. MiRNA-target networks can also be 
visualised through integration of the interactive web interface of CytoscapeWeb 
(Lopes et al., 2010). Visualization of neighbouring interactions help researchers 
to understand complex MTIs, and assists in unravelling the physiological 
mechanisms associated with these networks (Hsu et al., 2014).  
Each MTI is allocated a unique miRTarBase identification number. Within the 
graphical user interface (GUI) of miRTarBase, searching for “hsa-miR-21” yielded 
numerous matches, not strictly for “hsa-miR-21” as an exact string match. The 
first match made was to the mature miRNA “hsa-miR-21-5p”, interacting with 
the gene target, “RASGRP1”. This MTI has the miRTarBase entry ID, MIRT000019. 
Opening the link of this miRTarBase ID brought up a host of information, 
including tabs for the miRNA, the target gene, the evidences collected, 
expression values, and gene set enrichments.   
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miRecords 
miRecords is a database housing both a curation of experimentally validated 
MTIs, and a miRNA-target prediction tool, which utilises 11 miRNA target 
prediction algorithms. The miRecords database can be accessed at 
http://c1.accurascience.com/miRecords/.  
The current curation of miRecords’ Validated Targets, released on April 27 2013, 
contains 2 705 records of miRNA-target interactions for 644 miRNAs and 1901 
gene targets across 9 animal species. This release of the miRecords database of 
validated-targets can be downloaded in Excel file format at http://c1.accurascien 
ce.com/miRecords/download_data.php?v=4.  
The Predicted Targets section of miRecords utilises the miRNA-target prediction 
algorithms of 11 software tools: DIANA-microT, MicroInspector, miRanda, 
MirTarget2, miTarget, NBmiRTar, PicTar, PITA, RNA22, RNAhybrid, and 
TargetScan/TargetScanS. The miRecords database is constructed in the form of a 
relational database using MySQL software (Xiao et al., 2009).  
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9. AIMS AND OBJECTIVES 
The main aim of this study was to investigate the miRNA-gene interactions 
potentially involved in the pathogenesis of Systemic Lupus Erythematosus. Using 
curated datasets of miRNAs and genes which have been associated with lupus in 
largely unrelated studies, the associations of these molecules to their targets was 
determined in the miRTarBase and miRecords databases of experimentally-
validated targets. The objectives of this study included generating miRNA-target 
interaction networks for the data generated from the analyses, to identify new, 
candidate genes and miRNAs which were placed in interaction networks built 
using the curated data, and to identify genes and miRNAs which interacted with 
known lupus-associated genes and miRNAs, but have not been reported in 
recent biomedical literature to have associations with SLE-pathogenesis. Through 
further assessment of the proposed novel interactions, the new, candidate genes 
and miRNAs found through the analyses described herein hold the potential to 
be therapeutic targets and biomarkers for lupus. 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
10. METHODOLOGY 
10.1. Overview   
For this study, recent biomedical literature was carefully perused for the curation 
of miRNAs and genes which have been associated with lupus pathogenesis as 
shown in Figure 2. A list of differentially-expressed lupus-associated genes was 
also included in this study. Two databases containing experimentally-validated 
target prediction for miRNAs – miRTarBase and miRecords – were interrogated 
using a bioinformatics scripting language, Python (iPython Version: 2.2.0, Python 
Version: 2.7.8, and all self-written Python scripts can be viewed at the following 
GitHub web link: https://github.com/StephP15/MSc_Thesis_2015. SLE-
associated gene names selected directly from literature, and Ensembl gene IDs 
for the differentially-expressed genes, were both verified for their existence as 
records in the Ensembl BioMart database. With a written Python script, miRNA 
names were verified for their existence as IDs in a downloaded file containing the 
miRBase database.  
For both the curated genes and miRNAs, corresponding targets were identified in 
miRTarBase, and miRecords. Subsequently, a cross-analysis of the input data, 
with the targets found, revealed which miRNAs, and genes were present in both 
the starting lists and the outputs generated. The cross-analysis therefore 
revealed how many genes were reported to be associated with SLE in recent 
literature, and were found to be targets for lupus-associated miRNAs. Similarly, 
the cross-analysis revealed how many miRNAs reported to be associated with 
SLE, were also found to target known, lupus-associated genes.  
The genes regulated by ten or more miRNAs, and the miRNAs targeting ten or 
more genes were then prioritized as the top regulators in this study. Using 
Ingenuity Pathway Analysis (IPA) software, analyses were performed on the top 
regulators to generate biological networks influenced by these genes and 
miRNAs. By overlaying the core networks with various prepared datasets, I was 
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 Figure 2: An overview of the methods designed, and used in this study 
able to visually identify nodes within the networks containing integral genes or 
miRNAs.  
I was also able to identify key genes or miRNAs which were supplied by the IPA 
database to complete the networks, but were not present in the curated lists of 
lupus-associated genes, and miRNAs, or differentially-expressed lupus genes. 
These key genes or miRNAs can be considered as candidate molecules integral to 
pathways largely associated with known lupus genes and miRNAs. These 
molecules may provide insight into the missing links in recent biomedical 
research performed for lupus pathogenesis, and can be considered as potential 
targets for therapeutics, and further research.  
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10.2. Database selection 
10.2.1. Database for miRNA verification  
10.2.1.1. miRBase database 
Due to the complexity of miRNA annotation as described in 8.2.6.3, I chose to 
verify the SLE-associated miRNA IDs identified from literature.  In order to 
perform this verification, I identified miRBase as a highly suitable database for 
this important preparatory step, which precedes target identification.  
The latest curation of miRBase, version 21, was released in June 2014. miRBase is 
a database which houses annotated miRNA sequences and target data. On the 
20th of May 2015, annotated miRNA sequences were downloaded at the 
following web link: http://www.mirbase.org/ftp.shtml. Mature miRNA sequences 
for all species in this database, listed in fasta format, were downloaded as the 
original file, ‘mature.fa’, at ftp://mirbase.org/pub/mirbase/CURRENT/mature.fa. 
gz. An entry in ‘mature.fa’ contained the following six fields: miRNA, miRBase ID, 
genus, species, miRNA name, and sequence. 
A GFF3 file containing the genome coordinates for all human miRNA sequences 
was downloaded on the 27th of June at the following web link: 
ftp://mirbase.org/pub/mirbase/-CURRENT/genomes/hsa.gff3. This file contained 
the following nine fields: seq_id which contained the chromosome number, 
source, type=> miRNA or miRNA_primary_transcript, start position, end position, 
score, strand, phase, and attributes => ID; Alias; Name; Derives_from. The 
curation date for this data is the 22nd of June 2014, and the data is stored in      
GFF3 format. Genome build ID: GRCh38, with the Genome-build-accession: 
NCBI_Assembly:GCA_000001405.15 was used. This file contains information for 
both predicted pre-miRNA sequences, as well as mature miRNA sequences.  
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10.2.2. Database for gene name/ gene ID verification 
10.2.2.1. Ensembl BioMart 
Release 80 (May 2015) of the Ensembl BioMart database was the most updated 
version of this genome repository at the time of analyses, and was used to verify 
the existence of the lupus-associated gene names retrieved from literature, as 
HGNC symbols. Ensembl BioMart was also used to convert the Ensembl Gene IDs 
of the differentially-expressed lupus genes provided by Dr Wendy Kröger’s meta-
analysis. As a consequence of verification in the database, the differentially-
expressed genes were converted from ENSG IDs to HGNC symbols.  
10.2.3. Databases for miRNA/gene target identification 
As reported in Table 2, several databases containing MTI data were carefully 
assessed based on relevance of data for this study, accessibility of data, the year 
of last curation of the database, the type of target prediction reported, and the 
number of miRNA-target interactions reported for human. The miRTarBase, 
miRecords, microRNA.org, and TargetScan.human databases were considered as 
possible databases to be used as sources for the miRNA-target interactions 
needed for this study.  
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Table 2: Summary of database assessment at the time of database selection (March 2015). A total number of MTIs for human was not available for miRecords, or TargetScan.human. A 
total count of MTIs was also not available for TargetScan.human.  
Database Accessibility of data Version Curation Type of Target 
Prediction 
Total number 
of MTIs 
reported 
Number of 
MTIs 
reported for 
human 
Ref. 
miRTarBase http://miRTarBase.mbc.nc
tu.edu.tw/php/download.
php?opt=list 
 in Excel format  
4.5 November 
01, 2013 
Experimentally 
validated 
51 460 38 113 (Hsu et al., 2014) 
miRecords http://c1.accurascience.co
m/miRecords/download_d
ata.php?v=4 
in Excel format 
4 April 27,  
2013 
 Experimentally 
validated 
 Algorithm-
Predictions 
2705  (Xiao et al., 2009) 
microRNA.org http://www.microrna.org/
microrna/getDownloads.d
o in text file format  
August 
2010 
November 
01, 2010 
Experimentally 
validated 
2623 1100 (Betel, Wilson, 
Gabow, Marks, 
and Sander, 2008) 
TargetScan.h
uman 
http://www.targetscan.org
/cgi-
bin/targetscan/data_down
load.cgi?db=vert_40 data 
can be downloaded in text 
file format 
4.1 January, 
2008 
TargetScan 
algorithm 
  http://www.targe
tscan.org/vert_40
/docs/help.html  
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10.3. Data curation 
 
 
10.3.1. SLE-associated miRNAs 
As seen in Figure 3, recent biomedical literature was perused to identify miRNAs 
which have been associated with lupus pathogenesis. When a miRNA was 
reported to be associated with lupus pathogenesis, attempts were made to find 
a secondary article also reporting similar findings for the given miRNA. No editing 
was made to the miRNA name before adding to the list of lupus-associated 
miRNAs. 
10.3.2. SLE-associated Genes: from literature 
A list of lupus-associated genes was compiled by manual curation from recent 
biomedical literature. Attempts were made to find a secondary article which 
reported a similar finding for the gene reported to be associated with SLE 
pathogenesis.  
10.3.3. Differentially-expressed SLE-associated genes 
A list of genes which demonstrated differential expression with lupus 
pathogenesis, was obtained from Dr Wendy Kröger (manuscript submitted), and 
utilised in this study with her permission. A full list of these Ensembl IDs can be 
found in ADDENDUM A. 
Figure 3: An overview of the methods used for data curation. The numbered orange boxes describe the 
data curation process, while the blue boxes on the right describe the origin of the miRNA, and gene lists 
used as source data in this study.   
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Using a collection of existing microarray data, Dr Kröger’s meta-analysis entailed 
identifying differentially-expressed genes in the PBMCs obtained from lupus 
patients, and which were compared to control samples. The meta-analysis 
revealed that the differentially-expressed genes identified from the study were 
implicated in interferon signalling, which was in concordance with the pathways 
reported in the data source. 
However, augmenting the findings in the individual sourced studies, the pathway 
analysis performed on the meta-analysis output revealed that TLR signalling, 
diapedesis, oxidative phosphorylation, and adhesion regulatory networks, were 
identified as the key pathways associated with the differentially-expressed genes 
found to be associated with the lupus patients in this study.  
10.4. Preparation of Data Nomenclature 
10.4.1.1. Preparation of SLE-associated miRNA IDs 
MiRNA ID assignment should follow the standard annotation rules described in 
the literature study. Thus, as shown in Figure 4, no changes were made to the 
miRNA IDs in preparation for their verification in miRBase, and their target 
identification.  
10.4.1.2. Preparation of SLE-associated gene names 
The list of lupus genes was prepared for analysis by firstly splitting the aliases in 
parentheses from the preceding gene which it was reported to be an alias for. 
Secondly, genes which had been paired were also separated for the purpose of 
this study, as shown in Figure 4.  
10.4.1.3. Preparation of differentially-expressed SLE-associated 
gene IDs 
The ‘EnsemblGeneID.txt’ file contained the Ensembl gene IDs of differentially-
expressed lupus-associated genes as collected by Dr Kröger. Because of the 
standard annotation used in Ensembl Gene ID nomenclature, no manual 
preparation or editing was performed on this file, as shown in Figure 4.  
 
 
 
 
39 
 
10.5. Verification of data 
10.5.1. Data set: SLE-associated miRNAs 
10.5.1.1.  Python Script 1: ‘PS01_June_28_miRBase_1.py’ 
The first three steps of this python script prepared the miRBase database for this 
verification step by merging the sequence annotation file, and the genome 
coordinates data file. Thus, the above python script performed the following 
steps sequentially:  
1) Filtered the contents of the ‘mature.fa’ file to extract only entries 
containing information for genus = ‘Homo’, species = ‘sapiens’, and for 
mature miRNA IDs, i.e. miRNA names starting with ‘hsa-miR-‘. 
2) Filtered the contents of the miRNA genome coordinates file (‘hsa.gff3’), 
to extract entries only for mature human miRNA sequences,  in which the 
miRNA name started with ‘hsa-miR- ‘.  
The unique miRBase accession numbers are the one truly stable characteristic of 
miRBase entries in which miRNA names may change over time due to advances 
in miRNA research, http://www.mirbase.org/help/nomenclature.shtml.  
Figure 4: An overview of the methods for data preparation. The numbered orange boxes show the transition 
of collected raw data being prepared for analyses. The blue boxes show how only the genes curated from 
literature underwent nomenclature preparation by means of splitting of paired genes and genes with aliases’ 
as retrieved from the source. 
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Thus, 
3) The ‘mature.fa’ file (containing the accession numbers for mature miRNA 
sequences was cross-referenced with the ‘hsa.gff3’ file (genome 
coordinates), on the basis of the miRBase accession number, provided as 
an ID in Attributes.  
The ‘mature.fa’ file contained miRNA sequences where the ‘hsa.gff3’ file did not, 
and the ‘hsa.gff3’ file contained genome coordinates, where the ‘mature.fa’ file 
did not. Therefore, on cross-referencing with the unique miRBase accession 
number, the two files were merged to create a more comprehensive file 
containing the following fields: microRNA_name, miRNA_accession number, 
Genus, Species, microRNA, miRNA sequence, chromosome, start genome 
coordinate, and end genome coordinate.  This data was recorded as a file named 
‘mirbase_complete.txt’. 
4) The first check for whether the miRNA names curated from literature 
were present as a record in the miRBase database was then performed. 
The list of lupus-associated miRNA names, curated from literature was 
fed to the python script ‘PS01_June_28_miRBase_1.py’ to test if the 
miRNA names were found as an exact string match to the entries in the 
miRNA name column of the miRBase database.  
As shown in Figure 5, if the input miRNA from the curated list 
‘microRNAs_assoc_SLE.txt’ matched perfectly as a string to the miRNA record in 
the ‘mirbase_complete.txt’ file, the results were written out to a file named 
‘perfect_match_in_miRBase.txt’. If the input miRNA name from the curated list 
‘microRNAs_assoc_SLE.txt’ did not make an exact string match to a miRNA 
record in the ‘mirbase_complete.txt’ file, the results were written out to a file 
named ‘no_match_in_miRBase.txt’. 
 
 
 
 
41 
 
 
10.5.1.2.  Python Script 2: ‘PS02_July_01_new_regexes.py’ 
Due to the complex annotation rules associated with miRNAs as described, for 
those miRNAs which did not match as a perfect string match in miRBase, I 
decided to employ regular expression code to perform a secondary search for 
miRNAs which may be related to those which did not match with the first 
verification step. Regular expression testing maximised the chance of retrieving 
closely related miRNA names for the curated miRNA IDs. Regular expressions 
allow the user to query for a defined partial match to a string sequence. Thus, to 
query miRNA IDs with regular expressions, I wrote three Python regular 
expressions for the miRBase database column containing the miRNA names, 
namely ‘hsa-miR-\d+’, ‘hsa-miR-\d\d\D’, and ‘hsa-miR-\d\d\d\D’.  
As shown in Figure 6, if the input miRNA name from the list of miRNAs which did 
not make an exact string match to a miRBase record 
(‘no_match_in_miRBase.txt’) matched with at least one of the three regular 
expressions described above, the miRNA was written to the output file named 
‘found_regex_matches_in_mirbase.txt’. If the input miRNA name from the list of 
miRNAs which did not make an exact string match to a miRBase record 
(‘no_match_in_miRBase.txt’) did not match with any of the three regular 
expressions described above, the miRNA was written to the output file named 
‘not_found_regex_matches_in_mirbase.txt’. MiRNAs which did not match a 
Figure 5: The numbered orange boxes shows how data proceeded to the first verification step for a perfect 
string match in miRBase. The blue boxes on the right shows how the miRNA list which did not undergo any 
nomenclature preparation proceeded to undergo the first verification step in the miRBase database 
(shown in blue). The attempt to identify a perfect string match for the unmodified miRNA IDs resulted in 
two files generated which are described as “Found”, and “Not Found”. 
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miRNA entry in the miRBase database using one of the three regular expressions 
were then manually checked for, using the Find tool in Microsoft Excel.  
 
10.5.2. Data set: SLE-associated gene names curated from literature 
10.5.2.1. Verification of the SLE-associated gene names 
On the 14th of July 2015, the curated genes were searched for in the Ensembl 
BioMart database, Release 80 (May 2015), to validate the existence of these 
genes in this repository of known, annotated genes as shown in Figure 7. The 
following parameters were selected: 
 Database tab: Ensembl Genes 80 
 Dataset tab: Homo sapiens genes (GRCh38.p2) 
 Filters tab:  
o Input external references ID list:  
 Selected to search as  HGNC symbol 
 ‘new_list.txt’ was the input text file containing the names 
of lupus-associated genes curated from literature 
 Attributes tab: desired information for output 
Figure 6: The orange boxes on the left of the figure shows the transition of miRNA IDs from the first 
verification step (as a perfect string match) to the second verification step (as a regular expression string 
match). The blue boxes on the right of the figure describes how miRNA IDs which did not produce a perfect 
string match during the first verification step in miRBase proceeded to undergo a second verification 
attempt using regular expression string matching in Python.  
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o associated gene name 
o Ensembl gene ID 
o gene start bp 
o gene end bp 
The result of this search, ‘mart_export.txt’, was saved to my local machine.   
 
10.5.2.2. Python Script 3:  
‘PS03_15_July_assoc_genes_prep_and_Biomart.py’ 
Using the above Python script, the ‘mart_export.txt’ file was analysed to 
determine which of the curated SLE-associated genes were found in BioMart, 
and which genes were not. The Python script employed exact-match filtering 
using “==”. If the associated gene name in ‘new_list.txt’ was present in the 
output of the BioMart search named ‘mart_export.txt’, then the gene name, 
verified in BioMart was written to the text file, ‘Biomart_assoc_gene_ 
MATCH_2.txt’. If a gene name was not found in the ‘mart_export.txt’ file, then 
the gene name was written to the ‘Not_Found_assoc_genes_in_BioMart_2.txt’ 
file, and was also searched for manually in the Ensembl BioMart search pane, in 
order to verify that the gene was indeed not present in the repository.  
 
 
Figure 7: The numbered orange boxes shows how data proceeded to the verification step. The blue boxes 
show how genes curated from literature underwent data preparation, followed by the verification of the 
individual gene names as HGNC symbols in Ensembl BioMart, resulting in two files containing the names of 
the genes which were “Found” in the BioMart database, and those which were “Not Found”. 
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10.5.3. Data set: Differentially-expressed SLE-associated gene IDs 
10.5.3.1. Verification of the existence of the differentially-
expressed lupus-associated gene names 
On the 16th of June 2015, the differentially-expressed genes were searched for in 
Ensembl BioMart, to validate these Ensembl IDs in this repository of known, 
annotated genes. The parameters used were: 
 Database tab: Ensembl Genes 80 
 Dataset tab: Homo sapiens genes (GRCh38.p2) 
 Filters tab:  
o Input external references ID list:  
 Selected to search as  Ensembl ID 
 ‘EnsemblGeneID.txt’ was the input text file containing the 
names of differentially-expressed lupus-associated genes 
 Attributes tab: desired information for output 
o ensembl gene ID 
o associated gene name 
o gene start bp 
o gene end bp 
o phenotype 
o status 
The result of this search, ‘mart_export.txt’, was saved to my local machine, and 
renamed as ‘BioMart_DE_genes.txt’. 
10.5.3.2. Python Script 4:  
‘PS04_16_July_DE_genes_thru_BioMart.py’ 
This script used the following files in the analysis: 
 ‘EnsemblGeneID.txt’ => the original file containing Ensembl Gene IDs of 
differentially-expressed SLE-associated genes 
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 ‘BioMart_DE_genes.txt’ => The output file of searching for those genes in 
BioMart 
Because of the standard annotation used in Ensembl Gene IDs, no manual 
preparation or editing was performed on this file. Using the above Python script, 
the file containing gene IDs which were matched in BioMart, 
‘BioMart_DE_genes.txt’, was then run through the above script and filtered 
against the original starting list of differentially-expressed gene IDs in 
‘EnsemblGeneID.txt’ to determine which genes were not found in BioMart.  
A sorted list of the output was generated, and furthermore, the first occurrence 
of each Ensembl gene ID match was retained for further analyses and written to 
a list, ‘ensembl_list_new.txt’. As shown in Figure 8, for each Ensembl Gene ID 
queried and found in BioMart, the Ensembl Gene ID searched for, along with all 
the attribute data accompanying it, was written to the output file 
‘Found_DE_genes_ALLinfo_in_BioMart.txt’. A subset of this output data, 
containing only the associated gene name for the matched Ensembl Gene IDs 
was written out to a separate file named ‘Found_DE_genes_in_BioMart.txt’. 
If the Ensembl Gene ID was not found in BioMart, the ID was written to a file 
named ‘Not_Found_DE_genes_in_BioMart.txt’. To confirm the results of the IDs 
written to ‘Not_Found_DE_genes_in_BioMart.txt’, a manual search was 
conducted for the IDs not found in BioMart. 
 
 
 
 
Figure 8: The numbered orange boxes describe how the differentially-expressed genes list in Ensembl ID 
format proceeded to the verification step for these IDs. The blue boxes show how this unmodified genes list 
- provided by Dr Kröger – underwent Ensembl gene ID verification as ENSG IDs in Ensembl BioMart, 
producing two lists -  IDs which were found in the database, and IDs which were not. 
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10.6. Target identification  
10.6.1. Identification of gene targets for SLE-associated miRNAs 
 
10.6.1.1. Python Script 5: 
‘PS05_05_July_miRTarBase_miRecords_for_PERFECT_MATCH. 
py’ 
10.6.1.1.1. miRTarBase 
The text file ‘perfect_match_in_miRBase.txt’, produced in 10.5.1.1, containing 
the names of the input miRNAs which matched as a perfect string match to 
miRNA names in the miRBase database, was then run through the above Python 
script. This Python script took each of the miRNA names and attempted to make 
an exact string match to the miRNA name present in the same ‘hsa-miR-‘ format 
in both the miRTarBase and the miRecords databases as shown in Figure 9. If the 
miRNA name was matched in the miRTarBase database, and the length of the 
corresponding gene name in the fourth column was greater than 1 string 
character, then the miRNA name, and the corresponding gene name was written 
out as a result to the output file ‘found_miRNA1_ALL_targets_in_ 
miRTarBase.txt’. If however, the miRNA name was not matched in the 
miRTarBase database, then the miRNA name was written to the output file 
‘NOT_found_miRNA1_ALL_ targets_in_miRTarBase.txt’.  
10.6.1.1.2. miRecords 
The text file ‘perfect_match_in_miRBase.txt’ was then also processed through 
the miRecords database, to identify miRNA-gene interactions in this validated-
targets database. If found in the miRecords database file, the miRNA and its 
associated gene targets were written to the text file ‘found_miRNA1_ALL_targets 
_in_miRecords.txt’. If the miRNA was not found in the miRecords database, the 
miRNA was written to ‘NOT_found_miRNA1_ALL_targets_in_miRecords.txt’. 
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10.6.1.2. Python Script 6: 
‘PS06_05_July_miRTarBase_miRecords_for_NOT_FOUND_IN_
MIRBASE.py’ 
10.6.1.2.1. miRTarBase 
The text file ‘no_match_in_miRBase.txt’, produced in 10.5.1.1., containing the 
names of the input miRNAs which did not match as an exact string match to 
miRNA names in the miRBase database, was then run through the above Python 
script. This Python script took each of the miRNA names and attempted to make 
an exact string match to the miRNA name, present in the same ‘hsa-miR-‘ format 
in both the miRTarBase and the miRecords databases. This script attempted to 
identify gene targets for the miRNAs which were not validated as exact string 
matches in the miRBase database.  
If the miRNA name was matched in the miRTarBase database, and the length of 
the corresponding gene name in the fourth column was greater than 1 string 
character, then the miRNA name, and the corresponding gene name was written 
out as a result to the output file ‘found_miRNA0_ALL_targets_in_ 
miRTarBase.txt’. If however, the miRNA name was not matched in the 
miRTarBase database, then the miRNA name was written to the output file 
‘NOT_found_miRNA0_ALL_ targets_in_miRTarBase.txt’.  
10.6.1.2.2. miRecords 
The text file ‘no_match_in_miRBase.txt’ was then also processed through the 
miRecords database, to identify miRNA-gene interactions in this validated-
targets database. If found in the miRecords database, the miRNA and its 
associated targets were written to the text file ‘found_miRNA0_ALL_ 
targets_in_miRecords.txt’. If the miRNA was not found in the miRecords 
database, the miRNA was written to ‘NOT_found_miRNA0_ALL_targets_in_ 
miRecords.txt’. 
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10.6.1.3. Python Script 7:       
 ‘PS07_05_July_miRTarBase_miRecords_for_FOUND_REGE
X_MATCH.py’ 
10.6.1.3.1. miRTarBase 
The text file ‘found_regex_matches_in_miRBase.txt’, produced in 10.5.1.2., 
containing the names of the input miRNAs which matched as regular expressions 
for the miRNAs in the miRBase database, was then run through the above script. 
As shown in Figure 10, gene targets were identified for the regular expression 
matched miRNAs in the miRTarBase and miRecords databases.  
If the miRNA name was matched in the miRTarBase database, and the length of 
the corresponding gene name in the fourth column was greater than 1 string 
character, then the miRNA name, and the corresponding gene name was written 
out as a result to the output file ‘found_miRNA2_ALL_targets_in_ 
miRTarBase.txt’. If however, the miRNA name was not matched in the 
Figure 9: The numbered orange boxes shows how the data which was verified as a perfect string match 
proceeded to target identification in two curated miRNA-Target Interactions (MTI) databases. The blue boxes 
describe how miRNAs which were found as a perfect string match in miRBase, underwent target 
identification in the miRTarBase and miRecords databases.  
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miRTarBase database, then the miRNA name was written to the output file 
‘NOT_found_miRNA2_ALL_ targets_in_miRTarBase.txt’.  
10.6.1.3.2. miRecords 
The text file ‘found_regex_matches_in_miRBase.txt’ was then also processed 
through the miRecords database, to identify miRNA-gene interactions in this 
validated-targets database.  If found in the miRecords database, the miRNA and 
its associated gene targets were written to the text file ‘found_miRNA2_ALL_ 
targets_in_miRecords.txt’. If however, the miRNA was not found in the 
miRecords database, the miRNA name was written to ‘NOT_found_miRNA2_ 
ALL_targets_in_miRecords.txt’. 
10.6.1.4. Python Script 8:      
 ‘PS08_05_July_miRTarBase_miRecords_for_NOT_FOUND
_REGEX_ MATCH.py’ 
10.6.1.4.1. miRTarBase 
The text file ‘not_found_regex_matches_in_mirbase.txt’, produced in 10.5.1.2., 
containing the names of the miRNAs which did not match with the second 
chance attempt of regular expression matching in miRBase, was then run though 
the above Python script, to determine if any of these miRNAs, not validated in 
miRBase, were recorded in the miRTarBase and miRecords database as having 
gene targets.  
If the miRNA name was matched in the miRTarBase database, and the length of 
the corresponding gene name in the fourth column was greater than 1 string 
character, then the miRNA name, and the corresponding gene name was written 
out as a result to the output file ‘found_miRNA3_ALL_targets_in_ 
miRTarBase.txt’. 
If however, the miRNA name was not matched in the miRTarBase database, then 
the miRNA name was written to the output file ‘NOT_found_miRNA3_ALL_ 
targets_in_miRTarBase.txt’. A manual check was also performed to confirm any 
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miRNAs which were not found in the miRTarBase database using the Python 
script.  
10.6.1.4.2. miRecords 
The text file ‘not_found_regex_matches_in_mirbase.txt’, was then also 
processed through the miRecords database, to identify miRNA-gene interactions 
in this validated-targets database. Importantly, the miRNAs not found as regular 
expression match in miRBase, is in fact a subset of the miRNAs not found as an 
exact string match in miRBase. Thus, the result of this match is a duplication of 
the match found in ‘no_match_in_mirbase.txt’. 
 
 
 
 
 
 
 
 
Figure 10: The numbered orange boxes describe the transition of data which has passed through the second 
verification step for regular expression string matches, to the target identification step. The blue boxes 
describe how unmodified miRNA IDs which did not pass the perfect string matching step during the first 
verification step, proceeded to a second verification step, producing two lists for miRNAs which were found 
in miRBase using the regular expressions, and the miRNAs which were not found in miRBase using this 
second method for ID verification. 
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10.6.2. Identification of miRNAs interacting with SLE-associated genes 
10.6.2.1. Python Script 9: ‘PS09_15_July_Genes1_thru_DBs.py’ 
The text file ‘BioMart_assoc_gene_MATCH_2.txt’, containing the names of the 
genes which passed both the matching in BioMart, and the case-matching in the 
Python script ‘PS03_15_July_assoc_genes_prep_and_Biomart.py’, was then run 
through the Python script ‘PS09_15_July_Genes1_thru_DBs.py’. This Python 
script took each of the gene names and attempted to make an exact string match 
to the gene name present in the same associated gene name format, in both the 
miRTarBase and the miRecords databases, in the fourth column and second 
column, respectively.  
10.6.2.1.1. miRTarBase 
As shown by the orange block numbered 5 in Figure 11, if the gene name was 
matched in the miRTarBase database, and the length of the corresponding 
miRNA name in the second column was greater than 1 string character, then the 
gene name, and the corresponding miRNA name was written out as a result to 
the output file ‘found_Genes1_ALL_targets_in_miRTarBase.txt’. The remaining 
genes which were found in Ensembl BioMart, but were not found in miRTarBase 
to interact with one or many miRNAs were written to the text file, 
‘NOT_found_Genes1_targets_in_miRTarBase.txt’. 
10.6.2.1.2. miRecords 
The text file ‘BioMart_assoc_gene_MATCH_2.txt’ was then also processed 
through the miRecords database to identify gene-miRNA interactions in this 
database of experimentally-validated targets, as shown in Figure 11. If the gene 
name was matched in the miRTarBase database, and the length of the 
corresponding miRNA name in the second column was greater than 1 string 
character, then the gene name, and the corresponding miRNA name was written 
out as a result to the output file ‘found_Genes1_ALL_targets_in_miRecords.txt’. 
The remaining genes which were found in Ensembl BioMart, but were not found 
in miRecords to interact with one or many miRNAs were written to the text file, 
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‘NOT_found_Genes1_ targets_in_miRecords.txt’. Selections of the genes not 
found in miRecords were manually checked for in the miRecords database file to 
confirm the findings.  
10.6.2.2. Python Script 10: ‘PS10_15_July_Genes2_thru_DBs.py’ 
The text file ‘Not_found_assoc_genes_in_BioMart_2.txt’, containing the names 
of the genes which failed both the matching in BioMart, and the case-matching 
in the Python script ‘PS03_15_July_assoc_genes_prep_and_BioMart.py’, was 
then run through the Python script ‘PS10_15_July_Genes2_thru_DBs.py’. This 
Python script took each of the gene names and attempted to make an exact 
string match to the gene name present in the same associated gene name 
format, in both the miRTarBase and the miRecords databases, in the fourth 
column and second column, respectively as shown in the bottom far right of 
Figure 11.  
10.6.2.2.1. miRTarBase 
If the gene name was matched in the miRTarBase database, and the length of 
the corresponding miRNA name in the second column was greater than 1 string 
character, then the gene name, and the corresponding miRNA name was written 
out as a result to the output file ‘found_Genes2_ALL_targets_in_miRTarBase.txt’. 
If the gene name was not matched in the miRTarBase database, the gene was 
written out to a text file ‘NOT_found_Genes2_targets_in_miRTarBase.txt’. 
10.6.2.2.2. miRecords 
The text file ‘Not_found_assoc_genes_in_BioMart_2.txt’ was then also 
processed through the miRecords database, to identify gene-miRNA interactions 
in this validated-targets database.  If gene interactions were found for these 
genes, the results were written out to the file 
‘found_Genes2_ALL_targets_in_miRecords.txt’. If gene interactions were not 
found for these genes in the miRecords database, these genes were written out 
to the file ‘NOT_found_Genes2_targets_in_miRecords.txt’. Selections of these 
were manually checked to confirm the findings. 
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10.6.3. Identification of miRNAs interacting with the Differentially-
expressed lupus-associated genes 
10.6.3.1. Python Script 11:  ‘PS11_16_July_DE_Genes_thru_DBs.py’ 
10.6.3.1.1. miRTarBase 
As shown in Figure 12, if the gene name, in HGNC gene name format from the 
file ‘Found_DE_genes_in_BioMart.txt’, was matched in the miRTarBase 
database, and the length of the corresponding miRNA name in the second 
column was greater than 1 string character, then the gene name, and the 
corresponding miRNA name was written out as a result to the output file 
‘found_DE_genes_ALL_targets_in_miRTarBase.txt’. The remaining genes which 
were found in Ensembl BioMart, but were not found as an entry in miRTarBase 
to interact with one or many miRNAs were written to the text file, 
‘NOT_found_DE_genes_targets_in_miRTarBase.txt’. 
10.6.3.1.2. miRecords 
The text file ‘Found_DE_genes_in_BioMart.txt’ was then also processed through 
the miRecords database, as shown in Figure 12, to identify gene-miRNA 
Figure 11: The orange boxes describe how data proceeded from verification to target identification in two 
curated MTIs databases. The blue boxes show how genes which underwent nomenclature preparation 
proceeded from verification in BioMart to the target identification in miRTarBase and miRecords. The number 
of genes curated from literature found, and not found in each of the MTI databases was recorded, along with 
the number of interactions with miRNAs found for each input gene, as indicated in parentheses. 
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interactions in this validated-targets database. If a differentially-expressed gene 
was found in the miRecords database, the gene along with its interactions was 
written to the text file ‘found_DE_genes_ALL_targets_in_miRecords.txt’. The 
remaining genes which were found in Ensembl BioMart to exist, but were not 
found as an entry in miRecords to interact with one or many miRNAs were 
written to the text file, ‘NOT_found_DE_genes_targets_in_miRecords.txt’. 
 
 
 
 
 
 
Figure 12: The orange boxes describe the transition of verified data to target identification. The blue boxes 
describe how unmodified Ensembl Gene IDs were verified in Ensembl BioMart. This verification step also 
provided a conversion of the Ensembl IDs to HGNC symbols. Thus, the Ensembl IDs which were “Not Found” 
in BioMart were excluded from Target Identification as indicated by the “N/A” on the right hand side of the 
figure. 
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10.7. Cross-Analysis of Interactions  
As shown in Figure 13, the 3 top-left green boxes joined together were cross-
analysed with the pooled unique interacting miRNAs in the bottom of the right-
hand side process. Similarly, the pooled genes which were verified in BioMart as 
shown by the blue box in the top right of the image were cross-analysed with the 
unique genes found to interact with the curated SLE-associated miRNAs.  
Figure 13: This figure describes the cross-analysis processing of the curated SLE-associated miRNAs and 
genes. Starting with data curation, proceeding to target identification, and lastly identifying which genes and 
miRNAs were found to interact with the curated data, and were also found in the initial curated data sets. 
 
 
 
 
56 
 
10.7.1. Cross-analysis of Lupus-associated miRNAs 
10.7.1.1. Pooling of miRNAs interacting with input gene lists 
All interacting miRNAs obtained in the analysis of lupus-associated genes and 
differentially-expressed genes were pooled into a single list for the cross-
analysis. This single list consisted of the curated list of miRNAs combined with 
the interacting miRNAs found in miRTarBase and miRecords. Each of the test 
scripts which are described below performed the pooling of interacting miRNAs 
and was identical in the three cross-analysis tests described. Thus, the only 
variable files were the input miRNAs to cross-analyse. 
The set() function in Python was used to create a list of unique gene-miRNA 
interactions – as the associated genes lists and differentially-expressed genes 
lists may contain overlapping interactions. To determine how many unique 
miRNAs were interacting with the input list of genes, the miRNA names were 
extracted from the interactions, and appended to a list named ‘mirnas_only.txt’. 
The items of the list of unique miRNAs were also written to a file named 
‘unique_interacting_miRNAs.txt’ for further pathway analysis. 
10.7.1.2. Test 1: starting list of VS interacting miRNAs                       
Python Script 12: ‘PS12_Test_miRNA_1.py’ 
The starting list of miRNA names curated from literature were analysed here to 
identify how many, and which of these miRNAs was present in the list of 
interacting miRNAs. These miRNAs had not yet been processed for verification as 
miRNA IDs in miRBase. If the miRNA in the curated/starting list was found in the 
list of miRNAs identified to interact with the curated list of SLE-associated genes, 
the miRNA-gene interaction was written to the output file, ‘starting_mirnas_ 
found_interactions.txt’. The miRNAs from the starting list which were found in 
the list of interacting miRNAs was written to the output file, 
‘starting_mirnas_IN_interacting.txt’. The miRNAs from the starting list which 
were not found in the list of interacting miRNAs was written to the output file, 
‘starting_mirnas_NOT_IN_interacting.txt’. 
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10.7.1.3. Test 2: Verified (==) and (=regex) VS interacting miRNAs         
Python Script 13: ‘PS13_Test_miRNA_2.py’ 
In this script, the miRNAs verified as an exact string match in miRBase, and the 
miRNAs verified as a regular expression in miRBase were pooled. Using the set() 
function in Python, a unique list of miRNAs was generated thus removing any 
duplicate miRNA names. The miRNAs from the list of verified genes associated, 
and differentially-expressed in lupus, which were not found in the list of 
interacting miRNAs were written to the output file ‘verified_mirnas_NOT_IN_ 
interacting.txt’. 
10.7.1.4. Test 3: Not verified VS interacting miRNAs                            
Python Script 14: ‘PS14_Test_miRNA_3.py’ 
This script analysed the miRNAs which did not pass the verification step as an 
exact string match in the collection of miRBase entries (‘no_match_in_ 
miRBase.txt’) For these miRNAs, if the miRNAs were found to interact with the 
SLE-associated-, and differentially-expressed genes, the miRNA-gene interactions 
were written to the output file, ‘not_verified_mirnas_found_interactions.txt’. Of 
these miRNAs not verified in miRBase, the miRNA names which were found in 
the list of interacting miRNAs were written to the output file 
‘not_verified_mirnas_IN_interacting.txt’. The miRNA names from the curated list 
of miRNAs, which were not found in the list of interacting miRNAs was written to 
the output file, ‘not_verified_mirnas_NOT_IN_interacting.txt’. 
10.7.2. Cross-analysis of Lupus-associated Genes 
10.7.2.1. Pooling of genes interacting with input miRNA list  
All gene interactions obtained in miRTarBase and miRecords from the analysis of 
the lupus-associated miRNAs were pooled into a single list for the cross-analysis 
of the associated lupus genes curated from literature, and the differentially-
expressed lupus genes obtained from Dr Wendy Kröger’s meta-analysis. Each of 
the test scripts which are described below performed the pooling of interacting 
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genes, and this process was identical in the two cross-analysis tests described. 
Thus, the only variable files were the input genes lists to cross-analyse. 
The set() function in Python was then used to create a list of unique miRNA-gene 
interactions (as shown in Figure 13), as the exact string match miRNAs and 
regular expression match miRNAs may have generated overlapping miRNA-gene 
interactions. To determine how many unique genes were interacting with the 
input list of miRNAs, the gene symbols were extracted from the interactions, and 
appended to a list named ‘genes_only.txt’.  
10.7.2.2. Test 1: Verified in BioMart VS interacting genes                 
Python Script 15: ‘PS15_Test_Gene_1.py’ 
This script analysed the list of unique genes created, by pooling the curated SLE-
associated, and differentially-expressed SLE-associated genes. These interactions 
were written to the output file, ‘verified_Genes_found_interactions.txt’. The 
genes from the pooled list of curated genes, which were verified in BioMart, and 
were found in the list of interacting genes, were written to the output file, 
‘verified_Genes_IN_interacting.txt’. The genes from the pooled list of curated 
genes, which were verified in BioMart, and were not found in the list of 
interacting genes, were written to the output file, ‘verified_Genes 
_NOT_IN_interacting.txt’. 
10.7.2.3. Test 2: NOT Verified in BioMart VS interacting genes      
Python Script 16: ‘PS16_Test_Gene_2.py’ 
The differentially-expressed SLE-associated genes were parsed to BioMart in 
Ensembl ID (ENSG) format. Thus, any gene IDs which were not found in BioMart 
could not be processed with the above script, because a conversion to HGNC 
symbol could not be performed. 
A manual search was performed to confirm the findings of Ensembl gene IDs not 
found in BioMart. If a gene not verified in BioMart was found in the pooled list of 
interacting genes, the interactions were written to the output file, 
‘verified_Genes_found_interactions.txt’. If any of the genes not verified in 
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BioMart were found in the pooled list of interacting genes, these genes were 
written to a file named ‘NOT_verified_Genes_IN_interacting.txt’. The genes from 
the list of genes not verified in BioMart, and which were not found in the list of 
interacting genes were written to the output file ‘NOT_verified_Genes_ 
NOT_IN_interacting.txt’.  
10.8. Prioritization of data for Pathway Analysis 
As described in the literature review (8.2.6), it has been well-established that a 
single miRNA has the ability to regulate multiple genes, whilst a single gene can 
also be targeted for regulation by multiple miRNAs. As this project involved 
creating a novel bioinformatics pipeline, a number of criteria were decided on at 
my own discretion, as described in detail below. These cut-off values can be 
adjusted in order to manipulate the amount of data included in the generation of 
the core networks.  
10.8.1. Identification of Top Regulating miRNAs 
From the cross-analysis of the curated SLE-associated miRNAs, a subset of these 
miRNAs was found to interact with the curated SLE-associated genes. For these 
miRNAs, those which were found to interact with ten or more SLE-associated 
genes were identified as the top regulating miRNAs for this dataset. This cut-off 
was a pragmatic choice, allowing for the generation of well-populated networks 
that were neither too complex, nor too sparse. The top regulating SLE-associated 
miRNAs were pooled with their corresponding interactions into a single text file 
named ‘all_top_regulating_miRNAs.txt’. 
10.8.2. Identification of Top Regulating Genes 
From the cross-analysis of the curated SLE-associated genes, a subset of these 
genes was found to interact with the curated SLE-associated miRNAs. For these 
genes, those which were found to interact with four or more SLE-associated 
miRNAs were identified as the top regulated genes for this dataset. This cut-off 
was also a pragmatic choice, allowing for the generation of well-populated 
networks that were neither too complex, nor too sparse.  The top regulated SLE-
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associated, and/or differentially-expressed genes were pooled with their 
corresponding interactions into a single text file named 
‘all_top_regulating_genes.txt’. 
10.9. Pooling of all top regulators 
The top regulated miRNAs and top regulating genes, along with their associated 
targets were pooled into a single data file named ‘all_top_regulated.txt’.  
10.10. Pathway Analysis 
10.10.1. Preparation of dataset files 
Two python scripts, Python Script 17: ‘PS17_prep_genes_for_IPA.py’ and Python 
Script 18: ‘PS18_prep_miRNAs_for_IPA.py’, were written to prepare the 
individual dataset files into lists of unique identifiers. 
10.10.1.1. Starting Genes and miRNAs 
All curated genes and miRNAs were pooled to create a non-unique list. Using the 
set() function in Python in each of the two scripts above, I created a unique list of 
curated identifiers. The unique lists of starting genes, and miRNAs were then 
copied and pasted into a text file named, ‘known_list.txt’.  
10.10.1.2. Interacting Genes and miRNAs 
The genes found to interact with the curated miRNAs, and the miRNAs found to 
interact with the curated genes, were pooled to create a list of IDs for the 
interacting molecules only. Using the set() function, a unique list of identifiers 
was created. The genes and miRNAs obtained from the analysis of interactions 
were then copied and pasted into a text document named, ‘new_list.txt’. 
10.10.1.3. All Genes and miRNAs (starting, and interacting) 
A list of unique starting genes which were verified in BioMart, along with the 
miRNAs verified in miRBase, along with their associated targets identified in 
miRTarBase and miRecords, were pooled into a single file named ‘big_list.txt’ to 
create a comprehensive dataset of all the molecules in this study.  
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10.10.1.4. All Top Regulating miRNAs and associated genes 
The text file prepared in 10.8.1, named ‘all_top_regulating_miRNAs.txt’ was used 
as the dataset file for all top regulating miRNAs identified, and the corresponding 
genes which they interacted with.  
10.10.1.5. All Top Regulated Genes and associated miRNAs 
The text file prepared in 10.8.2, named ‘all_top_regulating_genes.txt’ was used 
as the dataset file for all the top regulated genes identified from the cross-
analysis. This file also contained the miRNAs which the genes interacted with.  
10.10.1.6. All Top Regulated Genes and miRNAs and associations 
The text file prepared in 10.9, named ‘all_top_regulated.txt’ consisted of all the 
top regulated genes, and top regulating miRNAs, as well as their interactions. 
This dataset was used to form the skeleton of the regulatory networks.  
10.10.2. Uploading of datasets into Ingenuity Pathway Analysis  
Data was analysed through the use of QIAGEN’s Ingenuity® Pathway Analysis 
(IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). The networks, 
functional analyses, and other results were generated through the use of 
QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity). 
All prepared data sets were uploaded into IPA. The default Flexible Format was 
used as the format for data upload. For this study, the Identifier types selected 
were ‘Gene symbol – human (Hugo / HGNC, Entrez Gene)’ for the gene names, 
and miRBase (mature) for the miRNA IDs. Array platform used was kept at the 
default as ‘Not specified/applicable’. A dataset summary was also provided, 
showing how many of the raw data entries were mapped, and unmapped in the 
IPA database. Unmapped identifiers, not recognized by IPA, were not included in 
further analyses by the software program. For all mapped IDs, the recognized 
Symbol, Entrez Gene name, biological location, molecule type, and associated 
drugs, were also reported.   
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10.10.3. Core Analysis  
The Core Analysis in IPA was performed on all uploaded dataset files, and the 
following parameters were used when running the Core Analysis: the Reference 
Set used was the default Ingenuity Knowledge Base (Genes only), whereas I 
selected the relationships to consider as ‘Direct’ relationships only (Default: 
Direct and Indirect). The Interaction networks to generate were set at 70 
molecules per network (Default: 35), and 10 networks per analysis (Default: 10). I 
kept the default of using all data sources provided, and adjusted the Confidence 
to include Experimentally Observed and High (predicted) data (Default: 
Experimentally Observed only). I selected the species to only include Human 
(Default: Human, Mouse, Rat, Uncharacterized), and kept the default setting of 
no selected tissues and cell lines. Mutations were also kept at default, in which 
all were selected.  
10.10.3.1. Summary of Core Analysis 
The summary provided on the first tab contained an overview of the outputs 
described below. 
10.10.3.2. Canonical Pathways 
The canonical pathways tab provided a default bar chart view of the biological 
pathways associated with the dataset on which the Core Analysis was run. In IPA, 
Canonical Pathways can be viewed as a bar chart, line chart, or stacked bar chart. 
The orientation of the chart can also be presented as horizontal or vertical. On 
the Customize Chart tab, score cut-off values were selected at p-value greater 
than 1.3, using the Benjamini-Hochberg multiple testing correction. The graph 
style was selected to colour by default, with a threshold value of 0.05. The sort 
order selected was by Observation or Time-point, and the Score was selected as 
the Primary Y-axis parameter. A graph showing the overlap of pathways can also 
be viewed and exported.  
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10.10.3.3. Upstream Analysis 
The Upstream Analysis tab provided upstream regulators identified by IPA. The 
molecule type, p-value of overlap, and target molecules in the dataset was 
provided. This data was sorted by descending p-value, and exported in Excel 
format for reporting.  
10.10.3.4. Diseases and Functions 
The Diseases and Functions tab provided a graphical representation of the 
number of diseases annotated in categories, using data from the given dataset.  
All the data was exported in Excel format. In Excel, the data was sorted in 
descending order of number of molecules from my dataset found to be 
associated with these disease categories. Thereafter, disease categories were 
selected where ten or more of the molecules from my dataset were placed in 
these disease categories. Then, categories that had a p-value association of 
greater than 0.05 were removed from this list. A heat map was also generated 
and reported. Disease categories which appeared to be highly associated with 
SLE were selected for reporting.  
10.10.3.5. Networks 
The networks tab provided access to the networks generated by the Core 
Analysis. Networks were individually exported in the original image. Information 
regarding which molecules were placed in a generated network, along with the 
score, number of focus molecules, and the top diseases and functions for that 
network, were recorded. Focus molecules are the molecules from my input 
dataset and are displayed by IPA in bold font. The molecules in normal font are 
those added by IPA to complete the relationships between the focus molecules.  
10.10.4. Selection of networks 
Only networks which had more than two molecules in a network were selected 
as core networks for further processing. All information regarding the network 
formation was also recorded. 
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10.10.5. Viewing of original core networks 
Each core network was viewed in its original output as presented by IPA. This 
image was then exported in PNG format, without the inclusion of the analysis 
details.  
10.10.6. Expanding of network nodes 
For each network, nodes were identified and at my own discretion, spread out to 
create a network image with fewer overlapping relationship lines than in the 
original core network, thus making it clearer for viewing.  
10.10.7. Expanding of selected networks using the Grow Tool 
Using the Grow tool in the Build tab, molecules which appeared to be nodes (i.e. 
were linked to multiple molecules, and appeared to be a core molecule) were 
identified. Attempts were then made to expand these nodes, as well as 
molecules represented in white (those molecules added in by IPA), with the 
dataset of All Genes and miRNAs. This allowed for the maximisation of including 
as many molecules from my dataset of starting and interacting genes and 
miRNAs.   
Parameter settings for using Grow were set at adding direct interactions only, 
and adding a maximum of 25 molecules at a time. The dataset to be used for 
growing was limited to my specified All Genes and miRNAs dataset. Confidence 
level was kept at Experimentally Observed, and High (predicted), while species 
was selected as Human only, no Tissues and cell lines were selected, and all 
Mutations, and Relationship Types were kept at Default. .  
Where molecules were added, IPA represented these in dark pink. The purpose 
of using the Grow tool was to maximise the illustration of the interactions 
between the molecules within the dataset being analysed. Importantly, I only 
grew on nodes and molecules presented by the core networks, and I did not 
expand further on molecules which had been added as a result of Growing.  
Results of addition of molecules to the core networks were manually recorded 
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for reporting in the methods section. Expanded networks were then exported as 
images in PNG format. 
10.10.8. Preparation for overlays in Path Designer Mode 
Once each core network from the Top Regulated dataset was grown to include 
more elements from the All Genes and miRNAs dataset, the expanded network 
was taken into the Path Designer tool in IPA. After clearing the default 
background, all molecules were selected. For all the molecules, the fill colour was 
adjusted to white, the font colour remained the default black, the line colour 
remained the default dim grey, and the line thickness was adjusted to the second 
line thickness. This image was then exported in tagged image file format (TIFF) as 
the image prepared for overlays.  
10.10.9. Overlays on expanded core networks 
The skeleton dataset networks described in 10.10.8 were then overlaid with each 
of the sub-datasets shown in the left hand side column of Table 3. When moving 
from one overlay to the next, the previous overlay was cleared. When an overlay 
dataset was selected from the Overlay panel on the left of the screen, the 
overlay was shown in grey. Each molecule in grey was then manually selected 
and the fill colour was changed as shown in Table 3. As an exception, for the All 
Genes and miRNAs overlay, the molecules which were not overlaid, i.e. were in 
white, these molecules were selected and the fill colour changed to pink. This 
was to highlight the molecules which had been added in by IPA to connect the 
focus molecules in the network.  
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Table 3: The image fill colours used to highlight the overlays of sub-datasets on the Core Networks 
generated by the Core Analysis of the skeleton dataset. 
Sub-dataset which the  
Core Network was overlaid with: 
Fill Colour: 
All Top Regulated Genes and miRNAs 
and associations 
light green 
All Top Regulating miRNAs 
and associated genes 
blue 
All Top Regulated Genes 
and associated miRNAs 
orange 
All Genes and miRNAs 
(starting, and interacting) 
pink 
Starting Genes and miRNAs 
 
yellow 
Interacting Genes and miRNAs 
 
light wood 
10.11. Identification of possible SLE-associated genes (from 
Pathway Analysis) not reported in recent biomedical literature 
By careful examination of the differences between the network-overlays 
generated, candidate genes which were not present in the complete list of 
starting and interacting molecules, but were interacting with numerous 
molecules present in my dataset, were considered to be novel candidate SLE-
associated genes or miRNAs. Furthermore, molecules which were added by the 
IPA database, to complete the network, were also considered as potential novel 
candidate SLE-associated molecules. 
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11. RESULTS 
11.1. Database selection 
11.1.1. Database for miRNA verification 
11.1.1.1. miRBase database 
Version 21 of the miRBase database was downloaded for analyses in May 2015. 
The mature miRNA sequence annotation for all the species reported in this 
database was downloaded as the original file, ‘mature.fa’. This file contained 
71 656 lines, in fasta format. As fasta format entails two lines per data entry, this 
file contained 35 828 mature miRNA annotation entries.  
A GFF3 format file containing the genome coordinates of the miRNAs in the 
miRBase database was downloaded in June 2015. This file contained 4 707 lines, 
of which the first 13 lines were descriptive for file format and data sources. Thus, 
this file named ‘hsa.gff3’ contained 4 694 lines of genome coordinate data for 
both mature- and precursor human miRNA sequences.  
11.1.2. Database for gene name/ Ensembl Gene ID verification 
11.1.2.1. Ensembl BioMart 
At the time of analyses, Ensembl BioMart Release 80 was available for gene 
name and Ensembl Gene ID verification as HGNC symbols.  
11.1.3. Databases for miRNA/gene target identification 
I chose to work with miRTarBase and miRecords as the databases containing 
experimentally-validated miRNA-target interactions. These two databases, 
containing downloadable miRNA-target interactions, were the most frequently 
updated and curated databases amongst those described in Table 2.  
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11.2. Data curation 
11.2.1. SLE-associated miRNAs 
Through the careful perusal of recent scientific biomedical literature, 40 human 
miRNAs were reported to have been associated with lupus pathogenesis as 
shown in Figure 14, most reporting dysregulation in the various experiments 
performed. The forty miRNAs curated from literature and included as raw data in 
this study were: hsa-miR-21, hsa-miR-61, hsa-miR-78, hsa-miR-112, hsa-miR-126, 
hsa-miR-141, hsa-miR-142, hsa-miR-145, hsa-miR-150, hsa-miR-155, hsa-miR-
181, hsa-miR-184, hsa-miR-189, hsa-miR-198, hsa-miR-224, hsa-miR-298, hsa-
miR-342, hsa-miR-383, hsa-miR-629, hsa-miR-638, hsa-miR-663, hsa-miR-3148, 
hsa-miR-1224-3p, hsa-miR-1224-3P, hsa-miR-125a, hsa-miR-142-3p, hsa-miR-
146a, hsa-miR-148a, hsa-miR-17-5p, hsa-miR-17-92, hsa-miR-182-96-183, hsa-
miR-196a, hsa-miR-23b, hsa-miR-299-3p, hsa-miR-371-5p, hsa-miR-409-3p, hsa-
miR-423-5p, hsa-miR-483-5p, hsa-miR-513-5p, hsa-miR-516a-5p.  
These 40 unique miRNA IDs were recorded in a text file named 
‘microRNAs_assoc_SLE.txt’, for miRNAs which have been associated with SLE 
pathogenesis. The different sources for the miRNAs associated with lupus are 
reported in Table 4. 
 
 
Figure 14: This figure illustrates the data curation steps used in this study, along with the results of the 
curation step for each data set. Raw data was collected from literature for miRNAs and genes, and a list of 
differentially-expressed SLE-associated genes was provided by Dr Wendy Kröger, and included in this study 
with her permission. 
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Table 4: The distribution of sources for the curated list of 40 miRNAs. 
Source article  Number of miRNAs contributed 
Lu et al.        (2012)          - Primary source 6 
Tiffin et al.    (2013)     - Review 28 
Wang et al.  (2014)   - Primary source 1 
Zan et al.      (2014) - Review 5 
11.2.2. SLE-associated Genes: from literature 
Three peer-reviewed journal articles (see Table 5) contributed to a starting list of 
81 unique names of genes, as shown in Figure 14, which have been associated 
with lupus. 
Table 5: The distribution of sources for curated list of 81 lupus-associated genes. 
Source article  Number of genes contributed 
Lu et al.                         (2012)                 - Primary source 1 
De Azevedo Silva et al.   (2014)  - Review 8 
Tiffin et al.                     (2013)                       - Review 72 
11.2.3. Differentially-expressed SLE-associated genes 
A total of 749 Ensembl Gene IDs of differentially-expressed SLE-associated genes 
as collected by Dr Wendy Kröger was included in this study with her permission.   
11.3. Preparation of Data Nomenclature 
 
 
 
 
 
 
 
Figure 15: The orange boxes on the left describe the methods used in the preparation of data 
nomenclature. The blue boxes illustrate how the raw data of curated miRNAs, and the raw data of 
differentially-expressed SLE-associated genes did not undergo data preparation as indicated by an “N/A”. 
SLE-associated genes curated from literature underwent nomenclature processing, thereby increasing the 
count of raw data from 81 to 85 genes.  
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11.3.1. Preparation of SLE-associated gene names 
The 81 lupus-associated genes as collected from literature were: ACTN4, API5, 
ATF6B (CREBL1)*, ATG5, BANK1, BLK, C1QA, C1QB, C2, C4A, C4B, CD44, CRP, 
DNAJA1, ETS1, FCGR1A, FCGR1B, FCGR2A, FCGR2B, FCGR3A, FRK-PTPRD pair**, 
HLA-DRB1, HLA-DRB2, HLA-DRB3, ICA1, IKZF1, IL10, IL21, IRAK1 (MECP2)*, IRF5, 
IRF53, IRF8, ITGAM, JAZF1, KPNA1, LRRC18 (WDFY4)*, Lyn, MECP2, MICB, 
NMNAT2, NOTCH4, OR2H2, PDCD1, PHRF1, PPP2CA, PRDM1 (ATG5)*, PTN, 
PTPN22, PTTG1, PXK, RABGAPIL, RASGRP3, RPS6KA1, SCUBE1, SERPIND1-PARVB 
pair**, SKIV2L, SLC15A4, SPP1, STAT1, STAT4, STK17A, SYK ,TAP2, TLR7 ,TLR8, 
TLR9, TNFAIP3, TNFSF4, TNIP1, TRAF6, TREX1, TRIM27, TRIM31, TYK2, UBE2L3, 
UHRF1BP1, VDR, XKR6, XRCC1, XRCC3, XRCC4. 
The gene names indicated by an ‘*’ are directly followed by an alias gene name 
enclosed in parentheses, as taken from the source article. Thus, as shown in 
Figure 15, the list of lupus genes was then prepared for analysis by firstly splitting 
the aliases in parentheses. 
The gene names indicated by a ‘**’ are joined by a hyphen, and have been noted 
in their literature sources actively being associated with lupus, as a pair. The 
second step of preparing the SLE-associated genes curated from literature was to 
split these paired items, as shown in Figure 15. Thus, ATF6B (CREBL1) became 
two separate genes to be analysed: ATF6B, and CREBL1. IRAK1 (MECP2) became 
two separate genes to be analysed: IRAK1, and MECP2 (which was already in this 
list of associated lupus genes.  LRRC18 (WDFY4) became LRRC18, and WDFY4. 
PRDM1 (ATG5) became PRDM1, and ATG5 (which was also already present in 
this list of genes. FRK-PTPRD pair became FRK, and PTPRD. SERPIND1-PARVB pair 
became SERPIND1, and PARVB. 
 On the 14th of July, I accessed the GeneCards GUI at http://www.genecards.org/ 
to verify that the gene in parentheses was in fact a verified alias for the 
accompanying gene. Searching for the main gene, not in parentheses, I found 
that ATF6B gene (GCID: GC06M032065) had 11 alias’ of which CREBL1 was one.  
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IRAK gene (GCID: GC0XM154010) had 7 aliases, of which MECP2 was not listed as 
a known alias.  LRRC18 (GCID: 10M048909) has 5 alias’, of which WDFY4 was not 
listed as a known alias. PRDM1 (GCID: GC06P106086) had 13 alias’, of which 
ATG5 was not listed as a known alias for this gene.  
Even though these genes were not confirmed as aliases, they were included in 
the list of associated lupus genes, as they were collected from literature stating 
that they were involved in the pathogenesis of lupus. Thus, MECP2, WDFY4, and 
ATG5 were flagged for attention when miRNA interactions were determined in 
downstream analyses. Thus, the new list which was to be used in analyses 
consisted of 85 gene names: ACTN4, API5, ATF6B, ATG5, BANK1, BLK, C1QA, 
C1QB, C2, C4A, C4B, CD44, CREBL1, CRP, DNAJA1, ETS1, FCGR1A, FCGR1B, 
FCGR2A, FCGR2B, FCGR3A, FRK, HLA-DRB1, HLA-DRB2, HLA-DRB3, ICA1, IKZF1, 
IL10, IL21, IRAK1, IRF5, IRF53, IRF8, ITGAM, JAZF1, KPNA1, LRRC18, Lyn, MECP2, 
MICB, NMNAT2, NOTCH4, OR2H2, PARVB, PDCD1, PHRF1, PPP2CA, PRDM1, PTN, 
PTPN22, PTPRD, PTTG1, PXK, RABGAPIL, RASGRP3, RPS6KA1, SCUBE1, SERPIND1, 
SKIV2L, SLC15A4, SPP1, STAT1, STAT4, STK17A, SYK ,TAP2, TLR7 ,TLR8, TLR9, 
TNFAIP3, TNFSF4, TNIP1, TRAF6, TREX1, TRIM27, TRIM31, TYK2, UBE2L3, 
UHRF1BP1, VDR, WDFY4, XKR6, XRCC1, XRCC3, XRCC4. 
11.4. Verification of data 
11.4.1. Dataset: SLE-associated miRNAs   
11.4.1.1. Python Script 1: ‘PS01_June_28_miRBase_1.py’ 
 
 
 
 
 
Figure 16: The numbered orange boxes describe the methods used for the first attempt at verifying the 
data set. The blue boxes describe how the raw miRNA data undergoes verification, producing the results of 
the verification attempt for the miRNAs as perfect string matches in miRBase.  
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From the 40 miRNAs curated from literature, 14 miRNAs were found as an exact 
string match in miRBase. As 14 + 27 does not equate to 40 (starting number of 
miRNAs), I checked for duplicate miRNA entries in both output files. In this file, I 
found that ‘hsa-miR-516a-5p’ had been found twice in the ‘mirbase_ 
complete.txt’ file. All entry information is identical (most importantly the miRNA 
accession number), except for the start and end bp genome coordinates. Thus, 
the latter miRNA entry was removed from the dataset, and the first entry was 
retained for further analyses. The dataset was written to a file named ‘new_ 
perfect_match_in_miRBase.txt’, and contained 13 miRNAs. These 13 miRNAs 
were: hsa-miR-184, hsa-miR-198, hsa-miR-298, hsa-miR-638, hsa-miR-3148, hsa-
miR-1224-3p, hsa-miR-142-3p, hsa-miR-17-5p, hsa-miR-299-3p, hsa-miR-409-3p, 
hsa-miR-423-5p, hsa-miR-483-5p, and hsa-miR-516a-5p.  
As shown in Figure 16, from the starting list of 40 miRNAs, 27 miRNAs were not 
found as an exact string match in the miRBase database. These 27 miRNAs were: 
hsa-miR-21, hsa-miR-61, hsa-miR-78, hsa-miR-112, hsa-miR-126, hsa-miR-141, 
hsa-miR-142, hsa-miR-145, hsa-miR-150, hsa-miR-155, hsa-miR-181, hsa-miR-
189, hsa-miR-224, hsa-miR-342, hsa-miR-383, hsa-miR-629, hsa-miR-663, hsa-
miR-1224-3P, hsa-miR-125a, hsa-miR-146a, hsa-miR-148a, hsa-miR-17-92, hsa-
miR-182-96-183, hsa-miR-196a, hsa-miR-23b, hsa-miR-371-5p, hsa-miR-513-5p. 
The 27 miRNAs listed here did not match as an exact string match to any of the 
miRNA IDs in the miRBase database. Thus, these miRNAs were re-evaluated 
using regular expression analysis in Python.  
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11.4.1.2. Python Script 2: ‘PS02_July_01_new_regexes.py’ 
 
 
 
 
 
 
 
 
Of the 27 miRNAs which did not make an exact string match to a miRNA name in 
miRBase, 18 miRNAs matched to at least one of the regular expressions for the 
miRNA names in the miRBase entries, as shown in Figure 17. The combination of 
these three regular expressions allowed for the capturing of all possible miRNA 
nomenclature derivatives in miRBase records. The 18 miRNAs queried in the 
regular expression miRBase script resulted in 44 regular expression matches 
being made, as summarized in Table 7. The results are reported in Table 6. 
 
 
 
 
 
Figure 17: The orange boxes on the left describe the methods used to process the raw data through the 
sequential verification steps in miRBase. The blue boxes on the right describe the results of both verification 
steps for the raw miRNA data. miRNAs which passed the perfect string matching did not proceed to the 
second verification step, as indicated by “N/A”. The results of the regular expression matching in miRBase 
are reported in red font for the miRNAs which failed perfect string matching.  
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Table 6: Results of miRNA name matching in miRBase using Python Regular Expressions 
Original 
miRNA 
Regular expression miRNA 
match in miRBase 
Original miRNA Regular expression miRNA 
match in miRBase 
hsa-miR-21 hsa-miR-21-5p 
hsa-miR-21-3p 
hsa-miR-342 hsa-miR-342-5p 
hsa-miR-342-3p 
hsa-miR-126 hsa-miR-126-5p 
hsa-miR-126-3p 
hsa-miR-383 hsa-miR-383-5p 
hsa-miR-383-3p 
hsa-miR-141 hsa-miR-141-5p 
hsa-miR-141-3p 
hsa-miR-629 hsa-miR-629-5p 
hsa-miR-629-3p 
hsa-miR-142 hsa-miR-142-5p 
hsa-miR-142-3p 
hsa-miR-663 hsa-miR-663a 
hsa-miR-663b 
hsa-miR-145 hsa-miR-145-5p 
hsa-miR-145-3p 
hsa-miR-125a hsa-miR-125a-5p 
hsa-miR-125a-3p 
hsa-miR-150 hsa-miR-150-5p 
hsa-miR-150-3p 
hsa-miR-146a hsa-miR-146a-5p 
hsa-miR-146a-3p 
hsa-miR-155 hsa-miR-155-5p 
hsa-miR-155-3p 
hsa-miR-148a hsa-miR-148a-5p 
hsa-miR-148a-3p 
hsa-miR-181 hsa-miR-181a-5p 
hsa-miR-181a-3p 
hsa-miR-181a-2-3p 
hsa-miR-181b-5p 
hsa-miR-181b-3p 
hsa-miR-181b-2-3p 
hsa-miR-181c-5p 
hsa-miR-181c-3p 
hsa-miR-181d-5p 
hsa-miR-181d-3p 
hsa-miR-196a hsa-miR-196a-5p 
hsa-miR-196a-3p 
hsa-miR-224 hsa-miR-224-5p 
hsa-miR-224-3p 
hsa-miR-23b hsa-miR-23b-5p 
hsa-miR-23b-3p 
  
As shown in Table 6, regular expression matching detected the original miRNA 
name as recorded with a ‘-3p’ or a ‘-5p’ denoting the arm of origin on the 
precursor hairpin miRNA structure. Furthermore, regular expression matching 
generated several paralogues (miRNAs differing by only one or two nucleotides 
in their sequence) for the original miRNA ‘hsa-miR-181’.  
Of the 27 miRNAs that did not make an exact string match in miRBase with the 
‘PS01_June_28_miRBase_1.py’ script, nine miRNAs did not match a miRBase 
entry using one of the three regular expressions in the ‘PS02_July_01_new_ 
regexes.py’ script.  These nine miRNAs were: hsa-miR-61, hsa-miR-78, hsa-miR-
112, hsa-miR-189, hsa-miR-1224-3P, hsa-miR-17-92, hsa-miR-182-96-183, hsa-
miR-371-5p, and hsa-miR-513-5p.  
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Each of the nine miRNAs was then searched for manually in the miRBase 
database using the Find tool in Excel. Eight of the nine miRNAs were confirmed 
to not be in the miRBase database, in any format (i.e. with a -3p, or 5p suffix). 
Only one miRNA, ‘hsa-miR-1224-3P’, was found with the manual search in 
miRBase as ‘hsa-miR-1224-3p’. Even though the miRNA name was found in this 
format, the miRNA ‘hsa-miR-1224-3P’ was not changed and resubmitted to the 
script, as this was an indication of a nomenclature error from source.  
       Table 7 : Summary of results for checking if ID is recorded in miRBase 
File Number of miRNAs 
‘perfect_match_in_miRBase.txt’ n = 13 / 40 
‘no_match_in_miRBase.txt’ 
‘found_regex_match_in_mirbase.txt’ 
 
‘not_found_regex_match_in_mirbase.txt’ 
n = 27 / 40 
       n = 18 / 27  
             {44 regular expression matches} 
       n = 9 / 27 
11.4.2. Dataset: SLE-associated gene names curated from literature 
11.4.2.1. Verification of the SLE-associated gene names 
On the 14th of July 2015, the 85 lupus-associated genes curated from literature, 
were searched for in Ensembl BioMart, to validate the existence of these genes 
in this repository of known, annotated genes.  
11.4.2.2. Python Script 3: 
‘PS03_15_July_assoc_genes_prep_and_Biomart.py’ 
The ‘ORIGINAL_assoc_SLE_genes.txt’ file contained the names of 82 lupus-
associated genes. Manual preparation of this genes list, by splitting paired genes, 
and aliases, resulted in the list being extended to contain 85 unique gene names, 
and this file was named ‘new_list.txt’ as shown as the result of Step 3 in Figure 
18. 
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Running the list of prepared, SLE-associated genes though Ensembl BioMart 
resulted in 163 non-unique gene matches being made in the Ensembl database. 
The sorting, and set() function in Python determined that 82 unique genes were 
matched in Ensembl BioMart as reported in Table 8. 
Table 8: Distribution of the 163 gene matches made in Ensembl BioMart, for 82 SLE-associated genes 
curated from literature. Each of the 82 genes was matched at least once as HGNC entries in Ensembl 
BioMart. “LYN” was highlighted in red in the table to indicate that it was not an exact string match to the 
curated gene “Lyn”, and required further assessment.  
Associated 
Gene 
Name 
Number of 
matches made 
in Ensembl 
Associated 
Gene 
Name 
Number of 
matches made 
in Ensembl 
Associated 
Gene 
Name 
Number of 
matches made 
in Ensembl 
ACTN4 1 IRAK1 1 SLC15A4 1 
API5 1 IRF5 1 SPP1 1 
ATF6B 4 IRF8 2 STAT1 2 
ATG5 1 ITGAM 1 STAT4 1 
BANK1 1 JAZF1 1 STK17A 1 
BLK 1 KPNA1 1 SYK 1 
C1QA 2 LRRC18 1 TAP2 8 
C1QB 2 LYN 1 TLR7 1 
C2 8 MECP2 1 TLR8 1 
C4A 5 MICB 8 TLR9 1 
C4B 6 NMNAT2 1 TNFAIP3 1 
CD44 1 NOTCH4 8 TNFSF4 1 
CRP 1 OR2H2 7 TNIP1 1 
DNAJA1 1 PARVB 1 TRAF6 1 
ETS1 1 PDCD1 2 TREX1 2 
FCGR1A 1 PHRF1 2 TRIM27 7 
FCGR1B 2 PPP2CA 1 TRIM31 8 
FCGR2A 1 PRDM1 1 TYK2 2 
FCGR2B 1 PTN 1 UBE2L3 1 
FCGR3A 2 PTPN22 1 UHRF1BP1 1 
Figure 18: The numbered orange boxes describe the methods used in the verification of curated SLE-
associated genes. The blue boxes report the results of the verification step for the prepared gene names in 
Ensembl BioMart. 
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FRK 1 PTPRD 1 VDR 1 
HLA-DRB1 6 PTTG1 1 WDFY4 1 
HLA-DRB2 1 PXK 1 XKR6 1 
HLA-DRB3 2 RASGRP3 1 XRCC1 1 
ICA1 1 RPS6KA1 2 XRCC3 1 
IKZF1 1 SCUBE1 1 XRCC4 1 
IL10 1 SERPIND1 1   
IL21 1 SKIV2L 6   
 
The python script determined that 81 out of the 85 genes were found in BioMart, 
and four out of the 85 starting genes were not found. These four genes were Lyn, 
CREBL1, RABGAPIL, and IRF53. Because the number of unique matches found in 
BioMart (n = 82) did not match the filtering of the Python script on exact string 
matching (n = 81), I checked which of the four genes were not found using the 
exact string match, but were in fact found in BioMart.  
I then found that because Ensembl BioMart performs string matching as not 
being Case-sensitive, Lyn was detected as ‘LYN’, and reported as being a match in 
BioMart.  Thus, ‘LYN’, as highlighted in red in the above table, was flagged for 
attention, in case a match was made in the subsequent target-matching scripts.  
On the 14th of July, I also manually checked in the Ensembl BioMart database at 
http://www.ensembl.org/BioMart/martview/e92cd50c9a75820c693577f48e739
a5a  to see if CREBL1, IRF53, or RABGAPIL were indeed not found as entries in the 
database. I found that CREBL1 was one of two aliases for the ATF6B gene 
(ENSG00000213676), which is ‘activating transcription factor 6 beta’. This is in 
concordance with the aliasing of ATF6B in the original list of 82 SLE genes. 
CREBL1 was however, not listed as its own gene entry in Ensembl, nor was IRF53 
found with the manual search in the Ensembl BioMart database. 
When searching manually for ‘RABGAPIL’, this gene was not found in Ensembl. 
However, the top suggestion made by the database was ‘rabgap1l’, a lowercase 
form of what was likely to have been a typographical error of this gene. Upon 
searching the source data, (Tiffin et al., 2013), this gene was listed as ‘RABGAPIL’ 
in Supplementary data table S-1. Referring to the source article for this table, 
(Ramos et al., 2010) , supplementary table S1-S2, downloaded on the 15th of July 
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at http://www.ncbi.nlm.nih.gov/pmc/articles/-PMC3128183/bin/NIHMS279925-
supplement-Supp_Table_S1-S2.doc , revealed that ‘RABGAP1L’ had indeed been 
misspelt when carried over to Tiffin et al. 2013. Thus, RABGAPIL was removed 
from the list of 85 lupus-associated genes, and RABGAP1L was added. This genes 
list was recorded as ‘new_list2.txt’.  
The text file, ‘new_list2.txt’, was then rerun through Ensembl BioMart, and 
subsequently the Python script ‘15_July_assoc_genes_prep_and_BioMart.py’, to 
identify which of the genes were found as entries in BioMart, with being aware 
of the capitalization of ‘Lyn’ as ‘LYN’ in the BioMart match, and the updated 
spelling of ‘RABGAP1L’. Of the 85 starting genes, 82 genes were found to be 
exact string matches in the output of BioMart, ‘mart_export2.txt’. The 82 genes 
were written to the output file ‘BioMart_assoc_gene_MATCH_2.txt’. A sorted list 
was made in this Python script, and the first occurrence of each gene match was 
recorded and written out with all the selected accompanying BioMart 
information to the output file ‘BioMart_assoc_gene_MATCH_All_Info_2.txt’. This 
data was used to compile Table 9. 
Table 9: The 82 SLE-associated genes curated from literature which were found in BioMart, and were 
retained for further analyses 
Associated Gene 
Name 
First Ensembl ID 
output 
Gene start bp Gene end bp 
ACTN4 ENSG00000130402 38647649 38731583 
API5 ENSG00000166181 43311963 43344529 
ATF6B ENSG00000228628 32191691 32204680 
ATG5 ENSG000000057663 106184476 106325820 
BANK1 ENSG00000153064 101411286 102074812 
BLK ENSG00000136573 11494001 11564604 
C1QA ENSG00000173372 22636506 22639608 
C1QB ENSG00000173369 22652762 22661538 
C2 ENSG00000206372 31888164 31936056 
C4A ENSG00000206340 31972402 31993060 
C4B ENSG00000228454 32007416 32028073 
CD44 ENSG00000026508 35138870 35232402 
CRP ENSG00000132693 159712289 159714589 
DNAJA1 ENSG00000086061 33025211 33039907 
ETS1 ENSG00000134954 128458761 128587558 
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FCGR1A ENSG00000150337 149782671 149792518 
FCGR1B ENSG00000198019 121087345 121096310 
FCGR2A ENSG00000143226 161505430 161524013 
FCGR2B ENSG00000072694 161581311 161678654 
FCGR3A ENSG00000203747 161541759 161550737 
FRK ENSG00000111816 115931149 116060758 
HLA-DRB1 ENSG00000206306 32449770 32595320 
HLA-DRB2 ENSG00000227442 32488465 32502952 
HLA-DRB3 ENSG00000231679 32444128 32521486 
ICA1 ENSG00000003147 8113184 8262687 
IKZF1 ENSG00000185811 50304124 50405101 
IL10 ENSG00000136634 206767602 206772494 
IL21 ENSG00000138684 122612628 122621069 
IRAK1 ENSG00000184216 154010500 154019980 
IRF5 ENSG00000128604 128937612 128950035 
IRF8 ENSG00000140968 85898803 85922609 
ITGAM ENSG00000169896 31259990 31332892 
JAZF1 ENSG00000153814 27830573 28180743 
KPNA1 ENSG00000114030 122421949 122514945 
LRRC18 ENSG00000165383 48909483 48935190 
MECP2 ENSG00000169057 154021573 154137103 
MICB ENSG00000231179 31561856 31578081 
NMNAT2 ENSG00000157064 183248237 183418602 
NOTCH4 ENSG00000204301 32194843 32224067 
OR2H2 ENSG00000229680 29587411 29588994 
PARVB ENSG00000188677 43999211 44172949 
PDCD1 ENSG00000276977 241849881 241858908 
PHRF1 ENSG00000274780 576461 612472 
PPP2CA ENSG00000113575 134194334 134226142 
PRDM1 ENSG00000057657 106086320 106109939 
PTN ENSG00000105894 137227341 137343865 
PTPN22 ENSG00000134242 113813811 113871759 
PTPRD ENSG00000153707 8314246 10612723 
PTTG1 ENSG00000164611 160421822 160428744 
PXK ENSG00000168297 58332880 58426126 
RABGAP1L ENSG00000152061 174159410 174995308 
RASGRP3 ENSG00000152689 33436324 33564750 
RPS6KA1 ENSG00000117676 26529761 26575030 
SCUBE1 ENSG00000159307 43197283 43343388 
SERPIND1 ENSG00000099937 20773879 20787720 
SKIV2L ENSG00000204351 31959080 31969755 
SLC15A4 ENSG00000139370 128793191 128823983 
SPP1 ENSG00000118785 87975650 87983426 
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STAT1 ENSG00000115415 190964358 191020960 
STAT4 ENSG00000138378 191029576 191151596 
STK17A ENSG00000164543 43582758 43626786 
SYK ENSG00000165025 90801787 90898549 
TAP2 ENSG00000225967 32861254 32878050 
TLR7 ENSG00000196664 12867083 12890380 
TLR8 ENSG00000101916 12906620 12923169 
TLR9 ENSG00000239732 52221080 52226163 
TNFAIP3  NSG00000118503 137867188 137883312 
TNFSF4 ENSG00000117586 173183734 173207313 
TNIP1 ENSG00000145901 151029945 151093577 
TRAF6 ENSG00000175104 36487027 36510272 
TREX1 ENSG00000280804 48446710 48467645 
TRIM27 ENSG00000204713 28903002 28923989 
TRIM31 ENSG00000233573 30093221 30103423 
TYK2 ENSG00000105397 10350529 10380676 
UBE2L3 ENSG00000185651 21549447 21624034 
UHRF1BP1 ENSG00000065060 34792015 34883138 
VDR ENSG00000111424 47841537 47943048 
WDFY4 ENSG00000128815 48684876 48982956 
XKR6 ENSG00000171044 10896045 11201366 
XRCC1 ENSG00000073050 43543040 43580473 
XRCC3 ENSG00000126215 103697609 103715504 
XRCC4 ENSG00000152422 83077498 83353787 
 
This run of the script also revealed that three genes were not matched in 
BioMart. These genes were CREBL1, Lyn, and IRF53 and were written to the 
output file ‘Not_Found_assoc_genes_in_BioMart_2.txt’. As previously reported, 
manual checking in Ensembl confirmed that these three genes were not present 
as entries in this database of curated genes. 
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11.4.3. Dataset: Differentially-expressed SLE-associated gene IDs 
 
 
 
 
 
11.4.3.1. Verification of the existence of the differentially-
expressed lupus associated gene IDs 
On the 16th of June 2015, 749 Ensembl Gene IDs were searched for as HGNC 
symbols in Ensembl BioMart to validate the existence of these Ensembl IDs in 
this repository of known, annotated genes. Of the 749 differentially-expressed 
genes, 736 genes were found as HGNC symbols in BioMart, and 13 Ensembl Gene 
IDs were flagged as deprecated IDs. The results of the verification step are 
reported in Figure 19. 
11.4.3.2. Python Script 4: 
‘PS04_16_July_DE_genes_thru_BioMart.py’ 
The ‘EnsemblGeneID.txt’ file contained the Ensembl gene IDs of 749 
differentially-expressed lupus-associated genes. Of the 749 Ensembl Gene IDs 
submitted for verification as records, 1151 non-unique matches were made in 
BioMart. Using the sort() function in Python, a sorted list was generated, and 
furthermore, code was included to retain only the entry of the first occurrence of 
each Ensembl gene ID matched. This sorted list was written to 
‘ensembl_list_new.txt’. With sorting, and filtering, 1151 non-unique ID matches 
was reduced to 736 unique ID matches in BioMart. 
Figure 19: The orange boxes on the left describe the methods used to verify the curated data of 
differentially-expressed genes. The blue boxes on the right describe the results of verifying the Ensembl 
gene IDs in the Ensembl BioMart database. Most of the curated gene IDs in this list was found as HGNC 
symbols in BioMart, and only 13 were reported as deprecated IDs.  
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In concordance with the number of unique gene IDs which were found in 
BioMart (n = 736), the remaining 13 Ensembl genes which were not found in 
BioMart, were appropriately written out to the text file named 
‘Not_Found_DE_genes_in_BioMart.txt’. These 13 differentially-expressed gene 
IDs are listed in Table 10. 
Table 10: The 13 differentially-expressed gene IDs which were reported as being removed from 
the BioMart database 
ENSG00000108294 ENSG00000203813 
ENSG00000155130 ENSG00000211630 
ENSG00000168242 ENSG00000235604 
ENSG00000171282 ENSG00000236249 
ENSG00000185044 ENSG00000256018 
ENSG00000198366 ENSG00000262556 
ENSG00000198518  
 
Upon manually searching in the BioMart GUI for each of these 13 Ensembl gene 
IDs, it was found that these were now listed as deprecated IDs and had been 
removed from the latest version of the database. 
11.5. Target Identification 
11.5.1. Identification of gene targets for SLE-associated miRNAs 
 
 
 
 
 
 
 
 
Figure 20: This figure describes the processing of the curated SLE-associated miRNAs, starting 
with data curation, proceeding to target identification, and lastly identifying which genes which 
were found to interact with the curated data. A (---) indicates that no tally of interactions was 
possible, due to no targets being found. 
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11.5.1.1. Python Script 5: 
‘PS05_05_July_miRTarBase_miRecords_for_PERFECT_MATCH. 
py’ 
11.5.1.1.1. miRTarBase 
Of the 13 miRNAs found as an exact string match in miRBase, 11 were found as 
exact string matches, and having corresponding gene targets, in the 
experimentally validated targets database miRTarBase. These 11 miRNAs 
collectively matched to 607 gene targets, as shown in Figure 21. Thus, 607 
miRNA-gene interactions for these 11 miRNAs were detected in the miRTarBase 
database, as shown in Table 11. These results were written to the output file 
‘found_miRNA1_ALL_targets_in_miRTarBase.txt’. 
Table 11: The 11 miRNAs found in miRTarBase, and their associated gene targets. A total of 607 
MTIs are reported for 11 miRNAs. Shown below is an abridged list of these 11 miRNAs, for which 
ten or less interacting genes were found. The full list can be found in ADDENDUM B. 
miRNA Number of gene targets Gene targets 
hsa-miR-184 3 AKT2, INPPL1, NFATC2 
hsa-miR-198 3 CCNT1, NTRK3, MYB 
hsa-miR-298 2 BACE1, CDKN1A 
hsa-miR-638 1 OSCP1 
hsa-miR-1224-3p 5 KMT2D, IGSF3, TCF12, HNRNPA3, 
CDC42EP1 
hsa-miR-142-3p 107  
hsa-miR-17-5p 310  
hsa-miR-299-3p 1 FXN 
hsa-miR-409-3p 6 PHF10, FGB, FGA, FGG, ANG, IFNG 
hsa-miR-423-5p 168  
hsa-miR-483-5p 1 MAPK3 
 
Two of the 13 miRNAs queried were not found in the miRTarBase database. 
These two miRNAs are ‘hsa-miR-3148’ and ‘hsa-miR-516a-5p’, and were written 
to ‘NOT_found_miRNA1_ALL_targets_in_miRTarBase.txt’. A manual check in the 
downloaded miRTarBase database dataset, ‘hsa_MTI.xls’, revealed that those 
two miRNAs were indeed not listed in the miRTarBase database for human 
miRNA-gene interactions.  
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11.5.1.1.2. miRecords 
Of the 13 miRNAs, for whom their existence was validated in the miRBase 
registry, only three miRNAs were identified in the miRecords database as having 
interacting gene targets. These results were written to the text file 
‘found_miRNA1_ALL_targets_in_miRecords.txt’. Collectively, these three miRNAs 
regulated five genes as shown in Table 12. 
Table 12: The 3 miRNAs found in miRecords, and their associated gene targets. 
miRNA Number of gene targets Gene targets 
hsa-miR-516a-5p 2 KLK10, SULF1 
hsa-miR-184 2 AKT2, NFAT1 
hsa-miR-17-5p 1 IL-8 
 
The remaining ten miRNAs from this list which were not listed in miRecords as 
having corresponding gene targets were: hsa-miR-198, hsa-miR-298, hsa-miR-
638, hsa-miR-3148, hsa-miR-1224-3p, hsa-miR-142-3p, hsa-miR-299-3p, hsa-miR-
409-3p, hsa-miR-423-5p, and, hsa-miR-483-5p. These miRNA names were written 
to ‘NOT_found_miRNA1_ALL_targets _in_miRecords.txt’. 
11.5.1.2. Python Script 6: 
‘PS06_05_July_miRTarBase_miRecords_for_NOT_FOUND_IN_
MIRBASE.py’ 
11.5.1.2.1. miRTarBase 
Of the 27 miRNAs that were not found as an exact string match in miRBase, none 
of these miRNAs were found as miRTarBase entries, and thus all were written 
out to the text file ‘NOT_found_miRNA0_ ALL_targets_in_miRTarBase.txt’. These 
miRNAs were: hsa-miR-21, hsa-miR-61, hsa-miR-78, hsa-miR-112, hsa-miR-126, 
hsa-miR-141, hsa-miR-142, hsa-miR-145, hsa-miR-150, hsa-miR-155, hsa-miR-
181, hsa-miR-189, hsa-miR-224, hsa-miR-342, hsa-miR-383, hsa-miR-629, hsa-
miR-663, hsa-miR-1224-3P, hsa-miR-125a, hsa-miR-146a, hsa-miR-148a, hsa-miR-
17-92, hsa-miR-182-96-183, hsa-miR-196a, hsa-miR-23b, hsa-miR-371-5p, hsa-
miR-513-5p. 
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11.5.1.2.2. miRecords 
Of the 27 miRNAs, for whom their existence was not validated in the miRBase 
registry, 13 miRNAs were identified in the miRecords database as having 
interacting gene targets, as shown in Table 13. Collectively, these 13 miRNAs 
regulated 180 target genes. 
Table 13: The 13 miRNAs found in miRecords, and their associated gene targets. Shown below is 
an abridged list of these 13 miRNAs, for which 10 or less interacting genes were found. The full 
list which was written to the text file ‘found_miRNA0_ALL_ targets_in_ miRecords.txt’ can be 
found in ADDENDUM C. 
miRNA Number of gene 
targets 
Gene targets 
hsa-miR-21 49  
hsa-miR-126 6 VCAM1, PIK3R2, CRKL,  IRS1, VEGFA, TOM1 
hsa-miR-141 13  
hsa-miR-145 19  
hsa-miR-150 7 gag-pol, cmyb, MYB, CCNE1, P2RX7, EGR2, MUC4 
hsa-miR-155 24  
hsa-miR-224 4 API5, KLK10, KLK1, AP2M1 
hsa-miR-342 1 DNMT1 
hsa-miR-146a 38  
hsa-miR-148a 6 DNMT3B, NR1I2, Rps6ka5, DNMT1, MSK1, CDNK1B,  
hsa-miR-17-92 2 PTPRO, HIF1A 
hsa-miR-196a 9 HOXB8, HOXC8, HOXD8, HOXA7,  IKBKB, ANXA1, KRT5, 
SPRR2C, S100A9 
hsa-miR-23b 2 PLAU, MET 
 
The remaining 14 miRNAs from this list which were not listed in miRecords as 
having corresponding gene targets were written out to a text file named 
‘NOT_found_miRNA0_ALL_targets_in_miRecords.txt’. They were: hsa-miR-61, 
hsa-miR-78, hsa-miR-112, hsa-miR-142, hsa-miR-181, hsa-miR-189, hsa-miR-383, 
hsa-miR-629, hsa-miR-663, hsa-miR-1224-3P, hsa-miR-125a, hsa-miR-182-96-
183, hsa-miR-371-5p, and hsa-miR-513-5p. Selections of these were manually 
checked to confirm these findings. 
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11.5.1.3. Python Script 7:                             
‘PS07_ 05_July_miRTarBase_miRecords_for_FOUND_ 
REGEX_MATCH.py’ 
 
 
 
 
 
 
 
 
 
 
11.5.1.3.1. miRTarBase 
Of the 44 miRNAs that were found as regular expression string matches in 
miRBase, 36 miRNAs were found as exact string matches and having 
corresponding gene targets in the experimentally validated targets database 
miRTarBase. These 36 miRNAs collectively matched to 2715 gene targets. Thus, 
2715 miRNA-gene interactions for these 36 miRNAs were detected in the 
miRTarBase database and are reported in Table 14.  
Figure 21: The orange boxes describe the sequential processing of data from verification as a 
regular expression match in miRBase to the Target Identification in two curated MTI databases. 
The blue boxes on the right of the figure report the results of the target identification for the two 
datasets created as result of the second verification step. These miRNAs which were either 
matched as a regular expression string match, or were not matched as a regular expression, were 
then assessed for target identification in miRTarBase and miRecords. The number of miRNAs 
found in both miRTarBase, and miRecords were recorded, along with the total number of 
interactions found (in parentheses) for that dataset. Where targets were not found in a 
database, a “---“ was used to indicate that no count of interactions could be derived. 
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Table 14: The 36 miRNAs found in miRTarBase, and their associated gene targets. Shown below is 
an abridged list of these 36 miRNAs, for which 10 or less interacting genes were found. The full 
list can be found in ADDENDUM D. 
miRNA Number of gene targets Gene targets 
hsa-miR-21-5p 489  
hsa-miR-21-3p 2 SUV420H1, MED25 
hsa-miR-126-5p 6 SLC45A3, PTPN7, ADAM9, MMP7, CXCL12, 
CSGALNACT1 
hsa-miR-126-3p 30  
hsa-miR-141-3p 37  
hsa-miR-142-5p 1 NFE2L2 
hsa-miR-142-3p 107  
hsa-miR-145-5p 89  
hsa-miR-150-5p 15  
hsa-miR-155-5p 717  
hsa-miR-155-3p 1 IRAK3 
hsa-miR-181a-5p 237  
hsa-miR-181a-2-3p 1 ARID1A 
hsa-miR-181b-5p 97  
hsa-miR-181c-5p 17  
hsa-miR-181c-3p 1 MMP25 
hsa-miR-181a-3p 2 NANOG, HOOK3 
hsa-miR-181d-5p 25  
hsa-miR-224-5p 17  
hsa-miR-342-5p 29  
hsa-miR-342-3p 83  
hsa-miR-383-5p 4 IRF1, VEGFA, IGF1R, PRDX3 
hsa-miR-629-5p 4 HNF4A,HIST1H2AC,ATP5G2, ZCCHC6 
hsa-miR-629-3p 2 DDX3X, ATP5B 
hsa-miR-663a 5 JUNB, JUNB, TCEAL1, HSPG2, CDK1 
hsa-miR-663b 1 HRASLS5 
hsa-miR-125a-5p 137  
hsa-miR-125a-3p 10 IP6K2, PFAS, TTC8, ARFGEF1, E2F8, GLUL, 
LEPRE1, IGF2BP2, NUP62, ATP6V1B2  
hsa-miR-146a-5p 66  
hsa-miR-146a-3p 1 PLXNA1 
hsa-miR-148a-5p 2 GALK2, ACTR1A 
hsa-miR-148a-3p 81  
hsa-miR-196a-5p 222  
hsa-miR-196a-3p 1 RPS26 
hsa-miR-23b-5p 3 PRODH, SPEN, EIF4B 
hsa-miR-23b-3p 173  
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11.5.1.3.2. miRecords 
Of the 44 miRNAs for whom their existence was validated in the miRBase registry 
as matching to a regular expression, only one miRNA was identified in the 
miRecords database as having interacting gene targets. This miRNA had 6 gene 
targets in the miRecords database and they are listed in Table 15. 
Table 15: The single miRNA found in miRecords, and its associated gene targets 
miRNA Number of gene targets Gene targets 
hsa-miR-125a-5p 6 ERBB2, ERBB3, LIN28, ARID3B, 
TP53, HuR 
 
The other 43 miRNAs matched with a regular expression in miRBase, not listed in 
miRecords as having corresponding gene targets were: hsa-miR-21-5p, hsa-miR-
21-3p, hsa-miR-126-5p, hsa-miR-126-3p, hsa-miR-141-5p, hsa-miR-141-3p, hsa-
miR-142-5p, hsa-miR-142-3p, hsa-miR-145-5p, hsa-miR-145-3p, hsa-miR-150-5p, 
hsa-miR-150-3p, hsa-miR-155-5p, hsa-miR-155-3p, hsa-miR-181a-5p, hsa-miR-
181a-2-3p, hsa-miR-181b-5p, hsa-miR-181b-3p, hsa-miR-181c-5p, hsa-miR-181c-
3p, hsa-miR-181a-3p, hsa-miR-181b-2-3p, hsa-miR-181d-5p, hsa-miR-181d-3p, 
hsa-miR-224-5p, hsa-miR-224-3p, hsa-miR-342-5p, hsa-miR-342-3p, hsa-miR-383-
5p, hsa-miR-383-3p, hsa-miR-629-5p, hsa-miR-629-3p, hsa-miR-663a, hsa-miR-
663b, hsa-miR-125a-3p, hsa-miR-146a-5p, hsa-miR-146a-3p, hsa-miR-148a-5p, 
hsa-miR-148a-3p, hsa-miR-196a-5p, hsa-miR-196a-3p, hsa-miR-23b-5p, hsa-miR-
23b-3p. Selections of these were manually checked to confirm these findings. 
11.5.1.4. Python Script 8: 
‘PS08_05_July_miRTarBase_miRecords_for_NOT_FOUND_ 
REGEX_MATCH.py’ 
11.5.1.4.1. miRTarBase 
Of the nine miRNAs that were not found as an exact string match, or regular 
expression string match in miRBase, none of these miRNAs were found in the 
miRTarBase database and thus no corresponding gene targets were established. 
These nine miRNAs were: hsa-miR-61, hsa-miR-78, hsa-miR-112, hsa-miR-189, 
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hsa-miR-1224-3P, hsa-miR-17-92, hsa-miR-182-96-183, hsa-miR-371-5p, hsa-miR-
513-5p. 
A manual check of these miRNAs revealed that all nine miRNAs were not present 
in the miRTarBase database. However, ‘hsa-miR-1224-3P’ was present in the 
miRTarBase database as ‘hsa-miR-1224-3p’ with a lowercase –p suffix. Because 5 
gene targets (KMT2D, IGSF3, TCF12, HNRNPA3, CDC42EP1) were found for ‘hsa-
miR-1224-3p’, this miRNA was flagged for checking in source literature, and not 
resubmitted to the miRTarBase database as ‘hsa-miR-1224-3p’.  
11.5.1.4.2. miRecords 
Of the nine miRNAs, for whom their existence was not validated as a regular 
expression string match in the miRBase registry, one miRNA was identified in the 
miRecords database as having two interacting gene targets as shown in Table 16.  
Table 16: Of the 40 curated miRNAs, nine miRNAs were not verified in the miRBase database. Of 
these 9 miRNAs, only one miRNA was found in the miRecords database, having two gene targets.  
miRNA Number of gene targets Gene targets 
hsa-miR-17-92 2  PTPRO, HIF1A 
 
The remaining eight miRNAs from this list which were not listed in miRecords as 
having corresponding gene targets were: hsa-miR-61, hsa-miR-78, hsa-miR-112, 
hsa-miR-189, hsa-miR-1224-3P, hsa-miR-182-96-183, hsa-miR-371-5p, hsa-miR-
513-5p. 
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11.5.2. Identification of miRNAs interacting with SLE-associated genes 
11.5.2.1. Python Script 9:  ‘PS09_15_July_Genes1_thru_DBs.py’ 
 
 
 
 
 
 
 
11.5.2.1.1. miRTarBase 
From the 83 genes which were found as non-case sensitive matches in the 
BioMart search, 82 genes were found as case-sensitive, exact string matches in 
the filtering Python script ‘PS09_15_July_Genes1_thru_DBs.py’. 
Of these 82 genes, 47 genes were found in the miRTarBase database. These 47 
genes collectively matched to 174 interacting miRNAs. Thus, 174 miRNA-gene 
interactions for these 47 genes were detected in the miRTarBase database and 
are reported in Table 17. 
 
 
Figure 22: The orange boxes on the left describe the sequential processing of verified data to the 
target identification. The blue boxes describe how the associated gene names which were 
“Found” and “Not Found” in Ensembl BioMart underwent target identification in miRTarBase 
and miRecords. For both datasets, the number of genes found in each database was reported, 
along with the count of the interactions reported in parentheses. Where no genes were found in 
miRTarBase, or miRecords, a “---“ indicated that no count of miRNA-Target Interactions could be 
reported. 
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Of the 82 lupus-associated genes, 35 genes were not identified in miRTarBase to 
have target interactions with miRNAs. These genes were: ATG5, BANK1, BLK, 
C4A, C4B, CRP, FCGR1A, FCGR2A, FCGR2B, FCGR3A, HLA-DRB1, HLA-DRB2, HLA-
DRB3, ICA1, IL21, IRF8, ITGAM, LRRC18, MICB, OR2H2, PARVB, PDCD1, PTN, 
SCUBE1, STAT4, STK17A, TAP2, TLR7, TLR8, TLR9, TNFSF4, TREX1, TRIM31, XRCC3, 
XRCC4, and were written to a text file named  ‘NOT_found_Genes1_targets 
_in_miRTarBase.txt’. 
Table 17: A complete list 47 lupus-associated genes curated from literature, and verified in Ensembl 
BioMart along with the corresponding interacting miRNAs identified in miRTarBase.  
Gene Number of 
interacting 
miRNAs 
Interacting miRNAs 
API5 2 hsa-miR-224-5p, hsa-miR-183-5p 
ATF6B 1 hsa-miR-197-3p 
C1QA 1 hsa-miR-335-5p 
C1QB 1 hsa-miR-26b-5p 
C2 2 hsa-miR-335-5p, hsa-miR-142-3p 
DNAJA1 3 hsa-miR-30a-5p, hsa-miR-16-5p, hsa-miR-193b-3p 
ETS1 
 
10 hsa-miR-125b-5p, hsa-miR-9-5p, 
hsa-miR-222-3p, hsa-miR-200b-3p,  
hsa-miR-31-5p, hsa-miR-155-5p, 
hsa-miR-193b-3p, hsa-miR-208a-3p, 
hsa-miR-10a-5p, hsa-miR-30c-5p 
FCGR1B 1 hsa-miR-26b-5p 
FRK 1 hsa-miR-335-5p 
IKZF1 1 hsa-miR-26b-5p 
IL10 1 hsa-miR-106a-5p 
IRF5 1 hsa-miR-22-3p 
JAZF1 2 hsa-miR-31-5p, hsa-miR-96-5p 
KPNA1 
 
5 hsa-miR-34a-5p, hsa-miR-103a-3p,  
hsa-miR-30a-5p, hsa-miR-16-5p,  
hsa-miR-186-5p 
NMNAT2 3 hsa-miR-9-5p, hsa-miR-122-5p, hsa-miR-615-3p 
NOTCH4 3 hsa-miR-34c-5p, hsa-miR-181c-5p, hsa-miR-18a-3p 
PHRF1 
 
4 hsa-miR-1229-3p, hsa-miR-92b-3p,  
hsa-miR-193b-3p, hsa-miR-222-3p 
PPP2CA 2 hsa-miR-340-3p, hsa-miR-197-3p 
PRDM1 
5 hsa-miR-9-5p, hsa-miR-127-3p, hsa-miR-125b-5p, hsa-miR-
30a-5p, hsa-miR-877-3p 
PTPN22 2 hsa-miR-181a-5p, hsa-miR-1 
PTPRD 
 
6 hsa-miR-429, hsa-miR-200a-3p, hsa-miR-200c-3p, hsa-miR-
141-3p, hsa-miR-1, hsa-miR-200b-3p 
PTTG1 
 
5 hsa-miR-423-5p, hsa-miR-320a, hsa-miR-186-5p, hsa-miR-
26a-5p, hsa-miR-17-5p 
PXK 1 hsa-miR-744-5p 
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RABGAP1L 1 hsa-miR-1 
RASGRP3 1 hsa-miR-21-5p 
RPS6KA1 2 hsa-miR-125b-5p, hsa-miR-193b-3p 
SERPIND1 1 hsa-miR-335-5p 
SKIV2L 1 hsa-miR-222-3p 
SLC15A4 3 hsa-miR-124-3p, hsa-miR-151a-5p, hsa-miR-186-5p 
SPP1 3 hsa-miR-299-5p, hsa-miR-335-5p, hsa-miR-146a-5p 
STAT1 
 
4 hsa-miR-145-5p, hsa-miR-146a-5p,  
hsa-miR-34a-5p, hsa-miR-615-3p 
SYK 3 hsa-miR-99b-3p, hsa-miR-615-3p, hsa-miR-331-3p 
TNFAIP3 
 
6 hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-29a-3p, hsa-
miR-21-5p, hsa-miR-26b-5p, hsa-miR-24-3p 
TNIP1 3 hsa-miR-221-3p, hsa-miR-324-3p, hsa-miR-181a-5p 
TRAF6 2 hsa-miR-146a-5p, hsa-miR-146b-5p 
TRIM27 2 hsa-miR-421, hsa-miR-1260b 
TYK2 1 hsa-miR-124-3p 
UBE2L3 3 hsa-miR-122-5p, hsa-miR-423-5p, hsa-miR-93-5p 
UHRF1BP1 3 hsa-miR-34a-5p, hsa-miR-192-5p, hsa-miR-652-3p 
VDR 2 hsa-miR-125b-5p, hsa-miR-27b-3p 
WDFY4 1 hsa-miR-335-5p 
XKR6 1 hsa-miR-335-5p 
XRCC1 
4 hsa-miR-34a-5p, hsa-miR-92b-3p, hsa-miR-193b-3p, hsa-
miR-186-5p 
 
11.5.2.1.2. miRecords 
The text file ‘BioMart_assoc_gene_MATCH_2.txt’ was then also processed 
through the miRecords database, to identify gene-miRNA interactions in this 
validated-targets database. Of the 82 genes which were validated in both 
Ensembl BioMart search, and the Python script filtering step, 11 genes were 
identified in the miRecords database as being regulated by 18 unique miRNAs, as 
shown in Table 18. 
The remaining 71 genes from this list which were not found in the miRecords 
database as having interactions with miRNAs were:  ACTN4, ATF6B, ATG5, 
BANK1, BLK, C1QA, C1QB, C2, C4A, C4B, CRP, DNAJA1, FCGR1A, FCGR1B, FCGR2A, 
FCGR2B, FCGR3A, FRK, HLA-DRB1, HLA-DRB2, HLA-DRB3, ICA1, IKZF1, IL10, IL21, 
IRF5, IRF8, ITGAM, JAZF1, KPNA1, LRRC18, MECP2, MICB, NMNAT2, OR2H2, 
PARVB, PDCD1, PHRF1, PPP2CA, PTN, PTPN22, PTTG1, PXK, RASGRP3, RPS6KA1, 
SCUBE1, SERPIND1, SKIV2L, SPP1, STAT4, STK17A, SYK, TAP2 ,TLR7, TLR8, TLR9, 
TNFAIP3, TNFSF4, TNIP1, TREX1, TRIM27, TRIM31, TYK2, UBE2L3, UHRF1BP1, 
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VDR, WDFY4, XKR6, XRCC1, XRCC3, XRCC4. These results were written to the text 
file named ‘found_Genes1_ALL_targets_in_miRecords.txt’. 
Table 18: The 11 genes from the differentially-expressed SLE-associated genes dataset, for which 
interacting miRNAs were found in miRecords.  
Gene Number of 
interacting 
miRNAs 
Interacting miRNAs 
API5 1 hsa-miR-224 
CD44 2 hsa-miR-373, hsa-miR-34a 
ETS1 1 hsa-miR-155 
IRAK1 1 hsa-miR-146a 
NOTCH4 3 hsa-miR-34b, hsa-miR-34c, hsa-miR-181c 
PRDM1 1 hsa-miR-9 
PTPRD 
 
5 hsa-miR-141, hsa-miR-200a, hsa-miR-200b, 
hsa-miR-200c, hsa-miR-429 
RABGAP1L 1 hsa-miR-1 
SLC15A4 1 hsa-miR-124 
STAT1 1 hsa-miR-146a 
TRAF6 1 hsa-miR-146a 
 
11.5.2.2. Python Script 10:  ‘PS10_15_July_Genes2_thru_DBs.py’ 
11.5.2.2.1. miRTarBase 
No gene interactions were found for the 3 genes ‘Lyn’, ‘CREBL1’, ‘IRF53’. These 
three genes were curated from literature sources, but were not verified in 
Ensembl BioMart to exist as Ensembl entries. Thus, these gene names were 
written to the file ‘NOT_found_Genes2_targets_in _miRTarBase.txt’. 
11.5.2.2.2. miRecords 
No gene interactions were found for ‘Lyn’, ‘CREBL1’, or ‘IRF53’ in miRecords, and 
thus this output file contained no entries. These three genes ‘Lyn’, ‘CREBL1’, 
‘IRF53’ were written to the file ‘NOT_found_Genes2_targets_in_miRecords.txt’. 
A manual check using the Find tool in Excel confirmed that these three genes 
were not present in the miRecords database.  
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11.5.3. Identification of miRNAs interacting with the Differentially-
expressed lupus-associated genes 
 
 
 
 
 
 
 
 
11.5.3.1. Python Script 11:  ‘PS11_16_July_DE_Genes_thru_DBs.py’ 
11.5.3.1.1. miRTarBase 
From the input list of 749 Ensembl Gene IDs, 736 IDs were matched, as shown in 
Figure 23, and written with the corresponding associated gene name for further 
analysis. Of the 736 genes found, 496 genes were found in the miRTarBase 
database and were written to a text file named 
‘found_DE_genes_ALL_targets_in_miRTarBase.txt’. These 496 genes collectively 
matched to 1497 non-unique interacting miRNAs. Thus, 1497 miRNA-gene 
interactions for these 496 genes were detected in the miRTarBase database and 
can be viewed in ADDENDUM E. The remaining 240 differentially-expressed SLE-
Figure 23: The orange boxes on the left describe the methods used to proceed from verification of 
data to target identification. The blue boxes on the right describe the results of the verification of 
Ensembl Gene IDs in Ensembl BioMart, followed by the target identification in miRTarBase and 
miRecords. The number of genes found in each database is reported, along with the count of the 
interactions reported in parentheses. Ensembl Gene IDs which did not pass the verification in 
BioMart were not processed further as no conversion could be made to HGNC symbols for target 
identification. “N/A” indicates that the IDs not found in BioMart were not processed further, 
therefore not reporting any target interactions, as illustrated by “---“. 
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associated genes were not found as records in the miRTarBase database and 
were written to the text file, ‘NOT_found_DE_genes_targets_in_miRTarBase.txt’.  
11.5.3.1.2. miRecords 
Of the 736 genes validated in Ensembl BioMart search, 45 genes were identified 
in the miRecords database as having interacting miRNAs. Collectively, these 45 
genes had 80 target interactions listed in this database. These 80 MTIs are shown 
in Table 19. A total of 691 of the 736 differentially-expressed SLE-associated 
genes were not found as gene records in the miRecords database and were 
written to the error file ‘NOT_found_DE_genes_targets_in_miRecords.txt’. 
Table 19: The 45 out of 736 differentially-expressed SLE genes which were found to have 
interacting miRNAs in the miRecords database 
Gene Number of 
interacting miRNAs 
Interacting miRNAs 
ABCA1 3 hsa-miR-33a,hsa-miR-33b, hsa-miR-758 
ADAR 1 hsa-miR-1 
AP1M2 1 hsa-miR-124 
ATP11A 1 hsa-miR-122 
CCND1 13 hsa-miR-302a, hsa-miR-195, hsa-miR-424,                   
hsa-miR-16, hsa-miR-20a, hsa-miR-17,                        
hsa-miR-34a, hsa-miR-296-5p, hsa-miR-19a,                   
hsa-miR-15a, hsa-miR-503, hsa-miR-155,                         
hsa-miR-302c 
CCND3 2 hsa-miR-424, hsa-miR-16 
CDH1 1 hsa-miR-9 
CDKN1A 5 hsa-miR-21, hsa-miR-17, hsa-miR-106a,                 
hsa-miR-93, hsa-miR-106b 
COL4A1 1 hsa-miR-29c 
CTGF 4 hsa-miR-124, hsa-miR-18a 
hsa-miR-19a, hsa-miR-19b 
ERBB4 3 hsa-miR-372, hsa-miR-302d, hsa-miR-19a 
FA2H 1 hsa-miR-124 
FAM3C 1 hsa-miR-21 
FGF20 1 hsa-miR-433 
FSCN1 2 hsa-miR-145, hsa-miR-133a 
H3F3B 4 hsa-miR-1, hsa-miR-16, hsa-miR-15a,                              
hsa-miR-125b 
HERC6 2 hsa-miR-15a, hsa-miR-16 
HNRNPK 1 hsa-miR-21 
HOMER2 1 hsa-miR-125b 
HOXA7 1 hsa-miR-196a 
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IGFBP5 1 hsa-miR-140-5p 
IRAK1 1 hsa-miR-146a 
KRT7 3 hsa-miR-30a, hsa-miR-133a,  
hsa-miR-145 
LRRC1 1 hsa-miR-124 
MAFB 1 hsa-miR-130a 
MATR3 1 hsa-miR-155 
MBNL2 2 hsa-miR-302d, hsa-miR-372 
MCPH1 1 hsa-miR-146a 
MMP1 1 hsa-miR-222 
MMP16 1 hsa-miR-146b-5p 
NETO2 1 hsa-miR-1 
OSMR 1 hsa-miR-122 
PARP16 1 hsa-miR-124 
PPP2R2A 1 hsa-miR-222 
PRKD1 2 hsa-miR-124, hsa-miR-17 
RBL1 1 hsa-miR-17 
RELN 1 hsa-miR-128 
SLC16A1 2 hsa-miR-376a*, hsa-miR-124 
SNCA 1 hsa-miR-7 
STOM 1 hsa-miR-124 
STX11 1 hsa-miR-373 
SULF1 1 hsa-miR-516a-5p 
UBE2Q1 1 hsa-miR-338-3p 
UGP2 2 hsa-miR-15a, hsa-miR-16 
YWHAZ 1 hsa-miR-375 
11.6. Pooling of Interactions 
11.6.1. Pooling of miRNAs interacting with input gene lists 
With pooling, the list of all interactions contained 1769 gene-miRNA interactions 
for both databases. From this, 1738 unique gene-miRNA interactions were 
identified from the pooled list of all interacting miRNAs. From the 1738 unique 
gene-miRNA interactions, 291 unique miRNAs were found to interact with input 
genes being evaluated.  
11.6.2. Pooling of genes interacting with input miRNA list  
With pooling, the list of all interactions contained 3515 miRNA-gene interactions 
for both databases. To determine how many unique genes were interacting with 
the input list of miRNAs, the gene symbols were extracted from the interactions, 
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and appended to a list named genes_only. From the 3401 unique gene-miRNA 
interactions, 2702 unique genes were found to interact with miRNAs being 
evaluated. 
11.7. Cross-Analysis of Interactions 
 
Figure 24: This figure describes the results of the processing the curated SLE-associated miRNAs 
and genes, starting with data curation, proceeding to target identification, and lastly identifying 
which gene and miRNAs which were found to interact with the curated miRNAs, and genes, 
respectively. 
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11.7.1. Cross-Analysis of Lupus-associated miRNAs 
11.7.1.1. Test 1: starting list of n= 40 VS interacting miRNAs n = 291 
Python Script 12: ‘PS12_Test_miRNA_1.py’ 
From the starting list of 40 miRNAs shown in the green box in the top far left of 
Figure 24, 13 miRNAs were found in the list of interacting miRNAs, and were 
written to the output file ‘starting_mirnas_IN_interacting.txt’. Shown in the 
bottom far left of Figure 24, these 13 miRNAs were: hsa-miR-141, hsa-miR-142-
3p, hsa-miR-145, hsa-miR-146a, hsa-miR-155, hsa-miR-17-5p, hsa-miR-196a, hsa-
miR-21, hsa-miR-224, hsa-miR-298, hsa-miR-409-3p, hsa-miR-423-5p, hsa-miR-
516a-5p. The miRNA-gene interactions were written to the text file ‘starting_ 
mirnas_found_interactions.txt’. 
Table 20: The 13/40 starting miRNAs - not yet verified in miRBase - which were found in the list 
of interacting miRNAs as output from the analysis of the genes’ list of interactions 
13 miRNAs from starting list of 
n = 40 
No. of 
Interactions 
Gene interactions 
hsa-miR-141 1 PTPRD 
hsa-miR-142-3p 2 C2, C4BPB 
hsa-miR-145 2 FSCN1, KRT7 
hsa-miR-146a 4 IRAK1, MCPH1, STAT1, TRAF6 
hsa-miR-155 3 CCND1, ETS1, MATR3 
hsa-miR-17-5p 19 ARIH1, ATXN7, CCL1, CCND1, CDKN1A, 
CTSA, DCBLD2, GNAS, IGFBP5, IRAK1, 
KAT2A, PTTG1, RBL1, RPL37, RPS27A, 
RPSA, SMAD4, SYNDIG1, TRA2B 
hsa-miR-196a 1 HOXA7 
hsa-miR-21 3 CDKN1A, FAM3C, HNRNPK 
hsa-miR-224 1 API5 
hsa-miR-298 1 CDKN1A 
hsa-miR-409-3p 1 FGG 
hsa-miR-423-5p 11 CCNI, DRAP1, HIST2H2BE, HOXA7, 
MYBL2, NFKB2, PTTG1, RPL18A, SLC7A2, 
UBE2L3, YWHAZ 
hsa-miR-516a-5p 1 SULF1 
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For these 13 starting miRNAs, 50 interacting genes were found for the pooled list 
of associated- and differentially-expressed genes as shown in Table 20. From 
these 13 starting miRNAs, unverified in miRBase, hsa-miR-17-5p and hsa-miR-
423-5p had the most gene interactions in the two databases, interacting with 19 
and 11 genes, respectively. The miRNAs from the starting list which were not 
found in the list of interacting miRNAs was written to the output file 
‘starting_mirnas_NOT_ IN_interacting.txt’. These 27 miRNAs were: hsa-miR-112, 
hsa-miR-1224-3P, hsa-miR-1224-3p, hsa-miR-125a, hsa-miR-126, hsa-miR-142, 
hsa-miR-148a, hsa-miR-150, hsa-miR-17-92, hsa-miR-181, hsa-miR-182-96-183, 
hsa-miR-184, hsa-miR-189, hsa-miR-198,  hsa-miR-23b, hsa-miR-299-3p, hsa-miR-
3148, hsa-miR-342, hsa-miR-371-5p, hsa-miR-383, hsa-miR-483-5p, hsa-miR-513-
5p, hsa-miR-61, hsa-miR-629, hsa-miR-638, hsa-miR-663, hsa-miR-78. 
11.7.1.2. Test 2: Verified (==) and (=regex) VS interacting miRNAs 
Python Script 13: ‘PS13_Test_miRNA_2.py’ 
In this script, the miRNAs verified as a perfect string match in miRBase, and the 
miRNAs verified as a regular expression in miRBase were pooled. A total of 57 
miRNAs - 13 found as an exact string match, and 44 regular expression matches, 
see step 1 and step 2 of miRNA verification in BioMart – were cross-analysed for 
being present in the list of 291 unique interacting miRNAs. By using the Python 
set() function, a unique set of miRNAs was created to remove any duplicate 
miRNA names. The list of 57 miRNAs, verified in BioMart, was reduced to 56 
miRNAs. From this list of 56 unique miRNAs, 22 miRNAs were found in the list of 
interacting miRNAs, and were written to the output file ‘verified_mirnas_IN_ 
interacting.txt’, as shown in the bottom right of Figure 25. These 22 miRNAs 
were: hsa-miR-125a-5p, hsa-miR-126-3p, hsa-miR-141-3p, hsa-miR-142-3p, hsa-
miR-145-5p, hsa-miR-146a-5p, hsa-miR-148a-3p, hsa-miR-155-5p, hsa-miR-17-
5p, hsa-miR-181a-5p, hsa-miR-181b-5p, hsa-miR-181c-5p, hsa-miR-196a-5p, hsa-
miR-21-5p, hsa-miR-224-5p, hsa-miR-23b-3p, hsa-miR-298, hsa-miR-342-3p, hsa-
miR-409-3p, hsa-miR-423-5p, hsa-miR-516a-5p, hsa-miR-629-5p. These 
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interactions were written to the output file ‘verified_mirnas_found_ 
interactions.txt’, and the interactions are shown in Table 20. 
Table 21: The 22/56 starting miRNAs, which were verified in miRBase, and were found in the list 
of interacting miRNAs as output from the analysis of the genes lists. 
22 miRNAs from                      
verified list              
  (n = 56) 
No. of 
Interactions 
Gene interactions 
hsa-miR-125a-5p 8 ATP5G2, CDKN1A, COL4A1, FERMT1,  
LAMB1, MACF1, OTUB2, TNFAIP3 
hsa-miR-516a-5p 1 SULF1 
hsa-miR-141-3p 2 PTPRD, ZFPM2 
hsa-miR-148a-3p 4 AMELX, CCNI, CYCS, MPP5 
hsa-miR-196a-5p 9 CCND1, EPHA7, HOXA7, NAP1L4, RANBP9,  
TAB2, TRA2B, TSPAN12, ZBTB24 
hsa-miR-142-3p 4 C2, C4BPB, C2, C4BPB 
hsa-miR-342-3p 2 ATXN7, FAM3C 
hsa-miR-409-3p 1 FGG 
hsa-miR-21-5p 20 ARID4A, CCR1, DDX46, EIF4A2, ELOVL4, FAM3C, FAM46A, 
HNRNPK, MPP5, MYEF2, NETO2, PHACTR2, PLAT, 
RASGRP3, RUFY3, SYNE2, TCF21, TNFAIP3, ZNF587, ZNF667 
hsa-miR-298 1 CDKN1A 
hsa-miR-145-5p 8 CDKN1A, CTGF, FAM3C, FSCN1,  
FZD7, KRT7, MMP1, STAT1 
hsa-miR-629-5p 2 ATP5G2, HIST1H2AC 
hsa-miR-17-5p 19 ARIH1, ATXN7, CCL1, CCND1, CDKN1A, CTSA, DCBLD2, 
GNAS, IGFBP5, IRAK1, KAT2A, PTTG1, RBL1, RPL37, 
RPS27A, RPSA, SMAD4, SYNDIG1, TRA2B 
hsa-miR-146a-5p 15 CDKN1A, ERBB4, IFI27, IFI44, IFI44L, IFIT1, IFIT3, IRAK1, 
ISG15, OASL, OLFML2A, SMAD4, SPP1, STAT1, TRAF6 
hsa-miR-181a-5p 10 GCNT1, H3F3B, HEY2, KAT2B, PRLR,  
PTPN22, SIK2, TAB2, TCF21, TNIP1 
hsa-miR-181b-5p 2 KAT2B, RPL18A 
hsa-miR-23b-3p 7 ACTN4, CCT7, GHITM, HNRNPK,  
RPS27A, SLC16A1, TAB2 
hsa-miR-181c-5p 1 NOTCH4 
hsa-miR-155-5p 35 CCND1, CDH6, CHAF1B, CLDN1, CTSA, DRAP1, ETS1, 
FAM135A, FAM3C, GHITM, GNAS, HAX1, HSPA4L, IMPAD1, 
MAFB, MATR3, MECP2, MPP5, NCAPD2, PDE3A, PHF14, 
PPFIBP1, PPP2R2A, RBM22, RIF1, SLC35F2, SMAD4, 
SMARCE1, STIM1, SYNE2, TAB2, UGT8, VAV2, YWHAZ, 
ZNF273 
hsa-miR-423-5p 11 CCNI, DRAP1, HIST2H2BE, HOXA7, MYBL2, NFKB2, PTTG1, 
RPL18A, SLC7A2, UBE2L3, YWHAZ 
hsa-miR-224-5p 2 API5, SMAD4 
hsa-miR-126-3p 1 PGR 
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For these 22 miRNAs verified for their existence as a record in miRBase, 165 
interactions were found for the pooled list of associated- and differentially-
expressed genes, as shown in Table 21. From these 22 miRNAs, hsa-miR-155-5p 
had the most interactions, regulating 35 genes. This miRNA was followed by hsa-
miR-21-5p and hsa-miR-7-5p, which regulated 20 and 19 genes, respectively.  
The 34 miRNAs which were verified in miRBase, but were not found to interact 
with the SLE-associated genes were written to the text file,   
verified_mirnas_NOT_IN_interacting.txt. The miRNA IDs written to this file were: 
hsa-miR-1224-3p, hsa-miR-125a-3p, hsa-miR-126-5p, hsa-miR-141-5p, hsa-miR-
142-5p, hsa-miR-145-3p, hsa-miR-146a-3p, hsa-miR-148a-5p, hsa-miR-150-3p, 
hsa-miR-150-5p, hsa-miR-155-3p, hsa-miR-181a-2-3p, hsa-miR-181a-3p, hsa-miR-
181b-2-3p, hsa-miR-181b-3p, hsa-miR-181c-3p, hsa-miR-181d-3p, hsa-miR-181d-
5p, hsa-miR-184, hsa-miR-196a-3p, hsa-miR-198, hsa-miR-21-3p, hsa-miR-224-
3p, hsa-miR-23b-5p, hsa-miR-299-3p, hsa-miR-3148, hsa-miR-342-5p, hsa-miR-
383-3p, hsa-miR-383-5p, hsa-miR-483-5p, hsa-miR-629-3p, hsa-miR-638, hsa-
miR-663a, hsa-miR-663b. 
11.7.1.3. Test 3: Not verified (n=27) VS interacting miRNAs               
Python Script 14: ‘PS14_Test_miRNA_3.py’ 
The above script analysed 27 miRNAs (‘no_match_in_miRBase.txt’) which failed 
the verification step as an exact string match in the miRBase database. From this 
list of 27 unique miRNAs, seven miRNAs were found in the list of interacting 
miRNAs, as shown in the far bottom right of Figure 24, and were written to the 
output file ‘not_verified_mirnas_IN_interacting.txt’. These seven miRNAs were: 
hsa-miR-141, hsa-miR-145, hsa-miR-146a, hsa-miR-155, hsa-miR-196a, hsa-miR-
21, hsa-miR-224. 
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Table 22: The 7/27 miRNAs - NOT verified in miRBase - which were found in the list of interacting 
miRNAs as output from the analysis of the genes lists. 
7 miRNAs  
from unverified list of n = 27 
No. of  
Interactions 
Gene 
 interactions 
hsa-miR-141 1 PTPRD 
hsa-miR-145 2 FSCN1, KRT7 
hsa-miR-146a 4 IRAK1, MCPH1, STAT1, TRAF6 
hsa-miR-155 3 CCND1, ETS1, MATR3 
hsa-miR-196a 1 HOXA7 
hsa-miR-21 3 CDKN1A, FAM3C, HNRNPK 
hsa-miR-224 1 API5 
 
The gene interactions for the seven miRNAs which failed verification in BioMart 
were written to the output file ‘not_verified_mirnas_found_interactions.txt’ and 
are reported in Table 22. For these seven miRNAs not found as a record in 
miRBase, 15 interactions were found for the pooled list of SLE-associated- and 
differentially-expressed genes. From these seven miRNAs, hsa-miR-146a had the 
most interactions, regulating four genes.  
The remaining 20 miRNAs which were not found in the list of interacting miRNAs 
was written to the output file, ‘not_verified_mirnas_NOT_IN_interacting.txt’. 
These 20 miRNAs were:  hsa-miR-112, hsa-miR-1224-3P, hsa-miR-125a, hsa-miR-
126, hsa-miR-142, hsa-miR-148a, hsa-miR-150, hsa-miR-17-92, hsa-miR-181, hsa-
miR-182-96-183, hsa-miR-189, hsa-miR-23b, hsa-miR-342, hsa-miR-371-5p, hsa-
miR-383, hsa-miR-513-5p, hsa-miR-61, hsa-miR-629, hsa-miR-663, hsa-miR-78. 
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11.7.2. Cross-Analysis of Pooled Lupus-associated and Differentially-
Expressed Genes: 
11.7.2.1. Test 1: Verified in BioMart, n= 813 VS interacting genes 
Python Script 15: ‘PS15_Test_Gene_1.py’ 
The list of SLE-associated genes (n = 82), and the differentially-expressed SLE 
genes (n = 736), which passed the verification step in BioMart were pooled into a 
single list of test genes (n = 818). Using the set() function in Python, a unique list 
of test genes was created. The list of 818 starting genes, verified in BioMart, was 
reduced to a list of 813 unique genes. 
From the list of 813 unique genes verified in BioMart, 127 genes were found in 
the list of 2702 unique interacting genes, and were written to the output file 
‘verified_Genes_IN_interacting.txt’. For these 127 genes, 183 miRNA interactions 
were found cumulatively. Their interactions identified with the SLE-associated- 
and differentially-expressed genes being assessed, were written to the output 
file ‘verified_Genes_found_interactions.txt’ and were reported in Table 23. 
The 686 genes from the unique starting list of 813 genes which were not found in 
the list of interacting genes were written to the output file 
‘verified_Genes_NOT_IN_interacting.txt’. 
Table 23: The 127/813 lupus-associated genes - verified in BioMart - which were found in the 
result of interacting genes as output from the analysis of the lupus-associated miRNA list. 
Gene 
name 
No. of 
Interactions 
miRNA 
interactions 
Gene 
name 
No. of 
Interactions 
miRNA 
interactions 
ACTN4 1 hsa-miR-23b-3p MCPH1 1 hsa-miR-146a, 
AMELX 1 hsa-miR-148a-3p MECP2 1 hsa-miR-155-5p 
API5 2 hsa-miR-224,                        
hsa-miR-224-5p 
MMP1 1 hsa-miR-145-5p 
ARID4A 1 hsa-miR-21-5p, MPP5 3 hsa-miR-148a-3p, 
hsa-miR-155-5p, 
hsa-miR-21-5p 
ARIH1 1 hsa-miR-17-5p MYBL2 1 hsa-miR-423-5p 
ATP5G2 2 hsa-miR-125a-5p,                    
hsa-miR-629-5p 
MYEF2 1 hsa-miR-21-5p 
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ATXN7 2 hsa-miR-17-5p,             
hsa-miR-342-3p 
NAP1L4 1 hsa-miR-196a-5p 
C2 1 hsa-miR-142-3p NCAPD2 1 hsa-miR-155-5p 
C4BPB 1 hsa-miR-142-3p NETO2 1 hsa-miR-21-5p 
CCL1 1 hsa-miR-17-5p NFKB2 1 hsa-miR-423-5p 
CCND1 4 hsa-miR-155,                             
hsa-miR-155-5p,                  
hsa-miR-17-5p,                    
hsa-miR-196a-5p 
NOTCH4 1 hsa-miR-181c-5p 
CCNI 2 hsa-miR-148a-3p,                    
hsa-miR-423-5p           
OASL 1 hsa-miR-146a-5p 
CCR1 1 hsa-miR-21-5p OLFML2A 1 hsa-miR-146a-5p 
CCT7 1 hsa-miR-23b-3p OTUB2 1 hsa-miR-125a-5p 
CDH6 1 hsa-miR-23b-3p PDE3A 1 hsa-miR-155-5p 
CDKN1A 6 hsa-miR-125a-5p,  
hsa-miR-145-5p,  
hsa-miR-146a-5p,  
hsa-miR-17-5p,  
hsa-miR-21, 
 hsa-miR-298 
PGR 1 hsa-miR-126-3p 
CHAF1B 1 hsa-miR-155-5p PHACTR2 1 hsa-miR-21-5p 
CLDN1 1 hsa-miR-155-5p PHF14 1 hsa-miR-155-5p 
COL4A1 1 hsa-miR-125a-5p PLAT 1 hsa-miR-21-5p 
CTGF 1 hsa-miR-145-5p PPFIBP1 1 hsa-miR-155-5p 
CTSA 2 hsa-miR-155-5p,  
hsa-miR-17-5p 
PPP2R2A 1 hsa-miR-155-5p 
CYCS 1 hsa-miR-148a-3p PRLR 1 hsa-miR-181a-5p 
DCBLD2 1 hsa-miR-17-5p PTPN22 1 hsa-miR-181a-5p 
DDX46 1 hsa-miR-21-5p PTPRD 2 hsa-miR-141,  
hsa-miR-141-3p 
DRAP1 2 hsa-miR-155-5p,  
hsa-miR-423-5p 
PTTG1 2 hsa-miR-17-5p, 
hsa-miR-423-5p 
EIF4A2 1 hsa-miR-21-5p RANBP9 1 hsa-miR-196a-5p 
ELOVL4 1 hsa-miR-21-5p RASGRP3 1 hsa-miR-21-5p 
EPHA7 1 hsa-miR-196a-5p RBL1 1 hsa-miR-17-5p 
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ERBB4 1 hsa-miR-146a-5p RBM22 1 hsa-miR-155-5p 
ETS1 2 hsa-miR-155,  
hsa-miR-155-5p 
RIF1 1 hsa-miR-155-5p 
FAM135A 1 hsa-miR-155-5p RPL18A 2 hsa-miR-181b-
5p, hsa-miR-423-
5p 
FAM3C 5 hsa-miR-145-5p,  
hsa-miR-155-5p,  
hsa-miR-21,                 
hsa-miR-21-5p, 
hsa-miR-342-3p 
RPL37 1 hsa-miR-17-5p 
FAM46A 1 hsa-miR-21-5p RPS27A 2 hsa-miR-17-5p, 
hsa-miR-23b-3p 
FERMT1 1 hsa-miR-125a-5p RPSA 1 hsa-miR-17-5p 
FGG 1 hsa-miR-409-3p RUFY3 1 hsa-miR-21-5p 
FSCN1 2 hsa-miR-145,  
hsa-miR-145-5p 
SIK2 1 hsa-miR-181a-5p 
FZD7 1 hsa-miR-145-5p SLC16A1 1 hsa-miR-23b-3p 
GCNT1 1 hsa-miR-181a-5p SLC35F2 1 hsa-miR-155-5p 
GHITM 2 hsa-miR-155-5p,  
hsa-miR-23b-3p 
SLC7A2 1 hsa-miR-423-5p 
GNAS 2 hsa-miR-155-5p,  
hsa-miR-17-5p 
SMAD4 4 hsa-miR-146a-5p, 
hsa-miR-155-5p, 
hsa-miR-17-5p,                  
hsa-miR-224-5p 
H3F3B 1 hsa-miR-181a-5p SMARCE1 1 hsa-miR-155-5p 
HAX1 1 hsa-miR-155-5p SPP1 1 hsa-miR-146a-5p 
HEY2 1 hsa-miR-181a-5p STAT1 3 hsa-miR-145-5p, 
hsa-miR-146a, 
hsa-miR-146a-5p, 
HIST1H2AC 1 hsa-miR-629-5p STIM1 1 hsa-miR-155-5p 
HIST2H2BE 1 hsa-miR-423-5p SULF1 1 hsa-miR-516a-5p 
HNRNPK 3 hsa-miR-21,  
hsa-miR-21-5p,  
hsa-miR-23b-3p 
SYNDIG1 1 hsa-miR-17-5p, 
HOXA7 3 hsa-miR-196a,  
hsa-miR-196a-5p,  
hsa-miR-423-5p 
SYNE2 2 hsa-miR-155-5p, 
hsa-miR-21-5p 
HSPA4L 1 hsa-miR-155-5p TAB2 4 hsa-miR-155-5p, 
hsa-miR-181a-5p, 
hsa-miR-196a-5p,                 
hsa-miR-23b-3p 
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IFI27 1 hsa-miR-146a-5p TCF21 2 hsa-miR-181a-5p, 
hsa-miR-21-5p 
IFI44 1 hsa-miR-146a-5p TNFAIP3 4 hsa-miR-125a-5p, 
hsa-miR-21-5p, 
hsa-miR-125a-5p,                 
hsa-miR-21-5p 
IFI44L 1 hsa-miR-146a-5p TNIP1 1 hsa-miR-181a-5p 
IFIT1 1 hsa-miR-146a-5p TRA2B 2 hsa-miR-17-5p, 
hsa-miR-196a-5p 
IFIT3 1 hsa-miR-146a-5p TRAF6 2 hsa-miR-146a, 
hsa-miR-146a-5p 
IGFBP5 1 hsa-miR-17-5p TSPAN12 1 hsa-miR-196a-5p 
IMPAD1 1 hsa-miR-155-5p UBE2L3 1 hsa-miR-423-5p 
IRAK1 6 hsa-miR-146a,  
hsa-miR-146a-5p,  
hsa-miR-17-5p,  
hsa-miR-146a,  
hsa-miR-146a-5p,  
hsa-miR-17-5p 
UGT8 1 hsa-miR-155-5p 
ISG15 1 hsa-miR-146a-5p VAV2 1 hsa-miR-155-5p 
KAT2A 1 hsa-miR-17-5p YWHAZ 2 hsa-miR-155-5p, 
hsa-miR-423-5p, 
KAT2B 2 hsa-miR-181a-5p,  
hsa-miR-181b-5p 
ZBTB24 1 hsa-miR-196a-5p 
KRT7 2 hsa-miR-145,  
hsa-miR-145-5p 
ZFPM2 1 hsa-miR-141-3p 
LAMB1 1 hsa-miR-125a-5p ZNF273 1 hsa-miR-155-5p 
MACF1 1 hsa-miR-125a-5p ZNF587 1 hsa-miR-21-5p 
MAFB 1 hsa-miR-155-5p ZNF667 1 hsa-miR-21-5p 
MATR3 2 hsa-miR-155,  
hsa-miR-155-5p 
   
11.7.2.2. Test 2: NOT Verified in BioMart, n = 3 VS interacting 
genes                                                                                  
Python Script 16: ‘PS16_Test_Gene_2.py’ 
Of the 749 differentially-expressed lupus genes, in Ensembl ID format, 13 gene 
IDs were reported as deprecated IDs within the database and thus were not 
processed further. Of the 85 lupus-associated genes curated from literature, 
three genes, namely CREBL1, IRF53, and Lyn, were not found in the BioMart 
database. None of these three genes were found in the list of interacting genes, 
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and an empty file was created and named 
‘NOT_verified_Genes_IN_interacting.txt’, demonstrating no interactions being 
obtained. All three genes curated from literature and not verified in BioMart, 
were written to the file ‘NOT_verified_Genes_NOT_IN_interacting.txt’. 
11.8. Identification of Top Regulating miRNAs 
From the cross-analysis of the curated SLE-associated miRNAs, 42/123 non-
unique miRNAs was found to interact with the curated SLE-associated genes. Of 
the 42 non-unique starting miRNAs, six miRNAs were identified to interact with 
ten or more SLE-associated genes, as shown in Table 24. 
Table 24: The six miRNAs which were identified to interact with 10 or more SLE-associated genes  
 miRNA name: No. of miRNA -> gene 
interactions: 
 hsa-miR-17-5p 19 
 hsa-miR-423-5p 11 
 hsa-miR-21-5p 20 
 hsa-miR-146a-5p 15 
 hsa-miR-181a-5p 10 
 hsa-miR-155-5p 35 
Total : 6 110 
 
Thus, the six top regulating SLE-associated miRNAs were pooled with their 
corresponding interactions and written to a file named ‘all_top_regulating_ 
miRNAs.txt’. This file contained 116 raw data entries to be used in pathway 
analysis. 
11.9. Identification of Top Regulated Genes 
From the cross-analysis of the pooled list of curated SLE-associated- and 
differentially-expressed genes, 127/813 genes were found to interact with the 
curated SLE-associated miRNAs. Of the 127 genes, seven genes were identified to 
interact with four or more SLE-associated miRNAs as shown in Table 25.  
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Table 25: The seven genes which were identified to interact with 4 or more SLE-associated 
miRNAs  
 Gene name: No. of gene -> miRNA 
interactions: 
 CCND1 4 
 CDKN1A 6 
 FAM3C 5 
 SMAD4 4 
 TAB2 4 
 TNFAIP3 4 
 IRAK1 6 
Total: 7 33 
 
Thus, the seven top regulating SLE-associated genes were pooled with their 
corresponding interactions and written to a file named ‘all_top_regulating_ 
genes.txt’, to be used in biological pathway analysis. 
11.10. Pooling of all Top Regulators 
The top regulated miRNAs and top regulating genes were pooled into a single 
data file named ‘all_top_regulated.txt’. The six top regulating miRNAs along with 
the 110 associated gene targets, and the seven top regulated genes along with 
the 33 interacting miRNAs were pooled to create a file of all the top regulated 
elements from this study. Thus, the file contained a list of 156 raw data entries 
which was used in pathway analysis. 
11.11. Pathway Analysis 
11.11.1. Preparation of dataset files 
Two python scripts, Python Script 17: ‘PS17_prep_genes_for_IPA.py’ and Python 
Script 18: ‘PS18_prep_miRNAs_for_IPA.py’, were written to prepare the 
individual dataset files into lists of unique identifiers. 
11.11.1.1. Starting Genes and miRNAs 
Using Python Script 17: ‘PS17_prep_genes_for_IPA.py’, the starting list of genes 
and miRNAs was created by pooling the known SLE-associated genes from 
literature (n = 82), the known list of differentially-expressed genes, verified in 
BioMart (n = 736), and the known miRNAs curated from literature (n = 57). Using 
the set() function in this Python script, the list of 875 items was reduced to a list 
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of 869 unique identifiers. These 869 identifiers were then uploaded into IPA as a 
dataset. Of the total, 866 identifiers were mapped, and three identifiers were 
unmapped in the IPA database. The three unmapped IDs were: ‘HLA-DRB2’, ‘RP1-
152L7.5’, and ‘RP4-802A10.1’.  
11.11.1.2. Interacting Genes and miRNAs 
The list of interacting genes and miRNAs was produced as a result of pooling the 
interacting targets, as obtained by the analysis of the miRTarBase, and 
miRecords databases. For the curated miRNAs which were verified in miRBase, 
2702 unique gene interactions were identified. For the starting genes verified in 
Ensembl BioMart, 291 unique interacting miRNAs were identified collectively in 
miRTarBase and miRecords. Thus, the raw data file of interacting miRNAs and 
genes contained 2993 identifiers. Of the 2993 identifiers, 2969 IDs were mapped, 
and 24 IDs were unmapped in the IPA database.  
11.11.1.3. All Genes and miRNAs (starting, and interacting) 
A complete list of all verified, starting miRNAs and genes, as well as the 
interacting miRNAs and genes were pooled into a single list. As shown in 11.6.1 
and 11.6.2 respectively, 291 unique interacting miRNAs and 2702 unique 
interacting genes were pooled along with the starting, and verified differentially-
expressed genes, and genes curated from literature. This list contained a total of 
3868 entries.  
In a Python script, the set() function was employed to create a unique list of 
identifiers, and remove any duplicate entries. A unique list of 3713 entries was 
created and these were then analysed by IPA in preparation for analysis. Of the 
3713 entries, 3687 were mapped to identifiers in the IPA database, and 26 
identifiers remained unmapped.  
11.11.1.4. All Top Regulating miRNAs and associated genes 
As described in Table 24, six top regulating miRNAs and the 110 interacting genes 
were included for this dataset. Thus, this file contained 116 non-unique 
identifiers. All 116 identifiers were mapped in IPA, and duplicate entries were 
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flagged. Post preparation, this file contained 101 analysis-ready molecules, as 
determined by IPA. 
11.11.1.5. All Top Regulated Genes and associated miRNAs 
As shown in Table 25, seven top regulated genes were identified from the cross-
analysis, along with 33 interacting miRNAs. Therefore, this file contained 40 
identifiers. Duplicate entries were flagged and as a result, this dataset contained 
22 analysis-ready molecules.  
11.11.1.6. All Top Regulated Genes and miRNAs and associations 
This dataset comprised of the pooled top regulators and their associations, as 
described in 11.10. The raw data list contained 156 identifiers, and after 
processing by IPA, 108 unique analysis-ready molecules were reported.  
11.11.2. Uploading of datasets into IPA 
All prepared data sets were uploaded into IPA. A dataset summary was also 
provided, showing how many of the raw data entries were mapped, and 
unmapped in the IPA database, as shown in Table 26.  
Table 26: The dataset summary provided for the skeleton dataset submitted to IPA for Core 
Analyses 
Dataset Raw data No. of entries mapped 
in IPA 
No. of entries unmapped 
in IPA 
0BAll Top Regulated Genes and miRNAs and 
associations 
 
 
156 
 
156 
 
0 
1BAll Top Regulating miRNAs and associated 
genes 
 
 
116 
 
116 
 
0 
2BAll Top Regulated Genes and associated 
miRNAs 
 
 
40 
 
40 
 
0 
3BAll Genes and miRNAs (starting, and 
interacting) 
 
 
3713 
 
3687 
 
26 
4BStarting Genes and miRNAs 
 
 
869 
 
866 
 
3 
5BInteracting Genes and miRNAs 
 
 
2993 
 
2969 
 
24 
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For the ‘All Genes and miRNAs (starting, and interacting)’ dataset of 3713 
entries, 3687 data entries were mapped to identifiers in the IPA database. 
However, I noticed that not all the data entries were exact string matches to the 
curated data identifiers. Thus, I wrote two Python scripts named 
‘PS19_ALL_mapped_IDs_prepped.py’, and ‘PS20_Test_IPA_mapping’.  
The ‘PS19_ALL_mapped_IDs_prepped.py’ script analysed the dataset summary 
which I exported from IPA. I copied the contents of the ‘mapped’ IDs tab to a 
standard text file. The first column on the file was tested to identify which 
entries started with ‘hsa-‘. These entries were then stripped of the ‘hsa-‘ part, to 
standardise it against the second column, which was the mapped IDs identified 
by IPA, and already specified to be human. The modified first column was then 
manually copied, and pasted in an empty Excel spreadsheet.   
The second column, containing the IPA mappings, was then searched, to identify 
any IDs which were separated from additional information by an empty space, 
i.e. (‘ ‘). These mapped IDs were stripped of the empty space, and thus the first 
column retained. This modified second column was then manually copied, and 
pasted into the Excel document, in the column directly adjacent to the column 
which had been stripped of the ‘hsa-‘ string. This Excel sheet was then saved as a 
text file named ‘mapped_IDs.csv’.  
Thereafter, the ‘PS20_Test_IPA_mapping.py’ script was used to open the 
‘mapped_IDs.csv’ file, and then attempt to perform a perfect string match 
between the first column containing the input curated ID, and the corresponding 
second column containing the ID mapped in the IPA database.  
For the 3687 IDs mapped in the IPA database, 3466 input entries were matched 
as an exact string match, and were written to an output text file named 
‘mapped_IDs_exact_match.txt’, while 221 IDs were mapped to IDs in IPA which 
were not identical to the input ID, and were written to the output text file 
‘mapped_IDs_NOT_matched.txt’. These 221 curated entries, which were 
mapped to IDs not having exactly the same gene name in the IPA database, can 
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be found in ADDENDUM K. For the same dataset, 26 data entries were not 
mapped to the IPA database, and thus were excluded from the Core Analysis. 
They were: SHIP, IRF-5, pten, RP1-152L7.5, cmyb, RP4-802A10.1, MeCP2, HLA-
DRB2, MKK4, MCP2, tp63, Peli1, KGF, CTLA-4, MyD88, IL-8, MSK1, CDNK1B, IGF-
IR, NFAT1, HuR, Rps6ka5, gag-pol, FOG2, NT-3, hsa-miR-1274a.  
11.11.3. Core Analysis  
A core analysis, as shown in Figure 25, was run on the ‘All Top Regulated Genes 
and miRNAs and associations’ dataset file, as this dataset formed the skeleton of 
the regulatory networks. Using the parameters previously described, 156 entries 
of raw data were assessed in preparation for Core Analysis. IPA flagged and 
removed any duplicate entries creating a list of 108 Analysis-ready molecules.  
These were: ARID4A, ARIH1, ATXN7, CCL1,CCND1, CCNI, CCR1, CDH6, CDKN1A, 
CHAF1B, CLDN1, CTSA, DCBLD2, DDX46, DRAP1, EIF4A2, ELOVL4, ERBB4, ETS1, 
FAM135A, FAM3C, FAM46A, GCNT1, GHITM, GNAS, H3F3B, HAX1, HEY2, 
HIST2H2BE, HNRNPK, HOXA7, hsa-miR-125a-5p, hsa-miR-145-5p, hsa-miR-146a-
5p, hsa-miR-155, hsa-miR-17-5p, hsa-miR-181a-5p ,hsa-miR-196a-5p, hsa-miR-
21-5p, hsa-miR-224-5p, hsa-miR-23b-3p, hsa-miR-298, hsa-miR-342-3p, hsa-miR-
423-5p, HSPA4L, IFI27, IFI44, IFI44L, IFIT1, IFIT3, IGFBP5, IMPAD1, IRAK1,ISG15, 
KAT2A, KAT2B, MAFB, MATR3, MECP2, MPP5, MYBL2, MYEF2, NCAPD2, NETO2, 
NFKB2, OASL, OLFML2A, PDE3A, PHACTR2, PHF14, PLAT, PPFIBP1, PPP2R2A, 
PRLR, PTPN22, PTTG1, RASGRP3, RBL1, RBM22,RIF1, RPL18A, RPL37, RPS27A, 
RPSA, RUFY3, SIK2, SLC35F2, SLC7A2, SMAD4, SMARCE1, SPP1, STAT1, STIM1, 
SYNDIG1, SYNE2, TAB2, TCF21, TNFAIP3, TNIP1, TRA2B, TRAF6, UBE2L3, UGT8, 
VAV2, YWHAZ, ZNF273, ZNF587, ZNF667 . The Core Analysis was then run on this 
dataset of 108 molecules.  
The canonical pathways tab provided a default bar chart view of the biological 
pathways associated with the dataset on which the Core Analysis was run. Using 
the parameters described in the Methods section, a bar graph was generated for 
the Canonical Pathways identified for this dataset. The first quarter of the bar 
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graph is shown in Figure 26. Overlapping pathways were viewed and are shown 
in Figure 27. The heat map generated for this dataset is reported in Figure 28. 
11.11.3.1. Networks 
For the ‘All Top Regulated Genes and miRNAs and associations’ dataset, 
consisting of 108 analysis- ready molecules, the Core Analysis generated five 
networks. The network details for the skeleton dataset are shown in Table 29.
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11.11.3.2. Summary of Core Analysis 
 
 
 
 
 
 
 
 
 
.  
Figure 25: Summary of the Core Analysis performed by IPA. The core analysis reports on multiple parameters. The Top Canonical pathways, top upstream regulators, 
and top diseases for this dataset were selected for reporting. 
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11.11.3.3. Canonical Pathways 
Figure 26: The top 18 canonical pathways impacted by the 'All Top Regulated' dataset. This image shows that many of the genes and miRNAs in the ‘All Top Regulated’ dataset were 
mapped to important immune-regulatory pathways. These particularly included Interferon signalling, and Toll-like receptor signalling.  
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Figure 27: Generated in IPA, this image shows the overlap of 24 biological pathways.  
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Figure 28: A Heat map of all 25 diseases associated with this dataset. The heat map illustrated that many of the molecules in the skeleton dataset are associated with organismal injury processes, cancer, 
and cell cycle processes. 
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11.11.3.4. Upstream Analysis 
Table 27: The Top 25 Upstream regulators as determined by the IPA Core Analysis 
Upstream 
Regulator 
Molecule Type p-value of 
overlap 
Target molecules in dataset 
Histone h4 group 1.61E-04 CCND1,CDKN1A,PRLR,RBL1 
N-cor group 1.20E-03 CCND1,CDKN1A 
estrogen 
receptor 
group 1.75E-03 CCND1,ERBB4 
Creb group 1.94E-03 CCND1,CDKN1A,GNAS 
Histone h3 group 1.95E-03 CCND1,CDKN1A,PRLR,RBL1,SYNE2 
FKHR group 5.26E-03 CCND1 
TFIIH complex 5.26E-03 CDKN1A 
ISGF3 complex 5.26E-03 ISG15 
CALCOCO1 transcription 
regulator 
5.26E-03 CCND1 
ZBTB7C other 5.26E-03 CDKN1A 
CXXC1 transcription 
regulator 
5.26E-03 CDKN1A 
VENTX transcription 
regulator 
5.26E-03 CCND1 
PADI4 enzyme 1.05E-02 CDKN1A 
THRAP3 transcription 
regulator 
1.05E-02 CCND1 
TRIM29 transcription 
regulator 
1.05E-02 CDKN1A 
RPRD1B other 1.05E-02 CCND1 
FOXG1 transcription 
regulator 
1.05E-02 CDKN1A 
PRDM16 transcription 
regulator 
1.05E-02 CDKN1A 
HSF1 transcription 
regulator 
1.38E-02 EIF4A2,HSPA4L,TRA2B 
ZMIZ2 transcription 
regulator 
1.57E-02 CCND1 
TIP60 complex 1.57E-02 RBL1 
Cebp complex 2.60E-02 PRLR 
E2f group 3.74E-02 MYBL2,RBL1 
E2F8 transcription 
regulator 
4.13E-02 CCND1 
NR0B1 ligand-
dependent 
nuclear receptor 
4.13E-02 HSPA4L 
 
The analysis of upstream regulators showed the upstream regulators of the data 
in the skeleton dataset. The results are shown in Table 27. 
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11.11.3.5. Diseases and Functions 
A selection of the diseases and functions with a p-value below 0.05, which 
appeared to be associated with SLE pathogenesis can be seen in Table 28. A 
complete list of the result of the diseases and functions associated with this 
dataset can be found in ADDENDUM G. 
Table 28: Disease associations, generated by the Core Analysis of the All Top Regulated dataset, 
which at my discretion appeared to be associated with SLE. 
Categories Diseases or 
Functions 
Annotation 
p-Value Molecules # 
Molecules 
Immunological 
Disease 
systemic 
autoimmune 
syndrome 
1.59E-07 ARIH1,CCL1,CCR1,CTSA, 
H3F3A/H3F3B,IFIT1, 
IGFBP5,ISG15,MAFB, 
miR-155-5p,miR-17-5p, 
miR-196a-5p,miR-21-5p, 
miR-298, OASL,PTPN22, 
RPL18A,RPSA,SLC7A2, 
SPP1,STAT1,TNFAIP3, 
UBE2L3 
23 
Inflammatory 
Disease 
chronic 
inflammatory 
disorder 
5.77E-04 ARIH1,CCL1,CCR1, 
H3F3A/H3F3B,IGFBP5, 
MAFB,miR-155-5p,miR-17-5p 
,PDE3A,PTPN22,RASGRP3, 
RPL18A,RPSA,SLC7A2,SPP1, 
STAT1,TNFAIP3 
17 
Inflammatory 
Response 
inflammation of 
organ 
4.63E-05 ARIH1,H3F3A/H3F3B, 
IFI27,miR-125b-5p, 
miR-145-5p, 
miR-155-5p,miR-17-5p , 
miR-21-5p,miR-224-5p, 
miR-23a-3p,miR-423-5p, 
PDE3A,SPP1,STAT1, 
SYNE2,TNFAIP3 
16 
Inflammatory 
Response 
inflammation of 
body region 
1.31E-03 miR-125b-5p,miR-145-5p, 
miR-17-5p,miR-21-5p, 
miR-224-5p, miR-23a-3p, 
miR-423-5p,PDE3A,SPP1, 
STAT1 
10 
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Table 29: The five networks generated by IPA Core Analyses, using the skeleton dataset of Top regulating miRNAs and Top Regulated genes 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and Functions 
1 ABCC5,AGO2,ALOX12B,ARPC2,ATP6V0A1,BACH2,BRCA1, 
CARS,CDKN2A,CLDN1,DDX46,ERG,ESR1,ETS1,FAM3C,FOXD1, 
GAK,glutathione peroxidase,GTSE1,H3F3A/H3F3B,HEY2,HIF1A, 
HOXA7,IFI44,IFI44L,ISG15,MAGI1,MAPK12,MBD1,MECP2,mir-324, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-194-5p (miRNAs w/seed GUAACAG), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
NDUFA13,NFKB2,NOTCH1,NUCKS1,NUPR1,P4HA2, 
PFKFB3,PHACTR2,PSEN1,PTPN22,RBMS1,RPS27A, 
SESN2,SIK2,SLC2A12,SLC39A8,SLC7A2,SMARCE1, 
STAT3,STIM1,STX3,TMEM19,TMEM97,TNFAIP8L1,TNIP1,TP53, 
UNC5B,VCP,WDR91 
43 29 Cancer, Organismal Injury and 
Abnormalities, Reproductive 
System Disease 
2 AHSP,AKAP8,ASF1B,ATP13A2,BTG3,CCND1,CD274,CDCA7L, 
CDK14,CDKN1A,Creb,Cyclin A,DCBLD2,DCTPP1,DRAP1, 
ERBB4,ERMAP,estrogen receptor,EXOSC8,FANCI,G6PD,GNAS, 
HDAC9,HDAC10,HIST2H2BE,Histone H1,Histone h3,Histone h4, 
HNRNPK,HSD11B2,HSPH1,IFI27,IGFBP5,INS,KAT2B, 
LOC102724788/PRODH, 
39 27 Cell Cycle, Cancer, Organismal 
Injury and Abnormalities 
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miR-145-5p (and other miRNAs w/seed UCCAGUU), 
MTBP,MYBL2,MYC,MYEF2,NCAPD2,NPAT,Patched, 
PDE3A,PPP2R2A,PRLR,PTTG1,RBL1,RBM39,RIF1, 
RNA polymerase II,RPL10A,RPRD1B,RUFY3,SERINC3, 
SFRP1,SMAD4,SPTA1,STAT1,STOM,SYNE2,TCF21, 
TFAP2A,TPM3,WNT7B,YWHAQ,YWHAZ,ZMIZ2,ZNF451 
3 ARID4A,ARIH1,ATXN7,CCL1,CCR1,CD44,CHAF1B,CSF2RA, 
DDX58,EDARADD,EFTUD2,EIF4A2,GRB2,HAX1,HCLS1, 
HNRNPA3,HNRNPL,HSF1,HSPA4L,IFIT1,IFNB1,IL1R1,IL36B, 
IL7R,IRAK1,IRAK2,IRAK3,IRF4,KARS,KAT2A,KHDRBS1,KHDRBS3, 
Laminin,MAFB,MATR3, 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
OASL,PAX5,PELI1,PELI3,PHLDB1,PLAT,RBBP4,RPL18A,RPLP2, 
RPSA,SAP30,SERPINH1,SMARCA4,SNRNP200,SPP1,SWISNF, 
SYNCRIP,TAB2,TADA2A,TADA2B,TFF1,TLR7,TLR8,TNFAIP3, 
TNFRSF9,TNFRSF11A,TRA2B, TRAF6,TSPAN8,UBE2L3,VAV2, 
WDR34,WIPF1,ZC3HAV1 
37 26 Cellular Function and 
Maintenance, Cellular 
Development, Hematological 
System Development and 
Function 
4 CCNI,LIN28A 2 1 Cancer, Organismal Injury and 
Abnormalities, Cell Death and 
Survival 
5 CRB3,MPP5,MPP7 2 1 Cell-To-Cell Signalling and 
Interaction, Cellular Assembly 
and Organization, Cellular 
Function and Maintenance 
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11.11.4. Selection of networks 
Networks 1, 2, and 3 were selected for further analyses as they consisted of 29, 
27, and 26 of my focus molecules, respectively.  
11.11.5. Preparation of selected networks  
For each network, nodes were identified and at my own discretion, spread out to 
create a network image with fewer overlapping relationship lines than in the 
original core network.  
11.11.6. Expanding of selected networks using the Grow Tool 
Using the Grow tool in the Build tab, the complete dataset of starting miRNAs, 
and genes, and interacting miRNAs, and genes found in miRecords and 
miRTarBase, was used to expand each of the core networks. The results of 
expanding the 3 selected networks with the All Genes and miRNAs dataset are 
shown in Table 30, Table 31, and Table 32. 
11.11.6.1. Core Network 1 
Table 30: This table reports the number of molecules which were linked from the All Genes and 
miRNAs dataset to selected nodes in Core Network 1. The additions were performed by IPA using 
existing knowledge on gene interactions in the database.  
Node selected Number of molecules 
added 
Node selected Number of 
molecules added 
SMARCE1 11 NUPR1 25 
AGO2 25 RBMS1 1 
BACH2 0 FOXD1 1 
NOTCH1 17 miR-155-5p 3 
HEY2 2 miR-23a-5p 0 
miR-194-5p 1 miR-224-5p 0 
NDUFA13 0 miR-17-5p 8 
miR-298 0 FAM3C 0 
STIM1 2 MBD1 6 
PTPN 1 ATP6V0A1 0 
WDR91 0   
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11.11.6.2. Core Network 2 
Table 31: This table reports the number of molecules which were linked from the All Genes and 
miRNAs dataset to selected nodes in Core Network 2 
Node selected Number of 
molecules added 
Node selected Number of 
molecules 
added 
HDAC9 3 BTG3 0 
CDKN1A 1 INS 0 
estrogen receptor 12 ASF1B 1 
IRPRD1B 1 AHSP 1 
MTBP 2 RPL10A 1 
ZMIZ2 0 G6PD 1 
HSPH1 0 SPTA1 0 
SERPINC3 0 CD274 2 
CDCA7L 7 ATP13A2 0 
YWHAQ 11 EXOSC8 0 
TFAP2A 16 ZNF451 0 
Creb 19 SMAD4 25 
AKAP8 0 KAT2B 3 
RBM39 1 PRCR 1 
11.11.6.3. Core Network 3 
Table 32: This table reports the number of molecules which were linked from the All Genes and 
miRNAs dataset to selected nodes in Core Network 3 
Node selected Number of 
molecules 
added 
Node selected Number of 
molecules 
added 
TADA2A 2 SNRNP200 2 
KAT2A 4 EFTUD2 1 
ATXN 7 WIPF1 3 
PAX 5 PHLDB1 1 
TADA2B 1 TSPAN8 1 
CHAF1B 2 IL1R1 7 
RBBP4 9 HCLS1 1 
SAP30 0 KHDRB53 3 
IRF4 19 CSF2RA 0 
TNFRSF9 2 KHDRBS1 25 
TFF1 18 KARS 3 
EDARADD 0 PEL13 1 
TNFRSF11A 0 RPLP2 2 
HSF1 25 SYNCRIP1 1 
ZC3HAV1 0 miR-146a-5p 13 
 
A full-page print out of these three expanded networks, prepared for the 
overlays with the subsets of data, can be viewed in ADDENDUM H, ADDENDUM I, 
and ADDENDUM J.  
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11.11.7. Overlaying of Core Network 1 
As shown in Table 30, Core Network 1 was generated having 29 molecules from 
the dataset of All Top Regulated Genes and miRNAs being placed into a network 
of 70 molecules. The top diseases and functions found to be associated with 
molecules in Core Network 1 were cancer, organismal injuries and abnormalities, 
and reproductive system diseases.   
 
 
 
 
 
 
 
 
 
 
 
As can be seen in Figure 29, 43 of the curated genes and miRNAs were mapped 
onto Core Network 1, as highlighted in yellow. Most of these curated genes and 
miRNAs lie on the outskirts of the network, and are regulated by genes or 
miRNAs not in the starting list. Two genes and three miRNAs (outlined by the 
blue box) are present in the list of curated genes and miRNAs, but are all 
regulated by TP53, a gene not present in the starting list.  
Figure 29: Core Network 1 overlaid with Starting Genes and miRNAs. Of the 866 Starting Genes 
and miRNAs mapped in IPA, 43 IDs were found in Core Network 1, composed of 198 molecules. 
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In contrast, miR-17-5p, a curated miRNA ID (light green box), was shown to 
directly interact with eight genes not present in the starting list of IDs. Similarly, 
SMARCE1 (orange box) appeared as a node in this network, as it directly 
interacted with PGR, a curated gene, but was also shown to interact with 12 
genes not associated with SLE in recent literature. The NOTCH1 gene (outlined by 
the purple box) exhibited direct interactions with five known lupus-associated 
genes. One of the interactions, with the gene HEY2, was expanded and then 
further shown to also have direct interactions with the known lupus gene 
NOTCH4, as well as with NOTCH2, a gene not yet associated with lupus 
pathogenesis. 
It is evident from Figure 30 that most of the molecules in the list of interacting 
genes and molecules can be seen in Core Network 1, as highlighted in brown. As 
shown in Figure 29 and now in Figure 30, miR-17-5p, and SMARCE1 appear as a 
nodal miRNA, and nodal gene, respectively. However, in contrast to Figure 29, 
miR-17-5p and SMARCE1 are now also shown to each interact with numerous 
Figure 30: Core Network 1 overlaid with Interacting Genes and miRNAs. Of the 2969 Interacting Genes and miRNAs 
mapped in IPA, 162 IDs were found in Core Network 1, composed of 198 molecules. 
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genes from the list of interacting genes, gathered from the analysis through 
miRTarBase, and miRecords.  
The gene AGO2 was not identified as a starting gene in Figure 29. However, in 
Figure 30, AGO2 (yellow box) is identified as one of the genes shown to interact 
with a known lupus-associated miRNA. Here, AGO2 is also shown to interact 
directly with numerous miRNAs, which were found as new interactions for the 
known lupus-associated genes, and were not present in the starting list of lupus-
associated miRNAs.  
 
 
 
 
 
 
 
 
 
 
 
Figure 31 is overlaid with the ‘All Top Regulating miRNAs and associated genes’ 
list. These miRNAs were selected as they interacted with ten or more of the 
known lupus-associated genes. Of the six top regulating miRNAs selected to build 
the core networks (see 11.8), four miRNAs can be seen above. MiRNA miR-17-5p 
(light green box), which is also a miRNA from the starting list of miRNAs (see 
Figure 31: Core Network 1 overlaid with All Top Regulating miRNAs and associated genes. Of the 
116 All Top Regulating miRNAs, and associated gene targets mapped in IPA, 27 IDs were found in 
Core Network 1, composed of 198 molecules. 
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Figure 29)  is shown here to be one of the top regulating miRNAs for the starting 
list of lupus-associated genes.  
Interestingly, STIM1 and NFKB2 (orange box) are both shown here to be two 
genes which interact with the top regulating miRNAs. Unlike all of the other 
genes overlaid in Figure 31, these two genes are also shown to directly interact 
with each other, as well as with TP53, identified in Figure 29 to be a gene found 
to interact with a known lupus-associated miRNA.  
 
 
 
 
 
 
 
 
 
 
Figure 32 is overlaid with the ‘All Top Regulating genes and associated miRNAs’ 
list. These genes were selected as they interacted with ten or more of the known 
lupus-associated miRNAs. Of the seven top regulating genes selected to build the 
core networks (see 11.9), four genes can be seen above. Of the 33 miRNAs 
shown in 11.9 to be regulated by the seven top regulating genes, nine miRNAs 
can be identified here in Figure 32. STAT3, identified in Figure 32 as a gene 
interacting with a known lupus-associated miRNA, is also shown here to directly 
interact with miR-181a-5p, and miR-21-5p (outlined by a dark green box). TP53 
Figure 32: Core Network 1 overlaid with Top Regulated Genes and associated miRNAs. Of the 40 
All Top Regulating genes, and associated miRNA targets mapped in IPA, 13 IDs were found in 
Core Network 1, composed of 198 molecules. 
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(outlined by a blue box), was also identified in Figure 30 as a gene interacting 
with a known lupus-associated miRNA, is shown in Figure 32 to directly interact 
with four miRNAs (blue box) which interact with top regulated genes.  
 
  
 
  
 
 
 
 
 
 
 
Figure 33 is overlaid with all the top regulating genes and miRNAs, as well as 
their associations. In Core Network 1, this overlay shows that most of the genes 
and miRNAs from the ‘All Top Regulated’ dataset are widespread across the 
network.   
Figure 33: Core Network 1 overlaid with All Top Regulated Genes and miRNAs and associations. 
Of the 156 All Top Regulating Genes and miRNAs, and associated targets mapped in IPA, 32 IDs 
were found in Core Network 1, composed of 198 molecules. 
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Figure 34 was overlaid with the complete list of all curated genes and miRNAs, 
and their corresponding interactions obtained from the analysis of miRTarBase 
and miRecords. The genes and miRNAs which were not overlaid by the dataset 
were then selected and highlighted in pink, as shown above.  
A number of new genes, added in by IPA to complete Core Network 1, were 
placed centrally within the network. Of note, NUPR1, ESR1, and MED1 (all 
outlined by an orange box), are all genes which were not present in the starting 
list of genes, or in the list of genes interacting with known lupus-associated 
miRNAs. However, as demonstrated by the many genes connected to, and 
overlaid by the complete dataset of all the curated, and interactions data, 
NUPR1, ESR1, and MED1, are shown in this network to interact with many of the 
known lupus-associated genes and miRNAs, as well as those found to interact 
with the curated dataset.  
Figure 34: Core Network 1 overlaid with All Genes and miRNAs, IPA-added molecules in Pink. Of 
the 3687 All Genes and miRNAs, and associated targets mapped in IPA, 26 IDs were not overlaid in 
Core Network 1, and thus allowed for the identification of the molecules added 
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Three miRNAs (outlined in purple), miR-298, miR-194-5p, and mir-324, were also 
added by IPA to complete this network. These three miRNAs are all linked to 
CDKN2A, a gene which in Figure 30 was illustrated to be a new gene found by 
assessment of miRTarBase and miRecords, to interact with a known lupus-
associated miRNA.  
Three genes (outlined by a light green box), STX3, SLC39A8, and TNFAIP8L1, are 
all shown in Figure 34 to be important linking genes between the NUPR1, and 
ESR1 nodal genes, which have also been added in by IPA to complete this 
network.  
Another three genes (outlined by a blue box), P4HA2, FOXD1, and ATP6V0A1, are 
also genes which have been added in by IPA. However, it is important to also 
note that these three genes have direct interactions with genes which have been 
gathered through the interactions assessments of the curated miRNAs list with 
miRTarBase and miRecords. 
Similarly, a five of genes (outlined by a red box) were shown in Figure 34 to be 
key genes linking NUPR1 (an IPA-added gene) and TP53 (a gene found to interact 
with a known lupus-associated miRNA). Two genes, MAPK12 and TMEM97 
(yellow box), were shown to link the nodal genes TP53, and ESR1.  
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11.11.8. Overlaying of Core Network 2 
As can be seen in Table 29, Core Network 2 was generated as having 27 
molecules from the dataset of All Top Regulated Genes and miRNAs being placed 
into a network of 70 molecules. The top diseases and functions found to be 
associated with molecules in Core Network 2 were cell cycle functioning, cancer, 
and organismal injury and abnormalities.  
 
 
 
 
 
 
 
 
 
As can be seen in Figure 35, 54 of the curated genes and miRNAs were mapped 
onto Core Network 2. The distribution of these genes and miRNAs is widespread, 
with most of the molecules lying as inter-connectors between defined nodes.  
Of note, SMAD4, KAT2B, Histone h3, RNA polymerase II, and CCND1 (all outlined 
by a blue box), are all present in the curated list of genes and miRNAs, and they 
appear ad nodal genes in Core Network 2. Each of these nodal genes clearly 
interacted with a number of genes, which are not present in the starting list of 
genes.  
Figure 35: Core Network 2 overlaid with Starting Genes and miRNAs. Of the 866 Starting Genes 
and miRNAs mapped in IPA, 54 IDs were found in Core Network 2, composed of 207 molecules. 
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Interestingly, CCND1 also illustrates direct interactions with genes from the 
curated genes and miRNAs list, namely HIST2H2BE, RIF1, PTTG1, RUFY3, and 
STOM (orange boxes). 
Four genes, HNRNPK, MYBL2, RBL1, and IGFBBP5 (all outlined by a light green 
box) are also shown here to be present in the starting list of curated genes and 
miRNAs, but form integral connections between Histone h4 and MYC (both 
outlined by a red box), which are two genes not present in the starting list of 
genes.  
 
 
 
 
 
 
 
 
 
 
Figure 36 was generated by overlaying Core Network 2 with the list of all 
interacting miRNAs and genes obtained from the analysis of the curated genes 
and miRNAs, in miRTarBase, and miRecords. Most of the molecules in Core 
Network 2 were shown to consist of genes and miRNAs from the list of 
interactions.  However, eight genes (outlined by blue boxes), were present in the 
curated list of genes (see Figure 35), but were not found to interact with the list 
of miRNAs curated from literature.  
Figure 36: Core Network 2 overlaid with Interacting Genes and miRNAs. Of the 2969 Interacting 
Genes and miRNAs mapped in IPA, 157 IDs were found in Core Network 2, composed of 207 
molecules. 
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Figure 37 is overlaid with the ‘All Top Regulating miRNAs and associated genes’ 
list. Of the six top regulating miRNAs selected to build the core networks (see 
11.8), none of the miRNAs were overlaid above. A total of 27 genes, which were 
shown to interact with the top regulating miRNAs, were overlaid in Figure 35.  
Four genes, HNRNPK, MYBL2, RBL1, and IGFBP5 (all outlined by a light green 
box), were shown here to be regulated by the Top Regulating miRNAs. 
Interestingly, these four genes, were also overlaid with the starting list of lupus-
associated genes and miRNAs (see Figure 35), as well as by the list of interacting 
molecules (see Figure 36). Thus, these four genes can be said to be lupus-
associated in terms of literature source, as well as associated with lupus, because 
they have been identified as interacting with known lupus-associated miRNAs.   
Figure 37:  Core Network 2 overlaid with All Top Regulating miRNAs and associated genes. Of the 
116 All Top Regulating miRNAs, and associated gene targets mapped in IPA, 27 IDs were found in 
Core Network 2, composed of 207 molecules. 
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Figure 38 is overlaid with the ‘All Top Regulating genes and associated miRNAs’ 
list. Of the seven top regulating genes selected to build the core networks (see 
11.9), three genes can be seen above. Of the 33 miRNAs shown in 11.9 to be 
regulated by the seven top regulating genes, one miRNA miR-145-5p can be 
identified Figure 38, outlined by a blue box. Compared to Core Network 1 (Figure 
32), Core Network 2’s overlay with the All Top Regulated Genes, shows much 
fewer of this subset of data being present in Figure 38.   
Figure 38: Core Network 2 overlaid with Top Regulated Genes and associated miRNAs. Of the 40 
All Top Regulating genes, and associated miRNA targets mapped in IPA, 4 IDs were found in Core 
Network 2, composed of 207 molecules. 
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Figure 39: Core Network 2 overlaid with All Top Regulated Genes and miRNAs and associations. 
Of the 156 All Top Regulating Genes and miRNAs, and associated targets mapped in IPA, 28 IDs 
were found in Core Network 2, composed of 207 molecules. 
Figure 39 shows Core Network 2 overlaid with all the Top Regulated genes, 
miRNAs, and their corresponding interactions, as determined by analysis of 
miRTarBase and miRecords. All of the genes highlighted by the overlay above 
appear in either Figure 37 or Figure 38.  
 
 
 
 
 
 
 
 
 
Figure 40: Core Network 2 overlaid with All Genes and miRNAs, IPA-added molecules in Pink. Of 
the 3687 All Genes and miRNAs, and associated targets mapped in IPA, 25 IDs were not overlaid 
in Core Network 2, and thus allowed for the identification of the molecules added by IPA. 
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Figure 40 was overlaid with the complete list of all curated genes and miRNAs, 
and their corresponding interactions. Those genes not overlaid by the dataset, 
but added in by the IPA database, were selected and highlighted in pink.  
A  cluster consisting of five genes (outlined by a blue box) namely RBM39, BTG3, 
INS, ASF1B, AHSP, were all shown to interact with a known lupus-associated 
gene, Histone h3 (as seen in Figure 35), and also with Histone h4, a new gene 
added in by IPA to complete this section of Core Network 2.  
A number of genes (outlined by a light green box), were also added by IPA, and 
can be seen here to interact either directly or indirectly, with a starting- and 
interacting gene named CCND1, and MYC- which was only found to interact with 
a known lupus-associated miRNA.  
Of importance, Figure 40 shows how, along with Histone h4 already described, 
HDAC9, TFAP2A, YWHAQ, and estrogen receptor (all outlined by a red box), are 
new genes added by IPA, and appear to be nodal genes, interacting with 
numerous genes from the complete dataset of starting, and interacting genes 
and miRNAs.  
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11.11.9. Overlaying of Core Network 3 
As can be seen in Table 29, Core Network 3 was generated having 26 molecules 
from the dataset of All Top Regulated Genes and miRNAs being placed into a 
network of 70 molecules. The top diseases and functions found to be associated 
with molecules in Core Network 3 were cellular function and maintenance, 
cellular development, and haematological system development and function.  
 
 
 
 
 
 
 
 
 
 
 
Figure 41 is overlaid with the dataset containing all the curated genes and 
miRNAs. A total of 35 genes and one miRNAs were mapped onto Core Network 3 
above. Most of the genes mapped from this dataset lay on the periphery of the 
network. Of the 36 identifiers overlaid on this core network, only TRAF6, and 
miR-146a-5p appeared from this dataset to be a nodal gene and miRNA, 
respectively. 
 
Figure 41: Core Network 3 overlaid with Starting Genes and miRNAs. Of the 866 Starting Genes 
and miRNAs mapped in IPA, 56 IDs were found in Core Network 3, composed of 216 molecules 
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Figure 42 shows Core Network 3 overlaid with all the genes and miRNAs found to 
interact with the set of curated genes and miRNAs, showing an association with 
lupus pathogenesis. The distribution of the overlay is widespread across the 
network. However, it is interesting to note that three genes, IRF5, IRF8, and IRF9, 
are not overlaid by the interactions dataset. These three genes were however, 
overlaid by the starting genes and miRNAs dataset in Figure 41. Thus, these three 
genes are considered in recent literature, or reported in the meta-analysis, to be 
associated with SLE, but these three genes were according to the analysis of 
miRTarBase, and miRecords, not found to be regulated by any of the curated 
lupus-associated miRNAs. Most of the genes from the overlay dataset of 
interacting genes and miRNAs are shown to be interacting with nodal genes 
(outlined by a red box), which were not found in miRTarBase or miRecords, to 
interact with any of the known lupus-associated miRNAs.  
 
Figure 42: Core Network 3 overlaid with Interacting Genes and miRNAs. Of the 2969 Interacting 
Genes and miRNAs mapped in IPA, 164 IDs were found in Core Network 3, composed of 216 
molecules 
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Figure 43 is overlaid with the dataset of all the miRNAs regulating 10 or more 
genes. Of the 32 identifiers overlaid, 31 were genes, and only one top regulating 
miRNA appeared in this network. The miRNA, miR-146a-5p, appeared in both the 
overlays for the starting, and the interacting datasets, see Figure 41 and Figure 
42, respectively. This miRNA also appears as a nodal miRNA, and the only nodal 
gene overlaid in Figure 43 is TRAF6 (both outlined by a red box).  
Figure 43: Core Network 3 overlaid with All Top Regulating miRNAs and associated genes. Of the 
116 All Top Regulating miRNAs, and associated gene targets mapped in IPA, 32 IDs were found in 
Core Network 3, composed of 216 molecules 
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Figure 44 shows the result of overlaying the dataset containing all genes 
regulated by ten or more miRNAs. Four genes and one miRNA from this dataset 
appeared in Core Network 3. It is interesting to note that these five molecules all 
appeared in Figure 43, in which all the top regulated miRNAs and the genes they 
regulated were overlaid, unlike that seen in Core Networks 1, and 2, in which 
there was a noticeable difference between the two overlays, see Figure 31 and 
Figure 32, Figure 37 and Figure 38.   
Figure 44: Core Network 3 overlaid with Top Regulated Genes and associated miRNAs. Of the 40 
All Top Regulating genes, and associated miRNA targets mapped in IPA, 5 IDs were found in Core 
Network 3, composed of 216 molecules 
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Figure 45 is a result of Core Network 3 being overlaid with the complete dataset 
of all the top regulated genes and their associated miRNAs, and all the top 
regulating miRNAs and their association. Thus, Figure 45 is a combined overlay of 
both datasets used in Figure 43 and Figure 44. Figure 45 thus shows that of the 
top regulators and their interactions, most of the molecules are widespread 
across the network, and few form nodes. Most molecules can be found at the 
periphery of nodal interactions.  
  
Figure 45: Core Network 3 overlaid with All Top Regulated Genes and miRNAs and associations. 
Of the 156 All Top Regulating Genes and miRNAs, and associated targets mapped in IPA, 32 IDs 
were found in Core Network 3, composed of 216 molecules. 
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Figure 46 was generated by first overlaying Core Network 3 with the complete 
list of starting, and interacting genes and miRNAs. Those molecules which were 
not overlaid were then manually selected and highlighted in pink.  
Of the 31 molecules highlighted in pink, seven genes were identified as nodal 
genes (all outlined by an orange box), which were not present in the curated 
genes and miRNAs list, or the interactions list derived from miRTarBase, and 
miRecords. These six genes were: TFF1, RBBP4, IRF4, HSF1, GRB2, KHDRBS1, and 
IL1R1.  
It is important to note that SMARCA4 (outlined by a blue box), is a gene overlaid 
only in Figure 42, yet it appears as an important node, interacting with numerous 
genes from the complete dataset of all curated and interaction data, as well as 
with new genes added by IPA.  
Figure 46: Core Network 3 overlaid with All Genes and miRNAs, IPA added molecules in Pink. Of 
the 3687 All Genes and miRNAs, and associated targets mapped in IPA, 31 IDs were not overlaid in 
Core Network 3, and thus allowed for the identification of the molecules added in by IPA to 
complete the network structure. 
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11.12. Identification of candidate SLE-associated genes from 
pathway analysis 
11.12.1. Core Network 1 
Core Network 1 consisted of 70 molecules, of which 29 were focus molecules 
from ‘All Top Regulated Genes and miRNAs and associations’ dataset file, and 
26 molecules were added by the IPA database to complete the network. A 
number of nodal genes, added in by IPA, could be identified in Figure 34. NUPR1, 
ESR1, and MED1, were identified as the set of nodal genes for this network. 
Linking NUPR1 and ESR1 were 3 more IPA-added genes, STX3, SLC39A8, and 
TNFAIP8L1.  
Another set of what may be described as “connector” genes, ATP6V0A1, FOXD1, 
and P4HA2, were also added in by IPA. They did not appear as nodes, however 
they were shown to interact with CSNK1A1, PSEN1, HIF1A, ETS1, and NUCKS1, all 
of which appeared in the overlay of interacting genes and miRNAs (see Figure 
30), but only ETS1 also appeared as a curated gene (see Figure 29) 
Four genes were also found to be highlighted in the overlay of interacting genes 
(see Figure 30), and were not overlaid by the starting dataset of curated genes 
and miRNAs, as seen in Figure 29. These four genes were AGO2, TP53, STAT3, 
and CDKN2A. These four genes were not found in the recent biomedical 
literature perused for this study, but were found in miRTarBase and/or 
miRecords, to interact with known, curated lupus-associated miRNAs. CDKN2A, a 
gene added in by IPA, was also shown to interact with three miRNAs, added in by 
IPA. These three miRNAs had the following identifiers: miR-298, miR-194-5p, and 
mir-324. Thus, the 28 molecules from Core Network 1 were considered as 
potential molecules which may be associated with important biological processes 
in SLE pathogenesis, but may not have been explored as such in recent lupus 
studies.  
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11.12.2. Core Network 2 
Core Network 2 consisted of 70 molecules, of which 27 were focus molecules 
from ‘All Top Regulated Genes and miRNAs and associations’ dataset file, and 
25 molecules were added by the IPA database to complete the network. A 
number of nodal genes, added in by IPA, could be identified in Figure 40. 
For Core Network 2, five nodal genes added in by the IPA database could be 
identified, namely YWHAQ, TFAP2A, HDAC9, estrogen receptor, and Histone h4. 
Histone h4 was also directly linked to Histone h3, a gene present in the starting 
list of curated genes and miRNAs (see Figure 35).  
CCND1 was overlaid as both a starting and interacting gene, while MYC was only 
overlaid as an interacting gene. Four IPA-added genes, namely RPRD1B, ZMIZ2, 
HSPH1, and SERINC3 were shown to link the interactions of CCND1 and MYC. 
ATP13A2 and EXOSC8 are two genes which were also added in by IPA, and shown 
to link MYC and RNA polymerase II. HDAC9, added in by IPA, was also shown to 
directly interact with KLF4, BCL6, and NR4A1, three genes which were not 
present in the starting list of genes, but were found to interact with known 
lupus-associated miRNAs curated from literature.  
A set of five genes, all added in by IPA, were illustrated in Figure 40 to interact 
directly with a known lupus-associated gene, Histone h3, as well as Histone h4, a 
gene added in by IPA. These five genes, RBM39, BTG3, INS, ASF1B, and AHSP thus 
formed an important link between Histone h3 and Histone h4.  
Thus, 20 genes from Core Network 2 were considered as potential molecules 
which may be associated with important biological processes in SLE 
pathogenesis, but may not have been explored as such in recent lupus studies. 
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11.12.3. Core Network 3 
Core Network 3 consisted of 70 molecules, of which 26 were focus molecules 
from ‘All Top Regulated Genes and miRNAs and associations’ dataset file, and 
31 molecules were added by the IPA database to complete the network. A 
number of nodal genes, added in by IPA, could be identified in Figure 46.  
Seven nodal genes were added by the IPA database and identified in Core 
Network 3. These seven genes were: HSF1, IRF4, RBBP4, TFF1, IL1R1, KHDRBS1, 
and GRB2. Each of these genes was shown to have direct associations with 
numerous genes found in miRTarBase and miRecords, interacting with data from 
the list of curated SLE-associated miRNAs. 
TADA2A and TADA2B, are two genes added in by IPA, which were also shown to 
interact with two known SLE-associated genes, KAT2A and ATXN7 (see Figure 
41). With the addition of TADA2A and TADA2B to the network, RBBP4, and TFF1 
were also added to the network by IPA, and allowed for the addition of 
numerous genes from the list of interacting genes and miRNAs.  
EDARADD and PELI3 were also added by IPA and formed connections with TAB2, 
and IRAK1 – two genes which were present both as starting genes and 
interacting genes. Interacting with TRAF6 and IRAK1, IL1R1 was added by IPA, 
and extended to interact with six genes found to be associated with known lupus 
miRNAs, and one gene (IL1A) only found as a curated gene. PGR was present as 
both a curated gene and a gene interacting with a known lupus –associated 
miRNA, and was found to be directly associated with IL1R1 – and IPA-added 
gene.  
SMARCA4, CD40, TLR4, AIMP1, and KARS were all found as genes interacting with 
known SLE-associated miRNAs (see Figure 42), but were not identified in the list 
of curated gene associated with SLE.  
KHDRBS1 and KHDRBS3 are two genes also added by IPA. KHDRBS1 appeared as 
a nodal gene, directly interacting with numerous genes found in miRTarBase and 
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miRecords, to be associated with known lupus miRNAs. KHDRBS3 was also found 
to directly interact with HNRNPR which was only overlaid as a starting gene, as 
well as with HNRNPH1 and HNRNPU, both which were not overlaid as starting 
genes, but were found to interact with known lupus miRNAs.  
Thus, 19 genes from Core Network 3 were considered as potential molecules 
which may be associated with important biological processes in SLE 
pathogenesis, but may not have been explored as such in recent lupus studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
147 
 
12. DISCUSSION 
12.1. Overview of this study 
MiRNAs are small molecules, ranging from 20 to 25 nucleotides in length. These 
biomolecules perform critical regulatory activities by binding to the target mRNA. 
By means of partially-complementary binding to the mRNA, miRNAs in animals 
are able to repress the production of the protein which would have been 
produced by the targeted mRNA. As a result, an abundance of studies have 
implicated aberrant gene expression in the onset and progression of numerous 
diseases, including Systemic Lupus Erythematosus, and at the centre of this gene 
regulation, lies the potent regulatory activities performed by miRNAs.  
This study aimed to develop, and subsequently employ a novel bioinformatics 
workflow, which used existing knowledge to identify potentially novel candidate 
molecules, which may be associated with SLE. The workflow described within this 
thesis  followed seven sequential steps, namely: data curation, data verification, 
target identification, cross-analysis of interactions, prioritization of top 
regulators, biological pathway analysis and lastly, the identification of novel 
candidate SLE-associated genes. Using curated lists of miRNAs and genes, I aimed 
to identify miRNA-target interactions in two well-established databases of 
experimentally-validated MTIs, namely miRTarBase and miRecords. Using both 
the miRTarBase and miRecords databases proved useful, as the former 
integrated the miRBase database, whilst the latter database reported no 
inclusion of the miRBase database. This difference between the two databases 
became evident during the target identification process.  
A total of 40 miRNA IDs, and 81 gene names (in associated gene name format) 
were curated from recent biomedical literature as molecules which have been 
associated with SLE pathogenesis. A total of 749 gene IDs (in Ensembl Gene ID 
format) which were found to be differentially-expressed in a meta-analysis of 
lupus studies, were also included in this study with the permission of Dr Wendy 
Kröger.  
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12.2. Lupus-associated miRNAs 
A total of 40 miRNA IDS were curated from four recently published peer-
reviewed articles, of which two were primary sources for data, and two articles 
were reviews of existing data. In adherence to the standardised nomenclature of 
miRNAs described in the literature study, no adjustments were made to any of 
the miRNA IDs. Before identifying in miRTarBase and miRecords which genes 
were known to interact with these curated miRNAs, the miRNA names 
underwent what proved to be an important verification step in a downloaded 
version of the miRBase database.  
The verification step aimed to first identify the curated miRNA IDs as exact 
(perfect) string matches in the miRBase database. If the curated miRNA ID was 
not found as is in the miRBase database, the ID then went through the second 
attempt verification step to identify the ID as a regular expression string. Thus, 
the aim of the first verification step (perfect string match) of the miRNAs in the 
miRBase database was not to discard any miRNAs that were not found in the 
database. It was rather to flag those that did not match the records in miRBase 
for attention, so as to invoke a check in the literature source for any 
typographical errors. It was also important not to deliberately alter the name of 
the miRNA, so as to avoid future errors. Thus, any alterations were only 
performed in a forward direction in terms of miRNA nomenclature, and by using 
the regular expressions described. 
To support the identification of paralogues of the original miRNA curated from 
literature, regular expression string testing was employed using the Python script 
‘PS02_July_01_new_regexes.py’. Regular expression testing allowed for the 
identification of closely-related sequences (paralogues) which differed by only 
one or two nucleotides, and are indicated by the addition of a lettered suffix 
following its numeric value. Thus, regular expression testing allowed for the 
identification of records in the miRBase database which included a ‘-3p’ or a ‘-5p’ 
suffix, proving itself an asset in this workflow as it enabled the identification of 
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the original curated miRNA with its origin hairpin arm, where it would not have 
been identified as is in the miRBase database.  
Of the 40 curated miRNAs, 13 miRNAs were found as exact string matches in the 
miRBase database. Of these 13 miRNAs, 11 were found as records in the 
miRTarBase database, and two miRNAs were not. In contrast, only three of these 
13 miRNAs were found as records in the miRecords database.  Of significance, 
two of the three records found in miRecords, namely for ‘hsa-miR-184’ and ‘hsa-
miR-17-5p’, were also identified as part of the 11 miRNAs found in the 
miRTarBase database. However, when assessing the target identification, I found 
that 310 gene targets were identified for the miRNA ‘hsa-miR-17-5p’ in 
miRTarBase, but only one gene target, ‘IL-8’ was found for this miRNA in the 
miRecords database. Of importance, this single gene target, ‘IL-8’, identified for 
‘hsa-miR-17-5p’ in miRecords, was not one of the 310 gene targets identified in 
miRTarBase. Thus, despite the large difference in the number of reported 
miRNA-target interactions in miRTarBase and miRecords (51 460, and 2705 
respectively), it proved valuable to use more than one database for the detection 
of MTIs.  
Subsequently, the remaining 27 curated miRNA IDs, not found as exact string 
matches in miRBase, were subjected to regular expression testing, thereby 
increasing the chances of retrieving paralogue derivatives of the original curated 
miRNA. Of these 27 miRNAs, 18 miRNAs were matched in miRBase with a 
cumulative 44 regular expressions. Each of the 18 miRNAs matched using this 
secondary verification method yielded at least two resultant matches (‘original 
miRNA’ + ‘-3p’ or ‘-5p’). In addition, the original curated miRNA ‘hsa-miR-181’, 
which did not match as an exact string match in miRBase, revealed itself as a 
highly paralogous miRNA. This miRNA had seven known paralogues in miRBase, 
of which 4 paralogues had a record for both a ‘-3p’ and a ‘-5p’ miRNA sequence. 
The remaining 3 paralogues had a record for either a ‘-3p’ or a ‘-5p’ miRNA.  
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The regular expression string testing also identified two paralogues for ‘hsa-miR-
181’ which were identical in sequence, but which arose from a primary- or pre-
miRNAs which had a different locus in the genome. Subsequent target 
identification also revealed that the paralogues of ‘hsa-miR-181’ cumulatively 
matched to 380 gene targets in miRTarBase. However, none of the regular 
expressions for ‘hsa-miR-181’ were found as targets in the miRecords database. 
If the regular expression testing step had not been performed, these 380 gene 
targets for the regular expressions of this single miRNA would not have been 
included in the downstream analyses of this study, thereby limiting the degree to 
which biological networks could be generated for SLE.           
The regular expression miRNA ID testing also served to report possible 
nomenclature errors from the source article. This was demonstrated in (Tiffin et 
al., 2013), where both ‘miR-1224-3P’ and ‘miR-1224-3p’ were listed in 
Supplementary data file S-4, as miRNAs that have been implicated in the 
progression of lupus. Upon referring back to the source data for those two 
miRNAs, it was found in (Te et al., 2010) that a miRNA, referred to as ‘hsa-miR-
1224-3P’ was found in the article on nine occasions. There was no occurrence of 
‘hsa-miR-1224-3p’. It must however be noted that the nomenclature of miRNAs 
used in this paper does not follow convention of using lowercase p’s in miRNAs 
having a -3p or -5p suffix, nor does this paper follow convention of using 
lowercase letters, directly following the numerical naming of the miRNA, as can 
be seen in multiple instances in the paper, e.g. ‘hsa-miR-125A-3P’. However, 
‘hsa-miR-1224-3p’ was found as an exact string match miRNA in the 
’PS01_June_28_miRBase_1.py’ Python script. The miRNA ‘hsa-miR-1224-3P’ was 
found in the miRTarBase database as ‘hsa-miR-1224-3p’ with a lowercase –p 
suffix. Because 5 gene targets (KMT2D, IGSF3, TCF12, HNRNPA3, CDC42EP1) 
were found for ‘hsa-miR-1224-3p’, this miRNA was simply flagged for checking in 
source literature, and not resubmitted to the miRTarBase database as ‘hsa-miR-
1224-3p’.  
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As shown in Table 13, ‘hsa-miR-21’ was found to have 49 gene targets in the 
miRecords database. The regular expression matched and verified miRNA ‘hsa-
miR-21-5p’ illustrated the dominance described for the mature miRNA produced 
from one arm of a precursor hairpin miRNA. Regular expression matching 
revealed that ‘hsa-miR-21-5p’ had 439 gene targets in miRTarBase, and Table 14 
showed ‘hsa-miR-21-3p’ having only two targets In miRTarBase. Thus, regular 
expression testing lead to a vast increase in the number of targets obtained for 
the dominant miRNA ‘hsa-miR’21-5p’. If only the original miRNA, ‘hsa-miR-21’ 
had been considered for target identification, almost 400 gene targets would 
have been missed and not included in the downstream analyses.   
Even though the miRNA ‘hsa-miR-516a-5p’ was not found in miRTarBase (see 
Table 11) this miRNA was found in miRecords to regulate two genes, KLK10 and 
SULF1 (see Table 12). This further demonstrated that even though miRecords 
had much fewer MTIs than miRTarBase, the miRecords database still had the 
potential to have MTIs that miRTarBase did not have. Therefore, considering 
multiple databases for obtaining miRNA-Target interactions has proven to be a 
valuable step prior to performing biological analyses.  
With the knowledge that miRNAs are able to regulate numerous genes, it may be 
hypothesised that the more interactions reported by a database increases the 
chances of obtaining a more realistic view of the regulatory capabilities of a given 
miRNA. This hypothesis was substantiated by the target identification for the 13 
miRNAs which matched perfectly to entries in the miRBase database. Of these 13 
miRNAs, 11 were found in miRTarBase, yielding a total of 607 miRNA-target 
interactions. In contrast, only three out of the 13 verified miRNAs were found to 
have targets reported in miRecords, and these three miRNAs cumulatively had 
five target interactions. Target identification in miRTarBase and miRecords 
revealed that miRNAs targeted one or multiple genes, e.g. ‘hsa-miR-342’ and 
‘hsa-miR-17-5p’, respectively.  
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The cross-analysis step in this bioinformatics workflow aimed to identify which 
genes and miRNAs from the curated datasets were in the output lists of 
interacting molecules retrieved from the miRTarBase and miRecords databases. 
The different sets of miRNAs which resulted from the verification step in 
miRBase, were cross-analysed with the outputs of the miRNA target 
identification step in miRTarBase and miRecords for the SLE-associated-, and 
differentially-expressed genes.  
For the cross-analysis of miRNAs, three datasets were selected: the raw curated 
list of miRNAs (n = 40), and the miRNAs which matched perfectly as a string 
record in miRBase (n = 13) pooled with the 44 miRNAs which were a result of 
regular expression verification in miRBase. The third dataset was the miRNAs 
which failed the verification step as a perfect string match in miRBase (n = 27). 
The data which matched as a perfect string match, and those which failed the 
perfect string match verification step in miRBase, are subsets of the curated 
dataset of miRNAs (n = 40). However, each of these datasets was subjected to 
cross-analysis in order to draw meaningful conclusions from the subsets of data, 
instead of only drawing a conclusion from the results of the starting dataset.   
Before performing the cross-analysis, the miRNAs which matched as a perfect 
string match (n = 13) in miRBase were pooled along with the miRNAs which were 
verified as a regular expression (n = 44). The pooled list (n = 57) was then 
subjected to the set() function in Python to create a unique list of miRNA names. 
As a result, the list of 57 miRNAs was reduced to 56 miRNAs. This observation 
lead to a further investigation into these two datasets because a perfect string 
match (first verification step) should never appear as a duplicate entry in the 
result of the regular expression match (second chance at verification), as these 
are sequential steps, i.e. these steps do not take place in parallel. Thus, upon 
investigation I found that both ‘hsa-miR-142’, and ‘hsa-miR142-3p’ were included 
as individual miRNAs curated from two separate literature sources, Zan et al. 
2014 and Tiffin et al. 2013, respectively. Thus, when each of these two miRNA 
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IDs was tested for being a perfect string match in the miRBase database, ‘hsa-
miR-142-3p’ was found to exist as such, whereas ‘hsa-miR-142’ did not. 
However, when the second verification step (regular expression) was employed 
on those miRNAs which did not match as an exact string match,  ’hsa-miR-142’ 
was then found in miRBase as two regular expression records, i.e. hsa-miR-142-
5p‘ and ‘hsa-miR-142-3p’. Thus, when pooling these two subsets of data verified 
in miRBase, a duplication of ‘hsa-miR-142-3p’ occurred, resulting in the need to 
create a unique list of miRNAs, which ordinarily should not be needed for these 
two distinct datasets.  
In the first cross-analysis test, the starting miRNAs (n = 40) were assessed against 
the interacting miRNAs (n = 291). Of these 40 miRNAs directly curated from 
literature, 13 miRNAs were identified in the list of 291 miRNAs found to interact 
with the SLE-associated genes curated for this study (from literature, and from Dr 
Kröger). Thus, 27 of these starting miRNAs, which have been described as 
associated with lupus pathogenesis, were not identified in the list of 291 miRNAs 
which were found to interact with the 813 unique genes which are known to be 
associated with SLE.  
Test 2 of the cross-analysis of miRNAs involved testing the pooled dataset 
consisting of a unique list (n = 56) of the miRNAs which had passed either the 
first or second verification step in miRBase, against the interacting miRNAs                   
(n = 291). Of these 56 miRNAs, 22 were found in the list of interacting miRNAs. 
Thus, 34 miRNAs, which were verified in miRBase as either an exact string match 
or a regular expression match for the original curated lupus-associated miRNA, 
were not identified in the list of 291 miRNAs found to interact with the known 
lupus-associated genes dataset.  
Lastly, Test 3 assessed the 27 miRNAs which failed verification in miRBase against 
the 291 miRNAs found to interact with the known lupus-associated genes. Seven 
out of the 27 miRNAs were identified in the list of 291 interacting miRNAs. 
However, 20 of these miRNAs, which were reported in literature to be associated 
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with SLE pathogenesis but were not verified as either a perfect string match or 
regular expression string match in miRBase, were not found in the list of 291 
miRNAs which were demonstrated to interact with the known lupus-associated 
genes list (n = 813). 
As previously described, the perfect string match sub-dataset (n = 13) and the 
miRNAs which failed verification in miRBase (n = 27) are both subsets of the list 
of starting miRNAs (n = 40) assessed in Test 1 of the cross-analysis. Thus, 
excluding the miRNAs for these datasets which were not found in the list of 
interacting miRNAs, it can be concluded that 34 miRNAs (Test 2), although 
curated from recent literature as being associated with SLE pathogenesis, were 
not identified in the list of 291 miRNAs found to interact with the curated SLE-
associated genes (n = 818). Thus, further investigations need to be made into 
assessing the miRNA-target interactions, and the biological relevance of the 
regulatory activities of these 34 miRNAs. 
12.3. Lupus-associated genes 
A total of 830 non-unique gene identifiers were originally collected for this study. 
A total of 81 genes (in associated gene name format) were curated from three 
recently published peer-reviewed biomedical research articles. This list 
comprised of one gene curated from a primary source article, and 80 unique 
gene names curated from two review articles. The remaining 746 genes (in 
Ensembl Gene ID format) were included in this study with the permission of Dr 
Wendy Kröger. These 749 genes were reported as being differentially-expressed 
during the observations of lupus pathogenesis.  
With the preparation of the associated gene names, as described in the Methods 
chapter, the starting list of 81 genes was adjusted to a new list of 85 unique 
genes, which had been split from their aliases and associated pairs. Once again, 
in adherence to the standardisation of Ensembl Gene ID notation, no manual 
alterations were made to these IDs collected during Dr Kröger’s meta-analysis of 
differentially-expressed lupus genes. 
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Both gene lists were individually submitted to the Ensembl BioMart tool in order 
to identify which of the genes submitted were matched as HGNC symbols in the 
database. The verification of the SLE-associated gene names as HGNC symbols 
revealed that 82 out of 85 genes and three out of 85 genes were found, and not 
found respectively in the BioMart database. The three genes which were not 
found were CREBL1, Lyn, and IRF53. This may be in concordance with the fact 
that GeneCards reported CREBL1 to be an alias for ATF6B, and ATF6B was 
verified in BioMart to exist. The curated gene “Lyn” was not found in BioMart as 
is. A gene named “LYN” was found in BioMart, but because it did not match the 
font case of “Lyn”, when searched for against the original input list of starting 
miRNAs, ‘Lyn’ was reported as an error as one of the three genes not found in 
BioMart. Because ‘Lyn’ was curated as such from the source, no adjustments 
were made to uppercase to suit the findings in BioMart. 
As described in 11.4.2.2, ‘RABGAP1L’ was initially incorrectly reported in the 
source article as ‘RABGAPIL’. Upon manual referral back to the original source 
article, the correct spelling of the gene was confirmed. ‘RABGAP1L’ was then 
confirmed as a gene in the Ensembl BioMart database, and subsequent target 
identification revealed a single miRNA interaction with ‘hsa-miR-1’. The manual 
checking of unverified gene names ensured that this gene was included in the 
analyses, with the correct nomenclature from the source article, and that targets 
were correctly reported. Thus, the BioMart verification of the Ensembl IDs for 
the differentially-expressed genes as a step prior to target identification, allowed 
for the accountability of all the curated Ensembl IDs with the conversion to 
HGNC symbols.  
The verification of the 749 Ensembl Gene IDs as HGNC symbols in BioMart also 
proved helpful as it identified 13 genes, which upon manual checking were found 
to be deprecated IDs. If this verification step had not been included as part of the 
workflow, and if target identification had been performed directly by simply 
converting all the ENSG IDs to their respective gene names using a tool such as 
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BioBDNet (http://biodbnet.abcc.ncifcrf.gov/db/db2db.php), these 13 deprecated 
genes would have either been incorrectly reported as “Not Found” in the 
miRTarBase or miRecords databases, or it may have been reported as “Found”, 
but may not have been a true gene name. Thus, using an updated version of 
Ensembl BioMart to verify the existence of these ENSG symbols as records in the 
database ensured that each of the gene IDs were correctly converted to HGNC 
symbols, and that the genes which had been removed from the database were 
reported as such. Thus, ensuring that target identification was only performed on 
the genes which had been verified to exist, and excluding those which were no 
longer recognised. 
Of the 85 genes curated from literature, 82 genes were verified in BioMart to 
exist, and three genes (CREBL1, IRF53, and Lyn). Of the 82 genes verified in 
BioMart, 47 genes were found to have interactions with miRNAs in the 
miRTarBase database, whereas only 11 of these 82 genes were found in the 
miRecords database. In contrast, the three genes which were not verified in 
BioMart, were also not found as records in either miRTarBase or miRecords. As in 
the verification step of the miRNAs, this verification of the genes in BioMart 
proved useful in identifying why these genes were not found in the target 
interactions databases; whether it was because they were not records in the 
databases (without verification, and submitting the complete list of 85 genes to 
the target databases), or more specifically, whether they were not confirmed as 
actual genes, and as a subset were submitted to the target databases. As seen in 
this study, the inclusion of the gene name verification in BioMart proved its 
worth as described by the latter scenario.  
For the cross analysis of the input genes with the output genes found to interact 
with the known SLE-associated miRNAs curated from literature, two tests were 
designed and performed. Test 1 consisted of testing the pooled SLE-associated 
genes and differentially-expressed genes which were verified to exist in BioMart 
(Totaln = 813), against the 2 702 genes found to interact with the known SLE-
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associated miRNAs. It was found that 127 out of 813 known lupus-associated 
genes were identified in the list of 2702 genes found to interact with known 
lupus-associated miRNAs.  Thus, of the 2702 unique genes found to interact with 
the known lupus miRNAs, 686 genes were not found in the starting list of curated 
genes. Therefore, it is suggested that the 686 genes which were found to interact 
with the known SLE-miRNAs, but were not identified in the starting list of genes, 
be further researched to identify the biological networks influenced by the 
activities of these 686 possibly dysregulated genes.  
Test 1 also revealed that a number of genes identified as targets for a given 
miRNA in miRTarBase or miRecords, were in fact not present in the starting list of 
curated genes. An example of this is where ‘hsa-miR-17-5p’ was found to have 
310 unique gene targets in miRTarBase, but in the cross-analysis, only 19 genes 
out of those 310 identified were in the list of curated genes. Because a multi-
systemic autoimmune disease is likely to be affected by the dysregulation of an 
abundance of genes, it is interesting that only 19 known lupus-associated genes 
out of the 310 targets identified for this miRNA was observed.  This was again  
seen in the analysis of ‘hsa-miR-423-5p’ where this miRNA was shown in 
miRTarBase to target 168 genes, but the cross-analysis showed that only 11 of 
these 168 where known-lupus associated genes. These findings suggest that 
there are possibly an abundance of genes regulated by the same miRNAs which 
may be involved in biological processes associated with lupus pathogenesis.  
Test 2 of the cross-analysis aimed to identify whether the three genes not 
verified in BioMart (CREBL1, IRF53, and Lyn) were present in the list of 2 702 
genes found to interact with the known SLE-miRNAs. It was subsequently found 
that none of these three genes were in the list of 2 702 genes.  
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12.4. Pathway Analysis 
Of the 813 unique genes evaluated in this study for MTIs, 736 genes were 
reported by the study performed by Dr Kröger, to be involved in biological 
pathways including that of interferon signaling, TLR signaling, diapedesis, 
oxidative phosphorylation, and adhesion regulatory networks. From this study, 
six datasets were created, all derived from (and including) the dataset containing 
all the genes and miRNAs which were curated, and those obtained from the 
determination of targets in miRTarBase and miRecords. The Core Analysis was 
run on the dataset file containing the top regulated genes and miRNAs, and their 
associated targets. These 108 molecules, determined by IPA as suitable for 
analysis, contained a mixture of genes and miRNAs which would form the 
skeleton of the overall network.  
For these top regulators and their associated targets, the Core Analysis revealed 
that majority of these molecules were implicated in one of five top canonical 
pathways. These top canonical pathways were Interferon signaling, TLR signaling 
(both in concordance with the findings of Dr Kröger), as well as three new 
pathways, namely iNOS signaling, IL11 signaling, and the role of PKR in Interferon 
induction and antiviral response. 
Numerous reviews have evaluated the role of nitric oxide (NO) in the onset of 
autoimmunity (Nagy et al., 2010; Oates and Gilkeson, 2006; Oates et al., 2010). It 
has been well-established that NO production in response to pathogen invasion 
assists with controlling T cell proliferation. However, when NO production shifts 
to an uncontrolled manner, there is a break down in immune self-tolerance as 
result of T cell dysfunction (Nagy et al., 2010). NO may, depending on its 
circulating concentration, either inhibit or promote the apoptotic pathway (Nagy 
et al., 2010). Therefore, with the knowledge that  impaired clearance of dead 
cells by means of apoptosis is a hallmark of lupus onset, it is likely that NO 
production through iNOS signaling plays an important role in the progression of 
lupus.  
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Another top canonical pathway listed was that of Interleukin-1 (IL-1) signaling.  
IL-1 is a potent inducer of acute inflammation – a phenotype  defining lupus-flare 
(Feghali and Wright, 1997). When involved in the NF-κB pathway,  IRAK1 (IL-1 
receptor associated kinase 1) has also been implicated in the activities of 
interferon production. It has been proposed that an overproduction of IFN may 
also contribute to the pathogenesis of SLE (Ceribelli et al., 2011). TLR signalling 
has also been described in numerous studies to play an important role in the 
maintenance of normal immune system functioning, and conversely, in the 
dysfunctioning of immune receptors during lupus flare. Genetic variations in TLRs 
have been described for various populations where lupus studies have been 
conducted, such as the study conducted on a Taiwanese population (Wang et al., 
2014). TLRs have been described extensively with regards to their role in the 
pathogenesis of SLE, as well as their regulation by a number of miRNAs (Deng et 
al., 2013; Quinn and O’Neill, 2011).  
In contrast to the top canonical pathways described for the skeleton dataset, the 
top diseases and biological functions shown to be associated with this dataset 
were all largely different from each other. However, due to multi-systemic 
nature of SLE pathogenesis, the disparity in the pathways described can be 
justified. Organismal injuries and connective tissue disorders are likely to 
describe pathways related to the overall damage and destruction inflicted by 
auto-antigens produced during the abnormal immune functioning. Endocrine 
system disorders describes the abnormalities  of immune cell production and 
circulation, an observation characteristic of lupus disease state. 
Lastly, the implication of cancer as a disease describes the overall malfunction of 
cell cycle regulation, and aptly describes the level to which the immune system 
can become dysregulated during lupus flare. The heat map in Figure 28 once 
again illustrated the degree to which the pathways implicated differed. 
Organismal injury and cancer pathways were shown to be predominantly 
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affected by the molecules present in the Core Analysis dataset, followed by cell 
cycle, and lastly, varieties of biological pathways.  
In coherence with the findings described above, Table 28 described that of the 
dataset of top regulated genes and miRNAs, and their associations, a number of 
molecules were identified to be associated with numerous immunological 
disease categories, including ‘systemic autoimmune syndrome’ in which 23 
molecules out of the dataset were implicated.  
12.5. Identification of novel, candidate SLE-associated genes from 
pathway analysis 
12.5.1. Genes not in the starting list of genes, but were found to interact 
with known lupus-associated miRNAs 
Across all three Core Networks, eighteen genes were found to be potentially 
novel SLE-associated candidate genes. These genes were not in the list of curated 
genes from recent biomedical literature, or Dr Kröger’s meta-analysis of lupus-
associated genes. A manual search in the data file containing all the curated 
genes and miRNAs revealed that these 18 genes were in fact not found in the 
datasets. Each of the genes were searched for in BioMart (September 2015 
version) to identify which phenotypes and biological processes, if any, have 
already been described and associated with the gene.  Using the search terms 
“SLE”, “lupus”, and “systemic lupus erythematosus” on the Excel file exported 
from BioMart, it was found that none of these genes had been associated with 
the lupus phenotype. Thus, dysregulation of these genes by miRNAs – as 
determined by the initial target identification in miRTarBase and miRecords, may 
suggest a dysregulation in biological processes described by BioMart. For 
reporting purposes, I have grouped the results of the phenotype descriptions 
into three categories, namely Cell cycle processes, Cancers, and Neurological 
diseases.  
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Of the 18 genes which were not in the list of 818 curated SLE-associated genes, 
but were found to interact with known lupus-associated miRNAs, 10 genes were 
reported by BioMart to be associated with cell cycle processes. Some of these 
genes were also reported to specifically be involved in the positive regulation of 
transcription from the RNA polymerase II promoter. These genes were: AGO2, 
CSNK1A1, HIF1A, NUCKS1, KLF3, NRF4A1, AIMP1, KARS, TLR4, and STAT3 (which 
was also implicated in an infantile onset form of multi-systemic autoimmune 
disease (OMIM: #615952)).  
Of the 18 genes, five genes were described to be associated with some form of 
cancer. CDKN2A was reported to be associated with melanomas (OMIM: 
#606719), BCL6 with lymphomas (OMIM: *109565), MYC with Burkett’s 
lymphoma (OMIM: #113970), and HNRNPH1 with leukaemia (OMIM: none 
available). Lastly, TP53 was found to be associated with a variety of cancers 
(OMIM: #614740), including hereditary breast and ovarian cancer syndrome, 
oesophageal cancer, lung cancer, and basal cell carcinoma.  
Three genes were reported to be associated with neurological diseases. PSEN1 
was reported to be associated numerous forms of neurological disorders such as 
semantic dementia (OMIM: 600274), progressive non-fluent aphasia (OMIM: 
600274), and Alzheimer disease 3 (OMIM: 607822). HNRNPU was associated 
with epileptic encephalopathy (OMIM: none available), and SMARCA4 was 
associated with mental retardation autosomal dominant 16 (OMIM: 614609).  
12.5.2. Genes which were added by IPA to complete the Core Networks  
Across the three Core Networks, a total of 44 genes, and three miRNAs were 
found to be added in by IPA to complete these networks. The genes were once 
again searched for as HGNC symbols in Ensembl BioMart (September 2015 
version), and a search in the exported Excel file revealed that the search phrases 
“systemic”, “autoimmune”, “lupus”, and “SLE” were not present in this data file 
for the IPA-added molecules. Of the three miRNAs added by IPA, only hsa-miR-
298 was found in the BioMart search. The miRNA was only reported to be found 
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on Chromosome 20, and no phenotypic information or PubMed source was 
available for this miRNA. The other two miRNAs were not found in this BioMart 
search. 
Of the 44 genes added in by IPA, 26 genes were identified as nodal genes, 
interacting with numerous other SLE-associated genes, and 18 genes were 
identified as ‘connector’ genes. Of the 26 nodal genes, two genes were not found 
in BioMart, namely estrogen receptor, and Histone h4. Thirteen genes were not 
found to have any phenotypic description in BioMart. These 13 genes were 
NUPR1, YWHAQ, ZMIZ2, HSPH1, SERINC3, HSF1, RBBP4, TFF1, IL1R1, KHDRBS1, 
KHDRBS2, TADA2A, and TADA2B.  
The remaining 11 genes were found in BioMart and associated with at last one 
known phenotype or biological process. ESR1 was described to be involved in 
estrogen resistance syndrome (Green et al., 1986). In the network overlay 
analyses, ESR1 was shown to interact with a number of IPA-added genes, as well 
as with three known lupus-associated genes (CCND1, MMP1, and NRIP1), and a 
number of genes found to interact with known lupus-associated miRNAs. 
Because of the strong prevalence of lupus in females compared to males, it is to 
be expected that various forms of the estrogen hormone may play a critical role 
in the pathogenesis of lupus. However, the ESR1 gene is yet to be reported in 
BioMart as being associated with SLE.  MED1 was described in this BioMart 
search as being involved in numerous biological processes including the process 
of androgen biosynthesis, chromatin binding, cell morphogenesis, and the 
differentiation of keratinocytes. MED1 was also described in Cui et al. 2012 to 
interact closely with HER2 in the regulation of Tamoxifen-resistant breast cancer 
cells in humans.  STX3 was described as being involved in the positive regulation 
of numerous biological processes including that of cell adhesion, cell 
proliferation, chemotaxis, and protein localization (Darios and Davletov, 2006).  
ATP13A2 was reported to be associated with the Parkinson disease 9, and Kufor-
Rakeb Syndrome phenotypes (OMIM: #606693). The manifestation of Parkinson 
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disease 9 was described here to be as a result of ATP13A2 deficiency. EXOSC8 
was reported to be involved in another neurological disorder, pontocerebellar 
hypoplasia (OMIM: #616081). TFAP2A was described to participate in numerous 
biological processes (OMIM: #113620), including kidney development, hard 
palate development, and mRNA export from the nucleus. Dysregulation in 
TFAP2A may thus result in the pathologies of the kidneys observed as a 
secondary disease in lupus patients. EDARADD was reported by this BioMart 
search to be associated with the phenotype of autosomal dominant- and 
recessive forms of a skin disorder named hypohidrotic ectodermal dysplasia 
(OMIM: 614900). IRF4 the interferon regulatory factor 4 gene was described to 
be associated with the pathology of myelomas, including the multiple systemic 
amyloidosis (OMIM: 254500). 
HDAC9 was described to be associated with a phenomenon known as Peter’s 
Anomaly (OMIM: none available), as well as with the positive regulation of the 
cell migration in sprouting angiogenesis, and RPRD1B was described to be 
involved in the dephosphorylation of RNA polymerase II at the C-terminal 
domain. GRB2 was described to be associated with cellular response to ionizing 
radiation, positive regulation of reactive oxygen species metabolic processes, the 
negative regulation of receptor internalization, and signal transduction in 
response to DNA damage PELI3 the retinoblastoma binding protein 4 gene, was 
described to be associated with the negative regulation of the extrinsic apoptotic 
signalling pathway, as well as the negative regulation of TNF-mediated signalling 
pathway.  
Across the three networks, a total of 18 genes were selected as ‘connector’ 
genes. Of these 18, 15 genes were found in BioMart, having no known 
phenotype description. These 15 genes were SLC39A8, TNFAIP8L1, SLCA12, 
SESN2, GTSE1, GAK, MAPK12, TMEM97, RBM39, BTG3, ASF1B, AHSP, ATP6V01, 
FOXD1, and P4HA2. A search in Google Scholar for GTSE1, and GAK with the 
phrase “gene in systemic lupus erythematosus” also revealed no published 
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literature on the associations of these two genes to lupus. Only three of the 
connector genes had phenotypes described for them in BioMart. These three 
genes were STX3, UNC5B, and INS. INS was reported by BioMart to have a known 
phenotypic description. INS, the gene encoding for insulin was described as being 
involved in numerous metabolic regulatory processes. STX3 was described to be 
involved in cell cycle processes and UNC5B was described to be a negative 
regulator of apoptosis. 
12.6. Bioinformatics pipeline review 
Linkage and association studies have been frequently used to identify rare 
variants exhibiting high penetrance in common disorders. However, the 
identification of common variants with decreased penetrance has proven 
problematic using these aforementioned methods (Armstrong et al., 2008). In a 
disease with complex aetiology such as SLE, many researchers have resorted to 
genome–wide approaches for elucidating the SNPs which may be associated with 
a disease phenotype.  
A disadvantage of GWAS methods is the high cost associated with the 
requirement to scan the entire genome in order to perform a comparison against 
a reference, in order to identify the SNPs (Armstrong et al., 2008). In order to 
reduce this level of expense, Armstrong et al. developed a software programme, 
Function2Gene, which integrates the searching of biomedical literature for SNPs 
associated with the query disease, followed by prioritization tactics defined by 
the user, and performed by the programme (Armstrong et al., 2008). Another 
disadvantage of GWAS studies is the high cost associated with genotyping a large 
number of samples in order to have adequate power required for statistical 
analyses, and for obtaining results with statistical significance (Hunter and Kraft, 
2007).  
A recent study by Song et al. described a bioinformatics pipeline for identifying 
miRNA-regulated RA-associated genes (Song et al., 2015). This study involved 
performing conditional literature search in PubMed for RA-associated genes 
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target by miRNAs, and downloading microarray and RNA-seq datasets from 
NCBI’s GEO database. miRNA target genes were predicted using TargetScan and 
miRDB. Once miRNA target genes were predicted and RA-associated miRNAs 
were identified, differentially-expressed RA genes were derived. Subsequently, 
functional analysis was performed on the differentially-expressed RA genes, and 
GO molecular functions were reported (Song et al., 2015).  
In contrast to the study by Armstrong et al., the pipeline designed and employed 
within this dissertation aimed to identify novel miRNAs and genes which were 
potentially associated with SLE, and did not include the analysis of SNP data. 
Similar to the study by Song et al., I performed an extensive literature search, 
and included a second dataset of differentially-expressed SLE genes, as provided 
by Dr Wendy Kröger. In contrast to the study by Song et al., I used the latest 
versions of miRTarBase and miRecords databases to identify miRNA-target 
interactions for my source data. There is also no mention by Song et al. that 
verification of miRNA IDs was performed, as I had completed as the initial 
verification step prior to target identification. 
 The study by Song et al. also reported on significantly enriched biological 
pathways using GO terms, whereas I reported the diseases and functions of the 
network datasets using the results generated from pathway analysis. Lastly, 
unlike either of these two studies, I included a comprehensive biological pathway 
analysis of my interaction-derived data using Ingenuity Pathway Analysis 
software. This pathway analysis generated graphical interaction networks for the 
input data, a heat map of the canonical pathways impacted, and subsequently 
allowed for the identification of potentially novel SLE-associated genes and 
miRNAs.  
12.7. Results in comparison to other SLE gene target 
identification studies 
This bioinformatics-based approach to identifying novel SLE-associated genes 
and miRNAs reported five top canonical pathways affected by the prioritized 
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dataset of top regulated genes and top regulating miRNAs. These five pathways 
were: Interferon signalling, TLR signalling, iNOS signalling, IL11 signalling, and the 
role of PKR in interferon induction and antiviral response. In agreement with 
these observations, it was also reported that TLR-signalling and Type-1 Interferon 
signalling are two of the canonical pathways containing SLE susceptibility loci 
(Harley et al., 2009). In contrast, Harley et al. also reported “immune complex 
processing” and “immune signal transduction” to be critical pathways involved in 
SLE progression, whereas single, specific components of the immune system 
were reported in this thesis to participate in SLE processes, and not at the more 
general functional pathway level.  
A total of 18 genes which were not present in the curated list were found in 
miRTarBase and/or miRecords to interact with known SLE-associated miRNAs. 
These were: AGO2, CSNK1A1, HIF1A, NUCKS1, KLF3, NRF4A1, AIMP1, KARS, TLR4, 
STAT3, CDKN2, BCL6, MYC, HNRNPH1, TP53, PSEN, HNRNPU, and SMARCA4. 
From the pathway analysis in IPA, a total of 44 genes, and three miRNAs were 
added by the IPA database to complete the core networks generated. These 
genes and miRNAs were not present in the curated lists, or in the lists of 
interactions. These 62 genes and three miRNAs are considered potentially novel 
SLE-associated genes which might be investigated in future experimental studies 
as potential biomarkers for the disease.  
As previously described, GWAS studies have dominated the bioinformatics-based 
approaches to identifying novel disease-associated genes. One such study 
identified AFF1 as a candidate SLE-disease gene in a Japanese population (Okada 
et al., 2012). This gene was however, not identified in my analysis as a gene to be 
interacting with a known SLE-associated miRNA, nor reported as an SLE-
associated, or differentially-expressed SLE gene. This clearly demonstrates that 
even with the extensive database knowledge used in Ingenuity Pathway Analysis 
software, as well as the integration of multiple data sources, the knowledge of 
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SLE-associated genes continues to be elucidated as more experiments are 
performed and reported on. 
A number of genes have been identified from GWAS studies as being candidate 
SLE-associated genes. These include TREX1, C1Q, TNFAIP3, IRF5, and many others 
(Harley et al., 2009). A number of these genes were also reported in the Results 
chapter of this dissertation as interacting with a known SLE-associated miRNA, 
thus adding an additional line of validation for the current study.  
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13. CONCLUSION 
To conclude, each of the IPA-added molecules described by the BioMart search 
could be placed in the three categories described for the genes which were 
found to interact with known lupus-associated genes. The three categories were 
cell cycle regulation, cancers, and neurological diseases. These IPA-added genes, 
in addition to the interacting genes which have been described to play significant 
roles in these three biological processes and pathologies, were through network 
analysis also shown to interact extensively with members of the curated genes 
and miRNA data set. Experimental validation is known to be labour-intensive, 
time-consuming, and costly. Thus, the in silico methods described in this 
dissertation allude to the potential benefits to performing these analyses for 
candidate molecules prior to experimentation, by improving the chances of 
investigating the true aetiological gene in the laboratory for validation  
13.1. Limitations of this study 
A few limitations can be described which may be addressed in order to improve 
the workflows developed and utilised in this bioinformatics-based study. First, 
the number of experimentally-validated miRNA targets reported in databases 
such as miRTarBase and miRecords used in this study, are limited by the current 
state of knowledge about miRNAs and their targets. These targets are also 
largely limited by the molecular experiments employed to validate miRNA 
functionality, but will improve over time as new techniques are developed and 
included in these experimental validations of miRNA targets. Thus, the 
bioinformatics methodologies proposed in this study should be reused in future, 
as more updated versions of these target-prediction databases are released.  
Second, the validation of interactions between miRNAs and the target genes are 
still not extensive, but this will improve with knowledge improving over time. 
Lastly, because of the complex aetiology associated with lupus, it is believed that 
the interplay between genetic susceptibility and environmental factors plays a 
critical role in the onset and progression of this disease. Thus, it is proposed that 
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at best, one can aim to identify general susceptibility genes and miRNAs 
associated with lupus, but that how these complex interactions play out is more 
difficult to determine.  
The approaches used in this study contribute at a level of mechanisms driving 
lupus, and gene networks with key nodes, rather than looking for specific 
causative genes. Thus, it may be more beneficial to use the data to identify 
general cellular mechanisms which may be relevant to lupus, as shown in this 
study, rather than attempting to isolate a few specific genes that drive the 
pathogenesis of the SLE.  
13.2. Future directions 
Further studies span across both biological experiments and bioinformatics 
analyses. For biological experiments, the nodal genes may be investigated in 
expression studies to determine whether they are in fact linked to the onset of 
SLE, and the progression of the disease. In terms of bioinformatics, it is proposed 
that the methodologies developed in this study be integrated into an automated 
database query system which may be freely accessible for researchers interested 
in investigating biological networks in this context. 
With the permission of the respective database or software creators, the 
automated system could integrate the freely-accessible and downloadable data 
from the miRBase, Ensembl BioMart, miRTarBase, and miRecords databases, as 
described in the Methods chapter of this study. The query system would also 
implement the automatic update of database versions, thereby ensuring that 
miRNA ID verification, and gene name or ID verification and conversion are 
performed using the latest versions of the databases. The automated update 
would also allow users to perform their analyses preferably with the updated 
miRTarBase, and miRecords databases, or with archived versions of these two 
databases. The Python scripts written for the Methods chapter of this study 
would be integrated into this query system to ease the identification of miRNA, 
or gene targets for the input list of genes, or miRNAs, respectively.  
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Because IPA is a licensed resource, automated integration of this tool would not 
be possible. However, an open-source tool such as Gene Ontology can be 
integrated to obtain the annotation of identified molecules according to known 
biological functions. Furthermore, using Cytoscape open-source software with 
the CyTargetLinker add-on application, KEGG or Reactome pathway analysis may 
be performed to visualise gene-miRNA interactions. Another open-source 
software tool, STRINGdb, may be integrated into the query system to provide 
protein-protein interaction visualisation for the dataset uploaded by the user.  
An important feature of this bioinformatics pipeline is that it integrates the 
verification of miRNA IDs and gene IDs using well-established and utilised open-
source resources. Thus, all subsequent analyses including the target 
identification and pathway analyses can be trusted to be accurate based on the 
fact that each ID was verified to exist as an entry in its respective data repository. 
Lastly, the query system would not be restricted to SLE, as it is purely based on 
the miRNA-gene interactions derived from the source databases, and thus can 
prove to be useful in its application to multiple fields of biomedical research.  
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15. ADDENDUM A: The complete list of 749 Ensembl Gene Identifiers of differentially-expressed 
lupus genes obtained from Dr Wendy Kröger 
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ENSG00000114487 ENSG00000188937 ENSG00000155760 ENSG00000169933 ENSG00000196159 ENSG00000115520 
ENSG00000114491 ENSG00000196116 ENSG00000158636 ENSG00000171189 ENSG00000196639 ENSG00000116830 
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ENSG00000148484 ENSG00000101057 ENSG00000072415 ENSG00000104332 ENSG00000135333 ENSG00000241484 
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16. ADDENDUM B:  A complete list of the genes found in 
miRTarBase to be targeted by miRNAs which were 
verified as a perfect string match in miRBase 
miRNA Number of 
gene targets 
Gene targets 
hsa-miR-184 3 AKT2, INPPL1, NFATC2 
hsa-miR-198 3 CCNT1, NTRK3, MYB 
hsa-miR-298 2 BACE1, CDKN1A 
hsa-miR-638 1 OSCP1 
hsa-miR-1224-3p 5 KMT2D, IGSF3, TCF12, HNRNPA3, CDC42EP1 
hsa-miR-142-3p 107 RAC1, ARNTL, TNIP3, VSIG1, PSMB5, HOXA13, NAP1L2, 
CLOCK, ARHGAP12, IRF2BP1, KCND3, MESP2, CRH, 
PITPNC1, SLC37A3, PPP2R2C, ARL14EP, CDCA4, SH2D1A, 
MROH7, ETNK2, PCDHB14, C2, FAM209A, PCDHGA2, 
KRTAP4-5, C4BPB, ZNF608, GPC4, GPD1L, EVI2B, ZNF236, 
NEFH, HSFY2, ZNF701, UGT2B17, INSIG2, TAS2R7, RGS5, 
TPSG1, ARL6IP6, PCDHGA10, SIGLEC10, MRGPRX1, AGBL2, 
PSMD12, BMP8A, C11orf16, INCENP, ALAD, TRIM36, 
AGTR2, TUBAL3, RNF170, NCKAP1, FAM65A, C7orf31, 
CLUAP1, ENAH, TMEM136, CLEC4D, KCTD12, ABCC9, 
CDC6, MCFD2, DOCK10, DCTN4, SECISBP2, KIAA1191, 
BRMS1L, SYT4, ARF4, FAM98A, RRM2B, UBE2W, ARL10, 
PCMTD2, CALCOCO2, MORF4L1, TSPAN6, GOLGA5, YES1, 
ARL15, FAM177A1, CA5B, NSFL1C, MAN1A2, SKP2, FBXO3, 
EDEM3, DNAJB4, CNIH4, CCNJ, RPE, CLIC4, TGFBR1, 
ZCCHC14, C5orf24, MORF4L2, SLC35F5, TAOK1, GNAQ, 
ITGAV, ATP2A2, BOD1, C9orf72, PROM1 
hsa-miR-17-5p 310 ZNFX1, CCL1, GPR137B, NABP1, NPAT, YES1, JAK1, PTEN, 
CDKN1A, PTPRO, PKD2, BCL2L11, E2F1, MAP3K12, BCL2, 
MEF2D, RUNX1, APP, VEGFA, MAPK9, DNAJC27, FBXO31, 
TGFBR2, TNFSF12, MUC17, BMPR2, CCND1, MYC, NCOA3, 
THBS1, SMAD4, ICAM1, SELE, CCND2, E2F3, RB1, RBL1, 
RBL2, WEE1, RND3, TCF3, HSPB2, MMP2, HBP1, SIRPA, 
MOB1B, FBXO28, TJP1, SLC35E2B, ZC3H18, UBE4A, 
DHX33, RPS27A, HIST1H4C, GDAP1, TMEM165, SOX4, 
TRIM11, MRPL40, PIGS, ND4, PPP1R15A, USP38, RAB23, 
LARP1, ZSWIM3, ADARB1, MEN1, FAM8A1, NPAS2, ATP6, 
STK11, ACOT2, ATF3, ASNS, RTTN, ZNF689, HTT, IMMT, 
TBC1D15, PSD3, HIST1H2AM, HUWE1, HIST3H2A, APEX1, 
AZIN1, RPS15A, COA1, CPE, MBNL1, IGFBP5, HNRNPU, 
ND2, PIK3CA, PAIP1, EEF1A1, MTRF1L, KAT2A, POGK, 
OPTN, MYCBP2, SYNDIG1, UBE2S, RYR2, HIST2H2AA3, 
COPS3, MGEA5, PELI1, CETN2, AGO1, RPL37, REEP5, 
MRPS6, CHD4, SLC25A3, MUC21, KDM4A, HIST2H4B, 
COX2, ATP5B, CBL, CNEP1R1, NOC2L, CANX, ENPP5, 
EARS2, RPL7, CAP1, UBE2C, RMDN1, SLC25A37, NFAT5, 
DCTPP1, MFHAS1, ASH1L, HDAC10, RBM5, UBE3C, 
DEPDC1, TRUB1, TMED10, MDK, ZBED3, LCOR, NUCKS1, 
KIF5C, WDR82, COX7B, SH3GLB2, TAF9B, NAPEPLD, ATRX, 
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PTBP1, FTH1, PLXNA1, OFD1, PER1, ARL9, ARHGAP5, 
SIPA1L3, QARS, ELP2, SURF4, RPL21, CTSA, EPB41L5, ABI2, 
UQCRFS1, TMEM9, MED12, NAGK, TSC2, GPM6A, SEPT2, 
TEFM, FASN, AMD1, TRA2B, DCUN1D4, PRICKLE1,SEPT11, 
CHST14, TRIM44, SON, SMIM15, LAPTM4A, CHTF8, 
SMAD3, NONO, EIF4G3, NOTCH2, SDHA, XIAP, DNMBP, 
TRAP1, EPB41L2, MED13, TMTC4, BACE1, POGZ, GDF11, 
GPI, MNT, VPRBP, PGAM1, KANSL1,GAPDH, PRPF8, 
FOPNL, TUBB4B, DPYSL2, NBR1, KIAA1919, ZNF507, 
BLVRA, PPP2R1A, DCBLD2, CLPTM1, ARHGEF7, HIST2H3A, 
FANCA, MORF4L2, RLF, RAB5B, TOB1, EFHC1, MTMR3, 
TNFRSF10B, GANAB, SLC16A2, RTN3, ERCC2, ATXN7, 
HSP90AA1, GLO1, LPIN1, LSM14A, ILF3, ANKRD27, TNPO3, 
NAT8L, PTTG1, ARPC2, HN1, SLC25A28, TRRAP, ELMO2, 
PCNX, TMEM19, PBXIP1, CCT6A, HDHD1, PLS1, RNF145, 
AK1, TCEA2, PLAG1, PDPK1, TNFAIP1, RTCA, TUT1, LAS1L, 
RPSA, TMSB10, ERLIN1, EHMT2, BAZ2A, ARHGAP10, 
PDLIM5, CCDC47, CPSF1, MTF1, C15orf41, NUFIP2, GNB1, 
IRAK1, CPS1, FXR2, SUOX, STIL, WAC, FER, EIF4G2, 
BTN3A1, TRIM8, RUNDC1, ZFYVE26, RNF146, PPP1CA, 
NAP1L1, ZIK1, MKI67, MAP3K8, ZNF598, TRIM71, 
KIF1A,MAP3K9, KMT2A, RALGAPA1,ZBTB5, PCGF5, GNAS, 
WASL, RBM12B, TXLNA, ARIH1, KCTD7, HEXIM1, DAPK3, 
PLEKHM1 
hsa-miR-299-3p 1 FXN 
hsa-miR-409-3p 6 PHF10, FGB, FGA, FGG, ANG, IFNG 
hsa-miR-423-5p 168 RABAC1, NMD3, YWHAZ, RGPD2, TSPYL6, HIST2H2BE, 
USP6, PGAM4, DIP2A, NOS1AP, IGDCC4, RC3H1, KIF1A, 
SRSF11, BCLAF1, RPS15A, CCNI, GDF11, FAM127A, NME2, 
COX1, ARPC1A, MYBL2, ND5, NDE1, CDKN2A, TDRKH, 
AKAP13, RPS10, PRPF38B, PPIAL4G, MRPL34, NDRG1, 
ZBTB34, ATP6, ZFP36L1, COQ6, EPM2AIP1, REPS1, AAR2, 
PPIA, MKNK2, DDX21, SLC6A6, RPS2, CSTB, ABCC5, PAK1, 
ERRFI1, CEACAM6, FHOD1, LMNB2, NECAP1, NPLOC4, 
PMPCA, C12orf10, DDX54, VAC14, RUNX1, FAM98A, EPN1, 
TMUB1, UBE2L3, FAM110B, MICALL1, PNRC1, DLX5, 
ZNF655, FAAH, ATN1, ATP6V1E1, SLC9A3R1, NOLC1, 
PLCB1, SQSTM1, CLSTN1, ULK1, ATP2B4, EPB41, 
HIST1H1C, AGPAT6, TPGS2, FKBP4, GNG12, RPS9, RPL18A, 
CCND2, PCBP1, AP3M1, PDPK1, WBP2, CLSPN, PTTG1, 
GGA3, GAPDH, ARHGDIA, KCTD2, RNF139, ARHGAP32, 
HIST1H2BK, SAR1B, PA2G4, UBE2D3, GTPBP1, HIST2H2BF, 
NUTM1, COPS7A, POLR3H, HIST1H1E, NFKB2, SLC7A2, 
TIMP3, PTMA, CSDE1, CD81, CCNF, HNRNPUL1, RCE1, 
FAM83H, HES4, FAM189B, SLC48A1, SNX8, ZYX, DRAP1, 
TEX2, C15orf39, LRCH4, CHD8, MYC, TRIM28, SEPN1, 
MIER2, HOXA7, PRRC2A, SRP54, PABPC1, SRM, GTF2F1, 
HIPK2, NEDD4L, COPZ1, GLUL, PPARGC1B, PKM, MTCH2, 
ACTG1, MTMR3, ARL6IP1, DDX24, TUBB, NSD1, PAX2, 
ATP5B, CEBPB, YARS, STRIP2, KCTD15, RPL23A, MFGE8, 
SF3B3, RPL10, SALL1, BCCIP, PSMD6, MED28, MESDC1, 
DAG1 
hsa-miR-483-5p 1 MAPK3 
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17. ADDENDUM C:  A complete list of the 13 unverified 
miRNAs, for which gene targets were found in 
miRecords 
miRNA Number of 
gene targets 
Gene targets 
hsa-miR-21 49 TPM1, NFIB, PDCD4, SERPINB5, CDKN1A, FAS, FAM3C, HIPK3, 
PRRG4, ACTA2, BTG2, BMPR2, SESN1, IL6R, SOCS5, GLCCI1, 
APAF1, SLC16A10, SGK3, RP2, CDK6, CFL2, RECK, TIMP3, 
MTAP, SOX5, JMY, TGFBR2, TGFBR3, HNRNPK, tp63, TOPORS, 
DAXX, TP53BP2, PPIF, PTEN, pten, TGFB1, RASA1, RASGRP1, 
E2F1, CDC25A, LRRFIP1, JAG1, MARCKS, Peli1, PPARA, STAT3, 
NT-3 
hsa-miR-126 6 VCAM1, PIK3R2, CRKL,  IRS1, VEGFA, TOM1 
hsa-miR-141 13 CLOCK, TGFB2, ZEB2, FOG2, ERBB2IP, BAP1, KLHL20, PTPRD, 
ELMO2, WDR37, MKK4, SIP1,  JAG1 
hsa-miR-145 19 PARP8, IRS1, MYC, FSCN1, CCNA2, MUC1, CLINT1, CBFB, 
PPP3CA, FBXO28, ACBD3, USP46, RASA1, CCDC25, C11orf58, 
IGF-IR, KRT7, RTKN, SOX9 
hsa-miR-150 7 gag-pol, cmyb, MYB, CCNE1, P2RX7, EGR2, MUC4 
hsa-miR-155 24 AGTR1, BACH1, LDOC1, MATR3, TM6SF1, RHOA, ETS1, MEIS1, 
MAP3K7IP2, CYR61, MyD88, FOXO3, SOCS1, SHIP, CEBPB, 
JARID2, KGF, IKBKE, SMAD2, FADD, MeCP2, CCND1, SPI1, 
CTLA-4 
hsa-miR-224 4 API5, KLK10, KLK1, AP2M1 
hsa-miR-342 1 DNMT1 
hsa-miR-146a 38 IRAK1, TRAF6, BRCA2, BRCA1, CXCR4, TBP, MCP2, CCNA2, 
PA2G4, FADD, METTL7A, CDKN3, PRR15, MCPH1, MCM10, 
POLE2, PDIK1L, VWCE, LTB, ELL3, RAD54L, KIF22, CFH, TMSL8, 
MR1, ATOH8, UHRF1, TRIM14, COL13A1, TIMELESS, PBLD, 
BLMH, NFIX, PEX11G, SDCBP2, PLEKHA4, IRF-5, STAT1 
hsa-miR-148a 6 DNMT3B, NR1I2, Rps6ka5, DNMT1, MSK1, CDNK1B,  
hsa-miR-17-92 2 PTPRO, HIF1A 
hsa-miR-196a 9 HOXB8, HOXC8, HOXD8, HOXA7,  IKBKB, ANXA1, KRT5, 
SPRR2C, S100A9 
hsa-miR-23b 2 PLAU, MET 
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18. ADDENDUM D: The 36 regular expression string 
matched miRNAs for which gene targets were found in 
the miRTarBase database 
miRNA Number of 
gene targets 
Gene targets 
hsa-miR-21-5p 489 RASGRP1, CDC25A, BCL2, WIBG, WFS1, TM9SF3, 
RTN4, RPS7, PLOD3, PDHA2, NCAPG, DERL1, BASP1, 
JAG1, REST, SMARCA4, SPRY2, DUSP10, TIMP3, SOX5, 
MTAP, DOCK7, DOCK5, RECK, PIAS3, E2F2, FMOD, 
TGFBR2, PTEN, E2F1, TGFBI, LRRFIP1, MARCKS, SP1, 
CCL20, TPM1, NFIB, CDK6, RP2, SGK3, SLC16A10, 
APAF1, GLCCI1, SOCS5, SESN1, BTG2, FAM3C, FAS, 
PDCD4, RHOB, ANP32A, SERPINB5, NFKB1, BMPR2, 
TGIF1, NCOA3, MYC, ERBB2, SPATS2L, EIF2S1, PCBP1, 
JMY, TOPORS, HNRNPK, DAXX, TP53BP2, TP63, 
TGFBR3, PPIF, MSH2, MSH6, TIAM1, ISCU, MEF2C, 
EIF4A2, ANKRD46, EGFR, IL1B, ICAM1, PLAT, PTX3, 
TNFAIP3, CCR1, CDK2AP1, DOCK4, PPARA, FASLG, 
SOD3, TCF21, SMAD7, PHIP, PALLD, BOC, DAAM1, 
C20orf194, COL5A2, TPRG1L, NIN, PPAP2A, TRIM38, 
DDR2, VPS54, KIAA1715, BAZ1B, LIN7C, USP34, GNE, 
ZBTB8A, CLOCK, LPGAT1, NIPBL, DDHD2, C2orf43, 
SGCB, FANCI, EDIL3, DTX3L, IREB2, MGAT4A, RAPH1, 
CYBRD1, SLAIN2, KIAA1551, SOX2, GTF2A1, RRAGC, 
PIGN, HPS5, SESTD1, MEF2A, ZBTB47, ELOVL4, EPHA4, 
ENAH, TBL1XR1, NBEA, TAF5, AP3M1, CD47, LATS1, 
CPEB3, RMND5A, KBTBD7, MEIS1, GNB4, MMP2, 
VEGFA, REV3L, TXLNG2P, SCAF11, HNRNPH1, PARP1, 
CERS6, SNRNP48, FUBP1, TGFB1, ANKRD28, SYNE2, 
OSBPL1A, RSPRY1, SRSF11, ASRGL1, RB1, EXOC8, 
IVNS1ABP, UTRN, ACAT1, PFKFB2, PDGFD, COBLL1, 
SAMD5, MOAP1, KLHL24, ZNF326, WHSC1, BTBD7, 
GAPVD1, TNS3, ESYT2, MYEF2, PKD2, PTAR1, PAN3, 
ZRANB1, MON2, RASEF, GNAQ, HERPUD2, MAP3K2, 
THOC2, RASGRP3, PHF17, USP7, GTF2I, MKNK2, 
CLCN5, TRIM2, LONRF2, EIF4EBP2, PHF16, ELOVL7, 
SASH1, RAB22A, SUZ12, SPIN1, POLR3B, ATP2B4, 
CCDC34, PGRMC2, TRPM7, GID4, PLEKHA1, MALT1, 
ZNF367, TMEM245, MBNL1, MORC3, ZNF35, FOXN3, 
NR2C2, FBXO3, GPAM, PM20D2, CLIP4, DMTF1, 
DDX46, ATRX, LMBR1, MUC1, TUBGCP5, RHOQ, TET1, 
CASC5, ARHGAP21, MDM4, LARS, FAXDC2, CDK19, 
LAMP2, MOXD1, AHSA2, PIK3C2A, TMEM2, IPP, RAI14, 
MYO9A, MRPS10, FBXL17, AGGF1, SLC26A2, PRKAB2, 
SREK1, FAM20B, ARMCX3, SERPINI1, DDAH1, 
PROSER1, PRICKLE2, JPH1, NAA30, FKBP5, TGFB2, 
ZMYM2, TRIM33, RAPGEF6, MTPN, GOLGA4, SACM1L, 
ATAD2B, FIGN, EPM2A, RAB6C, TSNAX, TRAPPC2, LIFR, 
CALD1, LYRM7, PIK3R1, RPS6KA3, ADNP, LRRC57, 
DUSP8, KLHL15, GXYLT2, PBRM1, SMNDC1, NCSTN, 
 
 
 
 
193 
 
PPM1L, MMP9, PARP9, CKAP5, CAPRIN1, CNTRL, 
PHTF1, MRAP2, MYCBP2, ITSN2, BCAT1, PPFIA4, 
YME1L1, ZNF667, ETNK1, CYP4V2, BRCA1, DOCK10, 
DMD, TMX4, PTBP3, APOLD1, CCT6P1, UBR3, NEK1, 
DYNC1LI2, CSNK1A1, ACTR2, TRIM59, SPTLC3, 
TMEM56, ZADH2, DDX3X, ZNF217, FAM217B, ZBTB20, 
FNBP1, ZFYVE16, VPS13A, B3GALNT1, SLC5A3, GPD1L, 
STRBP, PRKCE, TOP2A, SEC63, TAF1, MPP5, PTK2, 
GPD2, SSFA2, HECTD1, PAG1, SFXN1, HAPLN1, EIF5, 
KLHL42, NFAT5, SLC9A6, ZNF207, RALGPS2, FAM46A, 
MTMR12, KBTBD6, TNRC6B, ABCD3, PKNOX1, 
RAB11FIP2, PURB, LCORL, KLF5, ST6GAL1, GPR64, 
SKP2, ECI2, NUFIP2, GRPEL2, HS3ST3B1, ELAVL4, 
CORO2A, TTC33, AUTS2, AKAP9, NKTR, PTPN14, 
STXBP5, MGA, KIFAP3, SPG11, PER3, ZNF292, ZNF587, 
AIM1, DSE, SRPK2, TSHZ3, CEP97, DCAF10, PHF20, 
SEMA5A, PHACTR2, RABGAP1, VPS36, WNK1, NUBPL, 
LIMCH1, MTMR9, SERAC1, RUFY3, APPL1, PBX1, 
OSBPL3, WNT5A, REV1, FBXL2, HOXA9, MIB1, FMR1, 
SNX30, SLC17A5, PREPL, CCDC14, ARHGEF12, USP47, 
BTBD3, ARID4A, ATP11B, SLC31A1, DLG1, SOWAHC, 
RSF1, SNRK, PLD1, TLR4, VPS26A, ZYG11B, AGO4, 
TESK2, MAP3K1, RAB6A, PURA, OLR1, KLF9, ATMIN, 
PRPF39, AGO2, STAG2, ACBD5, AKT2, UGGT1, PRRC1, 
NT5C2, ZNF532, DCAF8, UBR5, PTPN3, ATF2, EXOC5, 
AFTPH, WDR7, FAM126B, PTGFR, PHF20L1, B3GNT5, 
GLG1, CEP152, HMGB3, BDH2, NETO2, ALMS1, 
SMC1A, PIGX, SAR1A, APC, SLMAP, SOCS4, ZBTB38, 
OSR1, FBXO11, SCRN1, PTPDC1, CCNG1, MEGF9, 
TNPO1, FERMT2, KAT6A, TNFRSF11B, WWC2, WNK3, 
WHSC1L1, VASH2, SLK, FILIP1L, DCP1A, RNF11, 
RDH11, PELI1, YOD1, STAT3, BCL6, OTUD1, TMEM147 
hsa-miR-21-3p 2 SUV420H1, MED25 
hsa-miR-126-5p 6 SLC45A3, PTPN7, ADAM9, MMP7, CXCL12, 
CSGALNACT1, 
hsa-miR-126-3p 30 PITPNC1, IGFBP2, KRAS, SPRED1, PLK2, EGFL7, 
SLC45A3, CCNE2, RGS3, TOM1, HOXA9, MERTK, CRK, 
VEGFA, PIK3R2, VCAM1, IRS1, E2F1, SOX2, TWF1, 
TWF2, PTPN7, DNMT1, SLC7A5, TEK, ADAM9, MMP7, 
CXCL12, PGR, RBMX 
hsa-miR-141-3p 37 MAPK14, ZEB2, ZEB1, DLX5, BAP1, ACVR2B, KLF5, 
STK3, TGFB2, SFPQ, CLOCK, BRD3, UBAP1, PTEN, 
ZFPM2,TRAPPC2P1, EIF4E, PPARA, NR0B2, YWHAG, 
ELAVL4, MAPK9, TFDP2, E2F3, SHC1, VAC14, TCF7L1, 
ELMO2, RASSF2, KLHL20, RIN2, SEPT7, HOXB5, 
ERBB2IP, KLF11, PTPRD, WDR37 
hsa-miR-142-5p 1 NFE2L2 
hsa-miR-142-3p 107 RAC1, ARNTL, TNIP3, VSIG1, PSMB5, HOXA13, 
NAP1L2, CLOCK, ARHGAP12, IRF2BP1, KCND3, MESP2, 
CRH, PITPNC1, SLC37A3, PPP2R2C, ARL14EP, CDCA4, 
SH2D1A, MROH7, ETNK2, PCDHB14, C2, FAM209A, 
PCDHGA2, KRTAP4-5, C4BPB, ZNF608, GPC4, GPD1L, 
EVI2B, ZNF236, NEFH, HSFY2, ZNF701, UGT2B17, 
INSIG2, TAS2R7, RGS5, TPSG1, ARL6IP6, PCDHGA10, 
 
 
 
 
194 
 
SIGLEC10, MRGPRX1, AGBL2, PSMD12, BMP8A, 
C11orf16, INCENP, ALAD, TRIM36, AGTR2, TUBAL3, 
RNF170, NCKAP1, FAM65A, C7orf31, CLUAP1, ENAH, 
TMEM136, CLEC4D, KCTD12, ABCC9, CDC6, MCFD2, 
DOCK10, DCTN4, SECISBP2, KIAA1191, BRMS1L, SYT4, 
ARF4, FAM98A, RRM2B, UBE2W, ARL10, PCMTD2, 
CALCOCO2, MORF4L1, TSPAN6, GOLGA5, YES1, ARL15, 
FAM177A1, CA5B, NSFL1C, MAN1A2, SKP2, FBXO3, 
EDEM3, DNAJB4, CNIH4, CCNJ, RPE, CLIC4, TGFBR1, 
ZCCHC14, C5orf24, MORF4L2, SLC35F5, TAOK1, GNAQ, 
ITGAV, ATP2A2, BOD1, C9orf72, PROM1 
hsa-miR-145-5p 89 BNIP3, SOX2, KLF4, MUC1, MYO6, CDKN1A, ITGB8, 
STAT1, YES1, CBFB, PPP3CA, CLINT1, IRS1, IRS2, 
VEGFA, TMOD3, HOXA9, FSCN1, MYC, FLI1, IFNB1, 
TIRAP, POU5F1, IGF1R, KRT7, PPM1D, MYRF, CPEB4, 
FZD7, ROBO2, SRGAP1, EIF4E, CDK4, SERPINE1, 
SWAP70, NEDD9, PAK4, DDX17, ERG, NRAS, ILK, CTGF, 
SOCS7, MDM2, ADAM17, CDH2, HDAC2, RTKN, F11R, 
ARL6IP5, AKR1B10, C11orf65, HLTF, GMFB, SERINC5, 
MEST, ALPPL2, NDRG2, DTD1, TPM3, MAP2K6, CEP19, 
TPRG1, GOLM1, CCDC43, MMP1, PTP4A2, TMEM9B, 
MMP12, MTMR14, ALDH3A1, NDUFA4, FAM3C, 
LYPLA2, FAM45A, PIGF, AP1G1, PHF17, NIPSNAP1, 
KREMEN1, MMP14, ABRACL, MIXL1, TSPAN6, PODXL, 
APH1A, ABHD17C, NANOG, MYO5A 
hsa-miR-150-5p 15 MYB, EGR2, VEGFA, P2RX7, IGF2, CXCR4, ZEB1, 
NOTCH3, FLT3, EP300, PTPRR, MS4A3, AGA,ATP13A3, 
TP53 
hsa-miR-155-5p 717 UQCRFS1, MEIS1, TAB2, MECP2, SOCS1, MSH6, MSH2, 
MLH1, INPP5D, DET1, SMAD5, HIVEP2, ZNF652, ZIC3, 
BACH1, JARID2, CSNK1A1, APC, WDFY1, VAMP3, 
UBE2J1, TXNRD1, TXNDC12, TRIP13, TRIM32, TRAM1, 
TNFRSF10A, TBCA, TACSTD2, SYPL1, SYNE2, SNAP29, 
SMAD1, SLC30A1, SH3BP4, SDCBP, SCAMP1, RHEB, 
RCOR1, RCN2, RAI14, RAB6A, RAB5C, RAB34, RAB27B, 
RAB23, PTPRJ, PRKCI, PRAF2, PPP5C, PPL, POLE4, 
POLE3, PODXL, PLXND1, PKN2, PICALM, PHC2, 
PDLIM5, PDE3A, NT5E, NARS, MYO1E, MYO10, MSI2, 
MPZL1, MOSPD2, MARC1, METTL7A, LY6K, LPL, UFL1, 
HSDL1, HSD17B12, GNA13, FMNL2, FADS1, DSG2, 
DPP7, DNAJC19, DNAJB1, DHX40, CYP51A1, CUL4B, 
CTNNB1, CLDN1, CHAF1A, CEBPB, CDK5RAP3, CBFB, 
BRPF3, BET1, ATP6V1C1, ATG3, ARL5B, ARL10, ARID2, 
ARFIP2, ARFIP1, ANKFY1, AMIGO2, TM6SF1, MATR3, 
LDOC1, PHF17, RHOA, AGTR1, PKIA, TP53INP1, IKBKE, 
FGF7, KDM3A, NFATC2IP, CUX1, BCAT1, SPI1, CTLA4, 
EDN1, FOXO3, MAFB, TSHZ3, RUNX2, JUN, IFNGR1, 
ZNF236, LAT2, PAPOLA, EHD1, SERTAD2, PELI1, 
KBTBD2, HNRNPA3P1, SLC39A10, KRAS, CAMTA1, 
NAMPT, CREBRF, ETS1, TLE4, FAR1, EDEM3, TWF1, 
C3orf58, SLC25A40, PSMG1, IKBIP, LCLAT1, VEZF1, 
SACM1L, DCAF7, ERMP1, KRT80, FLI1, DOCK4, CYR61, 
ICAM1, SELE, SMAD2, YB, SKI, GCSAM, CKAP5, 
IL13RA1, BCL6, MITF, MAP3K10, NOS3, UBR4, 9orf142, 
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MECR, LUC7L2, TCEA1, ANAPC16, C17orf80, SLC27A2, 
XPC, EIF3G, EIF2B5, UBA3, EIF3E, PCYOX1, EXOC7, 
QPCTL, DYNC2H1, GLIPR2, HEATR2, UGT8, HSPB11, 
CCDC137, GLB1, LRRC40, VBP1, MGST2, GNB4, JUP, 
DNAJC2, GOLPH3, DRAP1, NOB1, SLC1A5, AB14, YBX3, 
SLC39A14, UBE2J2, EIF4A1, CAB39L, EIF2B2, CNDP2, 
RTN3, TMBIM6, EIF4G2, CDC42BPB, MYD88, ADH5, 
EIF3C, QRICH1, CYFIP1, PSIP1, SIN3A, STK24, AGL, 
METAP2, SPIN1, FAM98B, ERI1, COLGALT1, UGDH, 
KIAA1715, XPO1, PALLD, MUT, RAP1B, BAG5, LPGAT1, 
GCFC2, EXOSC2, LNX2, ZNF248, CHD9, MEF2A, CAB39, 
CLUAP1, CARD11, PCDH9, ZNF561, CARHSP1, 
C16orf62, LIN7C, CBR4, ECI1, OSBPL10, EIF4E2, TGM2, 
SLC9A3R2, CHAF1B, PPFIBP1, UBXN1, ESRRA, GAPVD1, 
CTAGE5, RBM42, MFF, NEU1, SCD, UBE2D2, OVCA2, 
EIF3CL, AURKA, LEPREL2, FUBP1, RETSAT, MPP2, 
KIAA0368, NES, KIF22, PACSIN2, SLC25A19, IPO8, 
GPT2, OGFOD1, AKR7A2, TRMT1, MCAM, INA, SNX6, 
PDAP1, PCNT, FIP1L1, MTAP, CEP55, AIFM1, PPM1G, 
PAM16, PLK1, AURKB, NASP, NUPL2, NCKAP1, EXOC2, 
SEC24B, RRM2, GRPEL1, ALDH9A1, AP1G1, LUZP1, 
RPRD1A, AA25, RP2, NUP155, FAM105B, TMX3, 
ERGIC1, NFYC, BE2D3, SUZ12, GLIPR1, GPM6B, LRIF1, 
TAF5L, HERC4, MORC3, MBNL3, UPF2, KRT6B, FLNA, 
DAG1, TIMM13, BUD31, CUTA, STIM1, EOGT, GEMIN5, 
GNPNAT1, STXBP2, PCCB, EIF3J, CHRAC1, PLAUR, 
CISD2, BCL7C, TICAM2, KDM1A, PSEN1, STRN, 
SMARCD2, RARS, RBPJ, LARS, ALDH1A2, CNOT10, 
UBE2H, TNKS1BP1, PUS7, RPL39, CTSA, MBLAC2, 
GAR1, RAD1, NOLC1, FGF2, KDELC2, HSPA4L, PEBP1, 
PNPLA4, GHITM, FAM3C, PGRMC2, RPAP1, NCAPG, 
PDE12, TFCP2, L2HGDH, PRKAR2A, ARL5A, CD109, 
TOMM34, CFL2, AIMP1, CDC73, TRIO, PAXBP1, 
TSPAN14, INTS6, YWHAZ, PRKAR1A, SSX2IP, FAM199X, 
RAC1, PLS1, SAP30L, MRPS27, TNFAIP2, JUNB, SPCS1, 
CTNNA1, ASNS, H2AFY, NR3C1, AXL, RING1, CLTA, 
COL4A2, CNNM3, CTNNBL1, RQCD1, ATL2, CDK5, 
PPP2R2A, THOC7, DNMT1, MRPL16, RAB6C, HAX1, 
ABHD16A, ASB6, GPAM, CECR5, WDR11, NMD3, 
IGF2R, ACOT7, RRAGA, INTS7, YARS, FLNB, CORO1B, 
SUPT5H, KANK2, DIAPH3, FASTKD1, NSA2, FMNL3, 
CHTOP, STRBP, MARCKS, POLR1B, FNDC3B, CD3EAP, 
PSAT1, COPS3, DEGS1, OXCT1, PDK1, EIF3A, GMPS, 
OLR1, SMAD4, CD68, FLT1, CEP41, CIAPIN1, CCDC82, 
ACTR2, TRAK1, CYP2U1, SLC35F2, ZNF493, HAL, 
IL17RB, TBC1D14, ZNF254, GABARAPL1, IGJ, RAPGEF2, 
WBP1L, PBRM1, ABCC4, SPECC1, MAT2B, TFPI, EXOC3, 
PFDN4, HK2, TYSND1, C12orf10, CRAT, PLEKHA5, 
PACSIN3, F5, SMARCE1, CD81, VAV2, SLC7A1, OBSCN, 
MAVS, DMD, CARS2, SLC12A4, MRPS34, B4GALT1, 
KDELC1, PDCD10, NCAPD2, UBA2, ALDH5A1, FUBP3, 
MYO6, NAA50, MARC2, RIOK2, OSBPL9, DDX10, 
ATXN10, RAB30, DEK, PHF6, ARL8B, LEMD3, ZNF207, 
CSE1L, CPT1A, TTC37, MAN1A2, RICTOR, IMPAD1, 
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VPS4B, CLINT1, UBQLN2, RIF1, PNPT1, MRPL18, 
MAP3K14, ARMC2, LCORL, APAF1, MPP5, RAB11FIP2, 
NOVA1, RBAK, ARL15, MYO1D, LRRC59, CMSS1, 
LONP2, MUS81, ITGB4, DDB2, CAT, ATPAF1, TPBG, 
INTS4, TIMM8A, RBM22, MTFMT, WRB, DDRGK1, 
GMPPA, EEF1A2, RDH13, CLTC, NOTCH2, CARS, PTMS, 
CSNK1A1L, LUC7L3, TJP1, FDFT1, CDKN2A, AKR1C3, 
PNPLA8, S100A11, IER3IP1, FSTL1, SLC38A5, ATP6V1H, 
ITGB5, SRSF2, SLC7A11, ANXA2, DDX17, RAB2A, 
FOXK1, TMOD3, PSME4, ZNF384, GNAS, SNTB2, 
TMTC3, SLC30A7, ASPH, INTS8, CPD, EGFR, SRPK2, 
STAG2, TPRKB, VPS36, VCAM1, SMAD3, TTF1, 
FAM91A1, CCDC41, KIAA0430, CDC40, DCUN1D2, 
KLHL5, AGO4, HBP1, WWC1, WEE1, GOLT1B, PALD1, 
THBS1, DBN1, DHCR24, HSD17B7, NSUN5, TPP2, 
UAP1, OXNAD1, SSSCA1, EEF1E1, PHGDH, CCND1, 
ALDH3A2, CDK2, SGPL1, TSPAN3, ANPEP, PSME3, 
AGRN, GNL3L, VANGL1, RTFDC1, WNT5A, TMEM167A, 
CLIC4, MEST, TRIM24, CDH6, MMS22L, SKIV2L2, CCR9, 
DR1, RSF1, ANTXR1, SEPT11, HNRNPA3, IL8, ZNF83, 
PHF14, TBC1D8B, INPP5F, ARPC3, KRCC1, FAM177A1, 
UBTD2, SECISBP2, PAK2, SLC33A1, ZNF28, MCM8, 
SMARCA4, TCF12, TOMM20, UBQLN1, PDPR, MOV10, 
FAM120A, FAM96B, FKBP3, STAT3, NEUROG1, EPRS, 
CDH2, CDH13, ATP13A1, EIF3F, NUP62, GCLC, LSM3, 
HTRA1, CDK4, EPB41L2, COG2, CCT2, NUCKS1, PRSS21, 
INTS10, STX5, CIAO1, GLG1, TROVE2, ARGLU1, CALU, 
BRI3BP, RAD23B, PYGL, MRS2, KIF14, POLR2C, TPD52, 
MTHFD2, RNF2, LTN1, TMEM33, TNPO1, GSK3B, 
ADAM10, ERBB2IP, CCL2, NFKB1, IL6, CD36, RREB1, 
ZKSCAN5, ZNF611, ZNF273, VPS18, WHSC1L1, MASTL, 
MYBL1, GATM, E2F2, FAM135A, C3orf18, ARL6IP5 
hsa-miR-155-3p 1 IRAK3 
hsa-miR-181a-5p 237 DUSP6, NLK, GATA6, CDX2, PRAP1, PLAG1, RALA, 
PTPN22, PTPN11, DUSP5, BCL2, PROX1, KAT2B, 
CDKN1B, ZNF763, DDIT4, ATM, HIPK2, BCL2L11, HRAS, 
SIRT1, FOS, MTMR3, KLF6, MCL1, XIAP, GPR78, LFNG, 
LRRC17, CHRFAM7A, CD46, RASSF6, FXYD6, KCTD3, 
TSHR, ZNF558, C8A, ARL6IP6, ZNF426, ATF7IP2, PRR4, 
TCF21, PHOX2A, PROSC, PTPLAD1, GSTM2, FSIP1, 
KBTBD3, PTPRZ1, WNT3A, TUSC1, LRRN3, TMEM45A, 
ARF6, C1orf109, TAF15, PLXDC2, NMRK2, WNT2, 
ATG10, PRDX3, ZNF652, RTEL1-TNFRSF6B, GCNT1, 
PCDHB8, ENAH, ZNF25, S100A1, PLA2G4C, NOL4, SIX6, 
FKBP10, SMCHD1, OR11A1, INCENP, LPGAT1, CLUAP1, 
LYSMD3, CCDC6, BAG2, GPR83, PTGS2, ANKRD13C, 
RLF, FBXO28, ZNF350, TIAL1, RNF34, LCLAT1, 
KIAA1462, ZNF35, PITPNB, SCD, H3F3B, GATAD2B, 
LGALSL, TGIF2, MOB1A, SLC35B4, FAM160A2, NUPL1, 
GPRIN3, H1F0, ARHGAP12, SPRY2, TGFBR3, TMED4, 
MAP2K1, PUM1, TRIM2, FBXO33, NRP1, FAM47B, 
CCNG1, BRMS1L, OTUD1, ATP6V0E1, WNT16, CST5, 
SH3BGRL, GPR137B, OFCC1, IQCG, NKX3-2, OTX2, 
ROPN1L, TMEM14A, TAF2, IDS, FRA10AC1, COL27A1, 
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EPHA5, DCST1, ZNF562, EYA4, CHL1, TAAR6, SLCO2A1, 
TMEM257, HMGB2, HERC3, BTBD3, SRPK2, DNAJC7, 
ANKRD1, CFI, MRPS14, HEY2, MTMR12, ACOT12, 
KIAA0101, USP28, AMMECR1, BPGM, DSCR8, UGT3A1, 
HSD17B3, GADD45G, FBXO34, C1QTNF9, KLRC4, 
MOB3B, FKBP7, TBX4, TMPRSS11A, SNAI2, SLC7A11, 
NUDT12, COPS2, ZNF12, PRLR, PLCL2, ZNF594, 
METAP1, HSPA13, NR6A1, YOD1, SLC37A3, FBXO11, 
ZNF445, TM9SF3, ATP8A1, TMEM64, MOB1B, GNAI3, 
TAB2, SRSF7, DDX3X, KRAS, LBR, GIGYF1, KLHL42, 
TMEM132B, AFTPH, ZNF148, NOTCH2, NFYB, NOTCH1, 
SIK2, HOOK3, FAM222B, RPS8, STAG2, SMG1, PFKFB2, 
ZEB2, MAZ, RPL14, KCTD2, UBA2, DDX27, FAT1, 
HDAC6, TMEM192, LAMA3, HUWE1, ND2, HNRNPAB, 
OCA2, AP1M1, UCHL1, PGD, ZFP36L2, AKAP12, 
PABPC1, GANAB, PHPT1, H2AFY, TEAD4, KLHL15, 
PRRC2B, BRCA1, SOGA2, KIAA0100, PPP1R9A, MGAT5, 
TNIP1 
hsa-miR-181a-2-3p 1 ARID1A 
hsa-miR-181b-5p 97 NLK, GATA6, CDX2, CBX7, TIMP3, PLAG1, SIRT1, 
GRIA2, VSNL1, BCL2, KAT2B, TCL1A, MAP3K10, CYLD, 
TMED7, XIAP, MCL1, IGF1R, E2F1, NRD1, C20orf173, 
FAM5B, NDE1, KRI1, RBMX, DNAJB11, PTEN, EIF5A, 
KLHL7, NDC1, TMEM189, KPNB1, CAT, DTD2, USP10, 
LMCD1, MTOR, RPRD1A, THOC3, ZFHX3, MED14, 
PDHX, KPNA2, RPL18A, RPS7, UWE1, RNF187, ZNF526, 
HIST1H1E, EP300, INO80B, C5orf34, IFNGR1, ZXDC, 
MEPCE, NRBP1, ZNF503, UBB, SRRM2, NR2F1, 
RAP1GAP2, ARHGAP35, XPO6, ZNF747, MRPS23, 
SCAP, XRCC6, TRRAP, GANAB, C17orf100, RPS12, FBL, 
FUS, NEK3, TAF5L, RTFDC1, ZBTB20, DIDO1, ZBTB4, 
HIST2H4B, SEC24C, BPTF, DDHD1, ILF2, USP24, EIF4E2, 
OSBPL8, MYO1C, RPS8, RQCD1, FGFR1, PWP2, EIF3C, 
ATP6, ASB13, KIAA1524, C2orf69 
hsa-miR-181c-5p 17 NLK, GATA6, CDX2, NOTCH4, KRAS, NOTCH2, BCL2, 
TRIM2, SIRT1, BTBD3, BMPR2, IL2, TUB, UBR7, TIAL1, 
KIT, ISCA1 
hsa-miR-181c-3p 1 MMP25 
hsa-miR-181a-3p 2 NANOG, HOOK3 
hsa-miR-181d-5p 25 BCL2, HRAS, MGMT, NRD1, C20orf173, HMGB1, 
HSP90AB1, BORA, FCHO2, ENO1, HIST1H3D, PBX2, 
RPS14, PGAM1, DHRS4, CTC1, NID2, ATP6, PDHX, 
GAB1, RQCD1, MGRN1, C10orf35, EP300, ARID3B 
hsa-miR-224-5p 17 KLK10, CXCR4, CDC42, RAB9B, PDGFRB, SMAD4, 
NCOA6, FOSB, NIT1, AP2M1, CD40, API5, EYA4, 
EDNRA, PEBP1, ARSB, ADNP2 
hsa-miR-342-5p 29 UCP3, ATRX, PHF17, MCMBP, ROBO2, USP36, NUFIP2, 
VPS13D, EIF3D, CCNE1, AKR1B1, NFE2L1, KIF7, PTPRG, 
ELP3, SMARCA4, TBC1D22A, BCLAF1, ND2, TMEM109, 
PRRC2C, RNPS1, DDX1, MMACHC, GAPDH, PPIA, 
FAM65A, PSMC1, ANKRD12 
hsa-miR-342-3p 83 GEMIN4, BMP7, DNMT1, TMEM98, IDH3B, KPNA2, 
PRKCE, TRMT61A, ZNF766, FIGN, FIBP, ARIH2, 
KCTD15, RPS3A, NCAN, SLC6A12, RPS9, ATXN7, ISOC2, 
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CRB2, PPIE, PSAT1, GJA1, CANX, NOP2, VAPB, ATF4, 
BPTF, RPL26, NGRN, TNS3, RPL15, FN3KRP, METTL2A, 
VPS35, IDS, HNRNPC, ABL1, SLC30A9, RPL27A, GOT2, 
PRKCSH, RRM2, RFX3, CCND2, GART, ZNF430, NAPG, 
GTF2H2C, FAM3C, PWP2, PTRF, ZC3H12C, ACTG1, 
TRERF1, CBX1, TOMM70A, ZSCAN29, NABP2, HARS, 
INO80D, RALGAPB, EEF1A2, PA2G4, STRN, CCDC6, 
EXOSC1, EPB41, ZFC3H1, XPOT, UN, SOD2, EEF2, TCP1, 
TCF3, TUT1, RAP1, FOSL2, APTX, SF3B3, SF3B2, TACC1, 
CXADR 
hsa-miR-383-5p 4 IRF1, VEGFA, IGF1R, PRDX3 
hsa-miR-629-5p 4 HNF4A,HIST1H2AC,ATP5G2, ZCCHC6 
hsa-miR-629-3p 2 DDX3X, ATP5B 
hsa-miR-663a 5 JUNB, JUNB, TCEAL1, HSPG2, CDK1 
hsa-miR-663b 1 HRASLS5 
hsa-miR-125a-5p 137 TNFAIP3, CDKN1A, LIN28A, NTRK3, CD34, TP53, LIF, 
MTUS1, RARA, VEGFA, ERBB3, ERBB2, KLF13, BAK1, 
ARID3B, ELAVL1, CCL5, MMP11, HK2, ARPC5, E2F7, 
ZBTB10, CREB5, OMA1, OSTM1, MAPK8, RBM17, 
PUM2, NR1D2, HOXC4, SNX4, NDUFB6, NOP16, CRK, 
SLC1A5, PARD6B, TCEB2, PANX1, ZFAND1, CORO1C, 
CLDN12, ZNF776, TNPO2, EIF4EBP1, PDPK1, YES1, 
DUSP3, YOD1, ATXN1, TMEM101, ERMP1, GUCD1, 
RBAK, ATL2, OGT, PREPL, PPP2R5E, TFRC, G2E3, PLS3, 
TTC30B, RRP1B, COIL, NDEL1, ATXN7L3, PRC1, LIN28B, 
TOR1AIP2, KIAA0232, TOR4A, TPI1, PCDHGB2, 
UBE2G2, SPRTN, XPO1, THRAP3, OSBPL9, LBX2, 
SEPW1, PGM3, MACF1, PC, EEF1A1, TBC1D1, 
PLA2G4F, PEG10, ATP5G2, FBXO10, TDG, SP1, DLST, 
WNK3, RALBP1, RPS2, MRPL50, NIN, MORC2, ZZEF1, 
PDCL3, RPL35A, ND6, TPM4, RPL9, ENO1, CLCN7, 
COL4A1, NME2, GGCT, CGNL1, ZMYND19, MAT2A, 
NPM1, NNT, SRGAP2, EMID1, ATP5J2, STAT2, FERMT1, 
DIP2A, MAP3K1, SLFN11, AGTRAP, KIF6, TRMT2A, 
PAM, UNC45A, MAP2K7, LYPLA1, LAMB1, NCKIPSD, 
OTUB2, CASC4, ZDHHC9, ARHGAP12, YIPF4, IP6K1, 
C17orf80 
hsa-miR-125a-3p 10 IP6K2, PFAS, TTC8, ARFGEF1, E2F8, GLUL, LEPRE1, 
IGF2BP2, NUP62, ATP6V1B2  
hsa-miR-146a-5p 66 CXCR4, CFH, IRAK2, TLR2, FADD, TRAF6, IRAK1, ROCK1, 
BRCA2, BRCA1, TLR4, FAF1, CCNA2, PA2G4, IL8, 
NFKB1, CDKN1A, EGFR, MTA2, CD40LG, FAS, CDKN3, 
KIF22, ERBB4, SMAD4, WASF2, IRF7, PPP1R1C, ITGB2, 
SNTG2, RSAD2, BGLAP, SYT12, STAT1, IFIT1, IFITM1, 
OLFML2A, ISG15, IFITM3, RGS13, MTUS2, NMI, 
HSPA1A, TRIM22, ITGBL1, SPATS2L, IFI44, OASL, 
IFI44L, IFI27, LINC00304, STON2, BCL2A1, MX2,EPSTI1, 
OSBPL1A, IFIT5, C1orf21, GIMAP4, CCR9, SAMD9L, 
IFIT3, SPP1, SLPI, L1CAM, MSC 
hsa-miR-146a-3p 1 PLXNA1 
hsa-miR-148a-5p 2 GALK2, ACTR1A 
hsa-miR-148a-3p 81 DNMT1, HLA-G, TGIF2, DNMT3B, NR1I2, RPS6KA5, 
CCKBR, IRS1, ACVR1, BCL2, TMED7, GPATCH8, 
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TMEM14A, ANP32A, RAB1B, HSP90B1, POFUT1, CYCS, 
ADARB1, CBX3, UQCRQ, SPRY2, PAN3, KANSL1, GAS1, 
PTPN4, ZNF92, RAB10, PAPD4, HCCS, WAPAL, MPP5, 
ZNF490, RAB12, GNB5, SNAPIN, PSMD9, TRIM59, 
DYNLL2, SECISBP2L, LYSMD1, PBXIP1, MTMR9, 
DNAJB4, DSTYK, LBR, KIAA1549, DYRK1A, CDK19, 
RAB34, ARRDC3, PRNP, HOXC8, TMEM9B, RASSF8, 
BTBD3, TNRC6A, SESTD1, CDC25B, MRPL45, DENR, 
APPBP2, SLC2A3, PTPN23, VPS41, MSL3, AMELX, 
OR2C3, SLC25A3, APC, GOLIM4, MYCBP2, RPS17, 
HSPA4, WDTC1, HMGB1, MAP3K4, USP38, NONO, 
CCNI, AURKB 
hsa-miR-196a-5p 222 SPRR2C, S100A9, KRT5, ANXA1, HOXB8, HOXA7, 
HOXD8, HOXC8, HOXB7, BACH1, HMOX1, CDKN1B, 
HOXA5, PDCD4, SRRT, DIEXF, ZBTB24, NR4A1, ABT1, 
SPATA2, NHLRC3, RPUSD2, CEP120, PHC3, ZBTB6, 
C9orf41, PNP, COPS3, NUP50, ZNF763, FOXJ3, BIN3, 
C12orf4, RAD9A, PCGF3, KATNAL1, SLC10A7, LBR, 
BCL11A, GLMN, STK40, TMEM135, GGA3, POLR2D, 
LGR4, IGF2BP3, ESPL1, RFX5, SYT9, PEX13, IGF1R, 
SMCR7L, SLC30A6, RAB31, KPNA5, SLC20A1, TIMM23, 
IGDCC4, SMARCAD1, CCNT2, CCND2, USP24, TRPC3, 
SMC3, TMEM2, RDH10, C11orf57, FAM127A, PRUNE2, 
PRYD4, TMEM161B, CPEB3, FAM104A, RAB7L1, 
ITGAV, CPD, ZNF354B, TMEM194A, EPHA7, KIAA1804,  
DFFA, TSPAN12, LIN28B, ARHGAP28, IGF2BP1, 
CCDC47, HAND1, LLGL1, PGAM1, PSMC3, TMX2, 
KLHL7, RFC2, GLUL, NRXN1, GSTK1, HIST2H4B, SPEN, 
TAF15, SAP18, SNRPD1, MSL3, TSKU, KMT2C, LYRM2, 
UBE2Z, C19orf55, LRP2, ND4L, NKX6-1, BRMS1L, RPS2, 
RBMX, ZFP64, REEP2, MED13, MYCBP2, TRAPPC9, 
DNTTIP2, VDAC3, ZNF529, EWSR1, ATP6V1B2, RDH11, 
APP, PROSER1, HIST1H2BB, TAB2, TUBA1B, USP19, 
COX3, PSMD8, TRA2B, MRPL35, KCTD1, UBE2C, 
ZNF581, CNOT11, POTEG, MTRF1L, SRP9, BCORL1, 
NRBP1, LRRC41, ATP6, FKTN, RANBP9, SYVN1, NR2F6, 
ATG16L1, EIF2S3, ECHDC1, HAUS6, CKAP2L, IFNGR1, 
ANXA7, ENAH, FOXO1, NDFIP1, LSM14A, ATP1A1, 
SLC25A17, ZNF398, RASSF7, SBF1, TP53RK, MED12, 
FLNA, CCNE2, CANX, PRPF8, FRS2, KIF18B, U2AF2, 
SH3GL3, VCP, ETV3, BCS1L, ND5, ZCCHC11, RALGPS2, 
HUWE1, ACTB, UQCRC2, EIF2B4, GMFB, PALLD, 
CASP3, VCL, IPO5, PATL1, NAP1L4, RUFY2, TUBB, 
CCND1, GID8, VDAC2, SLC6A8, FXR2, SCN11A, AHSA1, 
ATG9A, NOTCH2, DYRK2, ND4, OAT, TRAP1, SKI, GLTP, 
EEF2, LSM3, GRIK4, PDE6D, MPP2, SAR1B, MAP4, 
RAB21, BUB1, OGFRL1, GOT2, NRDE2, SBNO1 
hsa-miR-196a-3p 1 RPS26 
hsa-miR-23b-5p 3 PRODH, SPEN, EIF4B 
hsa-miR-23b-3p 173 PRAP1, NOTCH1, E2F1, RB1, PLAU, MET, PTK2B, VHL, 
TAB3, TAB2, CHUK, SRC, PTEN, DHX57, CCDC88C, 
ACAT1, ZIC5, CEPT1, KIAA1279, G3BP1, BLOC1S2, 
CPEB3, ANKRD17, SPTY2D1, MED4, STAT5B, PNN, 
ARFIP1, AKAP11, SNRPC, PCMTD2, MCFD2, SOS1, 
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CATSPERB, RPS27A, MSH6, RBPMS2, HK1, BCL7B, 
MED13L, ATXN10, CDC73, FLNA, CUL4A, ZNFX1, 
WDR54, UQCRC2, HERC3, TNRC6B, CDK2, RPL19, 
ACTN4, ATP1A1, DDX47, CEP104, PPM1A, PPP1CB, 
CPSF7, GNS, SORCS2, LASP1, CAP1, RRAGD, TCF25, 
FAM168B, BCS1L, RMND5A, ILF2, GAPDH, ABCF1, 
CCT7, SLC9A6, DNAJC5, KDM1A, SSRP1, INPP4A, SBF1, 
PRPF6, GNB2L1, TCP1, ILVBL, PI4KB, AMOTL1, ATF7IP, 
BCL2L1, ZMYM2, GANAB, IMPDH2, GJA1, COX1, 
HIST2H4B, CDCA8, DIAPH1, PLOD1, HNRNPUL1, CRKL, 
AP4B1, RAB5B, STK11IP, PSMD14, CLUAP1, CD302, 
XPO1, GNA12, JAK1, PPARGC1B, CYB561D1, PRDX1, 
ABCC1, NHP2L1, AARS2, UBR3, RPN2, C11orf68, 
CPSF3L, MLLT6, DDX27, ITPR3, SYDE2, PRR14L, 
SUPT7L, BBS12, ATP5A1, EEF1A1, GHITM, EWSR1, 
EP300, PDCD6IP, SLC16A1, DMTN, CSDE1, HIF1AN, 
DONSON, DNMBP, KLHL2, RAF1, KANSL1, COPA, 
PHF10, CCNB2, LBR, DHX33, ECH1, RPL22, HNRNPK, 
ITFG1, UNC45A, C8orf33, SLC6A15, MAP4, RAD51, 
SOCS6, PSAP, WWP2, CLTA, ALDOA, HNRNPL, TPCN1, 
MPV17, NSD1, DGCR2, CDC20, PANK2, USP31, NMT1, 
TSR1, EIF4A1, E2F4, GTF2I, NPM1, EMC1, ABCC4, 
CMTM4 
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19. ADDENDUM E: The complete list of differentially-
expressed genes for which miRNA targets were found in 
the miRTarBase database  
Gene Interacting miRNAs 
ABCA1 hsa-miR-33b-5p, hsa-miR-33a-5p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-
miR-19a-3p, hsa-miR-27a-3p 
ACADS hsa-miR-26b-5p, hsa-miR-484, hsa-miR-92a-3p 
ACTN2 hsa-miR-7-5p 
ADAMTS5 hsa-miR-98-5p 
ADAR 
hsa-miR-1, hsa-miR-130b-3p, hsa-miR-93-5p, hsa-miR-1226-3p, hsa-miR-
625-5p, hsa-miR-484, hsa-miR-197-3p 
ADD3 hsa-miR-374b-5p, hsa-miR-124-3p, hsa-miR-24-3p 
ADGB hsa-miR-335-5p, hsa-miR-26b-5p 
ADH1A hsa-miR-132-3p 
ADIPOR1 hsa-miR-197-3p 
AHNAK2 hsa-miR-124-3p, hsa-miR-1, hsa-miR-16-5p 
AIPL1 hsa-miR-3615 
AMELX hsa-miR-320a, hsa-miR-148a-3p 
AMPD1 hsa-miR-10a-5p, hsa-miR-16-5p 
ANAPC5 hsa-miR-124-3p, hsa-miR-1227-3p, hsa-miR-26b-3p, hsa-miR-34a-5p, 
hsa-miR-93-5p, hsa-miR-30a-5p 
ANKRD26 hsa-miR-30a-5p 
AP1M2 hsa-miR-124-3p 
AP5S1 hsa-miR-15b-5p, hsa-miR-10a-5p 
APITD1 hsa-miR-182-5p 
ARHGAP22 hsa-miR-124-3p, hsa-miR-615-3p 
ARID4A hsa-miR-335-5p, hsa-miR-21-5p 
ARIH1 hsa-miR-425-5p, hsa-miR-17-5p 
ARL1 hsa-miR-130b-3p, hsa-miR-93-5p, hsa-miR-24-3p, hsa-miR-769-5p 
ARPC5L 
hsa-miR-335-5p, hsa-miR-124-3p, hsa-miR-16-5p, hsa-miR-615-3p, hsa-
miR-25-3p 
ASAP3 hsa-miR-335-5p 
ASPN hsa-miR-335-5p, hsa-miR-124-3p, hsa-miR-26b-5p 
ATAD2 
hsa-miR-106b-5p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-941, hsa-
miR-193b-3p, hsa-miR-17-3p 
ATP10A hsa-miR-335-5p 
ATP11A 
hsa-miR-744-5p, hsa-miR-769-5p, hsa-miR-484, hsa-miR-197-3p, hsa-
miR-92a-3p 
ATP5C1 hsa-miR-30b-5p, hsa-miR-16-5p 
ATP5G2 hsa-miR-629-5p, hsa-miR-185-5p, hsa-miR-149-5p, hsa-miR-125a-5p 
ATP5H hsa-miR-324-5p 
ATP6V1G1 hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-98-5p 
ATPAF2 hsa-miR-320a 
ATXN7 hsa-miR-192-5p, hsa-miR-423-3p, hsa-miR-342-3p, hsa-miR-92a-3p, hsa-
miR-17-5p 
BCAP31 hsa-miR-346, hsa-miR-29a-3p 
BRD8 hsa-miR-26b-5p, hsa-miR-24-3p, hsa-miR-92b-3p 
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C11orf30 hsa-miR-26b-5p 
C4BPB hsa-miR-142-3p, hsa-miR-124-3p 
CACNA1S hsa-miR-26b-5p 
CAPN11 hsa-miR-335-5p, hsa-miR-124-3p 
CASP8 hsa-miR-19b-1-5p, hsa-miR-26b-5p 
CASQ1 hsa-miR-335-5p, hsa-miR-26b-5p 
CBS 
hsa-miR-106b-3p, hsa-miR-652-3p, hsa-miR-615-3p, hsa-miR-193b-3p, 
hsa-miR-324-5p, hsa-miR-149-5p, hsa-miR-92a-3p 
CCDC102B hsa-miR-124-3p 
CCDC181 hsa-miR-26b-5p, hsa-miR-92a-3p 
CCDC59 hsa-miR-375, hsa-miR-24-3p, hsa-miR-16-5p 
CCL1 hsa-miR-17-5p 
CCL17 hsa-miR-148b-3p, hsa-miR-128-3p 
CCL19 hsa-miR-335-5p, hsa-miR-148b-3p, hsa-miR-9-5p 
CCND1 
hsa-miR-335-5p, hsa-miR-148b-3p, hsa-miR-9-5p, hsa-miR-20a-5p, hsa-
miR-195-5p, hsa-miR-193b-3p, hsa-miR-424-5p, hsa-miR-16-1-3p, hsa-
miR-34a-5p, hsa-miR-520b, hsa-miR-503-5p, hsa-miR-19b-1-5p, hsa-miR-
16-5p, hsa-miR-15a-5p, hsa-miR-365a-3p, hsa-miR-19a-3p, hsa-miR-
302a-3p, hsa-miR-15b-5p, hsa-miR-449a, hsa-miR-17-5p, hsa-miR-302c-
3p, hsa-miR-106b-5p, hsa-miR-34b-3p, hsa-miR-338-3p, hsa-miR-9-5p, 
hsa-miR-374b-5p, hsa-miR-425-5p, hsa-miR-155-5p, hsa-miR-1, hsa-miR-
183-5p, hsa-miR-93-5p, hsa-miR-26b-5p, hsa-miR-196a-5p, hsa-miR-92a-
3p 
CCND3 
hsa-miR-424-5p, hsa-miR-16-5p, hsa-miR-34a-5p, hsa-miR-195-5p, hsa-
miR-138-5p, hsa-miR-615-3p, hsa-miR-324-5p, hsa-miR-27b-3p 
CCNI 
hsa-miR-374b-5p, hsa-miR-26b-5p, hsa-miR-423-5p, hsa-miR-320a, hsa-
miR-148a-3p, hsa-miR-92a-3p 
CCR1 hsa-miR-21-5p 
CCT7 
hsa-miR-26b-5p, hsa-miR-877-3p, hsa-miR-615-3p, hsa-miR-598-3p, hsa-
miR-505-3p, hsa-miR-23b-3p, hsa-miR-92a-3p, hsa-miR-1260b 
CD177 hsa-miR-335-5p 
CDH1 
hsa-miR-9-5p, hsa-miR-25-3p, hsa-miR-193b-3p, hsa-miR-138-5p, hsa-
miR-26b-5p, hsa-miR-30c-5p 
CDH6 hsa-miR-155-5p 
CDKN1A 
hsa-miR-10b-5p, hsa-miR-942-5p, hsa-miR-145-5p, hsa-miR-182-5p, hsa-
miR-93-5p, hsa-miR-657, hsa-miR-654-3p, hsa-miR-639, hsa-miR-572, 
hsa-miR-520h, hsa-miR-520b, hsa-miR-520a-3p, hsa-miR-519e-3p, hsa-
miR-519d-3p, hsa-miR-519b-3p, hsa-miR-515-3p, hsa-miR-423-3p, hsa-
miR-372-3p, hsa-miR-363-3p, hsa-miR-345-5p, hsa-miR-299-5p, hsa-miR-
298, hsa-miR-28-5p, hsa-miR-20b-5p, hsa-miR-20a-5p, hsa-miR-208b-3p, 
hsa-miR-208a-3p, hsa-miR-17-5p, hsa-miR-132-3p, hsa-miR-125a-5p, 
hsa-miR-106b-5p, hsa-miR-503-5p, hsa-miR-106a-5p, hsa-miR-519a-3p, 
hsa-miR-96-5p, hsa-miR-302a-3p, hsa-miR-146a-5p, hsa-miR-146b-5p, 
hsa-miR-519c-3p, hsa-miR-335-5p, hsa-miR-98-5p, hsa-miR-1229-3p, 
hsa-miR-505-5p, hsa-miR-1260b 
CDO1 hsa-miR-124-3p 
CDS1 hsa-miR-335-5p, hsa-miR-324-5p 
CDV3 
hsa-miR-29c-3p, hsa-miR-124-3p, hsa-miR-103a-3p, hsa-miR-16-5p, hsa-
miR-92a-3p 
CDX4 hsa-miR-335-5p 
CELF2 hsa-miR-425-5p, hsa-miR-375, hsa-miR-324-5p 
CELSR3 hsa-miR-335-5p, hsa-miR-30c-5p 
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CENPI hsa-miR-215-5p, hsa-miR-192-5p 
CENPO hsa-miR-218-5p 
CEP112 hsa-miR-331-3p 
CHAF1B hsa-miR-193b-3p, hsa-miR-155-5p, hsa-miR-1, hsa-miR-484 
CHCHD2 
hsa-miR-320b, hsa-miR-1229-3p, hsa-miR-484, hsa-miR-221-3p, hsa-miR-
92a-3p 
CHI3L2 hsa-miR-335-5p 
CHP1 hsa-miR-16-5p 
CHPT1 
hsa-miR-16-5p, hsa-miR-375, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-
16-5p 
CHST12 hsa-miR-122-5p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-26b-5p 
CIRBP hsa-miR-30a-5p, hsa-miR-24-3p 
CLCA4 hsa-miR-335-5p, hsa-miR-128-3p 
CLDN1 hsa-miR-155-5p, hsa-miR-335-5p, hsa-miR-375, hsa-miR-29b-3p 
CLDN4 hsa-miR-335-5p 
CLEC11A hsa-miR-335-5p, hsa-miR-122-5p 
CLEC3B hsa-miR-335-5p 
CMPK1 
hsa-miR-374b-5p, hsa-miR-590-3p, hsa-miR-215-5p, hsa-miR-34a-5p, 
hsa-miR-10a-5p, hsa-miR-192-5p, hsa-miR-26b-5p, hsa-miR-16-5p, hsa-
miR-484 
CNIH3 hsa-miR-335-5p 
CNP 
hsa-miR-124-3p, hsa-miR-874-3p, hsa-miR-615-3p, hsa-miR-345-5p, hsa-
miR-30a-5p, hsa-miR-16-5p 
CNTNAP2 hsa-miR-218-5p, hsa-miR-99b-5p 
COG4 hsa-miR-615-3p, hsa-miR-18a-3p 
COL10A1 hsa-miR-335-5p 
COL4A1 
hsa-miR-29c-3p, hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-124-3p, hsa-
miR-218-5p, hsa-miR-769-3p, hsa-miR-18a-3p, hsa-miR-193b-3p, hsa-
miR-125a-5p, hsa-miR-100-5p, hsa-miR-99a-5p, hsa-miR-92a-3p, hsa-
miR-16-5p 
COMMD4 hsa-miR-502-3p, hsa-miR-500a-3p, hsa-miR-320a 
COQ10B hsa-miR-98-5p 
COX6B1 hsa-miR-320b, hsa-miR-130b-5p, hsa-miR-320a 
CPA1 hsa-miR-26b-5p 
CRTC3 hsa-miR-124-3p, hsa-miR-7-5p, hsa-miR-671-5p, hsa-miR-92a-3p 
CRYGC hsa-miR-335-5p, hsa-miR-26b-5p 
CTGF 
hsa-miR-124-3p, hsa-miR-18a-5p, hsa-miR-26a-5p, hsa-miR-205-5p, hsa-
miR-145-5p, hsa-miR-375 
CTSA 
hsa-miR-155-5p, hsa-miR-1296-5p, hsa-miR-503-5p, hsa-miR-130a-3p, 
hsa-miR-20a-5p, hsa-miR-17-5p 
CTTN 
hsa-miR-340-5p, hsa-miR-1, hsa-miR-34a-5p, hsa-miR-185-5p, hsa-miR-
92a-3p 
CYCS 
hsa-miR-148a-3p, hsa-miR-16-5p, hsa-miR-320c, hsa-miR-93-3p, hsa-
miR-361-5p 
CYP26B1 hsa-miR-103a-3p, hsa-miR-16-5p 
CYP2F1 hsa-miR-335-5p, hsa-miR-26b-5p 
CYP3A4 hsa-miR-27b-3p 
DCBLD2 
hsa-miR-197-3p, hsa-miR-192-5p, hsa-miR-33a-5p, hsa-miR-26b-5p, hsa-
miR-106a-5p, hsa-miR-17-5p 
DCPS hsa-miR-193b-3p 
DDAH2 hsa-miR-34a-5p 
DDX25 hsa-miR-26b-5p 
DDX46 hsa-miR-93-5p, hsa-miR-21-5p, hsa-miR-423-3p, hsa-miR-99a-5p 
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DDX56 
hsa-miR-34a-5p, hsa-miR-423-3p, hsa-miR-331-3p, hsa-miR-328-3p, hsa-
miR-92a-3p 
DDX60 hsa-miR-1, hsa-miR-26b-5p 
DEFA4 hsa-miR-335-5p 
DKK1 hsa-miR-29a-3p, hsa-miR-31-5p, hsa-miR-1 
DNAJC12 hsa-miR-26b-5p 
DRAP1 hsa-miR-155-5p, hsa-miR-1, hsa-miR-423-5p 
DRD4 hsa-miR-124-3p 
DSG1 hsa-miR-148b-3p 
DSN1 hsa-miR-193b-3p, hsa-miR-215-5p, hsa-miR-192-5p 
DTNB hsa-miR-26b-5p 
DTX3 hsa-miR-320a 
DYNLT1 hsa-miR-326 
EIF1 
hsa-miR-30a-5p, hsa-miR-16-5p, hsa-miR-193b-3p, hsa-miR-186-5p, hsa-
miR-10b-5p, hsa-miR-10a-5p 
EIF1AY hsa-miR-26b-5p 
EIF4A2 hsa-miR-21-5p, hsa-miR-744-5p, hsa-miR-331-3p 
ELOVL2 hsa-miR-10a-5p, hsa-miR-26b-5p, hsa-miR-17-3p 
ELOVL4 hsa-miR-21-5p, hsa-miR-19b-3p, hsa-miR-30b-5p, hsa-miR-30c-5p 
ENPEP hsa-miR-320a 
EPHA7 
hsa-miR-196a-5p, hsa-miR-93-5p, hsa-miR-455-3p, hsa-miR-615-3p, hsa-
miR-331-3p, hsa-miR-125b-5p, hsa-miR-92a-3p 
EPPIN hsa-miR-26b-5p 
ERBB4 hsa-miR-372-3p, hsa-miR-19a-3p, hsa-miR-302d-3p, hsa-miR-146a-5p 
FABP3 hsa-miR-1 
FABP6 hsa-miR-335-5p 
FAM102A 
hsa-miR-335-5p, hsa-miR-122-5p, hsa-miR-1, hsa-miR-296-3p, hsa-miR-
320a 
FAM135A hsa-miR-335-5p, hsa-miR-155-5p, hsa-miR-26b-5p, hsa-miR-92a-3p 
FAM160B2 hsa-miR-484, hsa-miR-92a-3p 
FAM189A2 hsa-miR-215-5p, hsa-miR-192-5p 
FAM3C 
hsa-miR-21-5p, hsa-miR-375, hsa-miR-155-5p, hsa-miR-145-5p, hsa-miR-
34a-5p, hsa-miR-1227-3p, hsa-miR-1226-3p, hsa-miR-769-3p, hsa-miR-
92b-3p, hsa-miR-342-3p, hsa-miR-93-5p 
FAM46A 
hsa-miR-9-5p, hsa-miR-21-5p, hsa-miR-19b-3p, hsa-miR-484 hsa-miR-
346, hsa-miR-34a-5p 
FAT4 hsa-miR-132-3p 
FERMT1 hsa-miR-9-5p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-125a-5p 
FGF20 hsa-miR-433-3p 
FGFR2 hsa-miR-19b-1-5p, hsa-miR-125b-5p, hsa-miR-1, hsa-miR-186-5p 
FGG 
hsa-miR-409-3p, hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-144-3p, hsa-
miR-29c-3p  
FHL1 hsa-miR-335-5p 
FLG hsa-miR-124-3p 
FNDC4 hsa-miR-124-3p, hsa-miR-7-5p 
FOLR1 hsa-miR-375, hsa-miR-1 
FOXD3 hsa-miR-335-5p 
FRMPD4 hsa-miR-185-5p 
FRY hsa-miR-132-3p 
FSCN1 
hsa-miR-133b, hsa-miR-133a-3p, hsa-miR-145-5p, hsa-miR-143-3p, hsa-
miR-30a-5p, hsa-miR-221-3p, hsa-miR-17-3p 
FUT4 hsa-miR-199a-3p 
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FZD5 hsa-miR-26b-5p, hsa-miR-24-3p, hsa-miR-149-5p 
FZD7 hsa-miR-145-5p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-940 
GABBR2 hsa-miR-124-3p 
GAPDHS hsa-miR-335-5p 
GATA1 hsa-miR-335-5p 
GBX2 hsa-miR-335-5p 
GCNT1 hsa-miR-132-3p, hsa-miR-181a-5p 
GFOD1 
hsa-miR-130b-3p, hsa-miR-9-5p, hsa-miR-215-5p, hsa-miR-26b-5p, hsa-
miR-24-3p, hsa-miR-19b-3p, hsa-miR-1276, hsa-miR-484, hsa-miR-100-
5p 
GHITM 
hsa-miR-155-5p, hsa-miR-374b-5p, hsa-miR-484, hsa-miR-23b-3p, hsa-
miR-92a-3p, hsa-miR-31-5p 
GIP hsa-miR-335-5p, hsa-miR-9-5p 
GLRX5 hsa-miR-222-3p, hsa-miR-18a-5p 
GNAS hsa-miR-155-5p, hsa-miR-320b, hsa-miR-615-3p, hsa-miR-18a-3p, hsa-
miR-324-3p, hsa-miR-331-3p, hsa-miR-320a, hsa-miR-17-5p 
GNGT1 hsa-miR-335-5p 
GNPTAB hsa-miR-98-5p, hsa-miR-615-3p 
GNRHR hsa-miR-124-3p, hsa-miR-1, hsa-miR-26b-5p 
GP9 hsa-miR-335-5p 
GPLD1 hsa-miR-505-3p 
GPR135 hsa-miR-26b-5p 
GPR143 hsa-miR-148b-3p 
GREB1 hsa-miR-335-5p, hsa-miR-26b-5p 
GREM1 hsa-miR-124-3p 
GRIK2 hsa-miR-26b-5p 
GULP1 hsa-miR-335-5p, hsa-miR-215-5p, hsa-miR-192-5p 
GUSB hsa-miR-26b-5p, hsa-miR-760 
H3F3B 
hsa-miR-16-5p, hsa-miR-15a-5p, hsa-miR-1, hsa-miR-181a-5p, hsa-miR-
34a-5p, hsa-miR-32-5p, hsa-miR-22-3p, hsa-miR-1236-3p, hsa-miR-93-
3p, hsa-miR-652-3p, hsa-miR-324-5p 
HAX1 hsa-miR-155-5p, hsa-miR-331-3p 
HBE1 hsa-miR-335-5p 
HECA hsa-miR-26b-5p 
HECTD4 hsa-miR-335-5p, hsa-miR-296-3p, hsa-miR-149-5p 
HERC5 hsa-miR-1 
HERC6 hsa-miR-16-5p, hsa-miR-15a-5p 
HEY2 hsa-miR-148b-3p, hsa-miR-128-3p, hsa-miR-181a-5p 
HGD hsa-miR-335-5p, hsa-miR-26b-5p 
HIST1H2AC 
hsa-miR-34a-5p, hsa-miR-98-5p, hsa-miR-629-5p, hsa-miR-504-5p, hsa-
miR-330-3p, hsa-miR-221-3p, hsa-miR-92a-3p 
HIST1H2BD 
hsa-miR-98-5p, hsa-miR-744-5p, hsa-miR-455-3p, hsa-miR-296-3p, hsa-
miR-652-3p, hsa-miR-615-3p, hsa-miR-378a-3p, hsa-miR-3140-3p 
HIST2H2BE 
hsa-miR-34a-5p, hsa-miR-103a-3p, hsa-miR-16-5p, hsa-miR-877-3p, hsa-
miR-423-5p, hsa-miR-296-3p, hsa-miR-615-3p 
HLA-E hsa-miR-296-3p, hsa-miR-92a-3p 
HNRNPA2B1 
hsa-miR-103a-3p, hsa-miR-16-5p, hsa-miR-1296-5p, hsa-miR-877-3p, 
hsa-miR-615-3p, hsa-miR-191-5p, hsa-miR-27b-3p, hsa-miR-30c-5p, hsa-
miR-197-3p, hsa-miR-92a-3p, hsa-miR-1260b 
HNRNPK 
hsa-miR-450a-5p, hsa-miR-21-5p, hsa-miR-877-3p, hsa-miR-106b-3p, 
hsa-miR-615-3p, hsa-miR-503-5p, hsa-miR-484, hsa-miR-328-3p, hsa-
miR-125b-5p, hsa-miR-23b-3p, hsa-miR-15b-5p, hsa-miR-30c-5p, hsa-
 
 
 
 
206 
 
miR-1260b 
HNRNPR hsa-miR-18a-5p, hsa-miR-940, hsa-miR-130b-5p, hsa-miR-615-3p 
HOMER2 hsa-miR-375, hsa-miR-103a-2-5p 
HOXA7 hsa-miR-196a-5p, hsa-miR-423-5p, hsa-miR-31-5p 
HOXB9 hsa-miR-215-5p, hsa-miR-192-5p 
HOXD13 
hsa-miR-103a-3p, hsa-miR-423-3p, hsa-miR-149-5p, hsa-miR-10a-5p, 
hsa-miR-16-5p, hsa-miR-1260b 
HOXD3 hsa-miR-17-3p 
HRH1 hsa-miR-192-5p, hsa-miR-124-3p 
HSD17B7P2 hsa-miR-335-5p 
HSD3B1 hsa-miR-26b-5p 
HSPA4L hsa-miR-155-5p, hsa-miR-16-5p 
HTR2C hsa-miR-22-3p 
ICK hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-101-3p 
IDI1 hsa-miR-193b-3p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-26b-5p 
IFI27 hsa-miR-146a-5p 
IFI44 hsa-miR-146a-5p, hsa-miR-1, hsa-miR-26b-5p 
IFI44L hsa-miR-146a-5p, hsa-miR-124-3p 
IFI6 hsa-miR-375 
IFIT1 hsa-miR-375, hsa-miR-146a-5p, hsa-miR-1 
IFIT3 hsa-miR-146a-5p, hsa-miR-124-3p, hsa-miR-1, hsa-miR-92b-3p 
IFNA1 hsa-miR-122-5p 
IGFBP5 hsa-miR-140-5p, hsa-miR-331-3p, hsa-miR-17-5p 
IGLC2 hsa-miR-335-5p 
IGSF1 hsa-miR-425-5p, hsa-miR-577, hsa-miR-148b-3p, hsa-miR-10b-5p, hsa-
miR-10a-5p, hsa-miR-92a-3p, hsa-miR-16-5p 
IK hsa-miR-34a-5p, hsa-miR-92b-3p, hsa-miR-92a-3p 
IL11 
hsa-miR-204-5p, hsa-miR-211-5p, hsa-miR-379-5p, hsa-miR-124-3p, hsa-
miR-1 
IL15 hsa-miR-215-5p, hsa-miR-192-5p 
IL1A hsa-miR-191-5p, hsa-miR-335-5p 
IL3 hsa-miR-26b-5p 
IL37 hsa-miR-335-5p 
IL5 hsa-miR-335-5p, hsa-miR-454-5p 
IMPAD1 hsa-miR-155-5p, hsa-miR-16-5p 
IMPG1 hsa-miR-26b-5p 
IRAK1 
hsa-miR-146a-5p, hsa-miR-146b-5p, hsa-miR-215-5p, hsa-miR-192-5p, 
hsa-miR-1226-3p, hsa-miR-744-5p, hsa-miR-330-5p, hsa-miR-93-3p, hsa-
miR-193b-3p, hsa-miR-423-3p, hsa-miR-328-3p, hsa-miR-132-3p, hsa-
miR-222-3p, hsa-miR-92a-3p, hsa-miR-17-5p 
IRAK4 hsa-miR-215-5p, hsa-miR-192-5p 
IRF9 hsa-miR-106b-5p 
ISG15 hsa-miR-146a-5p, hsa-miR-1 
ISG20 hsa-miR-335-5p, hsa-miR-1 
ISOC1 hsa-miR-652-3p 
ITGA1 hsa-miR-335-5p, hsa-miR-1 
ITPKB hsa-miR-186-5p, hsa-miR-183-5p 
IVD hsa-miR-124-3p, hsa-miR-503-5p, hsa-miR-484 
JMJD6 hsa-miR-484, hsa-miR-92a-3p, hsa-miR-1260b 
KALRN hsa-miR-335-5p 
KAT2A 
hsa-miR-124-3p, hsa-miR-1, hsa-miR-615-3p, hsa-miR-331-3p, hsa-miR-
183-5p, hsa-miR-92a-3p, hsa-miR-17-5p 
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KAT2B 
hsa-miR-181a-5p, hsa-miR-181b-5p, hsa-miR-25-3p, hsa-miR-32-5p, hsa-
miR-92a-3p, hsa-miR-93-5p, hsa-miR-106b-5p, hsa-miR-19a-3p, hsa-miR-
19b-3p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-26b-5p 
KCND1 hsa-miR-1, hsa-miR-26b-5p 
KCNJ16 hsa-miR-148b-3p 
KCNK5 hsa-miR-335-5p 
KDM5A hsa-miR-335-5p 
KIAA1644 hsa-miR-335-5p, hsa-miR-26b-5p, hsa-miR-1226-3p 
KLC1 hsa-miR-197-3p, hsa-miR-34a-5p 
KLHL23 
hsa-miR-128-3p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-101-3p, hsa-
miR-24-3p, hsa-miR-183-5p, hsa-miR-10a-5p 
KLK3 hsa-miR-335-5p 
KLK7 hsa-miR-335-5p 
KNG1 hsa-miR-128-3p 
KRT7 
hsa-miR-133a-3p, hsa-miR-199a-3p, hsa-miR-125b-5p, hsa-miR-195-5p, 
hsa-miR-145-5p, hsa-miR-30a-3p, hsa-miR-7-5p 
KXD1 hsa-miR-505-5p, hsa-miR-193b-3p, hsa-miR-378a-5p, hsa-miR-10a-5p 
LAIR2 hsa-miR-335-5p 
LAMB1 
hsa-miR-335-5p, hsa-miR-16-5p, hsa-miR-760, hsa-miR-500a-3p, hsa-
miR-193b-3p, hsa-miR-125a-5p 
LCAT hsa-miR-26b-5p 
LGR5 hsa-miR-124-3p 
LLGL2 hsa-miR-335-5p 
LMO7 hsa-miR-98-5p, hsa-miR-16-5p 
LOXL2 hsa-miR-192-5p 
LRCH3 hsa-miR-320a 
LRRC1 hsa-miR-124-3p, hsa-miR-22-3p 
LY6E hsa-miR-877-3p, hsa-miR-744-5p 
MACF1 
hsa-miR-335-5p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-16-5p, hsa-
miR-296-3p, hsa-miR-615-3p, hsa-miR-125a-5p, hsa-miR-222-3p, hsa-
miR-30d-5p, hsa-miR-92a-3p 
MAD2L1BP hsa-miR-151a-5p, hsa-miR-615-3p 
MAFB hsa-miR-130a-3p, hsa-miR-155-5p, hsa-miR-135b-5p, hsa-miR-335-5p 
MAP2 hsa-miR-335-5p 
MAPK6 hsa-miR-128-3p, hsa-miR-100-5p, hsa-miR-99a-5p, hsa-miR-15a-5p 
MATR3 
hsa-miR-155-5p, hsa-miR-200b-3p, hsa-miR-1, hsa-miR-7-5p, hsa-miR-
26b-5p, hsa-miR-24-3p, hsa-miR-744-5p, hsa-miR-615-3p, hsa-miR-186-
5p, hsa-miR-185-5p, hsa-miR-149-5p, hsa-miR-125b-5p, hsa-miR-30b-5p, 
hsa-miR-30c-5p, hsa-miR-18a-5p 
MBNL2 
hsa-miR-372-3p, hsa-miR-302d-3p, hsa-miR-218-5p, hsa-miR-335-5p, 
hsa-miR-101-3p, hsa-miR-98-5p 
MCM6 
hsa-miR-193b-3p, hsa-miR-1, hsa-miR-215-5p, hsa-miR-34a-5p, hsa-miR-
192-5p, hsa-miR-1180-3p 
MCPH1 hsa-miR-335-5p, hsa-miR-15b-5p, hsa-miR-10a-5p 
METTL2B hsa-miR-375, hsa-miR-484, hsa-miR-92a-3p 
MGST3 hsa-miR-26b-5p 
MISP hsa-miR-335-5p, hsa-miR-124-3p 
MLLT4 
hsa-miR-335-5p, hsa-miR-124-3p, hsa-miR-346, hsa-miR-15b-5p, hsa-
miR-92a-3p 
MMP1 hsa-miR-222-3p, hsa-miR-145-5p 
MMP16 hsa-miR-146b-5p, hsa-miR-31-5p 
MPP5 hsa-miR-375, hsa-miR-130b-3p, hsa-miR-155-5p, hsa-miR-7-5p, hsa-miR-
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148a-3p, hsa-miR-192-5p, hsa-miR-21-5p, hsa-miR-93-3p 
MROH9 hsa-miR-335-5p 
MRPS18B hsa-miR-26b-5p, hsa-miR-615-3p, hsa-miR-484 
MRPS2 hsa-miR-98-5p, hsa-miR-26b-5p, hsa-miR-16-5p, hsa-miR-744-5p 
MSLN hsa-miR-335-5p 
MUC13 hsa-miR-148b-3p, hsa-miR-132-3p, hsa-miR-128-3p 
MYBL2 hsa-miR-149-3p, hsa-miR-423-5p, hsa-miR-505-3p, hsa-miR-92a-3p 
MYEF2 
hsa-miR-26b-5p, hsa-miR-21-5p, hsa-miR-125b-5p, hsa-miR-10a-5p, hsa-
miR-92a-3p 
MYF6 hsa-miR-9-5p 
MYH1 hsa-miR-23a-3p 
MYH10 
hsa-miR-1274a, hsa-miR-106b-3p, hsa-miR-92b-3p, hsa-miR-505-3p, hsa-
miR-197-3p, hsa-miR-26a-5p, hsa-miR-23a-3p 
MYLIP 
hsa-miR-20b-5p, hsa-miR-106a-5p, hsa-miR-19b-3p, hsa-miR-92a-3p, 
hsa-miR-340-5p, hsa-miR-93-5p, hsa-miR-186-5p 
MYLPF hsa-miR-335-5p 
NAP1L4 hsa-miR-196a-5p 
NBEAL2 hsa-miR-93-5p 
NCAPD2 
hsa-miR-193b-3p, hsa-miR-155-5p, hsa-miR-16-5p, hsa-miR-1303, hsa-
miR-93-3p, hsa-miR-615-3p, hsa-miR-92b-3p, hsa-miR-484, hsa-miR-331-
3p, hsa-miR-186-5p, hsa-miR-222-3p, hsa-miR-3620-3p 
NDUFA7 hsa-miR-186-5p, hsa-miR-92a-3p 
NDUFA9 hsa-miR-16-5p, hsa-miR-100-5p 
NDUFB1 hsa-miR-26b-5p 
NDUFS1 hsa-miR-615-3p, hsa-miR-324-5p, hsa-miR-221-3p 
NDUFS5 hsa-miR-1296-5p 
NEBL hsa-miR-125b-5p 
NEIL1 hsa-miR-335-5p 
NETO2 hsa-miR-1, hsa-miR-375, hsa-miR-24-3p, hsa-miR-21-5p, hsa-miR-20a-5p 
NEUROD1 hsa-miR-30a-5p 
NFKB2 hsa-miR-193b-3p, hsa-miR-98-5p, hsa-miR-423-5p 
NKG7 hsa-miR-335-5p 
NLGN4X hsa-miR-148b-3p, hsa-miR-26b-5p 
NNMT hsa-miR-124-3p, hsa-miR-98-5p 
NOL10 hsa-miR-148b-3p, hsa-miR-124-3p, hsa-miR-935 
NOX4 hsa-miR-148b-3p 
NPPB hsa-miR-375 
NPR3 hsa-miR-16-5p, hsa-miR-30a-5p, hsa-miR-335-5p, hsa-miR-98-5p 
NR4A3 hsa-miR-124-3p, hsa-miR-10b-5p, hsa-miR-26b-5p 
NRIP1 hsa-miR-590-3p, hsa-miR-24-3p, hsa-miR-615-3p, hsa-miR-15b-5p 
NTF3 hsa-miR-200c-3p, hsa-miR-335-5p 
NYX hsa-miR-26b-5p 
OAS1 hsa-miR-335-5p 
OAS2 hsa-miR-335-5p, hsa-miR-132-3p, hsa-miR-7-5p 
OASL hsa-miR-146a-5p, hsa-miR-124-3p, hsa-miR-1 
OCLN hsa-miR-335-5p 
OLFML2A hsa-miR-335-5p, hsa-miR-146a-5p 
OSMR hsa-miR-335-5p, hsa-miR-98-5p 
OTUB2 hsa-miR-335-5p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-125a-5p 
P2RX5 hsa-miR-98-5p 
PAPD7 
hsa-miR-423-3p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-32-5p, hsa-
miR-106b-3p, hsa-miR-93-5p 
PARP12 hsa-miR-98-5p 
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PARP16 
hsa-miR-124-3p, hsa-miR-590-3p, hsa-miR-193b-3p, hsa-miR-215-5p, 
hsa-miR-192-5p 
PCNP hsa-miR-18a-5p, hsa-miR-186-5p 
PCSK5 hsa-miR-107 
PCSK7 hsa-miR-652-3p 
PCYT1A hsa-miR-26a-5p 
PDE3A hsa-miR-155-5p, hsa-miR-128-3p 
PDLIM1 hsa-miR-26b-5p, hsa-miR-504-5p, hsa-miR-320a, hsa-miR-92a-3p 
PGR hsa-miR-126-3p 
PHACTR2 hsa-miR-124-3p, hsa-miR-21-5p, hsa-miR-378a-3p, hsa-miR-185-5p 
PHF14 hsa-miR-155-5p, hsa-miR-128-3p, hsa-miR-122-5p, hsa-miR-183-5p 
PIP4K2C 
hsa-miR-193b-3p, hsa-miR-877-3p, hsa-miR-125b-5p, hsa-miR-101-3p, 
hsa-miR-32-5p, hsa-miR-26b-5p, hsa-miR-193b-3p 
PIR hsa-miR-1 
PLAT hsa-miR-204-5p, hsa-miR-21-5p, hsa-miR-335-5p 
PLCXD1 hsa-miR-98-5p, hsa-miR-296-3p 
PLOD2 
hsa-miR-221-3p, hsa-miR-98-5p, hsa-miR-26b-5p, hsa-miR-425-5p, hsa-
miR-615-3p, hsa-miR-183-5p, hsa-miR-1260b 
PLSCR1 hsa-miR-132-3p, hsa-miR-18a-3p, hsa-miR-10a-5p, hsa-miR-99a-5p 
PML hsa-miR-335-5p, hsa-miR-423-3p, hsa-miR-378a-3p 
POLR2J hsa-miR-124-3p 
PPARGC1A 
hsa-miR-23a-3p, hsa-miR-335-5p, hsa-miR-98-5p, hsa-miR-421, hsa-miR-
425-3p, hsa-miR-378a-5p 
PPFIBP1 hsa-miR-335-5p, hsa-miR-155-5p 
PPIC hsa-miR-26b-5p 
PPP2R2A 
hsa-miR-31-5p, hsa-miR-222-3p, hsa-miR-155-5p, hsa-miR-1, hsa-miR-
30a-5p, hsa-miR-26b-5p, hsa-miR-92a-3p 
PQLC3 hsa-miR-9-5p, hsa-miR-124-3p 
PRLR hsa-miR-181a-5p 
PRR11 hsa-miR-128-3p, hsa-miR-122-5p 
PSG3 hsa-miR-124-3p, hsa-miR-1 
PSMA6 hsa-miR-30e-5p 
PTGDS hsa-miR-335-5p 
PTGES hsa-miR-335-5p, hsa-miR-124-3p, hsa-miR-125b-5p 
PTHLH hsa-miR-33a-5p 
PTPN21 hsa-miR-615-3p 
RAB1A hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-19b-3p, hsa-miR-16-5p 
RAB40A hsa-miR-335-5p 
RAB40B hsa-miR-204-5p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-26b-5p 
RAB5A 
hsa-miR-101-3p, hsa-miR-130a-3p, hsa-miR-130b-3p, hsa-miR-33a-5p, 
hsa-miR-18a-5p 
RABGGTA hsa-miR-26b-5p 
RAD54L2 hsa-miR-26b-5p 
RAI2 hsa-miR-186-3p 
RANBP9 hsa-miR-101-3p, hsa-miR-196a-5p 
RASAL2 
hsa-miR-98-5p, hsa-miR-26b-5p, hsa-miR-15a-3p, hsa-miR-125b-5p, hsa-
miR-99a-5p, hsa-miR-92a-3p 
RBL1 hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-106b-5p 
RBM22 hsa-miR-155-5p 
RELN hsa-miR-128-3p, hsa-miR-138-5p, hsa-miR-10a-5p 
RIBC2 hsa-miR-124-3p 
RIF1 
hsa-miR-155-5p, hsa-miR-103a-3p, hsa-miR-16-5p, hsa-miR-421, hsa-
miR-186-5p, hsa-miR-183-5p, hsa-miR-93-5p, hsa-miR-24-3p 
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RNF10 
hsa-miR-877-3p, hsa-miR-130b-5p, hsa-miR-484, hsa-miR-320a, hsa-miR-
222-3p 
RPA1 hsa-miR-1301-3p, hsa-miR-615-3p, hsa-miR-339-5p, hsa-miR-31-5p 
RPL11 hsa-miR-505-5p, hsa-miR-92a-3p 
RPL18A 
hsa-miR-744-5p, hsa-miR-423-5p, hsa-miR-421, hsa-miR-652-3p, hsa-
miR-503-5p, hsa-miR-301a-3p, hsa-miR-106b-5p, hsa-miR-186-5p, hsa-
miR-149-5p, hsa-miR-181b-5p, hsa-miR-92a-3p, hsa-miR-20a-5p 
RPL37 
hsa-miR-744-5p, hsa-miR-324-5p, hsa-miR-191-5p, hsa-miR-34a-5p, hsa-
miR-17-5p 
RPS27A 
hsa-miR-30b-5p, hsa-miR-23b-3p, hsa-miR-30c-5p, hsa-miR-26a-5p, hsa-
miR-17-5p 
RPS27L hsa-miR-484 
RPSA 
hsa-miR-16-5p, hsa-miR-1227-3p, hsa-miR-769-3p, hsa-miR-615-3p, hsa-
miR-132-3p, hsa-miR-107, hsa-miR-25-3p, hsa-miR-22-3p, hsa-miR-17-
5p, hsa-miR-3200-3p 
RSU1 hsa-miR-34a-5p, hsa-miR-7-5p 
RUFY3 
hsa-miR-124-3p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-21-5p, hsa-
miR-505-3p 
RUVBL2 hsa-miR-1229-3p, hsa-miR-324-3p, hsa-miR-92a-3p 
RXFP3 hsa-miR-335-5p, hsa-miR-26b-5p 
S100A7 hsa-miR-26b-5p 
S100A7A hsa-miR-26b-5p 
SAMD9 hsa-miR-30a-5p 
SATB2 
hsa-miR-31-5p, hsa-miR-34a-5p, hsa-miR-192-5p, hsa-miR-320b, hsa-
miR-505-5p, hsa-miR-320a, hsa-miR-149-5p 
SCAF8 hsa-miR-877-3p, hsa-miR-29b-3p, hsa-miR-92a-3p 
SCARF1 hsa-miR-548q 
SCLY hsa-miR-375, hsa-miR-193b-3p, hsa-miR-92a-3p 
SCN1A hsa-miR-93-3p 
SCO2 hsa-miR-26b-5p 
SEC61G hsa-miR-26b-5p, hsa-miR-1260b 
SEC62 hsa-miR-30a-5p, hsa-miR-1 
SEMA3D hsa-miR-193a-3p 
SEPT8 hsa-miR-324-5p 
SF1 hsa-miR-186-5p, hsa-miR-935, hsa-miR-320a, hsa-miR-221-3p 
SFRP1 hsa-miR-335-5p 
SH3BP5 hsa-miR-130b-3p, hsa-miR-103a-3p, hsa-miR-193b-3p 
SH3PXD2A 
hsa-miR-335-5p, hsa-miR-130b-3p, hsa-miR-124-3p, hsa-miR-93-5p, hsa-
miR-33a-5p, hsa-miR-24-3p, hsa-miR-331-3p 
SHPK hsa-miR-124-3p, hsa-miR-615-3p 
SIGLEC8 hsa-miR-335-5p 
SIK2 hsa-miR-1229-3p, hsa-miR-125b-5p, hsa-miR-181a-5p 
SLC15A1 hsa-miR-92b-3p 
SLC16A1 
hsa-miR-376a-5p, hsa-miR-124-3p, hsa-miR-484, hsa-miR-376a-3p, hsa-
miR-128-3p, hsa-miR-615-3p, hsa-miR-320a, hsa-miR-23b-3p 
SLC25A36 hsa-miR-124-3p, hsa-miR-222-3p 
SLC29A2 hsa-miR-93-5p 
SLC2A10 hsa-miR-335-5p 
SLC35F2 hsa-miR-155-5p, hsa-miR-98-5p 
SLC35F6 hsa-miR-373-3p, hsa-miR-1226-3p 
SLC38A4 hsa-miR-335-5p 
SLC7A2 
hsa-miR-9-5p, hsa-miR-192-5p, hsa-miR-101-3p, hsa-miR-24-3p, hsa-
miR-423-5p, hsa-miR-30c-2-3p, hsa-miR-615-3p 
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SLC9A2 hsa-miR-16-5p  
SLC9A7 hsa-miR-335-5p 
SMAD4 
hsa-miR-224-5p, hsa-miR-26a-5p, hsa-miR-483-3p, hsa-miR-18a-5p, hsa-
miR-17-5p, hsa-miR-19a-3p, hsa-miR-20a-5p, hsa-miR-92a-3p, hsa-miR-
146a-5p, hsa-miR-199a-5p, hsa-miR-130a-3p, hsa-miR-301a-3p, hsa-miR-
454-3p, hsa-miR-182-5p, hsa-miR-130b-3p, hsa-miR-155-5p, hsa-miR-
186-5p, hsa-miR-93-5p, hsa-miR-19b-3p 
SMARCE1 
hsa-miR-155-5p, hsa-miR-103a-3p, hsa-miR-26b-5p, hsa-miR-328-3p, 
hsa-miR-30c-5p, hsa-miR-1260b 
SMG5 
hsa-miR-708-5p, hsa-miR-130b-5p, hsa-miR-106b-3p, hsa-miR-193b-3p, 
hsa-miR-331-3p 
SNCA hsa-miR-7-5p, hsa-miR-153-3p 
SNX16 hsa-miR-124-3p, hsa-miR-103a-3p, hsa-miR-96-5p, hsa-miR-16-5p 
SPTBN5 hsa-miR-335-5p 
SSPN hsa-miR-335-5p 
ST6GALNAC5 hsa-miR-148b-3p 
STIM1 hsa-miR-155-5p, hsa-miR-769-3p, hsa-miR-17-3p 
STK10 hsa-miR-484 
STOM hsa-miR-124-3p 
STX11 hsa-miR-373-3p 
SULF1 hsa-miR-516a-3p, hsa-miR-124-3p 
SULT1E1 hsa-miR-199a-5p, hsa-miR-124-3p 
SYNDIG1 hsa-miR-17-5p 
SYNE2 
hsa-miR-155-5p, hsa-miR-193b-3p, hsa-miR-148b-3p, hsa-miR-9-5p, hsa-
miR-1, hsa-miR-34a-5p, hsa-miR-26b-5p, hsa-miR-21-5p, hsa-miR-484 
TAAR2 hsa-miR-335-5p 
TAB2 
hsa-miR-155-5p, hsa-miR-23b-3p, hsa-miR-181a-5p, hsa-miR-98-5p, hsa-
miR-15b-5p, hsa-miR-196a-5p 
TATDN2 hsa-miR-423-3p, hsa-miR-34a-5p, hsa-miR-615-3p, hsa-miR-222-3p 
TBCEL hsa-miR-92a-3p 
TBX3 hsa-miR-128-3p, hsa-miR-22-3p, hsa-miR-1226-3p 
TCF20 hsa-miR-149-5p 
TCF21 hsa-miR-21-5p, hsa-miR-181a-5p 
TCL1B hsa-miR-9-5p, hsa-miR-7-5p 
TCP11 hsa-miR-122-5p 
TCTN1 hsa-miR-324-3p 
TDRD7 hsa-miR-26b-5p 
TF hsa-miR-335-5p 
TFDP1 hsa-miR-935 
TFPT hsa-miR-26b-5p 
THAP10 hsa-miR-26b-5p, hsa-miR-92b-3p 
THEM6 hsa-miR-124-3p, hsa-miR-215-5p, hsa-miR-192-5p 
TLL1 hsa-miR-335-5p 
TLR3 hsa-miR-124-3p 
TLX1 hsa-miR-340-5p, hsa-miR-26b-5p 
TM4SF1 hsa-miR-128-3p 
TMA16 hsa-miR-92a-3p 
TMCO3 hsa-miR-26b-5p, hsa-miR-30c-5p 
TMEM59 hsa-miR-30a-5p, hsa-miR-149-5p, hsa-miR-1260b 
TMOD2 hsa-miR-335-5p, hsa-miR-34a-5p, hsa-miR-484 
TNFAIP3 
hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-29a-3p, hsa-miR-21-5p, 
hsa-miR-26b-5p, hsa-miR-24-3p 
TNFSF15 hsa-miR-26b-5p 
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TNNT2 hsa-miR-335-5p 
TPX2 hsa-miR-193b-3p 
TRAF2B 
hsa-miR-10b-5p, hsa-miR-10a-5p, hsa-miR-1, hsa-miR-378a-3p, hsa-miR-
30c-5p, hsa-miR-196a-5p, hsa-miR-17-5p 
TRAF3IP1 hsa-miR-877-3p, hsa-miR-92a-3p, hsa-miR-25-3p 
TRPC6 hsa-miR-124-3p 
TRPM4 hsa-miR-335-5p, hsa-miR-1 
TSC22D2 
hsa-miR-375, hsa-miR-98-5p, hsa-miR-26b-5p, hsa-miR-1227-3p, hsa-
miR-320a, hsa-miR-221-3p 
TSPAN12 hsa-miR-196a-5p, hsa-miR-101-3p, hsa-miR-26b-5p 
TTF2 
hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-16-5p,                            hsa-
miR-183-5p 
TUSC3 hsa-miR-128-3p, hsa-miR-26b-5p, hsa-miR-1229-3p, hsa-miR-25-3p 
TXNL1 hsa-miR-26a-5p, hsa-miR-16-5p 
UBE2Q1 
hsa-miR-338-3p, hsa-miR-103a-3p, hsa-miR-16-5p, hsa-miR-1226-3p, 
hsa-miR-93-3p, hsa-miR-186-5p 
UBL5 hsa-miR-18a-5p, hsa-miR-877-5p, hsa-miR-324-5p 
UBP1 hsa-miR-183-5p, hsa-miR-34a-5p, hsa-miR-182-5p 
UGP2 
hsa-miR-16-5p, hsa-miR-15a-5p, hsa-miR-193b-3p, hsa-miR-32-5p, hsa-
miR-106b-5p 
UGT8 
hsa-miR-148b-3p, hsa-miR-155-5p, hsa-miR-1, hsa-miR-215-5p, hsa-miR-
192-5p, hsa-miR-16-5p, hsa-miR-1260b 
UMPS hsa-miR-197-3p, hsa-miR-124-3p 
UNC5C hsa-miR-335-5p 
UQCR11 hsa-miR-106b-3p, hsa-miR-615-3p 
USP18 hsa-miR-221-3p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-26b-5p 
VAMP8 hsa-miR-193b-3p, hsa-miR-124-3p, hsa-miR-7-5p, hsa-miR-16-5p 
VAV2 hsa-miR-155-5p, hsa-miR-877-3p, hsa-miR-193b-3p, hsa-miR-320a 
WIF1 hsa-miR-335-5p 
WIPF2 hsa-miR-92a-3p 
WNT3 hsa-miR-335-5p, hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-1301-3p 
WNT7B hsa-miR-335-5p 
XAF1 hsa-miR-335-5p 
YWHAZ 
hsa-miR-193b-3p, hsa-miR-375, hsa-miR-155-5p, hsa-miR-1, hsa-miR-
30a-5p, hsa-miR-1229-3p, hsa-miR-877-3p, hsa-miR-455-3p, hsa-miR-
423-5p, hsa-miR-615-3p, hsa-miR-484, hsa-miR-340-3p, hsa-miR-378a-
3p 
ZBTB24 hsa-miR-151a-3p, hsa-miR-196a-5p, hsa-miR-98-5p 
ZBTB25 hsa-miR-26b-5p 
ZBTB3 hsa-miR-93-5p 
ZFP37 hsa-miR-935, hsa-miR-320a 
ZFPM2 
hsa-miR-141-3p, hsa-miR-200a-3p, hsa-miR-200b-3p, hsa-miR-200c-3p, 
hsa-miR-429, hsa-miR-26b-5p 
ZFY hsa-miR-26b-5p 
ZNF135 hsa-miR-335-5p 
ZNF273 hsa-miR-155-5p, hsa-miR-215-5p, hsa-miR-192-5p 
ZNF286A hsa-miR-331-3p 
ZNF3 hsa-miR-193b-3p 
ZNF318 
hsa-miR-744-5p, hsa-miR-320a, hsa-miR-149-5p, hsa-miR-10b-5p, hsa-
miR-10a-5p, hsa-miR-197-3p 
ZNF408 hsa-miR-339-5p 
ZNF451 hsa-miR-335-5p, hsa-miR-124-3p 
ZNF518A hsa-miR-335-5p 
 
 
 
 
213 
 
ZNF551 hsa-miR-26b-5p, hsa-miR-92a-3p 
ZNF587 hsa-miR-21-5p, hsa-miR-106b-5p, hsa-miR-548aa 
ZNF606 hsa-miR-103a-3p 
ZNF646 hsa-miR-378a-5p, hsa-miR-320a, hsa-miR-30b-5p 
ZNF667 hsa-miR-21-5p, hsa-miR-345-5p 
ZNF706 hsa-miR-106b-5p, hsa-miR-93-5p, hsa-miR-20a-5p 
ZNF80 hsa-miR-186-5p 
ZPBP hsa-miR-335-5p 
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20. ADDENDUM F: A complete list of the miRNAs 
interacting with 47 lupus-associated genes curated from 
literature, and verified in Ensembl BioMart  
Gene Number of 
interacting 
miRNAs 
Interacting miRNAs 
ACTN4 21 hsa-miR-1, hsa-miR-935, hsa-miR-744-5p, hsa-miR-296-3p, 
hsa-miR-769-5p, hsa-miR-652-3p, hsa-miR-615-3p, hsa-miR-
92b-3p, hsa-miR-193b-3p, hsa-miR-339-5p, hsa-miR-324-3p, 
hsa-miR-324-5p, hsa-miR-378a-5p, hsa-miR-320a, hsa-miR-
185-5p, hsa-miR-23b-3p, hsa-miR-182-5p, hsa-miR-96-5p, 
hsa-miR-26a-5p, hsa-miR-23a-3p, hsa-miR-16-5p 
API5 2 hsa-miR-224-5p, hsa-miR-183-5p 
ATF6B 1 hsa-miR-197-3p 
C1QA 1 hsa-miR-335-5p 
C1QB 1 hsa-miR-26b-5p 
C2 
 
2 hsa-miR-335-5p, hsa-miR-142-3p 
CD44 
 
15 hsa-miR-708-5p, hsa-miR-328-3p, hsa-miR-373-3p, hsa-miR-
199a-3p, hsa-miR-520c-3p, hsa-miR-34a-5p, hsa-miR-608, 
hsa-miR-330-3p, hsa-miR-216a-5p, hsa-miR-1, hsa-miR-30a-
5p, hsa-miR-16-5p, hsa-miR-744-5p, hsa-miR-320a, hsa-miR-
15b-5p 
DNAJA1 
 
3 hsa-miR-30a-5p, hsa-miR-16-5p, hsa-miR-193b-3p 
ETS1 
 
10 hsa-miR-125b-5p, hsa-miR-9-5p, hsa-miR-222-3p, hsa-miR-
200b-3p, hsa-miR-31-5p, hsa-miR-155-5p, hsa-miR-193b-3p, 
hsa-miR-208a-3p, hsa-miR-10a-5p, hsa-miR-30c-5p 
FCGR1B 1 hsa-miR-26b-5p 
FRK 1 hsa-miR-335-5p 
IKZF1 1 hsa-miR-26b-5p 
IL10 1 hsa-miR-106a-5p 
IRAK1 15 hsa-miR-146a-5p, hsa-miR-146b-5p, hsa-miR-215-5p, hsa-
miR-192-5p, hsa-miR-1226-3p, hsa-miR-744-5p, hsa-miR-
330-5p, hsa-miR-93-3p, hsa-miR-193b-3p, hsa-miR-423-3p, 
hsa-miR-328-3p, hsa-miR-132-3p, hsa-miR-222-3p, hsa-miR-
92a-3p, hsa-miR-17-5p 
IRF5 1 hsa-miR-22-3p 
JAZF1 2 hsa-miR-31-5p, hsa-miR-96-5p 
KPNA1 
 
5 hsa-miR-34a-5p, hsa-miR-103a-3p, hsa-miR-30a-5p, hsa-miR-
16-5p, hsa-miR-186-5p 
MECP2 13 hsa-miR-802, hsa-miR-155-5p, hsa-miR-199a-3p, hsa-miR-
195-5p, hsa-miR-19a-3p, hsa-miR-122-5p, hsa-miR-212-3p, 
hsa-miR-199a-5p, hsa-miR-124-3p, hsa-miR-148b-3p,hsa-
miR-425-3p, hsa-miR-331-3p, hsa-miR-92a-3p 
NMNAT2 3 hsa-miR-9-5p, hsa-miR-122-5p, hsa-miR-615-3p 
NOTCH4 3 hsa-miR-34c-5p, hsa-miR-181c-5p, hsa-miR-18a-3p 
PHRF1 4 hsa-miR-1229-3p, hsa-miR-92b-3p, hsa-miR-193b-3p, hsa-
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miR-222-3p 
PPP2CA 2 hsa-miR-340-3p, hsa-miR-197-3p 
PRDM1 
5 hsa-miR-9-5p, hsa-miR-127-3p, hsa-miR-125b-5p, hsa-miR-
30a-5p, hsa-miR-877-3p 
PTPN22 2 hsa-miR-181a-5p, hsa-miR-1 
PTPRD 
 
6 hsa-miR-429, hsa-miR-200a-3p, hsa-miR-200c-3p,                     
hsa-miR-141-3p, hsa-miR-1, hsa-miR-200b-3p 
PTTG1 
 
5 hsa-miR-423-5p, hsa-miR-320a, hsa-miR-186-5p, hsa-miR-
26a-5p,  
hsa-miR-17-5p 
PXK 1 hsa-miR-744-5p 
RABGAP1L 1 hsa-miR-1 
RASGRP3 1 hsa-miR-21-5p 
RPS6KA1 2 hsa-miR-125b-5p, hsa-miR-193b-3p 
SERPIND1 1 hsa-miR-335-5p 
SKIV2L 1 hsa-miR-222-3p 
SLC15A4 3 hsa-miR-124-3p, hsa-miR-151a-5p, hsa-miR-186-5p 
SPP1 3 hsa-miR-299-5p, hsa-miR-335-5p, hsa-miR-146a-5p 
STAT1 
4 hsa-miR-145-5p, hsa-miR-146a-5p, hsa-miR-34a-5p, hsa-miR-
615-3p 
SYK 3 hsa-miR-99b-3p, hsa-miR-615-3p, hsa-miR-331-3p 
TNFAIP3 
6 hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-29a-3p,                   
hsa-miR-21-5p, hsa-miR-26b-5p, hsa-miR-24-3p 
TNIP1 3 hsa-miR-221-3p, hsa-miR-324-3p, hsa-miR-181a-5p 
TRAF6 2 hsa-miR-146a-5p, hsa-miR-146b-5p 
TRIM27 2 hsa-miR-421, hsa-miR-1260b 
TYK2 
 
1 hsa-miR-124-3p 
 
UBE2L3 3 hsa-miR-122-5p, hsa-miR-423-5p, hsa-miR-93-5p 
UHRF1BP1 3 hsa-miR-34a-5p, hsa-miR-192-5p, hsa-miR-652-3p 
VDR 2 hsa-miR-125b-5p, hsa-miR-27b-3p 
WDFY4 1 hsa-miR-335-5p 
XKR6 1 hsa-miR-335-5p 
XRCC1 
4 hsa-miR-34a-5p, hsa-miR-92b-3p, hsa-miR-193b-3p, 
hsa-miR-186-5p 
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21. ADDENDUM G: Diseases and Functions which were associated with the Core Networks 
generated by the All Top Regulators (Genes and miRNAs, and associated targets) dataset 
Categories Diseases or Functions 
Annotation 
p-Value Molecules # Molecules 
Cancer, Endocrine 
System Disorders, 
Gastrointestinal Disease, 
Organismal Injury and 
Abnormalities 
pancreatic cancer 1.85E-03 CCND1,CCR1,CDKN1A,ERBB4,ETS1,GNAS, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC),PLAT, 
SMAD4,SPP1,SYNE2,YWHAZ 
19 
Cancer, Endocrine 
System Disorders, 
Gastrointestinal Disease, 
Organismal Injury and 
Abnormalities 
ductal pancreatic 
carcinoma 
6.86E-10 CDKN1A, ,SMAD4,SPP1 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC) 
10 
Cancer, Gastrointestinal 
Disease, Organismal 
Injury and Abnormalities 
gastrointestinal tract 
cancer 
1.52E-03 ARID4A,ATXN7,CCND1,CDH6,CDKN1A,CLDN1, 
DCBLD2,DRAP1,EIF4A2,ERBB4,ETS1,FAM135A, 
FAM46A,GNAS,H3F3A/H3F3B,HAX1,HOXA7,IFI27, 
IGFBP5,KAT2B,MAFB,MATR3,miR-125b-5p 
 (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
58 
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miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-423-5p (and other miRNAs w/seed GAGGGGC), 
MYBL2,MYEF2,NCAPD2,NFKB2,PDE3A,PHACTR2, 
PLAT,PPFIBP1,PTTG1,RBL1,RBM22,RIF1,RPL18A, 
SIK2,SMAD4,SPP1,STAT1,SYNDIG1,SYNE2,TCF21, 
TNFAIP3,TRA2B,UGT8,VAV2,YWHAZ,ZNF667 
Cancer, Gastrointestinal 
Disease, Organismal 
Injury and Abnormalities 
colorectal cancer 5.08E-03 ARID4A,ATXN7,CCND1,CDH6,CDKN1A,CLDN1, 
DRAP1,EIF4A2,ERBB4,ETS1,FAM135A,FAM46A, 
GNAS,IFI27,IGFBP5,KAT2B,MAFB,MATR3, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-423-5p (and other miRNAs w/seed GAGGGGC), 
MYBL2,MYEF2,NCAPD2,NFKB2,PDE3A,PHACTR2, 
PLAT,PTTG1,RBL1,RBM22,RIF1,SIK2,SMAD4,SPP1, 
STAT1,SYNE2,TCF21,TNFAIP3,UGT8,VAV2,YWHAZ 
49 
Cancer, Gastrointestinal 
Disease, Organismal 
Injury and Abnormalities 
upper gastrointestinal 
tract cancer 
2.73E-06 ARID4A,CCND1,CDKN1A,DCBLD2,ERBB4,FAM135A, 
GNAS,H3F3A/H3F3B,HAX1,HOXA7,IGFBP5, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
32 
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miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MYBL2,PDE3A,PLAT,PPFIBP1,PTTG1,RIF1,RPL18A, 
SIK2,SMAD4,SPP1,SYNDIG1,SYNE2,TRA2B,VAV2,ZNF667 
Cancer, Gastrointestinal 
Disease, Organismal 
Injury and Abnormalities 
upper gastrointestinal 
tract tumor 
5.42E-06 ARID4A,CCND1,CDKN1A,DCBLD2,ERBB4,FAM135A, 
GNAS,H3F3A/H3F3B,HAX1,HOXA7,IGFBP5, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MYBL2,PDE3A,PLAT,PPFIBP1,PTTG1,RIF1,RPL18A, 
SIK2,SMAD4,SPP1,SYNDIG1,SYNE2,TRA2B,VAV2, 
ZNF667 
32 
Cancer, Gastrointestinal 
Disease, Organismal 
Injury and Abnormalities 
gastroesophageal 
cancer 
2.33E-05 ARID4A,CCND1,CDKN1A,DCBLD2,ERBB4,FAM135A, 
GNAS,HOXA7, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed 
UCACAUU),MYBL2,PDE3A,PLAT,PPFIBP1,PTTG1, 
RIF1,RPL18A,SIK2,SMAD4,SPP1,SYNDIG1,SYNE2, 
TRA2B,VAV2,ZNF667 
28 
Cancer, Gastrointestinal 
Disease, Organismal 
Injury and Abnormalities 
gastro-esophageal 
carcinoma 
2.77E-04 ARID4A,DCBLD2,ERBB4,FAM135A,GNAS,HOXA7, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
24 
 
 
 
 
219 
 
MYBL2,PDE3A,PLAT,PPFIBP1,PTTG1,RIF1,RPL18A, 
SIK2,SMAD4,SPP1,SYNDIG1,SYNE2,TRA2B,ZNF667 
Cancer, Gastrointestinal 
Disease, Organismal 
Injury and Abnormalities 
gastroesophageal 
adenocarcinoma 
3.90E-03 ARID4A,DCBLD2,ERBB4,FAM135A,GNAS,HOXA7, 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MYBL2,PDE3A,PLAT,PPFIBP1,RIF1,RPL18A,SIK2, 
SMAD4,SYNDIG1,SYNE2,TRA2B,ZNF667 
20 
Cancer, Gastrointestinal 
Disease, Organismal 
Injury and Abnormalities 
gastric cancer 5.56E-03 ARID4A,DCBLD2,ERBB4,GNAS,HOXA7, 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed 
UCACAUU),MYBL2,PDE3A,PLAT,PPFIBP1,RIF1, 
SIK2,SMAD4,SPP1,SYNDIG1,SYNE2,ZNF667 
19 
Cancer, Gastrointestinal 
Disease, Organismal 
Injury and Abnormalities 
esophageal cancer 4.08E-06 CCND1,CDKN1A,FAM135A, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
PDE3A,PTTG1,RPL18A,SMAD4,SPP1,SYNE2, 
TRA2B,VAV2 
14 
Cancer, Gastrointestinal 
Disease, Organismal 
Injury and Abnormalities 
esophageal 
carcinoma 
1.15E-04 FAM135A, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
PDE3A,PTTG1,RPL18A,SMAD4,SPP1,SYNE2,TRA2B 
11 
Cancer, Hematological 
Disease, Immunological 
Disease, Organismal 
Injury and Abnormalities 
leukemia 4.65E-03 ARIH1,CCND1,CDKN1A,GNAS,HEY2,IFI27,IFI44L, 
IFIT1,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
RIF1,RPL37,SMAD4,SYNE2,TNIP1 
19 
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Cancer, Hematological 
Disease, Immunological 
Disease, Organismal 
Injury and Abnormalities 
lymphocytic cancer 4.72E-04 CCND1,CDKN1A,ETS1,IRAK1, 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed CUCACAC), 
TNFAIP3,TNIP1,YWHAZ 
12 
Cancer, Hematological 
Disease, Immunological 
Disease, Organismal 
Injury and Abnormalities 
lymphoproliferative 
malignancy 
1.29E-03 CCND1,CDKN1A,IFI27,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed CUCACAC), 
RIF1,SYNE2,TNFAIP3 
12 
Cancer, Hematological 
Disease, Immunological 
Disease, Organismal 
Injury and Abnormalities 
non-Hodgkin's 
disease 
7.71E-04 CCND1,CDKN1A,ETS1, 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed CUCACAC), 
TNFAIP3,TNIP1,YWHAZ 
11 
Cancer, Hematological 
Disease, Organismal 
Injury and Abnormalities 
hematological 
neoplasia 
4.63E-05 ARIH1,CCND1,CDKN1A,ETS1,GNAS,HEY2, 
IFI27,IFI44L,IFIT1,IFIT3,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed CUCACAC), 
PDE3A,RIF1,RPL37,RPS27A,SMAD4,SPP1,STIM1, 
30 
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SYNE2,TNFAIP3,TNIP1,YWHAZ 
Cancer, Hematological 
Disease, Organismal 
Injury and Abnormalities 
hematologic cancer 4.10E-04 ARIH1,CCND1,CDKN1A,ETS1,GNAS,HEY2,IFI27, 
IFI44L,IFIT1,IFIT3,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed CUCACAC), 
PDE3A,RIF1,RPL37,SMAD4,STIM1,SYNE2,TNFAIP3, 
TNIP1,YWHAZ 
27 
Cancer, Hematological 
Disease, Organismal 
Injury and Abnormalities 
myeloproliferative 
disorder 
1.24E-03 ARIH1,CCND1,GNAS,HEY2,IFI44L,IFIT1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
PDE3A,RPL37,RPS27A,SMAD4,SYNE2,TNIP1 
17 
Cancer, Immunological 
Disease, Organismal 
Injury and Abnormalities 
lymphatic node 
tumor 
2.44E-04 CCND1,CDKN1A,ETS1, 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed CUCACAC), 
SPP1,TNFAIP3,TNIP1,YWHAZ 
12 
Cancer, Neurological 
Disease, Organismal 
Injury and Abnormalities 
central nervous 
system tumor 
8.58E-04 CDKN1A,ERBB4,FAM3C,GNAS,H3F3A/H3F3B, 
IGFBP5,IRAK1, 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
PTTG1,SMAD4,SMARCE1,SPP1,UGT8,YWHAZ 
16 
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Cancer, Neurological 
Disease, Organismal 
Injury and Abnormalities 
gliomatosis 4.39E-03 CDKN1A,ERBB4,FAM3C,GNAS,H3F3A/H3F3B, 
IGFBP5, 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
PTTG1,SMAD4,SPP1,UGT8,YWHAZ 
13 
Cancer, Neurological 
Disease, Organismal 
Injury and Abnormalities 
central nervous 
system cancer 
7.72E-03 CDKN1A,ERBB4,FAM3C,GNAS,H3F3A/H3F3B, 
IGFBP5,IRAK1, 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
PTTG1,SMAD4,UGT8 
13 
Cancer, Neurological 
Disease, Organismal 
Injury and Abnormalities 
astrocytoma 3.44E-03 CDKN1A,ERBB4,FAM3C,GNAS,H3F3A/H3F3B,IGFBP5, 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
PTTG1,SMAD4,UGT8,YWHAZ 
12 
Cancer, Organismal 
Injury and Abnormalities 
tumorigenesis of 
tissue 
7.26E-05 ARID4A,ARIH1,ATXN7,CCND1,CCR1,CDH6,CDKN1A, 
CHAF1B,CLDN1,CTSA,DCBLD2,DRAP1,EIF4A2, 
ELOVL4,ERBB4,ETS1,FAM135A,FAM46A,GHITM, 
GNAS,H3F3A/H3F3B,HAX1,HEY2,HIST2H2BE, 
HNRNPK,HOXA7,HSPA4L,IFI27,IFI44,IFI44L,IFIT1, 
IFIT3,IGFBP5,IRAK1,ISG15,KAT2A,KAT2B,MAFB,MATR3, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
93 
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MPP5,MYBL2,MYEF2,NCAPD2,NETO2,NFKB2,OASL, 
OLFML2A,PDE3A,PHACTR2,PLAT,PPFIBP1,PPP2R2A, 
PRLR,PTPN22,PTTG1,RASGRP3,RBL1,RBM22,RIF1, 
RPL18A,RPL37,RPS27A,RUFY3,SIK2,SLC7A2,SMAD4, 
SPP1,STAT1,STIM1,SYNDIG1,SYNE2,TAB2,TCF21, 
TNFAIP3,TNIP1,TRA2B,TRAF6,UGT8,VAV2,YWHAZ, 
ZNF273,ZNF667 
Cancer, Organismal 
Injury and Abnormalities 
epithelial cancer 4.43E-05 ARID4A,ARIH1,ATXN7,CCND1,CCR1,CDH6,CDKN1A, 
CHAF1B,CLDN1,CTSA,DCBLD2,DRAP1,EIF4A2,ELOVL4, 
ERBB4,ETS1,FAM135A,FAM46A,GHITM,GNAS, 
H3F3A/H3F3B,HAX1,HIST2H2BE,HNRNPK,HOXA7,HSPA4L, 
IFI27,IFI44,IFI44L,IFIT1,IFIT3,IGFBP5,IRAK1,ISG15,KAT2A, 
KAT2B,MAFB,MATR3, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,MYEF2,NCAPD2,NETO2,NFKB2,OASL, 
OLFML2A,PDE3A,PHACTR2,PLAT,PPFIBP1,PPP2R2A, 
PRLR,PTPN22,PTTG1,RASGRP3,RBL1,RBM22,RIF1, 
RPL18A,RPL37,RPS27A,RUFY3,SIK2,SLC7A2,SMAD4, 
SPP1,STAT1,STIM1,SYNDIG1,SYNE2,TAB2,TCF21, 
TNFAIP3,TNIP1,TRA2B,TRAF6,UGT8,VAV2,YWHAZ, 
ZNF273,ZNF667 
 
92 
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Cancer, Organismal 
Injury and Abnormalities 
abdominal cancer 3.94E-03 ARID4A,ARIH1,ATXN7,CCND1,CCR1,CDH6,CDKN1A, 
CHAF1B,CLDN1,CTSA,DCBLD2,DRAP1,EIF4A2,ERBB4, 
ETS1,FAM135A,FAM46A,GHITM,GNAS,H3F3A/H3F3B, 
HNRNPK,HOXA7,HSPA4L,IFI27,IFI44,IFI44L,IFIT1,IFIT3, 
IGFBP5,IRAK1,ISG15,KAT2B,MAFB,MATR3, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
miR-423-5p (and other miRNAs w/seed GAGGGGC), 
MPP5,MYBL2,MYEF2,NCAPD2,NETO2,NFKB2,OASL, 
OLFML2A,PDE3A,PHACTR2,PLAT,PPFIBP1,PRLR, 
PTPN22,PTTG1,RASGRP3,RBL1,RBM22,RIF1,RPL37, 
RUFY3,SIK2,SLC7A2,SMAD4,SPP1,STAT1,STIM1, 
SYNDIG1,SYNE2,TAB2,TCF21,TNFAIP3,TNIP1,TRA2B, 
TRAF6,UGT8,VAV2,YWHAZ,ZNF273,ZNF667 
86 
Cancer, Organismal 
Injury and Abnormalities 
adenocarcinoma 2.13E-03 ARID4A,ARIH1,ATXN7,CCND1,CCR1,CDKN1A, 
CHAF1B,CLDN1,CTSA,DCBLD2,DRAP1,EIF4A2, 
ELOVL4,ERBB4,ETS1,FAM135A,FAM46A,GHITM, 
GNAS,HOXA7,HSPA4L,IFI27,IFI44,IFI44L,IFIT3, 
IGFBP5,KAT2B,MATR3, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
70 
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miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MPP5,MYBL2,MYEF2,NCAPD2,NETO2,NFKB2, 
OLFML2A,PDE3A,PHACTR2,PLAT,PPFIBP1,PRLR, 
PTPN22,RASGRP3,RBL1,RBM22,RIF1,RPL18A,SIK2, 
SLC7A2,SMAD4,SPP1,STAT1,SYNDIG1,SYNE2, 
TNFAIP3,TRA2B,TRAF6,UGT8,VAV2,YWHAZ, 
ZNF273,ZNF667 
Cancer, Organismal 
Injury and Abnormalities 
abdominal carcinoma 6.39E-03 ARID4A,ARIH1,ATXN7,CCND1,CCR1,CDKN1A, 
CHAF1B,CLDN1,CTSA,DCBLD2,DRAP1,EIF4A2, 
ERBB4,ETS1,FAM135A,FAM46A,GHITM,GNAS, 
HOXA7,HSPA4L,IFI27,IFI44,IFIT3,KAT2B,MATR3, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,NCAPD2,NETO2,NFKB2,OLFML2A, 
PDE3A,PHACTR2,PLAT,PPFIBP1,PRLR,PTPN22, 
RASGRP3,RBL1,RBM22,RIF1,SIK2,SLC7A2,SMAD4, 
SPP1,STAT1,SYNDIG1,SYNE2,TNFAIP3,TRA2B, 
TRAF6,UGT8,VAV2,YWHAZ,ZNF273,ZNF667 
 
 
 
64 
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Cancer, Organismal 
Injury and Abnormalities 
urogenital cancer 1.97E-06 ARID4A,ARIH1,CCND1,CCR1,CDH6,CDKN1A, 
CHAF1B,CTSA,DRAP1,EIF4A2,ERBB4,FAM135A, 
GHITM,GNAS,HNRNPK,HSPA4L,IFI27,IFI44,IFI44L, 
IFIT3,IGFBP5,IRAK1,ISG15,KAT2B, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,NETO2,OLFML2A,PDE3A,PLAT,PRLR, 
PTPN22,PTTG1,RASGRP3,RBL1,RIF1,SIK2,SLC7A2, 
SMAD4,SPP1,STAT1,STIM1,SYNE2,TCF21,TNIP1, 
TRA2B,TRAF6,UGT8,VAV2,ZNF273,ZNF667 
61 
Cancer, Organismal 
Injury and Abnormalities 
pelvic cancer 2.51E-05 ARID4A,CCND1,CDKN1A,CHAF1B,CTSA,DRAP1, 
EIF4A2,ERBB4,FAM135A,GHITM,GNAS,HSPA4L, 
IFI27,IFI44,IFI44L,IFIT3,IGFBP5,IRAK1,ISG15,KAT2B, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
57 
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MPP5,MYBL2,NETO2,NFKB2,OLFML2A,PDE3A, 
PLAT,PRLR,PTPN22,PTTG1,RASGRP3,RBL1,RIF1, 
SIK2,SLC7A2,SMAD4,SPP1,STAT1,STIM1,SYNE2, 
TCF21,TNIP1,TRA2B,TRAF6,UGT8,VAV2,ZNF667 
Cancer, Organismal 
Injury and Abnormalities 
breast or colorectal 
cancer 
2.62E-03 ARID4A,ATXN7,CCND1,CDH6,CDKN1A,CLDN1, 
DRAP1,EIF4A2,ERBB4,ETS1,FAM135A,FAM46A, 
GNAS,H3F3A/H3F3B,HAX1,HEY2,HIST2H2BE, 
IFI27,IFIT1,IGFBP5,KAT2B,MAFB,MATR3, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-423-5p (and other miRNAs w/seed GAGGGGC), 
MYBL2,MYEF2,NCAPD2,NFKB2,PDE3A,PHACTR2, 
PLAT,PRLR,PTTG1,RBL1,RBM22,RIF1,SIK2,SMAD4, 
SPP1,STAT1,SYNE2,TCF21,TNFAIP3,TRA2B,UGT8, 
VAV2,YWHAZ 
56 
Cancer, Organismal 
Injury and Abnormalities 
endometrioid 
carcinoma 
9.96E-04 ARID4A,CCND1,CHAF1B,CTSA,DRAP1,EIF4A2, 
ERBB4,FAM135A,GHITM,GNAS,HSPA4L,IFI44,IFIT3, 
KAT2B,miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR,PTPN22, 
RASGRP3,RBL1,RIF1,SLC7A2,SPP1,STAT1,SYNE2, 
TRA2B,TRAF6,UGT8,VAV2,ZNF667 
 
 
36 
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Cancer, Organismal 
Injury and Abnormalities 
breast or ovarian 
cancer 
1.01E-04 CCND1,CDKN1A,CLDN1,EIF4A2,ERBB4,ETS1, 
GNAS,H3F3A/H3F3B,HAX1,HEY2,HIST2H2BE,IFI27, 
IFIT1,KAT2B, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYBL2,PLAT,PRLR,PTTG1,SIK2,SMAD4,SPP1, 
STAT1,TRA2B,YWHAZ 
30 
Cancer, Organismal 
Injury and Abnormalities 
lymphohematopoietic 
cancer 
2.02E-04 ARIH1,CCND1,CDKN1A,ETS1,GNAS,HEY2,IFI27, 
IFI44L,IFIT1,IFIT3,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed CUCACAC), 
PDE3A,RIF1,RPL37,SMAD4,SPP1,STIM1,SYNE2, 
TNFAIP3,TNIP1,YWHAZ 
28 
Cancer, Organismal 
Injury and Abnormalities 
cancer of secretory 
structure 
1.35E-03 CCND1,CCR1,CDKN1A,ERBB4,ETS1,GNAS,IFI44L, 
IRAK1,ISG15, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
28 
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miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
MPP5,MYBL2,PLAT,RBL1,SMAD4,SPP1,STAT1, 
STIM1,SYNE2,YWHAZ 
Cancer, Organismal 
Injury and Abnormalities 
Lymphoid Cancer and 
Tumors 
1.46E-04 ARIH1,CCND1,CDKN1A,ETS1,GNAS,HEY2,IFI27, 
IFI44L,IFIT1,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed CUCACAC), 
PDE3A,RIF1,RPL37,RPS27A,SMAD4,SPP1,SYNE2, 
TNFAIP3,TNIP1,YWHAZ 
27 
Cancer, Organismal 
Injury and Abnormalities 
head and neck 
neoplasia 
1.01E-02 CCND1,CDKN1A,DCBLD2,ERBB4,ETS1,FAM135A, 
FAM3C,FAM46A,GNAS,H3F3A/H3F3B,HAX1, 
HNRNPK,HOXA7,IGFBP5,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed 
UCACAUU),PTTG1,SMAD4,SPP1,STAT1,TNFAIP3 
27 
Cancer, Organismal 
Injury and Abnormalities 
head and neck cancer 1.44E-06 CCND1,CDKN1A,DCBLD2,ERBB4,ETS1,FAM3C, 
GNAS,H3F3A/H3F3B,HAX1,HNRNPK,IGFBP5,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
24 
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miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed 
UCACAUU),PTTG1,SMAD4,SPP1,STAT1,TNFAIP3 
Cancer, Organismal 
Injury and Abnormalities 
lymphoid cancer 1.18E-03 ARIH1,CCND1,CDKN1A,ETS1,GNAS,HEY2,IFI27, 
IFI44L,IFIT1,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed 
CUCACAC),RIF1,RPL37,SMAD4,SPP1,SYNE2, 
TNFAIP3,TNIP1,YWHAZ 
24 
Cancer, Organismal 
Injury and Abnormalities 
malignant neoplasm 
of aerodigestive tract 
6.50E-10 CCND1,CDKN1A,DCBLD2,ERBB4,FAM135A, 
GNAS,H3F3A/H3F3B,HAX1,IGFBP5, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
PDE3A,PTTG1,RPL18A,SMAD4,SPP1,SYNE2, 
TRA2B,VAV2 
23 
Cancer, Organismal 
Injury and Abnormalities 
squamous-cell 
carcinoma 
3.60E-08 CCND1,CDKN1A,DCBLD2,EIF4A2,ERBB4,HAX1, 
HIST2H2BE,IFI27,IFI44,IFIT1,IGFBP5, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
23 
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miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-298 (miRNAs w/seed GCAGAAG),PTTG1, 
SMAD4,SPP1 
Cancer, Organismal 
Injury and Abnormalities 
advanced malignant 
tumor 
1.74E-10 CCND1,CDH6,ERBB4,IGFBP5,KAT2B,MAFB, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MYBL2,PLAT,PTTG1,RBL1,RPS27A,SMAD4,SPP1, 
STAT1,TCF21,YWHAZ 
22 
Cancer, Organismal 
Injury and Abnormalities 
advanced stage solid 
tumor 
2.43E-09 CCND1,CDH6,ERBB4,IGFBP5,MAFB, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed 
UCACAUU),MYBL2,PLAT,PTTG1,RPS27A,SPP1, 
STAT1,TCF21,YWHAZ 
19 
Cancer, Organismal 
Injury and Abnormalities 
upper aerodigestive 
tract carcinoma 
7.83E-08 DCBLD2,ERBB4,FAM135A,GNAS,HAX1,IGFBP5, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed 
UCACAUU),PDE3A,PTTG1,RPL18A,SMAD4,SPP1, 
SYNE2,TRA2B 
 
19 
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Cancer, Organismal 
Injury and Abnormalities 
metastatic solid 
tumor 
6.48E-10 CCND1,CDH6,ERBB4,IGFBP5,MAFB, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed 
UCACAUU),PLAT,PTTG1,RPS27A,SPP1,STAT1, 
TCF21,YWHAZ 
18 
Cancer, Organismal 
Injury and Abnormalities 
benign neoplasia 1.01E-05 CCND1,CDKN1A,EIF4A2,ERBB4,GNAS,IFI44L, 
IFIT1,IFIT3,IGFBP5, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MYBL2,NETO2,PRLR,PTTG1,SPP1,STAT1 
18 
Cancer, Organismal 
Injury and Abnormalities 
head and neck 
carcinoma 
5.37E-08 CCND1,CDKN1A,DCBLD2,ERBB4,ETS1,GNAS, 
HAX1,IGFBP5, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC),PTTG1, 
SMAD4,SPP1 
17 
Cancer, Organismal 
Injury and Abnormalities 
connective or soft 
tissue tumor 
2.99E-05 CCND1,CDKN1A,ERBB4,GNAS,IFI44L,IFIT1,IFIT3, 
IGFBP5, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
PRLR,PTTG1,SPP1 
15 
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Cancer, Organismal 
Injury and Abnormalities 
serous neoplasm 1.98E-04 CDKN1A,EIF4A2,GNAS,IGFBP5,IRAK1,ISG15, 
MYBL2,PRLR,PTTG1,SIK2,SPP1,STAT1,TCF21, 
TNIP1 
14 
Cancer, Organismal 
Injury and Abnormalities 
clear-cell 
adenocarcinoma 
4.15E-03 ARIH1,CDKN1A,EIF4A2,ERBB4,GNAS, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
NETO2,PRLR,SMAD4,STAT1,ZNF273 
12 
Cancer, Organismal 
Injury and Abnormalities 
ductal carcinoma 9.87E-07 CCND1,CDKN1A, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC),SMAD4,SPP1 
11 
Cancer, Organismal 
Injury and Abnormalities 
benign connective or 
soft tissue neoplasm 
4.44E-05 CCND1,ERBB4,GNAS,IFI44L,IFIT1,IFIT3,IGFBP5, 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
PRLR,PTTG1 
11 
Cancer, Organismal 
Injury and Abnormalities 
upper aero-digestive 
squamous cell 
carcinoma 
1.07E-05 DCBLD2,ERBB4,HAX1,IGFBP5, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
PTTG1,SPP1 
10 
Cancer, Organismal 
Injury and Abnormalities 
primary neoplasm 2.82E-05 IFI27 
,miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
10 
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PRLR,SMAD4,SPP1 
Cancer, Organismal 
Injury and Abnormalities 
adenoma 7.81E-04 CCND1,CDKN1A,EIF4A2,GNAS, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYBL2,PRLR,SPP1,STAT1 
10 
Cancer, Organismal 
Injury and 
Abnormalities, Renal 
and Urological Disease 
urinary tract tumor 6.28E-06 ARIH1,CCND1,CCR1,CDH6,CDKN1A,EIF4A2,ERBB4, 
GNAS,HNRNPK,IFIT3,IGFBP5,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
NETO2,PDE3A,PLAT,PTPN22,SMAD4,SPP1,SYNE2, 
TCF21,ZNF273 
26 
Cancer, Organismal 
Injury and 
Abnormalities, Renal 
and Urological Disease 
urinary tract cancer 3.01E-05 ARIH1,CCND1,CCR1,CDH6,CDKN1A,EIF4A2,ERBB4, 
GNAS,HNRNPK,IFIT3,IGFBP5,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
NETO2,PDE3A,PLAT,PTPN22,SMAD4, 
SPP1,SYNE2,TCF21,ZNF273 
24 
Cancer, Organismal 
Injury and 
Abnormalities, Renal 
and Urological Disease 
Bladder Cancer and 
Tumors 
1.31E-05 CCND1,CDKN1A,EIF4A2,ERBB4,GNAS, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
PDE3A,PLAT,PTPN22,SMAD4,SPP1,SYNE2,TCF21 
16 
Cancer, Organismal 
Injury and 
Abnormalities, Renal 
and Urological Disease 
renal cancer 1.09E-03 ARIH1,CCR1,CDH6,CDKN1A,EIF4A2,ERBB4,GNAS, 
HNRNPK,IFIT3,IGFBP5,IRAK1, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU),NETO2, 
SMAD4,ZNF273 
16 
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Cancer, Organismal 
Injury and 
Abnormalities, Renal 
and Urological Disease 
bladder cancer 4.15E-04 CCND1,CDKN1A,EIF4A2,ERBB4,GNAS, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
PDE3A,PLAT,PTPN22,SMAD4,SPP1,SYNE2,TCF21 
13 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
genital tumor 4.21E-06 ARID4A,CCND1,CDKN1A,CHAF1B,CTSA,DRAP1, 
EIF4A2,ERBB4,FAM135A,GHITM,GNAS,HSPA4L, 
IFI27,IFI44,IFI44L,IFIT1,IFIT3,IGFBP5,IRAK1, 
ISG15,KAT2B, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR, 
PTPN22,PTTG1,RASGRP3,RBL1,RIF1,SIK2,SLC7A2, 
SMAD4,SPP1,STAT1,STIM1,SYNE2,TCF21,TNIP1, 
TRA2B,TRAF6,UGT8,VAV2,ZNF667 
56 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
female genital 
neoplasm 
1.29E-07 ARID4A,CCND1,CDKN1A,CHAF1B,CTSA,DRAP1, 
EIF4A2,ERBB4,FAM135A,GHITM,GNAS,HSPA4L, 
IFI27,IFI44,IFI44L,IFIT1,IFIT3,IGFBP5,IRAK1,ISG15, 
KAT2B, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
55 
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miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR,PTPN22, 
PTTG1,RASGRP3,RBL1,RIF1,SIK2,SLC7A2,SMAD4, 
SPP1,STAT1,STIM1,SYNE2,TCF21,TNIP1,TRA2B, 
TRAF6,UGT8,VAV2,ZNF667 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
genital tract cancer 3.08E-06 ARID4A,CCND1,CDKN1A,CHAF1B,CTSA,DRAP1, 
EIF4A2,ERBB4,FAM135A,GHITM,GNAS,HSPA4L, 
IFI27,IFI44,IFI44L,IFIT3,IGFBP5,IRAK1,ISG15,KAT2B, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR,PTPN22, 
PTTG1,RASGRP3,RBL1,RIF1,SIK2,SLC7A2,SMAD4, 
SPP1,STAT1,STIM1,SYNE2,TCF21,TNIP1,TRA2B, 
TRAF6,UGT8,VAV2,ZNF667 
55 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
tumorigenesis of 
genital organ 
3.57E-06 ARID4A,CCND1,CDKN1A,CHAF1B,CTSA,DRAP1, 
EIF4A2,ERBB4,FAM135A,GHITM,GNAS,HSPA4L, 
IFI27,IFI44,IFI44L,IFIT3,IGFBP5,IRAK1,ISG15,KAT2B, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
55 
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miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG),MPP5, 
MYBL2,NETO2,OLFML2A,PLAT,PRLR,PTPN22, 
PTTG1,RASGRP3,RBL1,RIF1,SIK2,SLC7A2, 
SMAD4,SPP1,STAT1,STIM1,SYNE2,TCF21, 
TNIP1,TRA2B,TRAF6,UGT8,VAV2,ZNF667 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
female genital tract 
cancer 
2.20E-07 ARID4A,CCND1,CDKN1A,CHAF1B,CTSA,DRAP1, 
EIF4A2,ERBB4,FAM135A,GHITM,GNAS,HSPA4L, 
IFI27,IFI44,IFIT3,IGFBP5,IRAK1,ISG15,KAT2B, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR, 
PTPN22,PTTG1,RASGRP3,RBL1,RIF1,SIK2, 
SLC7A2,SMAD4,SPP1,STAT1,STIM1,SYNE2, 
TCF21,TNIP1,TRA2B,TRAF6,UGT8,VAV2,ZNF667 
53 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
tumorigenesis of 
reproductive tract 
2.40E-07 ARID4A,CCND1,CDKN1A,CHAF1B,CTSA,DRAP1, 
EIF4A2,ERBB4,FAM135A,GHITM,GNAS,HSPA4L, 
IFI27,IFI44,IFIT3,IGFBP5,IRAK1,ISG15,KAT2B, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
53 
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miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR, 
PTPN22,PTTG1,RASGRP3,RBL1,RIF1,SIK2, 
SLC7A2,SMAD4,SPP1,STAT1,STIM1,SYNE2, 
TCF21,TNIP1,TRA2B,TRAF6,UGT8,VAV2,ZNF667 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
uterine tumor 1.98E-07 ARID4A,CCND1,CHAF1B,CTSA,DRAP1,EIF4A2, 
ERBB4,FAM135A,GHITM,GNAS,HSPA4L,IFI44, 
IFI44L,IFIT1,IFIT3,IGFBP5,IRAK1,ISG15,KAT2B, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR, 
PTPN22,PTTG1,RASGRP3,RBL1,RIF1,SLC7A2, 
SPP1,STAT1,STIM1,SYNE2,TCF21,TNIP1,TRA2B, 
TRAF6,UGT8,VAV2,ZNF667 
51 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
uterine cancer 2.96E-07 ARID4A,CCND1,CHAF1B,CTSA,DRAP1,EIF4A2 
,ERBB4,FAM135A,GHITM,GNAS,HSPA4L,IFI44, 
IFIT3,IGFBP5,IRAK1,ISG15,KAT2B, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
49 
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miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR, 
PTPN22,PTTG1,RASGRP3,RBL1,RIF1,SLC7A2, 
SPP1,STAT1,STIM1,SYNE2,TCF21,TNIP1,TRA2B, 
TRAF6,UGT8,VAV2,ZNF667 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
endometrial cancer 8.38E-06 ARID4A,CCND1,CHAF1B,CTSA,DRAP1,EIF4A2, 
ERBB4,FAM135A,GHITM,GNAS,HSPA4L,IFI44,IFIT3, 
IGFBP5,IRAK1,ISG15,KAT2B, 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR,PTPN22, 
PTTG1,RASGRP3,RBL1,RIF1,SLC7A2,STAT1,SYNE2, 
TCF21,TNIP1,TRA2B,TRAF6,UGT8,VAV2,ZNF667 
44 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
uterine carcinoma 2.97E-04 ARID4A,CCND1,CHAF1B,CTSA,DRAP1,EIF4A2,ERBB4, 
FAM135A,GHITM,GNAS,HSPA4L,IFI44,IFIT3,KAT2B, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-298 (miRNAs w/seed GCAGAAG), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR,PTPN22, 
RASGRP3,RBL1,RIF1,SLC7A2,STAT1,SYNE2,TRA2B, 
39 
 
 
 
 
240 
 
TRAF6,UGT8,VAV2,ZNF667 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
female genital tract 
adenocarcinoma 
1.13E-03 ARID4A,CCND1,CDKN1A,CHAF1B,CTSA,DRAP1, 
EIF4A2,ERBB4,FAM135A,GHITM,GNAS,HSPA4L, 
IFI44,IFIT3,KAT2B, 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR,PTPN22, 
RASGRP3,RBL1,RIF1,SIK2,SLC7A2,SPP1,STAT1, 
SYNE2,TRA2B,TRAF6,UGT8,VAV2,ZNF667 
38 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
endometrial 
carcinoma 
2.34E-03 ARID4A,CCND1,CHAF1B,CTSA,DRAP1,EIF4A2, 
ERBB4,FAM135A,GHITM,GNAS,HSPA4L,IFI44, 
IFIT3,KAT2B,miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PRLR,PTPN22, 
RASGRP3,RBL1,RIF1,SLC7A2,STAT1,SYNE2,TRA2B, 
TRAF6,UGT8,VAV2,ZNF667 
35 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
adenocarcinoma in 
endometrium 
3.66E-03 ARID4A,CCND1,CHAF1B,CTSA,DRAP1,EIF4A2,ERBB4, 
FAM135A,GHITM,GNAS,HSPA4L,IFI44,IFIT3,KAT2B, 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MPP5,MYBL2,NETO2,OLFML2A,PLAT,PTPN22, 
RASGRP3,RBL1,RIF1,SLC7A2,STAT1,SYNE2,TRA2B, 
TRAF6,UGT8,VAV2,ZNF667 
34 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
breast cancer 7.50E-06 CCND1,CDKN1A,CLDN1,EIF4A2,ERBB4,ETS1,GNAS, 
H3F3A/H3F3B,HAX1,HEY2,HIST2H2BE,IFI27,IFIT1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
28 
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miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYBL2,PLAT,PRLR,PTTG1,SMAD4,SPP1,STAT1, 
TRA2B,YWHAZ 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
Prostate Cancer and 
Tumors 
2.30E-03 CCND1,CDKN1A,GNAS,IFI44L,IRAK1,ISG15, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed 
AGCUUAU),MPP5,MYBL2,RBL1,SPP1,STAT1,STIM1 
16 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
prostate cancer 4.95E-03 CCND1,CDKN1A,IFI44L,IRAK1,ISG15, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed 
AGCUUAU),MPP5,MYBL2,RBL1,SPP1,STAT1,STIM1 
15 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
carcinoma in breast 1.11E-02 CCND1,CDKN1A,EIF4A2,ERBB4,ETS1,IFI27,IFIT1, 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYBL2,PRLR,SMAD4,SPP1,TRA2B 
14 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
benign neoplasm of 
female genital organ 
1.30E-05 CDKN1A,EIF4A2,GNAS,IFI44L,IFIT1,IFIT3,IGFBP5, 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
PRLR,PTTG1,SPP1,STAT1 
13 
Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
 
female genital tract 
serous cancer 
2.15E-05 CDKN1A,EIF4A2,IGFBP5,IRAK1,ISG15,MYBL2, 
PRLR,PTTG1,SPP1,STAT1,TCF21,TNIP1 
12 
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Cancer, Organismal 
Injury and 
Abnormalities, 
Reproductive System 
Disease 
HER2 negative 
hormone receptor 
negative breast 
cancer 
9.56E-08 CCND1,CDKN1A,ERBB4,ETS1,GNAS, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
MYBL2,PLAT,SPP1,STAT1 
10 
Cancer, Organismal 
Injury and 
Abnormalities, 
Respiratory Disease 
respiratory system 
tumor 
8.89E-08 CCND1,CDKN1A,EIF4A2,ERBB4,GNAS,HIST2H2BE, 
IRAK1,KAT2A,MAFB, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MYEF2,PPP2R2A,RPS27A,SMAD4,SPP1,STAT1, 
SYNE2,YWHAZ 
26 
Cancer, Organismal 
Injury and 
Abnormalities, 
Respiratory Disease 
lung cancer 7.10E-08 CCND1,CDKN1A,EIF4A2,ERBB4,GNAS,HIST2H2BE, 
IRAK1,KAT2A,MAFB, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MYEF2,PPP2R2A,RPS27A,SMAD4,SPP1,STAT1, 
SYNE2,YWHAZ 
 
25 
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Cancer, Organismal 
Injury and 
Abnormalities, 
Respiratory Disease 
non-small cell lung 
cancer 
1.61E-05 CCND1,CDKN1A,EIF4A2,ERBB4,HIST2H2BE, 
KAT2A,MAFB, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
MYEF2,PPP2R2A,RPS27A,SMAD4,SPP1,STAT1, 
SYNE2,YWHAZ 
19 
Cancer, Organismal 
Injury and 
Abnormalities, Skeletal 
and Muscular Disorders 
smooth muscle tumor 4.47E-05 CDKN1A,ERBB4,IFI44L,IFIT1,IFIT3,IGFBP5, 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
PTTG1,SPP1 
10 
Cell Cycle cell cycle progression 4.77E-04 CCND1,CDKN1A,ETS1,IGFBP5,KAT2B,MECP2, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
PTTG1,RBL1,SMAD4,SMARCE1,STAT1 
14 
Cell Cycle interphase of tumor 
cell lines 
6.83E-06 CCND1,CDKN1A,ETS1,IGFBP5,KAT2A, 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYBL2,PPP2R2A,RBL1,SPP1,STAT1 
12 
Cell Death and Survival cell death 2.70E-06 ATXN7,CCND1,CDKN1A,ELOVL4,ERBB4,ETS1, 
GNAS,HAX1,HNRNPK,HOXA7,IFI27,IFIT3,IGFBP5, 
IRAK1,ISG15, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
36 
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MYBL2,NFKB2,PLAT,PPP2R2A,PTTG1,SMAD4, 
SMARCE1,SPP1,STAT1,STIM1,TNFAIP3,TRAF6, 
UBE2L3,YWHAZ 
Cell Death and Survival apoptosis 1.64E-07 CCND1,CDKN1A,ELOVL4,ERBB4,ETS1,GNAS, 
HAX1,HNRNPK,HOXA7,IFI27,IFIT3,IGFBP5,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYBL2,NFKB2,PLAT,PPP2R2A,PTTG1,SMAD4, 
SMARCE1,SPP1,STAT1,STIM1,TNFAIP3,TRAF6, 
YWHAZ 
33 
Cell Death and Survival necrosis 7.73E-07 ATXN7,CCND1,CDKN1A,ELOVL4,ERBB4,ETS1, 
GNAS,HAX1,HNRNPK,HOXA7,IGFBP5,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYBL2,NFKB2,PLAT,PPP2R2A,PTTG1,SMAD4, 
SMARCE1,SPP1,STAT1,STIM1,TNFAIP3,TRAF6, 
UBE2L3,YWHAZ 
33 
Cell Death and Survival cell death of tumor 
cell lines 
3.04E-06 CCND1,CDKN1A,ERBB4,ETS1,GNAS,HAX1, 
HNRNPK,HOXA7,IGFBP5, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
28 
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miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYBL2,NFKB2,PPP2R2A,PTTG1,SMAD4,SMARCE1, 
SPP1,STAT1,STIM1,TNFAIP3,TRAF6,UBE2L3,YWHAZ 
Cell Death and Survival apoptosis of tumor 
cell lines 
1.08E-06 CCND1,CDKN1A,ERBB4,ETS1,GNAS,HAX1, 
HNRNPK,HOXA7,IGFBP5, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
NFKB2,PPP2R2A,PTTG1,SMAD4,SMARCE1,SPP1, 
STAT1,STIM1,TNFAIP3,TRAF6,YWHAZ 
25 
Cell Death and Survival cell viability 1.43E-03 CCND1,CCR1,CDKN1A,ERBB4,IRAK1, 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYBL2,NFKB2,PPP2R2A,PTPN22,RPSA,SPP1, 
TNFAIP3,UBE2L3 
16 
Cell Death and Survival cell viability of tumor 
cell lines 
3.53E-03 CCND1,CDKN1A,ERBB4,IRAK1, 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
NFKB2,PPP2R2A,PTPN22,RPSA,SPP1,UBE2L3 
13 
Cellular Development differentiation of cells 3.95E-09 CCND1,CCR1,CDKN1A,DCBLD2,ERBB4,ETS1, 
HAX1,HOXA7,IGFBP5,KAT2B,MAFB, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
23 
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miR-21-5p (and other miRNAs w/seed AGCUUAU), 
PLAT,SMAD4,SPP1,STAT1,STIM1,TRAF6 
Cellular Development, 
Cellular Growth and 
Proliferation 
proliferation of tumor 
cell lines 
2.64E-08 ARID4A,ARIH1,CCND1,CDKN1A,ERBB4,ETS1, 
GNAS,HNRNPK,HOXA7,IGFBP5,KAT2A,KAT2B, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
PLAT,PTPN22,PTTG1,RBL1,SMAD4,SMARCE1, 
SPP1,STAT1,STIM1,TAB2,TRAF6,YWHAZ 
32 
Cellular Development, 
Cellular Growth and 
Proliferation 
proliferation of breast 
cancer cell lines 
8.83E-06 CCND1,CDKN1A,ERBB4,ETS1,GNAS,HNRNPK, 
IGFBP5,miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
SMARCE1,SPP1 
13 
Cellular Development, 
Cellular Growth and 
Proliferation 
proliferation of 
carcinoma cell lines 
6.40E-05 CCND1,CDKN1A,KAT2A, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
SPP1,TAB2,TRAF6,YWHAZ 
11 
Cellular Development, 
Cellular Growth and 
Proliferation 
proliferation of lung 
cancer cell lines 
1.04E-05 CCND1,CDKN1A,KAT2A, 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
SPP1,TAB2,TRAF6,YWHAZ 
 
10 
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Cellular Growth and 
Proliferation 
proliferation of cells 1.00E-08 ARID4A,ARIH1,CCND1,CCNI,CCR1,CDKN1A, 
DCBLD2,ERBB4,ETS1,GNAS,H3F3A/H3F3B, 
HNRNPK,HOXA7,IFIT3,IGFBP5,ISG15,KAT2A,KAT2B, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
MYBL2,NFKB2,PLAT,PRLR,PTPN22,PTTG1,RBL1, 
RPSA,SMAD4,SMARCE1,SPP1,STAT1,STIM1, 
TAB2,TNFAIP3,TRAF6,UBE2L3,YWHAZ 
45 
Cellular Movement cell movement 1.64E-06 CCL1,CCND1,CCR1,CDKN1A,DCBLD2,ERBB4,ETS1, 
GNAS,HAX1,HNRNPK,HOXA7,IGFBP5, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
NFKB2,PLAT,PTTG1,RUFY3,SMAD4,SPP1,STAT1, 
STIM1,TAB2,YWHAZ 
26 
Cellular Movement migration of cells 6.23E-07 CCL1,CCND1,CCR1,CDKN1A,DCBLD2,ETS1, 
GNAS,HAX1,HNRNPK,HOXA7,IGFBP5, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
NFKB2,PLAT,PTTG1,RUFY3,SMAD4,SPP1,STAT1, 
STIM1,TAB2,YWHAZ 
25 
Cellular Movement invasion of cells 1.26E-07 CCL1,CCND1,CCR1,CDKN1A,ERBB4,ETS1, 20 
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GNAS,HAX1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
PLAT,PTTG1,RPSA,SMAD4,SPP1,STAT1 
Cellular Movement invasion of tumor cell 
lines 
1.37E-07 CCND1,CCR1,CDKN1A,ERBB4,ETS1,GNAS,HAX1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
PLAT,PTTG1,RPSA,SMAD4,SPP1,STAT1 
19 
Cellular Movement migration of tumor 
cell lines 
2.56E-06 CCL1,CCND1,CDKN1A,DCBLD2,ETS1,GNAS,HAX1, 
HNRNPK, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
PLAT,PTTG1,SMAD4,SPP1,STAT1,STIM1 
18 
Connective Tissue 
Disorders, 
Immunological Disease, 
Inflammatory Disease, 
Skeletal and Muscular 
Disorders 
rheumatoid arthritis 3.87E-04 ARIH1,CCL1,CCR1,H3F3A/H3F3B,IGFBP5,MAFB, 
miR-155-5p (miRNAs w/seed UAAUGCU), 
PTPN22,RPL18A,RPSA,SLC7A2,SPP1,STAT1, 
TNFAIP3 
 
 
 
 
 
14 
 
 
 
 
249 
 
 
Connective Tissue 
Disorders, 
Immunological Disease, 
Inflammatory Disease, 
Skeletal and Muscular 
Disorders 
systemic lupus 
erythematosus 
1.14E-09 CTSA,IFIT1,ISG15, 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-298 (miRNAs w/seed GCAGAAG), 
OASL,PTPN22,SPP1,TNFAIP3,UBE2L3 
12 
Connective Tissue 
Disorders, Inflammatory 
Disease, Skeletal and 
Muscular Disorders 
Rheumatic Disease 3.68E-08 ARIH1,CCL1,CCR1,CTSA,H3F3A/H3F3B,IFIT1, 
IGFBP5,ISG15,MAFB, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-298 (miRNAs w/seed GCAGAAG), 
OASL,PTPN22,RPL18A,RPSA,SLC7A2,SPP1,STAT1, 
TNFAIP3,UBE2L3 
25 
Dermatological Diseases 
and Conditions 
psoriasis 9.70E-09 CCND1,HAX1,IFI27,IFI44,IFI44L,IFIT1,IFIT3,IRAK1, 
ISG15,MECP2, 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed CUCACAC), 
OASL,PLAT,STAT1,TNFAIP3,TNIP1 
20 
Gene Expression expression of RNA 3.90E-08 ARID4A,CCND1,CDKN1A,EIF4A2,ERBB4,ETS1, 
HAX1,HEY2,HNRNPK,HOXA7,IFI27,IGFBP5,IRAK1, 
KAT2A,KAT2B,MECP2,MYBL2,NFKB2,PRLR,PTPN22, 
PTTG1,RBL1,RPL37,SMAD4,SMARCE1,STAT1,TAB2, 
TCF21,TNFAIP3,TNIP1,TRAF6,UBE2L3 
 
32 
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Gene Expression transcription 4.31E-06 ARID4A,CCND1,CDKN1A,ERBB4,ETS1,HAX1,HEY2, 
HNRNPK,HOXA7,IFI27,KAT2A,KAT2B,MECP2,MYBL2, 
NFKB2,PRLR,PTPN22,PTTG1,RBL1,SMAD4,SMARCE1, 
STAT1,TAB2,TCF21,TRAF6,UBE2L3,ZNF417/ZNF587 
27 
Gene Expression transcription of RNA 1.27E-05 ARID4A,CCND1,CDKN1A,ERBB4,ETS1,HAX1,HEY2, 
HNRNPK,HOXA7,IFI27,KAT2A,KAT2B,MECP2,MYBL2, 
NFKB2,PRLR,PTTG1,RBL1,SMAD4,SMARCE1, 
STAT1,TAB2,TCF21,TRAF6,UBE2L3 
25 
Gene Expression transcription of DNA 3.82E-05 ARID4A,CCND1,ERBB4,ETS1,HAX1,HEY2, 
HNRNPK,HOXA7,IFI27,KAT2A,KAT2B,MECP2,MYBL2, 
NFKB2,PTTG1,SMAD4,SMARCE1,STAT1,TCF21,TRAF6,UBE2L3 
21 
Gene Expression activation of DNA 
endogenous 
promoter 
5.50E-05 ARID4A,CCND1,ETS1,HAX1,HEY2,HNRNPK, 
HOXA7,IFI27,KAT2A,KAT2B,MYBL2,NFKB2, 
PTTG1,SMAD4,STAT1,TCF21,TRAF6 
17 
Hematological Disease, 
Immunological Disease 
lymphoproliferative 
disorder 
3.33E-04 CCND1,CDKN1A,ETS1,IFI27,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-342-3p (miRNAs w/seed CUCACAC), 
RIF1,SYNE2,TNFAIP3,TNIP1,YWHAZ 
16 
Hereditary Disorder autosomal dominant 
disease 
3.08E-04 ATXN7,CCND1,ELOVL4,ERBB4,HEY2,MAFB, 
NFKB2,PTTG1,RPSA,SMAD4,STAT1,STIM1,SYNE2 
13 
Immunological Disease systemic autoimmune 
syndrome 
1.59E-07 ARIH1,CCL1,CCR1,CTSA,H3F3A/H3F3B,IFIT1, 
IGFBP5,ISG15,MAFB, 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-196a-5p (and other miRNAs w/seed AGGUAGU), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-298 (miRNAs w/seed GCAGAAG), 
23 
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OASL,PTPN22,RPL18A,RPSA,SLC7A2,SPP1, 
STAT1,TNFAIP3,UBE2L3 
Infectious Diseases Viral Infection 6.96E-04 FAM135A,H3F3A/H3F3B,HIST2H2BE,HNRNPK, 
HOXA7,IFIT1,IFIT3,ISG15,KAT2A, 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYEF2,OASL,PDE3A,PLAT,PPP2R2A,PTTG1, 
RPS27A,RPSA,SPP1,STAT1,UBE2L3,ZNF417/ZNF587 
23 
Inflammatory Disease chronic inflammatory 
disorder 
5.77E-04 ARIH1,CCL1,CCR1,H3F3A/H3F3B,IGFBP5,MAFB, 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC) 
,PDE3A,PTPN22,RASGRP3,RPL18A,RPSA 
,SLC7A2,SPP1,STAT1,TNFAIP3 
17 
Inflammatory Response inflammation of 
organ 
4.63E-05 ARIH1,H3F3A/H3F3B,IFI27, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-423-5p (and other miRNAs w/seed GAGGGGC), 
PDE3A,SPP1,STAT1,SYNE2,TNFAIP3 
16 
Inflammatory Response inflammation of body 
region 
1.31E-03 miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
miR-224-5p (miRNAs w/seed AAGUCAC), 
miR-23a-3p (and other miRNAs w/seed UCACAUU), 
miR-423-5p (and other miRNAs w/seed GAGGGGC), 
PDE3A,SPP1,STAT1 
 
10 
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Metabolic Disease amyloidosis 2.89E-04 CCND1,DDX46,FAM3C,IGFBP5, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
PDE3A,PLAT,SLC7A2,YWHAZ 
13 
Metabolic Disease, 
Neurological Disease, 
Psychological Disorders 
Alzheimer's disease 2.33E-03 DDX46,FAM3C, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
PDE3A,PLAT,SLC7A2,YWHAZ 
11 
Neurological Disease progressive motor 
neuropathy 
8.72E-05 CDKN1A,EIF4A2,ERBB4,GNAS,H3F3A/H3F3B, 
IFIT1,ISG15, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC),SPP1 
13 
Neurological Disease, 
Skeletal and Muscular 
Disorders 
neuromuscular 
disease 
2.74E-04 CHAF1B,EIF4A2,FAM3C,GHITM,GNAS, 
H3F3A/H3F3B,IFIT1,ISG15, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
miR-145-5p (and other miRNAs w/seed UCCAGUU), 
miR-146a-5p (and other miRNAs w/seed GAGAACU), 
miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-17-5p (and other miRNAs w/seed AAAGUGC), 
SPP1,TRAF6,YWHAZ 
16 
Organismal Survival organismal death 3.33E-06 CCND1,HNRNPK,HOXA7,IRAK1, 
miR-125b-5p (and other miRNAs w/seed CCCUGAG), 
12 
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miR-155-5p (miRNAs w/seed UAAUGCU), 
miR-181a-5p (and other miRNAs w/seed ACAUUCA), 
miR-21-5p (and other miRNAs w/seed AGCUUAU), 
MYBL2,SPP1,STAT1,TNFAIP3 
Protein Synthesis metabolism of 
protein 
5.39E-04 ARIH1,EIF4A2,HNRNPK,IGFBP5,KAT2A,PLAT, 
RPL37,SMAD4,SPP1,TNFAIP3,TNIP1,UBE2L3 
12 
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22. ADDENDUM H: Core Network 1 expanded, and prepared for overlays 
 
 
 
 
 
 
 
 
Figure 47: Core Network 1 prepared for overlays 
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23. ADDENDUM I: Core Network 2 expanded, and prepared for overlays 
Figure 48: Core Network 2 prepared for overlays 
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24. ADDENDUM J: Core Network 3 expanded, and prepared for overlays 
  
 
Figure 49: Core Network 3 prepared for overlays 
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25. ADDENDUM K: The 221 curated, and prepared 
identifiers, which were mapped to identifiers in IPA not 
having exactly the same name 
Raw Data ID ID Mapped in IPA Raw Data ID ID Mapped in IPA 
APITD1 APITD1/APITD1-CORT miR-200 mir-8* 
ARHGAP8 ARHGAP8/PRR5-
ARHGAP8 
miR-200a-3p miR-141-3p 
ATP6 MT-ATP6 miR-200b mir-8* 
C19orf55 PROSER3 miR-200c mir-8* 
C2orf43 LDAH miR-200c-3p miR-200b-3p 
C4A C4A/C4B* miR-208b-3p miR-208a-3p 
C4B C4A/C4B* miR-20 mir-17* 
CBS CBS/LOC102724560 miR-20a-5p miR-17-5p 
CCDC41 CEP83 miR-20b-5p miR-17-5p 
CDY2A CDY1 miR-21 mir-21 
COX1 MT-CO1 miR-211-5p miR-204-5p 
COX2 MT-CO2 miR-212-3p miR-132-3p 
COX3 MT-CO3 miR-215-5p miR-192-5p 
DNAAF5 DNAAF5* miR-222 mir-221 
FAM105B OTULIN miR-222-3p miR-221-3p 
FAM5B BRINP2 miR-224 mir-224 
FCGR3A FCGR3A/FCGR3B* miR-23b-3p miR-23a-3p 
FCGR3B FCGR3A/FCGR3B* miR-23b-5p miR-23a-5p 
GPR64 ADGRG2 miR-25-3p miR-92a-3p 
H3F3B H3F3A/H3F3B miR-26b-5p miR-26a-5p 
HEATR2 DNAAF5* miR-27b-3p miR-27a-3p 
HIST2H2AA3 HIST2H2AA3/HIST2H2AA
4 
miR-28-5p miR-708-5p 
HSFY2 HSFY1/HSFY2 miR-298 mir-298 
HSPA1A HSPA1A/HSPA1B miR-299-3p miR-299a-3p 
IFNA1 IFNA1/IFNA13 miR-299-5p miR-299a-5p 
IGJ JCHAIN miR-29a-3p miR-29b-3p 
IL8 CXCL8 miR-29c mir-29 
KIAA1279 KIF1BP miR-29c-3p miR-29b-3p 
KLHL23 KLHL23/PHOSPHO2-
KLHL23 
miR-301a-3p miR-130a-3p 
LEPRE1 P3H1 miR-302 mir-302* 
LEPREL2 P3H3 miR-302a-3p miR-291a-3p 
LIN28 LIN28A* miR-302c mir-302* 
LIN28A LIN28A* miR-302c-3p miR-291a-3p 
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MAP3K7IP2 TAB2* miR-302d mir-302* 
ND2 MT-ND2 miR-302d-3p miR-291a-3p 
ND4 MT-ND4 miR-30 mir-30 
ND4L MT-ND4L miR-30a-5p miR-30c-5p 
ND5 MT-ND5 miR-30b-5p miR-30c-5p 
ND6 MT-ND6 miR-30c-2-3p miR-30c-1-3p 
PHF16 JADE3 miR-30d-5p miR-30c-5p 
PHF17 JADE1 miR-30e-5p miR-30c-5p 
PRODH LOC102724788/PRODH miR-3148 MIR3148 
PTPLAD1 HACD3 miR-32-5p miR-92a-3p 
PWP2 LOC102724159/PWP2 miR-320 mir-320 
RAB6C RAB6C/WTH3DI miR-320c miR-320b 
RAB7L1 RAB29 miR-324-3p miR-1913 
RGPD2 RGPD3 miR-326 mir-326 
SGK3 C8orf44-SGK3/SGK3 miR-33 mir-33* 
SIP1 GEMIN2 miR-33a-5p miR-33-5p 
SMCR7L MIEF1 miR-33b mir-33* 
SOGA2 MTCL1 miR-33b-5p miR-33-5p 
TAB2 TAB2* miR-346 mir-346 
TMSB10 TMSB10/TMSB4X miR-34 mir-34* 
TMSL8 TMSB15A miR-34b mir-34* 
TRAPPC2P1 TRAPPC2B miR-34c mir-34* 
TXLNG2P TXLNGY miR-34c-5p miR-34a-5p 
ZNF587 ZNF417/ZNF587 miR-3615 mir-3615 
miR-1 miR-1-3p miR-363-3p miR-92a-3p 
miR-103a-2-5p miR-103-1-5p miR-365a-3p miR-365-3p 
miR-103a-3p miR-103-3p miR-372 mir-290 
miR-106 mir-17* miR-372-3p miR-291a-3p 
miR-106a-5p miR-17-5p miR-373 mir-373 
miR-106b mir-17* miR-373-3p miR-291a-3p 
miR-106b-5p miR-17-5p miR-375 mir-375 
miR-107 mir-103 miR-376a* miR-376a-5p 
miR-10b-5p miR-10a-5p miR-421 mir-95 
miR-122 mir-122 miR-424 mir-322 
miR-124 miR-124-3p miR-424-5p miR-16-5p 
miR-125a-5p miR-125b-5p miR-429 mir-8* 
miR-125b miR-125b-5p miR-433 mir-433 
miR-126-3p miR-126a-3p miR-449 mir-449 
miR-126-5p miR-126a-5p miR-454-3p miR-130a-3p 
miR-1260b mir-1260b miR-484 mir-484 
miR-1276 mir-1276 miR-502-3p miR-501-3p 
miR-128 miR-128-3p miR-503 mir-503 
miR-1303 mir-1303 miR-519b-3p miR-519a-3p 
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miR-130 mir-130 miR-519c-3p miR-519a-3p 
miR-130b-3p miR-130a-3p miR-519d-3p miR-17-5p 
miR-133 miR-133a-3p miR-519e-3p miR-515-3p 
miR-133b mir-133 miR-520a-3p miR-291a-3p 
miR-135b-5p miR-135a-5p miR-520b mir-515* 
miR-141 mir-8* miR-520c-3p miR-291a-3p 
miR-145 mir-145 miR-520 mir-515* 
miR-146 mir-146 miR-548 miR-548aa 
miR-146b-5p miR-146a-5p miR-548q mir-548 
miR-148b-3p miR-148a-3p miR-572 mir-572 
miR-151a-3p miR-151-3p miR-577 mir-577 
miR-151a-5p miR-151-5p miR-608 mir-608 
miR-155 mir-155 miR-638 mir-638 
miR-15 mir-15* miR-639 mir-639 
miR-15a-5p miR-16-5p miR-657 mir-657 
miR-15b-5p miR-16-5p miR-663 mir-663* 
miR-16 miR-16-5p miR-663b mir-663* 
miR-17 mir-17* miR-7 miR-7a-5p 
miR-181a-3p miR-181a-1-3p miR-7-5p miR-7a-5p 
miR-181b-2-3p miR-181b-1-3p miR-758 mir-379 
miR-181b-3p miR-181b-1-3p miR-760 mir-760 
miR-181b-5p miR-181a-5p miR-769-3p miR-450b-3p 
miR-181c mir-181 miR-802 mir-802 
miR-181c-5p miR-181a-5p miR-9 miR-9-5p 
miR-181d-5p miR-181a-5p miR-92b-3p miR-92a-3p 
miR-184 mir-184 miR-93 mir-17* 
miR-18 mir-17* miR-93-5p miR-17-5p 
miR-193b-3p miR-193a-3p miR-935 mir-935 
miR-195 mir-15* miR-940 mir-940 
miR-195-5p miR-16-5p miR-942-5p miR-7028-3p 
miR-196 miR-196a-5p miR-98-5p let-7a-5p 
miR-198 mir-198 miR-99a-5p miR-100-5p 
miR-19 mir-19 miR-99b-3p miR-99a-3p 
miR-19a-3p miR-19b-3p miR-99b-5p miR-100-5p 
miR-19b miR-19b-3p   
 
 
 
 
 
 
 
 
